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Personalised cancer medicine foregrounds the experiences 
of cancer patients, carers and practitioners in the United 
Kingdom. The authors trace the promise and possibilities 
of new genomic approaches to cancer as they unfold 
through everyday encounters with novel research, tests and 
treatments in the cancer clinic and beyond. Contrasting 
powerful claims of transformation and benefit with the difficult 
and painstaking work involved in making sense of novel 
data, results and predictions, they show the different futures 
crafted across policy, practice and personal accounts. 
Representing the first book to investigate how personalised 
cancer medicine is reshaping the futures of cancer patients, 
carers and professionals in uneven and partial ways, this 
book makes an essential contribution to our knowledge of 
cancer medicine and society.
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Introduction
Exploring personalised cancer medicine
Personalised medicine for cancer is at the forefront of the new 
bioeconomy and visions for the future of healthcare. It promises 
treatments tailored to individuals’ genomes and those of their cancers, 
as well as more precise diagnosis, prognosis and prevention. Widely 
celebrated as revolutionary and transformational, the risks and ethical 
conundrums of personalised medicine are confronted every day by 
patients, clinicians and researchers, but are consistently underplayed 
in the mainstream media (Marcon et al. 2018). Cancer research has 
a long history of optimism: the hope of living well with and beyond 
cancer permeates much of contemporary life. But not everyone is 
set to benefit from these advances in cancer medicine, and concerns 
about hype and over-optimism can be found across practitioner, 
academic and patient communities. Cancer patients, their families, 
policymakers, practitioners and researchers are entwined in novel 
practices as they navigate the promises and pitfalls of personalised 
medicine. In this book we investigate these practices, focusing on 
what is involved in promoting, receiving and delivering personalised 
molecular predictions, diagnoses and treatments for cancer. How is 
the work of crafting the optimistic or more modest and contested 
futures of personalised cancer medicine distributed and to what 
end? What kinds of value – personal, social as well as economic 
– are created through these practices, and for whom (Dussauge et 
al. 2015; Birch 2017)? How might things be organised differently 
to produce different kinds of values and futures for cancer patients, 
healthcare providers and society more generally?
Our book is based on a five-year UK-based multi-sited qualitative 
study of a diversity of patient, carer, practitioner, researcher, manager 
and policymaker experiences and accounts of genomic medicine in 
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cancer, funded by a joint Senior Investigator Award in Society and 
Ethics from the Wellcome Trust.1 We draw on a rich diversity of 
interviews, observations in clinics, laboratories and public events as 
well as textual analysis of public, policy and professional literatures 
and media discourses.2 The focus of our study has been on genomics, 
the branch of molecular medicine concerned with mapping genomic 
profiles, and how this is reshaping cancer medicine and the experience 
of cancer. This has included diagnostic and predictive tests for cancer 
based on molecular profiling (shifting from single genes to panels of 
genes to whole genome and next generation sequencing); treatments 
targeted at cancers with particular molecular signatures (sometimes 
called tailored treatments or precision oncology); clinical trials of 
these new diagnostics and treatments, including new kinds of trials 
which offer combinations of treatments and/or adapt treatments 
over the course of the trial; and other research studies which gather 
molecular information about patients and their cancers to try to 
identify subtypes of cancer that are more responsive to particular 
treatments. We have also explored patient and public involvement 
in personalised cancer medicine, not just as service users or research 
participants, but as representatives on patient panels and other 
forms of involvement and engagement. Together, these activities 
and agendas are key parts of so-called P4 medicine, characterised 
as predictive, personalised, preventive and participatory (Hood and 
Friend 2011).
In a culture marked by enormous anticipation that biomedical 
innovations such as genomics may cure feared diseases such as 
cancer, it is hard to sound a note of caution without appearing to 
dash those very hopes. Maybe this can come across as a lack of 
compassion or even a disregard for those experiencing the disease 
and for those involved in their care. Our intentions could not be 
further from this – we want to put such experiences at the centre 
of our analysis because they are at the centre of personalised medicine. 
Yet we also want to address some of the wider, more distant processes 
of biomedical innovation, their drivers and their consequences. This 
involves unpicking how the cultural imperative to be hopeful and 
positive about the potential to overcome cancer, an imperative 
amplified by the promises offered by powerful molecular technologies, 
is enacted and experienced by people affected by cancer. Patients 
and their supporters frequently voice these hopes and obligations 
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not only for their own, but for other patients’ futures, invoking the 
need to extend these hopes to others. As one patient in our study 
commented: ‘I think it’s hugely exciting and I don’t know if the 
message has entirely got across to the public out there but it’s just 
so exciting.’ Together with their clinicians, patients try out new 
diagnostics and drugs, take part in research, trials, fundraising and 
campaigns to bring this future into being. These hopes peppered 
our encounters with practitioners too – in the words of one oncologist: 
‘My hope is that by continuing to dissect the genomics [of cancer] 
we will come up with better treatments for specific subgroups of 
cancers which are genomically driven.’ Being hopeful is not just an 
activity for the cancer clinic or clinical trial, it is part of everyday 
life too, marking encounters with friends and family, charitable 
fundraising and popular culture, where stories of the triumphs and 
losses of cancer are ever present. Governments, institutions, organisa-
tions and companies together with scientists, healthcare practitioners, 
politicians, business people and regulators also actively anticipate 
future benefits, including service improvements and cures as they 
seek to encourage participation and raise support and investment 
for genomic research, healthcare and bioscience infrastructure, 
including new molecular diagnostics and therapies for cancer. Policy 
discourses are replete with the language of hope and anticipation, 
asking us to ‘welcome the genomic era and deliver the genomic 
dream!’ (Davies 2017: 1).
These kinds of promissory discourses can be problematic for 
patients and professionals alike. Concerns have been raised about 
over-inflated expectations and harsh disappointments when test 
results are poor, or treatment options diminish, including when 
experimental and cutting-edge drugs cannot be accessed. One of 
the clinicians in our study clearly articulated this caution when 
noting, for all of the anticipation about exceptional responses, in 
the trial in which they are involved: ‘I think that’s fair to say, I mean 
I don’t think any of the patients I’ve seen has had a dramatic response 
to date.’ Frustrations with the sense of obligation always to be 
positive are also well documented, exemplified in feminist challenges 
to the ‘good patient’ and ‘pink washed’ cultures of breast cancer in 
particular (Ehrenreich 2001; Jain 2013; Steinberg 2015). As one 
patient in our study, reflecting on her experiences of being positive 
for family and friends fundraising on her behalf, said: ‘I’m a very 
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strong person … but it did get to the point where I just felt like I 
cannot cope with this’ (Stacey, see Chapter 6). Living in a culture 
of hope takes work and involves an emotional toll, no matter your 
orientation towards the promises of personalised, genomic medicine 
for cancer.
Traversing people’s experiences and personal accounts of living 
with the risks and realities of cancer developing, mutating, resisting, 
progressing and returning and the professional work to identify, 
prevent and mitigate the effects of cancer in busy laboratories and 
clinics, we look at the kinds of futures being crafted by the actors 
involved, and how they interact, inflect and at other times coexist 
in parallel planes as genomic medicine unfolds. Our key focus is on 
how cancer patienthood is developing in the genomic era, including 
how patient identities and collectives are evolving in the context 
of molecular information and interventions (Clark et al. 2003; 
Landzelius 2006; Sulik 2009). Our exploration of performing and 
living ‘patienthood’ brings such experience into dialogue with the 
wider drivers of personalised medicine. This covers questions of what 
counts as being a ‘good’ or ‘deserving’ patient living with cancer, its 
risks, mutations and remissions, and how patients construct hopeful 
futures of cure and prevention for themselves and others, as well as 
the more contingent futures where foreshortened lives with cancer 
can be made liveable. We also explore how crafting these futures 
takes time, resources and care from affected individuals, families and 
practitioners, teasing out the strategies of maintenance, the silences, 
engagements and even the avoidance that this involves. This work is, 
at times, intense and difficult; we consider how it takes place in the 
context of personhood more broadly, including other kinds of life 
strategies, working practices and political agendas which co-produce 
as well sometimes overshadow or interfere with crafting personal 
and collective futures. The futures of patient collectives (including 
families and former patients), institutions and workplaces also have 
to be hewn alongside the work of cancer management and control, 
including mutations in cancer patienthood as the types and risks 
of cancer are stratified along molecular lines. We consider how the 
accounts and practices we uncover trouble narrow understandings of 
individual responsibility and biomedical innovation as the engine of 
prosperity, linking this to wider struggles around futures, democracy 
and value in late capitalist societies.
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Future-crafting: great expectations and questions of value
More than a decade after the financial crisis, the slow growth of 
damaged economies and the politics of austerity in countries such 
as the UK have widened health inequalities and hollowed out public 
services. Cancer can be seen as a bellwether for late capitalist societies. 
Although survival rates for some cancers have improved in recent 
years (Arnold et al. 2019; Harrison et al. 2019), people’s chances 
of surviving cancer vary not only according to which cancer they 
have but also their socio-economic circumstances. In the UK, stubborn 
inequalities persist and improvements in outcomes are not evenly 
experienced. Cancer remains a major cause of death, while estimates 
suggest that in the UK, 38 per cent of cancers are preventable and 
almost half of cancer patients are diagnosed at a late stage.3 Incidence 
is on the increase, nationally and globally, due to ageing populations, 
with the most common cancers worldwide being lung, female breast, 
bowel and prostate cancer. Cancers with poor outcomes (e.g. liver, 
stomach) are more common in richer countries, but researchers have 
found that people living in poorer countries are experiencing increas-
ing rates of cancer (Merletti et al. 2011), and there are significant 
differences in survival (although not incidence) depending on race 
and ethnicity (Ward et al. 2004). With the exception of breast cancer 
and melanoma, cancer is more common among deprived groups in 
countries such as the UK. Research in England has found that people 
from the most deprived areas have the highest rates of lung and 
cervical cancer, whereas people from more affluent areas have higher 
rates of breast and skin cancer (Shack et al. 2008).4 Despite success 
stories due to improved treatments and prevention programmes, 
some cancers remain stubbornly incurable and some are less visible 
in research, fundraising and the media. Fear of cancer and of a lack 
of timely intervention are compounded by problems with health 
service provision, including in publicly funded systems such as the 
National Health Service (NHS) across the UK, which is currently 
experiencing severe staffing problems.5 Improved screening and 
prevention programmes, earlier diagnosis, and better, more effective 
treatments have improved cancer mortality rates for some cancers, 
but services are stretched, patient experiences are diverse, and access 
to expensive treatments including some chemotherapy may not be 
available to all. Charitable fundraising for individual treatments, 
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living costs and hospice treatment is on the increase, with patients 
and their families turning their leisure time and private lives over 
to public displays of worthiness in an effort to raise resources for 
targeted treatments not currently provided by the state.
The hope of personalised treatments for this most feared disease 
has long been part of a wider set of expectations and investments 
in scientific capacity and biomedical expertise in nations that have 
nurtured world-leading universities and hospitals as part of their 
global economic positioning. As countries such as the UK struggle 
to carve out a new economy in the face of nationalism, predatory 
capital and political upheaval, the bioeconomy has grown in impor-
tance. Harnessing the scientific and biomedical expertise and 
infrastructures of the country, particularly in the golden triangle of 
the south-east of England, together with the data and biological 
assets of the NHS, the UK has invested heavily in the genomic life 
sciences, with cancer a key site of collection, analysis and intervention. 
Working in close alliance with private capital, through a range of 
spin-out companies and multinationals, the UK national and devolved 
governments, together with major charitable funders and the expertise 
of the university sector, have developed an ambitious set of projects, 
trials, studies and initiatives to expand the new economy of per-
sonalised medicine. Patient data, tissue and other kinds of engagement 
and participation (for example, to improve genomic literacy), and 
involvement in research and uptake of services are key to the success 
of this new economy.
A new social contract with cancer patients is therefore emerging 
where their participation in research is becoming routinised as part 
of a drive to develop biomedical research and innovation and to 
improve health systems, services and patient outcomes. The vision 
is that patients’ participation will grow the economy and secure the 
longer-term future of the NHS, including via special licensing and 
profit-sharing agreements with industry. As a result, services will 
become more agile and efficient, avoiding unnecessary and ineffective 
treatments through a more personalised approach. A focus on prevent-
ing disease rather than having to spend money on treatment will 
generate further savings, with the rest of the profit realised by industry 
contributing to national economic growth more generally. Meanwhile, 
individual patients are supported in their quest for tailored therapies 
and diagnosis through a range of experimental and cutting-edge 
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treatments and trials. The industry, charities, advocates and carers 
encourage and enable patients to source new treatments, find new 
trials and even challenge bureaucratic decisions to extend their 
compromised futures. But not all patients or professionals are 
convinced of the logic of these investments or promised benefits, 
especially those who are too ill or those for whom new therapies 
remain beyond the horizon, only accessible for future patients, not 
patients in the here and now. As one patient advocate, Toni, com-
mented about precision medicine: ‘It’s got everything going for it 
in terms of making the gap even greater between the richer and the 
poorer countries because these drugs, by definition, are much more 
expensive but they have a huge difference in their … potential impact.’ 
Yet opportunities and capacities to voice this kind of concern or 
critique are constrained by the dual promise of innovation and hope 
that surrounds personalised cancer medicine.
How, then, can we understand and, more importantly, intervene 
in these possibilities, inequalities and silences around personalised 
cancer medicine to craft better futures for patients, healthcare workers, 
services and economies? To answer this question, we need to begin 
with what people are currently doing – to make personalised cancer 
medicine work in practice – to explore what future-crafting involves 
and what kinds of futures are being anticipated and pursued. We 
need to consider how futures overlap and impinge upon each other 
and widen our focus from the normative vision of these biomedical 
developments to consider what kinds of alternative futures people 
carve out through their encounters with personalised cancer medicine. 
And we need to attend to how value circulates through these 
approaches and agendas – what kinds of value are being sought or 
achieved, and how might this be otherwise?
There are many rich and varied traditions of social scientific 
and philosophical literatures on which we have drawn to guide 
our inquiry, detailed throughout the chapters that follow. We can, 
however, summarise some of our key influences here, by way of 
introduction.
First, we are influenced by feminist and science and technol-
ogy studies (STS) scholarship which seeks to change, as well as 
describe, the social world. This means that we aim to build on the 
rich description of what we have encountered in the course of our 
work, drawing from our findings to imagine different futures and 
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future-crafting activities that might be cultivated as a response to 
our inquiry. This is not only a matter of ‘putting ourselves in our 
story’ as a reflexive ethnographic project, but of actively grappling 
with our own version of future-crafting. We do not do this, first and 
foremost, as cancer patients, or relatives of current cancer patients, 
but as engaged scholars with a stake in our collective futures whatever 
role cancer might play. As part of this engaged scholarship we have 
also tried to remain sensitive to the gaps, silences and omissions in 
our research (Haraway 1988; Puig de la Bellacasa 2011; Murphy 
2012; Jain 2013), particularly the limitations in the range of voices 
and experiences that we have been able to document here, something 
we discuss further in Chapter 7. We also endeavour to reflect on 
our own practices of narrative as a craft – cutting, sewing, sticking, 
fitting, tinkering, patching data and analysis. In so doing we try to 
be mindful of the contingencies and relationalities, the messiness and 
stop–start nature of storytelling as future-crafting. This allows for 
the possibility of it being, at times, a relatively solitary individual 
practice and, at other times, a collective practice, enacted with others 
in one place, or across different localities and timescapes.
Second, and relatedly, we are putting patient and practitioner 
experiences of genomic medicine centre-stage, trying to pull together 
an analysis from a wide array of accounts and observations of how 
patients think and feel about their cancer and its treatment in the 
genomic era, and how practitioners keep patients in mind as they 
try to develop research and provide a service. We combine an interest 
in professional accounts and practices as well as policy approaches 
and agendas in an effort to understand how professional jurisdictions, 
epistemologies and organisations are changing in relation to per-
sonalised medicine (much of which is discussed in Chapter 1), with 
an interest in the complexities, tensions and contradictions of the 
lived experiences of patients. We are influenced by scholarship which 
prioritises attention to articulation work, care and emotional labour 
(Star 1985; James 1992; Twigg et al. 2011; Murphy 2015), work 
that is traditionally associated with women’s devalued contribution 
but that is also a key part of being a patient, a provider of healthcare 
and a worker in the service sector. This draws our attention to the 
routine, mundane, everyday work of genomic medicine for cancer 
as a form of craft, including the intricate and skilful work of patients 
or practitioners that may be invisible and undervalued but is crucial 
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to the test, treatment or research being conducted, and thereby 
closely linked to the work of crafting a future for ourselves and 
others. It also invites us to think critically about how care and other 
kinds of work can be experienced as neglect or inattention by others 
(Murphy 2015). We attend to how patient and carer identities and 
relationships are changing as they do some of the work of cancer 
research and treatment, not just as providers of data or care but as 
champions of new kinds of services and research, whether as rep-
resentatives, campaigners or supporters of fellow patients, engaging 
in new kinds of ‘evidence-based activism’ (Rabeharisoa et al. 2014) 
and biosociality which forms a crucial part of the landscape of 
contemporary biomedicine (Rose 2001).
Third, and finally, we are focusing on futures, both imagined and 
made, as crafting projects rooted in practice (Adam and Groves 
2007). There is a long and fascinating tradition of scholarship which 
investigates imaginaries and expectations as meta-discourses that 
perform the sociotechnical economy, establishing new markets and 
innovation (Hedgecoe and Martin 2003; Selin 2008; Tutton 2012; 
Jasanoff 2015; Brown and Rappert 2017). Medical humanities and 
the sociology of health and illness both have a rich seam of research 
on survivorship and identity-work where crafting ‘culturally plausible 
narratives’ (Frank 2003) involves embodied work in the lives of 
cancer survivors and the communities they come to feel responsibilities 
towards (see also Kaiser 2008; Kerr et al. 2019). But we know less 
about how contemporary cancer patients or prospective cancer 
patients engage with, take up or repudiate dominant expectations 
of prediction, personalisation, prevention and participation in this 
genomics era. As Michael (2017a) argues in his analysis of the 
enactment of ‘big’ and ‘little’ technoscience futures in which we are 
embroiled, there is a need to attend to how lived experiences and 
larger cultural and economic narratives interact. For us, these 
engagements, or indeed disengagements, need to be properly under-
stood if we are really to appreciate how innovation works in practice 
and how it can be improved or repurposed for social good. Questions 
of value (Dussauge et al. 2015) are key, and here we draw on the 
area of valuation studies which has focused attention on the kinds 
of value and processes of making value that characterise all facets 
of contemporary working and intimate lives. In addition to under-
standing how economic value is produced, we want to know what 
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other kinds of value are being made and come to light when we 
attend to the lived experience of innovations in the making, for 
recipients and subjects of research as well as professionals. This 
includes the value of being together with others, of feeling cared 
for and of worth, the value of an imagined community of other and 
future patients and of individual and collective meanings.
Our approach
We have tried to follow through on our commitment to lived experi-
ence, imagining other ways of generating and sharing value and 
attending to the craft work of future making through our own 
scholarship and ways of working. As a large team of researchers, 
we have taken on different roles and relationships to the project, 
the field and the writing of this book. We have also worked with 
others not represented as authors in this work, but whose contribu-
tions we have nevertheless sought to recognise as we write. It has 
been particularly important to us to write as a collective and to 
recognise the work of researchers who have done the bulk of data 
generation in the attribution of authorship for this work. At the 
same time, we note that we have not chosen to produce an edited 
collection or to attribute authorship of particular chapters as a way 
of delineating our contributions. Instead, we recognise that some 
of our team have had more of an input to specific chapters, and we 
have worked collectively to review and refine the analysis and writing 
as part of our wider collaborative efforts.
We conducted around 250 interviews with clinical and laboratory 
staff, patient advocates, people affected by cancer and some family 
members across a few UK cities between 2016 and 2019. The bulk 
of this fieldwork was performed by the researchers on the project 
(Tineke Broer, Choon Key Chekar, Sue Chowdhry, Emily Ross and 
Julia Swallow). This included interviews with patients and family 
members across five main case studies of genomic tests, studies, 
trials and treatments in NHS settings and private healthcare. We 
also carried out over sixty observations in clinics, laboratories and 
at public events, and a further set of digital observations across 
online platforms including cancer charity forums, Twitter, blogs and 
Facebook pages. Working with these groups and in these settings 
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has been difficult and complex, not least because patients are often 
very unwell. Many of the patients we interviewed as part of our 
work have died, sometimes shortly after the observations or interviews 
took place. This brings with it a strong obligation to respectfully 
analyse their accounts, in all of their complexity. Cancer experiences 
are highly personal and emotional, and capturing the details of these 
experiences without intruding or causing distress is a finely balanced 
undertaking. Not only does it involve empathising, sensing feelings 
and capacities to contribute, especially knowing when to stop 
interactions, but it encompasses navigation of the complex institu-
tional arrangements and representatives involved in cancer research 
and care. This spans the formal structures of ethical review and risk 
management as well as the organisational and logistical aspects of 
research studies, laboratories, clinics and patient pathways. It also 
involves working beyond physical institutions across virtual networks, 
to find people to engage with as part of the research, secure agreement 
for observations and analysis and ensure that patients and interested 
publics are able to shape our research agendas rather than simply 
act as research subjects or audiences. We had to work closely with, 
indeed rely upon, staff and patient advocates who acted as key 
gatekeepers for our study, and in so doing navigate the burdens we 
placed on their own time and resources, which were often stretched 
or in demand from numerous quarters. This included working with 
two Patient and Public Involvement groups we set up at the start 
of our research, who guided us throughout on the appropriate ways 
of involving and approaching patients regarding participation and 
in relation to the dissemination of our findings.
Our research took place at a time of crisis and worry about the 
future of the National Health Service after a prolonged period of 
low investment following the financial crisis of 2008 and an ongoing 
process of marketisation. It was also shaped by the cultural politics 
of Brexit in the UK and a growing discomfort about the politics 
and identities surrounding immigration, inequality and nationhood. 
Although this makes it a somewhat British story, it is also international 
in its implications and scope. We can trace the ways in which patient 
communities, promissory rhetoric, drugs, tissue, novel medicines 
and diagnostics traverse nations through our own case studies. Yet 
we also see many of the stories of genomics and data as national 
resources, and access to tests and treatments as patients’ rights and 
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responsibilities, in other national agendas and stories from patients 
in other countries. The complex and, at times, troubled context of 
the NHS clinics and laboratories made us particularly attentive to 
the activities and dedication of clinical and laboratory staff involved 
in making genomic medicine work for patients in the present and 
for the future.
We also became acutely aware of the gaps or absences in our 
inquiry as we made our way through the episodic encounters in the 
hospital or the community. We carried with us a strong sense of the 
more marginalised patients and social groups who we did not manage 
to speak with and include in our work, and the ever present danger 
that we would slip into the amplification of more articulate and 
insistent repertoires or ‘culturally plausible narratives’ (Frank 2003) 
as we conducted our research, as well as the difficulties of not 
sufficiently attending to or not being able to attend to silences, 
rejection and non-participation. We reflect more fully on this across 
each chapter and in particular in Chapter 7.
Below we detail the case studies and primary focus of each chapter, 
drawing out the main themes of our analysis, which we reflect 
upon in the concluding chapter. We briefly consider these recurrent 
themes here to provide a scaffold for the detailed analyses that 
follow and to highlight some of the implications of our work for 
scholarship about personalised medicine and other innovative health 
technologies.
First, understanding how hope operates involves grounding 
STS and other sociological analyses of promissory tropes in the 
everyday, tangled practices of personalised cancer medicine. A critical 
appreciation of the technoscientific promise of personalisation and 
attention to failures and disappointments in practice is vital, but 
we must also acknowledge the limits of critique, given the ways in 
which hopefulness around personalisation is a resource which can 
be taken up and reworked by embodied beings to craft liveable 
presents and futures. The value of critical engagement with tropes, 
discourses, templates and rhetoric is blunted and complicated by 
the messy realities of living with cancer or trying to care for those it 
affects. Attending to caring practices (including their limits), work, 
and the measurable and more diffuse kinds of care this generates 
has helped us to reorient our critical impulse to an appreciation of 
expectations as contingent, contradictory and in the making. We 
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ask our readers and other researchers to take this complexity to the 
heart of their engagements with the cancer encounters we capture 
here and to their scholarly inquiries with patients and practitioners 
more generally.
Second, our research has heightened our sense of discomfort with 
the experiential, identity-focused work of the sociology of health 
and illness where documenting individual narratives and lived 
experience takes precedence over engagement with the institutional, 
political or economic processes through which experiences are lived 
out. Working across our case studies has made us acutely aware of 
the institutional structures that determine who can access or remain 
on these novel treatments and tests, taking us well beyond questions 
of survivorship as identity-work to survivorship as part of a wider 
political economy of material and financial resources. Medical 
sociological approaches to cancer crafting that are primarily concerned 
with identities and experiences, focusing on studies of particular 
types of cancer patient or community, can all too easily miss this 
wider terrain of patient, practitioner, carer and post- or even pre-
cancer patienthood across which initiatives such as personalised 
medicine operate. Writing this back into their stories is a laborious 
and difficult process, but it is key to understanding how these 
technologies make their way through the world to impact patients 
and their carers.
Third, although we draw huge inspiration from theories and 
ideas of biosociality and citizenship where structures of feeling, 
responsibility and identity are interwoven with politics and economics, 
we find ourselves concerned that, once again, the focus on how 
experiences are organised into communities with particular subtypes 
or conditions does not readily fit with what we have encountered 
across our research, which is much more fluid and multi-layered 
than a focus on the molecular details of diagnostics might suggest. 
Patients are sometimes joined in shared agendas and pursuits in 
relation to their particular type of cancer, but they are often working 
with a diversity of other patients and allies, forming networks and 
collectives across molecular and bodily categories as well as across 
other social categories, including class and gender. We need to attend 
to these relationalities and the possibilities they bring for new kinds 
of cancer politics of solidarity in the era of personalisation, just as 
we must remain mindful of those patients, or groups of patients, 
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who are excluded or marginalised from these new collective and 
community formations.
Fourth, welding together the different layers of engagement with 
personalised medicine, traversing big and little futures, also involves 
thinking about the work of patients, carers and researchers together, 
crossing laboratory, corridor and clinical spaces and moving between 
physical and virtual worlds where patients and their allies form 
networks and agendas. This process of ‘moving across’ settings and 
subjects is not a research technique that is readily accommodated 
by disciplinary or institutional traditions, especially ethical review 
or risk management, but it is vital to gathering a nuanced understand-
ing of how personalised medicine operates at a range of levels, and, 
crucially, changes over time for individuals and collectives. We hope 
to have captured this despite the limitations of our work, and to 
advocate for a bolder form of interdisciplinary, ethnographic inquiry 
that co-researches with practitioners and patients to explore these 
new biomedical territories. These collaborative ways of working 
are vital to understanding and seeking to improve the benefits 
personalised medicine might bring to patients and practitioners alike.
Fifth, and finally, this study of genomics is part of a suite of social 
scientific and medical humanities research into innovative health 
technologies that have seen significant investment and interest from 
scientific institutions and policy actors. We have benefited from this 
interest and we are grateful for this support. But our study of genomics 
has, at times, felt like chasing a rainbow, as we switch between 
reading scientific and policy texts to the daily realities of the clinic, 
the laboratory or life with cancer. Researching with and caring for 
cancer patients, as well as living as best one can with cancer, certainly 
encompasses technological forms of personalisation and precision, 
but also involves navigating organisational and environmental 
infrastructures and barriers to care and science, work which can be 
relentless and at times overwhelming. We fail to capture this when 
we maintain a blinkered focus on the small numbers of patients – the 
unicorns, as one of the clinical trials assistants in our study described 
them – who benefit hugely from genomic personalisation. Even 
when we manage to capture the complexities of being part of genomic 
research or being on targeted treatment, we risk erasing the experi-
ences of patients and practitioners for whom these new technologies 
are not available, are maybe largely irrelevant or are just one part 
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of a wider picture of research and care. Researching genomics and 
other forms of personalised medicine needs to attend to all of these 
forms of non-participation to fully capture what these technologies 
mean for patients, practitioners and communities.
Book outline
Personalised medicine for cancer has many technologies, research 
initiatives and forms of care, including those in current practice, 
those in development and those anticipated. It has a variety of 
different meanings, interpretations and antecedents. In this book we 
will focus on a range of case studies of genomics and cancer that 
give insights into the main approaches and agendas in personalised 
medicine. Throughout these case studies we explore the different 
agendas, experiences and work involved in making the test, treatment 
or research trial/study work, and what kinds of value are derived 
in the process. We attend to the way responsibilities are distributed 
as futures are envisaged and enacted, how work is recognised and 
rewarded, what kinds of voices or experiences are discounted or 
absent from view, and how particular kinds of value are generated 
in the process. Here we add a further double P to our study of the 
P4 medicine agenda of which genomic medicine for cancer forms a 
part – practices of promise – alongside prediction, personalisation, 
prevention and participation. Throughout we highlight the constructed 
and contingent nature of these transformative agendas while also 
drawing attention to and at times querying their normative attributes.
Chapter 1 sets the scene for these case studies, drawing on 
STS and related literatures to trace the development of molecular 
understandings of cancer, tests and treatments and their place in 
the cancer clinic. The chapter covers the evolution of clinical trials 
and biobank research, including the rise of adaptive, basket and 
umbrella trials. We also explore the development of new molecular 
taxonomies of cancer and the implications of this fragmentation for 
research and treatment. The drive for personalisation is associated 
with new understandings of cancer as evolutionary and adaptive, 
and we explore how professionals make sense of this dynamism 
when developing treatment and understanding its effects, expressing 
both optimism and caution about their impact and potential. We 
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consider the new technologies and infrastructures that genomic 
medicine in cancer involves, particularly in relation to tissue, data 
and eligibility, as well as new professional arrangements, including 
multidisciplinary team working, national and international consortia 
and public–private collaborations. We explore expert disputes, for 
example about the effectiveness and value of new genomic approaches, 
particularly in relation to the development of flexible or adaptive 
trials. Throughout we reflect on what these developments mean for 
making personalised cancer medicine work in practice, key themes 
in the chapters to follow.
The next three chapters form a set; they look across a range of 
tests, treatments and research agendas in personalised cancer medicine 
in NHS patient care at the time of our study. We explore personalised 
medicine as healthcare practice and as clinical research, beginning, 
in Chapter 2, with a test that is now part of standard care, moving 
on to consider another test that was being utilised in a small feasibility 
study in Chapter 3, and then to a much larger national trial of 
targeted treatments discussed in Chapter 4.
Chapter 2 explores the promise of prediction and prevention of 
recurrence in personalised medicine for some kinds of breast cancer 
through the case of a genomic technique already widely adopted 
within the UK NHS: gene-expression profiling. Although breast 
cancer has seen rapid advances in diagnosis and treatment, and is 
often cited as one of the highest-profile cancers supported by well-
resourced research initiatives, it remains the most common cancer 
in the UK and represents 7 per cent of all cancer deaths.6 We consider 
a genomic test, Oncotype DX, which seeks to identify among early 
breast cancer patients those who would or would not benefit from 
chemotherapy to prevent future recurrence. The aim here is to limit 
exposure to chemotherapy, which can be toxic and debilitating. The 
test was made valuable to the health service, practitioners and patients 
as a means of prediction and prevention, including via practitioners’ 
and patients’ contributions to processes of regulatory and clinical 
decision making surrounding the test. Considering how the test was 
envisaged as a benefit to the NHS and to patients in policy, practitioner 
and patient accounts of their experiences of decision making regarding 
chemotherapy, we explore how it fitted in with already complex 
cancer experiences and hopes for a cancer-free future. We look at 
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how the narrative that the test offers reassurance and prediction 
came to dominate policy, but also consider situations where prediction 
and prevention were more contingent and provisional, particularly 
in the context of clinical encounters.
Chapter 3 explores another technique that offers personalised 
predictions of responses to treatments for cancer based on molecular 
profiling, this time for later stage gynaecological cancer patients 
seeking to prolong foreshortened futures in a non-curative context. 
Gynaecological cancers encompass cancer of the womb, ovaries, 
cervix, vagina and vulva and mainly affect post-menopausal women. 
Awareness of these cancers is low compared with other cancers such 
as breast cancer (in women); diagnosis and treatments and a range 
of campaigns and research agendas have been developed to address 
this. We consider a commercial test developed by a company for 
which we have adopted the pseudonym Virtue, not yet in routine 
use, that was embedded in a feasibility study in one hospital. We 
looked at how the feasibility study was part of building a network 
of collaborations and evidence to extend molecular tumour profiling 
in gynaecological and other cancers, and how expectations of precision 
and actionability were fashioned yet not always realised in practice; 
we focus in particular on the kinds of work this involved for 
practitioners and patients in the process.
In Chapter 4 we explore another route by which advanced cancer 
patients are offered the promise of tailored treatments that may 
prolong their lives, focusing on an adaptive multi-centre trial for 
lung cancer that aims to optimise treatments through a process of 
ongoing adaptation. Lung cancer has a lower public profile than 
some other cancers and it remains highly stigmatised because of its 
associations with smoking and higher prevalence among disadvantaged 
socio-economic groups. Concerted efforts are underway to enhance 
understanding of the disease and to develop new treatments. We 
show how the promise of the trial and targeted approaches offered 
a glimmer of hope for patients and practitioners coping with a bleak 
prognosis, exploring how the trial, treatments and patient and 
institutional futures were optimised in these very challenging cir-
cumstances (Montgomery 2017b). We look at how disappointments, 
failures and anxieties were navigated by patients and practitioners 
through containing scepticism backstage, calibrating expectations, 
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including lowering (personal) expectations of extended futures 
(Gardner et al. 2015), and cultivating expectations that other patients 
will benefit in the future instead.
The next two chapters explore personalised medicine approaches 
that are more novel and to some extent remote from standard NHS 
care, but nevertheless rooted in the institutional, political and 
economic dynamics of UK healthcare. Chapter 5 looks at a research 
study of great importance to the national project of building the 
bioeconomy, where patients involved in cancer treatment are being 
recruited, but where results are unlikely to impact directly on their 
care. Chapter 6 looks beyond the NHS to people who are not able 
to get treatments that they want as part of standard care because 
of the regulatory and approvals process, and so are involved in 
raising funds or self-funding these treatments privately. These kinds 
of personalised medicine are therefore more innovative and speculative 
than the cases discussed in the previous three chapters, and as such 
they involve a range of pioneers and vanguards. Both chapters are 
set within the context of considerable inequalities in access to care 
and research and in the burden of cancer across different socio-
economic groups (and indeed areas) in the UK, despite the public 
provision of a national health service which is free at the point of 
use. The ways the technologies are developing and are made available 
are shaped by the context of both austerity and marketisation of 
the NHS.
Chapter 5 is about large-scale national studies, recruiting patients 
with a range of cancers to collect extensive molecular information 
about cancer and ultimately inform routine patient care via precision 
medicine, focusing on Genomics England’s 100,000 Genomes Project. 
After discussing the rise of these mass-participation initiatives and their 
strong national imaginaries of economic development and cutting-edge 
healthcare, we explore how practitioners, patients and families made 
sense of their participation, and how this related to their investment 
in particular institutions and futures. We explore the participatory 
logic of these initiatives, and the ways in which informed consent 
processes and genomic literacy agendas were developed and enacted 
to increase participation. We contrast efforts to improve genomic 
literacy and informed consent by clearly demarcating personal benefits 
in terms of improved care from the research dividend to the NHS 
with blurred boundaries in practice. Patients and family members 
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were seeking care through participation and reworking efforts to 
improve their understanding to establish their worth as a patient 
and ensure optimal, personalised care into the future. We explore 
how this was managed by professionals to meet the aims of the 
programme despite their reservations about its value and implications.
While many cancer patients experience molecular diagnostics and 
targeted therapies as part of standard treatment or through clinical 
trials provided free-of-charge within the NHS, others turn to private 
providers to craft their own care pathways, utilising private health 
insurance, spending savings, taking out loans or raising money via 
crowdfunding online. In Chapter 6, we explore how practitioners, 
patients and their relatives seek to tailor their care and treatment 
pathways via these kinds of engagement with private healthcare. 
We examine the ambivalence about access to expensive experimental 
treatments as part of NHS or private care, and draw associations 
between optimisation, actionability and adaptability via personalised 
diagnosis and therapies and patient entrepreneurship and the intensi-
fied responsibilities for health and healthcare therein. Through this 
exploration we situate personalisation in relation to transformations 
in citizenship and consumption via social media platforms, and 
argue that this brings another layer of care, biosociality and identity 
work for patients and their relatives as they navigate the hopes and 
social obligations of personalised cancer therapies.
The final two chapters range across the material in the earlier 
chapters and bring in additional reflections about what is missing 
from the focus on personalisation, prediction and especially participa-
tion across our research, and in the wider public and personal 
narratives about personalised medicine we have been able to docu-
ment. Chapter 7 considers non-participation and exclusions as well 
as reservation, consternation and rejections around genomic medicine 
in our research and in the public sphere more generally. We investigate 
the particular social and cultural contexts in which disengagement 
and resistance are generated. Exploring negative views and experiences 
or simply a lack of response to genomic medicine, we consider when 
these kinds of personalised medicine are ‘not relevant to us’ and 
why some people just do not have the capacity or resources to 
engage with them. Rejecting or refusing opportunities to engage 
with genomic medicine also results from the awareness of contested 
priorities such as health equality or preventive healthcare as well 
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as a commitment to other forms of care. Not every patient can or 
wants to craft their own treatment pathway, or looks to the future 
with a sense of agency and control, and we reflect on what it means 
to opt out, be excluded or feel left behind by these kinds of research 
and care. We also discuss the ways in which different agencies and 
actors strive to tackle disengagement by reaching out to different 
communities to appeal to their sense of responsibility towards 
contributing to the prospects of better care for individuals and the 
community now and in the future. We argue that these practices 
present an important counterpoint to the dominant, inclusive vision 
of P4 medicine, particularly with regard to personalisation and 
participation.
In the Conclusion we draw together some broad conclusions 
from our case studies, reflecting on how future-crafting operates 
across the different groups, technologies, experiences, accounts and 
settings that we have explored and the kinds of work and value 
involved therein. We consider what rethinking and revaluing the 
kinds of work and futures we have encountered would mean for 
future research and practice.
Notes
1 Award number 104831/z/14/2 (2015–20). Ethics approval NHS REC 1 
and 2 and AREA Ethics Committee University of Leeds and University 
of Edinburgh Usher Research Ethics Group.
2 We have anonymised interview and observational data, using pseudonyms 
where we draw extensively on quotes and fieldnotes involving participants, 
and general designations when we use quotes or fieldnotes illustratively 
(e.g. ‘patient’ or ‘oncologist’).
3 www.cancerresearchUK.org/health-professional/cancer-statistics-for-the-UK 
(accessed 22 October 2019).
4 In England cancers with the lowest five-year survival estimates are meso-
thelioma (6.6%), pancreatic cancer (6.9%) and brain cancer (11.5%). 
Testicular cancer (96.8%), melonoma of skin (91.7%) and thyroid cancer 
(88.5%) have the highest five-year survival estimates (Nuffield Trust 
five-year cancer survival rates for adults in England between 2011 and 
2015, followed up to 2016). Breast cancer is the most common cancer in 
women worldwide. Survival has improved due to advances in treatment, 
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better screening programmes and awareness. Five-year survival rates for 
breast cancer in UK have improved, reaching 85.6% in 2010–14.
5 The UK has good screening arrangements but when compared to 
other similarly wealthy countries (e.g. Japan, Australia) (see www. 
nuffieldtrust.org.UK/resource/cancer-survival-rates (accessed 2 October 
2019)), Cancer Research UK estimates that more than 1 in 10 NHS 
diagnostic posts are unfilled and thousands more NHS staff will be needed 
in the future (see www.cancerresearchUK.org/get-involved/campaign-for-us/
shoulder-to-shoulder#Shoulder_to_shoulder_across_the_UK (accessed 2 
October 2019)).
6 www.cancerresearchUK.org/health-professional/cancer-statistics/statistics-
by-cancer-type/breast-cancer#heading-Two (accessed 28 October 2019).
1
Personalising cancer treatment and 
diagnosis through genomic medicine
In this chapter, we explore how the promise and the work of per-
sonalised cancer medicine has evolved as genomic medicine has 
advanced. We trace some of the forms of value this has generated 
for patients and practitioners, industry and economies, and set the 
scene for our wider exploration of how this kind of future-crafting 
is reshaping the roles and responsibilities of cancer patients and 
practitioners. Drawing on a range of social scientific literatures and 
studies on genomic medicine for cancer, together with data from 
our own case studies, we discuss how patients and their families 
are enrolled in cancer-related genomic medicine, not just as end-users, 
but as co-producers of genomic knowledge and technologies. We 
consider how this, in turn, enacts personal and collective futures 
where cancer, if not cured, will be held at bay by molecular monitoring 
and tailored treatments.
Throughout we try to shine a light on how patients as service 
users, research participants, representatives, advocates, campaigners 
and supporters of fellow patients as well as their carers, families 
and friends enact, query and transform promissory visions and 
agendas for personalised, predictive and preventative cancer medicine 
through different kinds of participation (and non-participation). We 
trace how patients and their families engage with personalised genomic 
medicine for cancer through various kinds of clinical and other 
encounters and partnerships. We explore co-production and efforts 
to ‘empower patients, researchers and providers to work together 
toward development of individualised care’ in the words of the 
mission statement of the US NIH Precision Medicine initiative,1 and 
trace the kinds of participation involved in ‘participatory medicine’ 
(Hood and Auffray 2013). As Prainsack (2017) notes, the emphasis 
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is on patients driving these new agendas, inviting them to generate 
data and push the boundaries of research and care. Drawing on 
Adams et al.’s discussion of anticipation and futures, it appears that 
personalised medicine ‘mobilizes everything and everyone’, aiming 
for certainty but working in a context of the ‘ever changing nature 
of truth’ (2009: 256, 246).
One key area of consideration is patients’ involvement in novel 
kinds of adaptive clinical trials that create moral, epistemic and 
commercial value through the continual negotiation of best possible 
futures for patients as individuals and as a collective (Montgomery 
2017a; 2017b). We investigate the rise of ‘experimental patients’ in 
molecular oncology; patients who are actively involved in crafting 
treatment regimes together with healthcare professionals, including 
as research participants. We will also explore how patients, including 
potential and past patients, together with others affected by cancer 
in their families, act as advocates for personalised genomic medicine, 
particularly in relation to access to trials and costly experimental 
drugs, as part of these anticipatory regimes (Adams et al. 2009). 
Although regulatory and healthcare systems are adapting to accom-
modate these novel interventions, concerns about access as well as 
cost-effectiveness have kept the issue of cancer drugs firmly on 
political and personal agendas. What kinds of collective and individual 
actions does this bring for cancer patients and their families seeking 
access to novel therapies or diagnostics? How does this perform 
hope and anticipation about the future of personalised medicine? 
What kind of value does this produce and for whom?
One of the difficulties with reviewing the evolution of personalised 
genomic medicine for cancer is knowing where to start. Rooting 
the ‘origin’ of personalised medicine in the development of targeted 
therapies such as Gleevec or Herceptin foregrounds one set of tech-
nologies at the expense of other kinds of research and innovation 
and other kinds of practices and actors involved in these processes. 
The risk of a potted or so-called ‘Whig’ history of personalised 
genomic medicine for cancer is that it replicates the kinds of nar-
ratives we need to examine critically. We can think of this as the 
‘magic bullet’ discourse – where a particular drug is given pride 
of place as the new cure for disease and stories are written about 
the heroic scientists and doctors involved in its development – a 
common cultural trope that can be found across policy, professional 
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and patient accounts. To avoid replicating this, we try to offer a set 
of reflections on interlinked social and technological developments 
that form part of the story of personalised genomic medicine for 
cancer. We have ordered this into sections and tried to give a sense 
of chronology for ease of reading, but we would like to stress that 
we have not ranked these sections by importance. We adopt the same 
approach for the remainder of the book which looks more closely 
at a series of case studies of personalised genomic medicine for 
cancer.
We have also tried to exercise caution around claims to novelty. 
Although we can see the transformative nature of current initiatives 
that are driving new practices, collaborations and partnerships, we 
must remember that personalised medicine is not entirely new. Clinical 
practice has always made adjustments, for example to dosages based 
on the individual characteristics of patients: one size has never fitted 
all, even with much evidence-based medicine being driven by standard 
protocols (Longo 2013). So we must take care to appreciate per-
sonalised medicine as a ‘rhetorical entity’ (Van Lente and Rip 1998), 
used by actors from industry, government, regulation, academia, 
patient advocacy and clinical practice ‘to not only describe a future 
state but to bring it into being’ (Tutton 2012: 1721). Approaching 
innovation as a series of incremental shifts and reassemblages of 
genomic and other data, together with wider agendas of personalisa-
tion and participation, we need to attend to ideas of patient centred-
ness, shared decision making, patient involvement and empowerment 
(Mead and Bower 2000; Greenhalgh 2009), as well as the integration 
of genomic information with an increasingly wide range of clinical, 
social and personal information.
Targeted treatments: a start to the story of personalised 
genomic medicine for cancer
Cancer came to be understood as a genetic disease in the 1980s 
when immunochemistry researchers began to coalesce around the 
so-called oncogene paradigm, approaching cancer as a subcellular 
disease to be treated by interfering with biochemical processes within, 
between and on cell surfaces. Focusing on the role of somatic, as 
opposed to germline (inherited), genetic mutations in stimulating 
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the excessive growth and division of cells which formed tumours, 
researchers identified candidate mutations and studied the expression 
of proteins in patients to identify subgroups of patients with these 
particular genetic variations. Attention turned to blocking the action 
of these genes through drugs – monoclonal antibodies. These act 
on the genetic signalling pathway to inhibit the production of specific 
proteins that encourage tumour growth. What was once understood 
as one type of cancer became subdivided into several different subtypes 
(Yeo and Guan 2017). Through these developments, biomarker 
testing and treatment became entwined in so-called ‘theragnostics’, 
shifting the process of regulatory approval to accommodate the 
integration of testing technologies into treatment decisions and 
provisions (Fujimura 1996; Morange 1997; van Helvoort 1999; 
Keating and Cambrosio 2011).
As efforts intensified to identify more and more mutations with 
potentially actionable (druggable) pathways and to test this through 
ever more complex clinical trials, patients’ participation in research 
grew. Of course, there is a long track record of patients being part 
of experiments in cancer medicine, but we see a shift in the scale 
and promise of experimentation developing over this period, as 
many more kinds of subtypes and targeted therapies emerged to be 
tried in combination (DeVita and Chu 2008; Keating and Cambrosio 
2011; Jain 2013). Research became almost routinised in contemporary 
cancer care.
The molecular turn in cancer has deep and complex roots, but 
there are two paradigmatic cases that are frequently invoked as part 
of its history: Gleevec and Herceptin. Through telling and retelling 
these stories, the possibilities of personalised genomic medicine for 
cancer are reproduced, generating support for medical research and 
more permissive regulation to facilitate more of these kinds of ‘wins’. 
Patients form an important part of these accounts, collectively and 
individually, as we now go on to explore.
Although Herceptin is the best-known case of early targeted 
therapies for cancer, scientists and social scientists have argued that 
it is actually imatinib (Gleevec), a small molecule that interferes 
with molecular pathways in chronic myeloid leukemia (CML), that 
is closer to a paradigm case. As Keating and Cambrosio have docu-
mented in the in-depth analysis in their book Cancer on Trial, Gleevec, 
as one of the early targeted therapies granted approval, ushered in 
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a ‘new era of therapeutic agents produced using the tools of molecular 
biology’ (2011: 303). This development was considered revolutionary: 
Dan Vasella, the CEO of Novartis, the manufacturers, called his 
co-authored book about the drug Magic cancer bullet: how a tiny 
orange pill is rewriting medical history (Vasella and Slater 2003).
Yet, as Keating and Cambrosio (2011) demonstrate, the transforma-
tive nature of Gleevec was not just a matter of molecular pathways, 
but of research and regulatory processes. The trial phases proceeded 
rapidly and involved higher numbers of patients than usual because 
of a demand for participation in the context of the hope of a cure. 
Participants on Phase 1 trials had typically failed standard therapy 
but were nevertheless considered healthy enough to withstand the 
trial. The results were described as remarkable, with the vast majority 
of patients who received doses greater than 300mg going into complete 
remission. But there was a catch: remission was linked to continued 
use, thereby transforming CML into a more manageable, longer-term 
condition.
Phase 2 trials followed from the initial success at Phase 1 and 
involved high numbers of participants, achieved in part through 
developing an international network of trial sites and the continued 
involvement of Novartis in trial audit and review. Patients, too, had 
a role in ensuring that such research took place via the involvement 
of patient groups and activists. Keating and Cambrosio (2011) note 
that a patient petition supporting the trial was launched on the 
internet by a Montreal CML patient, gathering 3,000 signatures 
within a matter of weeks. Novartis reported receiving many letters 
and phone calls from patients, and their relatives, seeking access to 
the drug.
Subsequent Gleevec trials also saw the same kind of active patient-
hood, including what Keating and Cambrosio call ‘epistemological 
activism’ (2011: 340). They give the example of patients with rare 
gastrointestinal tumours (GIST) who organised a patient group called 
the Life Raft Group. Because some GIST patients had been found 
to be responsive to Gleevec, this kind of public patienthood focused 
on sharing information on trials and data on side-effects and per-
formance. As personalised genomic medicine for cancer developed, 
these new kinds of patient collectives gained an increasing foothold 
in institutional practices such as data monitoring committees, as 
well as co-hosting meetings of various cancer stakeholders, in what 
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authors such as Callon and Rabeharisoa (2008) have described as 
hybrid research collectives.
Gleevec was approved rapidly by the US Food and Drug Admin-
istration (FDA), less than four years after the first human dose. Its 
success and promise caused regulatory processes to speed up to 
accommodate similar innovations. Alongside these novel regulatory, 
partnership and trial arrangements, Gleevec also introduced a new 
pricing structure which saw a departure from so-called blockbuster 
drugs to the provision of stratified, higher-priced medicines for smaller 
groups of patients, so-called ‘niche-busters’ (Keating and Cambrosio 
2011: 319).
As the GIST example illustrates, the approach taken with Gleevec 
is also being used for other cancers with similar molecular anomalies 
(Rajan 2006; Madhu 2017). Keating and Cambrosio (2011) note 
that these processes of redefinition were achieved in part via a 
proliferation of trials. By 2002 Gleevec had been part of over forty 
trials for a range of cancers sharing common molecular abnormalities. 
Gleevec also spawned a range of drug innovations. Given that a 
small number of patients can develop resistance to the drug, and 
changing the dose does not always help to manage this, this required 
patients to switch to other therapies. This introduces a ‘proliferation 
of targeted agents aimed at similar pathways or receptors [which] 
may transform the oncology drug market’ (Keating and Cambrosio 
2011: 327).
Gleevec is now an established part of treatment for CML and 
other cancers such as gastrointestinal tumours. Patients and practition-
ers have come to experience some of these cancers as chronic and 
treatable because of these molecular actors, further motivating the 
promissory discourses of personalisation and cure. One of our 
interviewees, Andrew, who had acute myeloid leukemia, described 
his leukemia as a group of terrorists being fought by the British 
Army, with Mylotarg (a targeted therapy) described as a ‘sniper’, 
able to target abnormal cells with greater precision: ‘It’s actually 
very encouraging, it’s very personalised and you think, this isn’t just 
generic, this is to give me as an individual person the best chance 
of survival here.’ However, other patients, who have been on targeted 
treatments long term, were less invested in the promise of personalisa-
tion as their treatment regimes, and indeed their cancer, became 
unremarkable in their everyday lives. Although one person who was 
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on Gleevec long term considered himself ‘lucky to have had that 
type of cancer’, and to be treated with targeted therapy to which 
he ‘responded very well’, he also described feeling like a ‘fraud’ 
because of the treatment’s success: ‘When people say, “how’s your 
leukemia?” it’s almost like I’d forgotten I’d got it.’ Others with 
blood cancers we interviewed were more anxious around the per-
sonalisation of treatment, expressing concern about resources. For 
example, one of our interviewees, Bianca, had been diagnosed with 
AML eighteen months prior to her interview, and had been referred 
urgently for treatment due to the severity of her condition. She 
described having a ‘weird’ leukemia profile, showing both a ‘good’ 
and ‘bad profile’ in terms of her chances of staying in remission 
following chemotherapy. This provoked uncertainty about her 
treatment plan, with the eventual decision that she undergo several 
rounds of chemotherapy to ‘get her into remission’, followed by a 
stem cell transplant. Bianca elaborated her mixed feelings about 
personalised treatment:
I suppose in a way it gives you confidence that the treatment you’re 
getting is as personal and appropriate for you … but … it’s also a 
little bit kind of worrying, because you think … if all kinds of leukaemia 
were exactly the same would … the ability to deal with leukaemia 
and have a good prognosis be higher if they were only, if there was 
only one brand of leukemia and you could focus everything on that, 
then would the outcomes improve, or because all these different brands 
exist and you’ve got to spend time dealing with all these different 
brands, does that mean eventual outcomes are going to be lower 
because resources are being spread more widely?
As this excerpt demonstrates, personalised genomic medicine sparks 
a range of responses from patients, from positivity to anxieties about 
the meanings and implications of personalisation for one’s own 
treatment, for other patients with different profiles and about access 
to treatment more generally. Making sense of these various options 
and their implications involves patients and their families in emotional 
labour, working with anxiety, as well as a sense of good fortune 
and gratitude.
Practitioners in this field also spoke of the complex negotia-
tion of the different kinds of treatment and research opportunities 
that characterised their work with patients, an ongoing process of 
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optimisation of treatment for patients as individuals and of developing 
yet more personalised regimens for future patients as part of a wider 
bioeconomy. This involved moving between different registers of 
anticipation and promise, as captured in the excerpt from a senior 
haematologist below:
there’s a drug we use here called Ibrutinib which is a so called BTK 
inhibitor and that blocks or counteracts the effect of a particular 
mutation in leukemia cells. And in some people that works brilliantly. 
But you can have a mutation in another gene called CARD11 which 
quite commonly occurs in association with it and it just doesn’t work 
at all … The very first precision medicine was a type of leukemia, a 
drug called imatinib [Gleevec], and that worked fantastically well. 
And when I started off everybody who acquired myeloid leukemia 
died within about three or four years, and now virtually nobody dies 
of chronic myeloid leukemia. Now imatinib cost thirty thousand a 
year per patient for life, and we’re going from – there’s twenty-five 
new patients in the region a year but there’s now something like five 
hundred people on active treatment (laughs) … And that’s just for one 
very rare cancer … So there’s a big economic argument here for only 
giving these drugs to people where it will work. But obviously the 
pharma companies would rather it was given to everybody (laughs). 
So it opens up a whole lot of areas like that as well. But at the clinical 
level, a lot of clinicians and patients would rather not know this, they 
would rather have the drug and see if it works rather than have an 
upfront prediction.
Here we see an account of a future of tailored medicine optimised 
to treat only patients who will benefit sitting alongside other accounts 
of tensions between providers and pharma and of patients and clini-
cians wanting to maintain uncertainty. This preserves a sense that 
their chances of success are being optimised – key themes that we 
will explore further throughout the book. At the same time, practition-
ers were also concerned about the proliferation of cancer subtypes 
and research activity in the blood cancer area, giving them a sense 
that they lacked specialisation and the capacity to deliver personalisa-
tion in a complex, ever-changing field, another key tension in our 
research. For example, two haematology nurses we talked with 
noted that the vast range of conditions meant that they are learning 
all the time and cannot become ‘too specialised’ when compared 
with colleagues in breast cancer care. Negotiating professional status 
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and expertise was an integral part of delivering these new opportuni-
ties and future possibilities for patients.
Patients are part of the Gleevec story as research subjects, advocates 
and beneficiaries, but as our own research demonstrates, their 
experiences of personalised treatments are more wide ranging and 
complex than the optimistic stories of magic bullets or even episte-
mological activism might suggest. We can identify similar patterns 
with Herceptin, arguably an even better-known exemplar of trans-
formative personalisation, as we now go on to discuss.
Herceptin’s story is a key part of the success narrative of person-
alised cancer medicine, eclipsing Gleevec in the public imaginary, not 
least because of the gender health politics surrounding breast cancer 
research and care (see Hedgecoe 2004; Abelson and Collins 2009; 
Keating and Cambrosio 2011). It was developed after scientists at the 
National Cancer Institute in the US found that a mutation in HER2 
(Human Epidermal Growth Factor Receptor 2) could cause normal 
cells to grow uncontrollably and that the gene’s protein was over-
expressed in around 30 per cent of breast cancers. It was subsequently 
shown that an antibody specific to HER2 could slow the growth of 
breast cancer cells in the laboratory. University scientists went on 
to collaborate with Genetech, a company that is widely regarded as 
the pioneer of biotechnology, to develop a HER2-specific antibody 
called Trastuzumab (Herceptin). In the 1990s, trials of Herceptin, in 
combination with chemotherapy for patients with metastatic cancers, 
showed positive outcomes, increasing the median survival rate for 
patients on a combination of Herceptin and chemotherapy by five 
months as compared with patients on chemotherapy alone. It was 
first licensed by the FDA in 1998, for use in patients with metastatic 
breast cancer, and subsequently approved in the UK in 2002. Use 
was extended quite quickly, from a treatment for metastatic breast 
cancer (on its own or in combination with a specific chemotherapy, 
paclitaxel) to a treatment for early-stage breast cancer. Roche, which 
acquired a major stake in Genetech in 1990, successfully sought to 
extend Herceptin’s licence to include early-stage breast cancers, and 
in 2006 the FDA licensed the drug for use with a combination of 
chemotherapies (doxorubicin, cyclophosphamide and paclitaxel) as 
an adjuvant treatment for patients with early-stage (localised) HER2 
positive breast cancer after surgery. Herceptin became Roche’s fifth 
highest-selling drug by 2002 (Hedgecoe 2004), worth £460 million, 
 Treatment and diagnosis through genomic medicine 31
and led to a 20 per cent increase in Genetech profits. Herceptin 
also heralded the ‘package’ approach to test/treatment that persists 
today. Roche funded HER2 tests before the drug was approved, thus 
ensuring that it became embedded in oncology practice, preparing 
a pathway for the drug once it was approved.
As with Gleevec, patients feature in the story of Herceptin as 
advocates, especially as lobbyists for extending the licence of this 
treatment to early-stage breast cancer via a concerted media campaign. 
There is a strong history of advocacy among breast cancer patients, 
including grassroots movements such as Breast Cancer Action in 
San Francisco Bay in the US (Klawiter 2004) through to large-scale 
commercially funded breast cancer awareness campaigns (Sulik 2014). 
This kind of advocacy presaged a more institutionalised role for 
patient involvement as well as contributing to the high profiles of 
breast cancer and breast cancer experience that have shaped public 
discourse of cancer, including around survivorship, access to drugs 
and prevention and early detection.
Abraham (2009) highlights the alliances with patients and patient 
organisations that were involved in the promissory agendas around 
Herceptin, noting that Roche reputedly engaged public relations 
companies to encourage women to campaign for access to the drug, 
including in the NHS in the UK, in so doing constituting its own 
version of engaged and optimistic patienthood. A 2006 BBC report 
by Sanchia Berg2 described the experience of the late Professor Lisa 
Jardine, professor of history, public intellectual and former chair of 
the Human Fertilisation and Embryology Authority, who was 
contacted on behalf of Roche to assist with her accessing Herceptin 
prior to NICE approval. Although Jardine was reportedly alarmed 
by this PR exercise and did not enter into an arrangement with 
Roche, the report noted a number of cases covered in the national 
media of women who had early-stage breast cancer and whose 
Primary Care Trust (PCT) had refused funding for Herceptin, with 
the emphasis on trying to ‘shame’ trusts into funding the treatment. 
Herceptin, and the associated test for HER2, was subsequently 
approved by NICE for early-stage breast cancer, but questions were 
asked about the involvement of Roche in these media cases and 
about the speed of the decision, which appeared to be rushed accord-
ing to some commentators in the Berg report, including Dr Richard 
Horton, the editor of The Lancet.
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Supportive press coverage featuring patient testimony is a feature 
of these campaigns for extended access. In a comparative analysis 
of UK and Canadian coverage of Herceptin, Abelson and Collins 
(2009) found that reporters presented individualistic perspectives 
on access to Herceptin as highly beneficial. This is echoed in a paper 
on the New Zealand context by Gabe et al., in which they describe 
coverage as being dominated by ‘personal stories drawing on the 
news frame of “desperate, sick women in double jeopardy because 
of callous government/incompetent bureaucracy”’ (Gabe et al. 2012: 
2358, quoting MacKenzie et al. 2008: 305). As Gabe et al. (2012) 
note, press coverage is shaped by press releases from companies 
and, in the case of Herceptin, Roche used this route effectively as 
part of its campaign for approvals. For example, a Roche press 
release covering the interim results of trials of Herceptin in early-stage 
breast cancers, apparently timed to coincide with the American 
Society for Clinical Oncology meeting in June 2005, noted that 
‘women with early stage HER-2 positive breast cancer reduced their 
risk of their cancer returning by 46 percent when using the targeted 
therapy Herceptin’ (Gabe et al. 2012: 2355, quoting Roche press 
release).3 Patient narratives, while providing a window on to the 
experience of cancer and all its hardships, can also be deployed 
strategically by pharma to garner support and demand. Indeed, 
individual cases and stories fit well with the individualising paradigm 
of personalised, precision medicine, providing authenticity through 
personal experience and individual successes and efforts. But patient 
groups can become assimilated in other kinds of campaigns too. 
Gabe et al. discuss the example of the Breast Cancer Advocacy 
Association in New Zealand, which lobbied regulators and govern-
ment to improve access, including supporting a 2008 court case by 
a group of ‘Herceptin Heroes’ which resulted in the regulator having 
to conduct further consultation to formulate policy. Through these 
practices the side-effects of drugs such as Herceptin, which include, 
among others, cardiac toxicity, are downplayed in favour of its 
promise of longer lives for patients.
As with Gleevec, new multinational consortia were developed to 
establish viable trials for the drug. HERA (HERceptin Adjuvant) 
was initially run by the not-for-profit Breast International Group, 
established in 1996 and supported by Roche. As Keating and 
Cambrosio (2011) discuss, this ‘consortia of consortia’ encompassed 
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numerous groups, hospitals, laboratories and centres, together with 
a patient organization, Europa Donna, which were represented on 
the trial committee. The complex arrangements for data governance 
and trial management, designed to maintain ‘scientific independence’ 
from industry, led to tensions with Roche, and careful configuration 
of data monitoring committees was required to maintain their col-
laboration (Keating and Cambrosio 2011: 329). The ‘molecular 
turn’ challenged a trial methodology already under strain as patients 
and clinicians sought out novel treatments and changed assessment 
criteria to demonstrate therapeutic benefit. Later trials designed to 
assess the efficacy of Herceptin also ran into difficulty as clinicians 
were reluctant to assign patients to the option when Herceptin was 
discontinued.
It is well established that clinicians and scientists worked closely 
with the manufacturer of Herceptin to gain approval for the drug 
through research trials and other studies. Gabe et al. (2012; see also 
Busfield 2006; Light 2010) give an example of this kind of co-
production, which features a review of Herceptin in the clinical 
setting by breast cancer researchers from Guy’s and St Thomas’s 
Hospital, London (Miles 2001). Although the author acknowledged 
support from industry, including Roche, Gabe et al. (2012) note 
that industry support is not mentioned in other papers, including 
a supportive review of recent trials, methods of HER2 testing and 
the combination use of Herceptin.
Patienthood in media and corporate narratives of Herceptin is 
framed in familiar registers of hope and despair. But as other social 
research demonstrates, the take-up of Herceptin, and patients’ and 
practitioners’ roles therein, was more complex and their attitudes 
were more ambivalent than these versions of patienthood suggest. 
Even though HER2 was one of only several targetable mutations 
where there was consensus about its predictive and prognostic value 
(it is now a routine test for invasive breast cancer in the UK), profes-
sionals were wary about the gap between the messy realities of 
treatment and patient expectations as it was introduced into practice 
(Tutton and Jamie 2013). Hedgecoe’s (2004; 2005) detailed work 
on the development of pharmacogenomics in a UK breast cancer 
clinic in the 2000s explores these themes. Hedgecoe observed how 
metastatic breast cancer patients could be tested for HER2, and 
Herceptin was offered to HER2+ patients (provided free by Roche), 
34 Personalised cancer medicine
but he notes that clinicians did not rush to test but sought to protect 
patients from information overload. In the words of one of Hedgecoe’s 
interviewees, it is only ‘At the point at which you can do something 
about it, then it [HER2 testing] becomes more relevant’ (Hedgecoe 
2005: 1204). Hedgecoe draws attention to other kinds of clinician 
ambivalence around HER2 testing in the UK at this time, including 
in comparison with practice elsewhere, notably the US, where, in 
2001, the American Society of Cancer Oncology recommended that 
HER2 testing be available to every primary breast cancer patient. 
He links UK clinicians’ reticence to view HER2 as ‘special’ to a 
general culture of keeping expenses down as compared to other 
healthcare systems. Clinicians’ concerns about managing patients’ 
expectations and dealing with disappointments (when HER2 over-
expression was not detected and Herceptin was not prescribed) 
increased their ambivalence about the test.
Patients also experience ambivalence about this kind of testing, 
even now that it is well established. Although many of the social 
scientific and popular narratives of Herceptin have focused on the 
activism for access to the drug in which some patients became 
involved, this kind of patient activity is not all that being on or 
accessing Herceptin involves. A particular issue arises here regarding 
being a HER2+ subtype patient entitled to Herceptin. Breast cancer 
patients must negotiate these kinds of typologies, and the resultant 
stratification of treatment experience, with their friends and other 
people they meet, as the excerpt below from an interview with Jane, 
in her early fifties, who had had cancer at a relatively young age 
and was on maintenance medication, illustrates:
There’s sort of the public perception is … there is just breast cancer 
and I thought that, but there isn’t, there are very different types and 
it can be very individual so … that’s sometimes quite hard when other 
people ask you about it, to try to say, well, I didn’t have the same 
thing as your mum.
‘Not being the same’ can introduce anxiety, doubt and concern, 
given that it can mean not accessing particular or familiar kinds of 
treatments like others. Another person with breast cancer who we 
interviewed, Yvette, described how she was offered surgery first, 
whereas her friend, another breast cancer patient with a popular blog, 
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was receiving neoadjuvant chemotherapy before surgery (the patient 
pathway for cases of triple negative or HER2+ cancers or for those 
women with larger tumours [Derks and van de Velde 2018]). This 
made Yvette wonder ‘why am I not getting that?’; she speculated 
about whether this was because her friend was receiving private 
healthcare, telling us that she did not understand ‘how they make 
those decisions’.
When we delve deeper into experiences of Herceptin and HER2, 
we find that breast cancer patients and practitioners, like blood 
cancer patients and practitioners using targeted treatments such as 
Gleevec, have a range of experiences of personalised genomic medicine 
for cancer that include, but also go beyond, the roles of enthusiastic 
research beneficiary or advocate. Patients and practitioners are 
weaving genomic medicine into their encounters with other patients, 
relatives, tests and treatments as they navigate their future and that 
of others. This involves a complexity of values and work, as we go 
on to explore further below. Here, patienthood begins to multiply 
as experiences and representations proliferate and diverge, but it 
also converges in dominant media and corporate tropes of active, 
engaged and sometimes desperate patients.
Targeted therapies proliferate
The promise of a suite of targeted therapies to give patients and 
clinicians more options to treat cancers as they resist, mutate and 
evolve over time is a powerful feature of personalised cancer medicine. 
As a recent report from the Institute of Cancer Research on improved 
access to targeted therapies asserts:
Cancer is enormously complex, and it can adapt and evolve in response 
to changes in its environment – including drug treatment. Only through 
radical innovation will we deliver the step-change improvements we 
need in cancer treatment, by attacking cancer in new ways that allow 
us to overcome or prevent drug resistance. We need to create a wider 
variety of targeted drugs and immunotherapies and find new treatment 
combinations that can block cancer’s escape routes.4
Popular culture and everyday talk is replete with personal stories 
of struggles around access, scientific breakthroughs and big futures 
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of cancer as a chronic, treatable disease. We can trace these narra-
tives across professional, popular and policy literatures, our own 
observations and interviews, much of which hinge on the idea of 
the drug as a potent force in the ongoing battle against cancer in 
both the body and the body politic. In this cultural narrative the 
next drug is always around the corner; radical innovation becomes 
routine, as one lung cancer consultant explained in relation to news 
of a recent approval:
And quite excitingly, just in this week … one of those drugs has just 
been NICE approved, … as a follow on treatment for patients who’ve 
stopped responding to the first tablet. So when you stop responding 
to the first tablet … instead of having to go and have chemotherapy 
you can go and have another tablet which … is targeted as well. So 
that gives you hope that you might then find a third tablet and a 
fourth tablet when they stop responding to that.
Many patients are already able to access tried and tested therapies 
such as Gleevec and Herceptin, but for other patients with different 
kinds of cancer, including lung cancer patients, drugs are more 
experimental and less readily accessible. In the UK, accessing drugs 
can involve making a case for exceptional or compassionate use, 
or joining a trial. It can also involve challenges to NHS trusts, NICE 
decision making and efforts to raise funds privately. For advanced 
or metastatic patients in particular, targeted drugs which offer extra 
months of life with symptoms held at bay are highly valued. However, 
for health systems, methodologies that determine efficacy based on 
a range of factors including quality of life, balancing wider public 
benefits through effective allocation of healthcare resources, mean 
that these benefits are not always sufficient to warrant approval. 
This has led to a series of disputes around access to tailored therapies, 
for example Avastin (for ovarian and colorectal cancer) and Kadcyla 
(for breast cancer) in the UK, with some patients turning to charitable 
fundraising or private funds to access these and other drugs. These 
campaigns can have a considerable media profile, giving a sense 
that these activities are both common and necessary, intensifying a 
media discourse of the NHS as failing to provide. This has enrolled 
patients in campaigning for access alongside others affected, as well 
as relatives and other advocates, something we discuss in Chapter 
6. For example, with regard to a recent campaign for access to 
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Avastin by a cervical cancer patient who had been denied treatments 
available in England but not in Wales, ITV news quoted the patient: 
‘I feel very angry about it, it’s so unfair – this is playing with people’s 
lives. But I’m fighting it for others both in England and Wales, and 
for those who are too afraid to speak out.’ 5 Patients seeking access 
to these kinds of treatments also have to navigate personal networks 
and complex healthcare provision, including sometimes predatory 
markets, as Keir, a campaigner for better drug access for cancer and 
other patients, described:
there are certain circumstances where … crowdfunding [is for] a 
medically reputable drug … But it’s horrendous that patients are being 
forced to take that, it’s a hugely stressful undertaking for them. They’re 
trying to do crowdfunding, they’ve got neighbours who are … running 
charity events … they’ve got to … give a huge amount of themselves 
to try and thank everybody, and engage everybody to try and get 
enough money in the door, on top … managing cancer treatment … 
trying to do their day job, and continue to bring up their kids … that 
is a real … system failure.
Uncertainties, doubts and disappointments have also proliferated 
alongside these drug developments and campaigns for access. As 
practitioners in our research often attested, cancer is complex and 
ever-changing, and drugs rarely deliver the kinds of benefits seen 
with the paradigmatic cases of Herceptin or Gleevec, as this oncologist 
describes:
No, no targeted therapy has yet made otherwise incurable metastatic 
cancer curable. What they have done has meant that in the same way 
that chemotherapy can prolong survival from six months to two or 
three years in breast cancer or bowel cancer, there are now diseases 
like melanoma and renal cancer where previously chemotherapy didn’t 
have a role where now patients can live two, three, four, sometimes 
longer. But they are only seeing results akin to what we see in breast 
cancer with hormone therapy or with Herceptin.
So … they haven’t been the, the sort of paradigm shift … which 
we had hoped they would be … fifteen years ago … the way these 
drugs were sold was that they were going to take cancer and turn it 
into a chronic disease, like hypertension or like diabetes … [this] a 
huge new era hasn’t materialised. What instead we’re seeing is a new 
generation of drugs, sometimes but not always … less toxic than 
chemotherapy that, that add to the armamentarium of treatment that 
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we have, but haven’t had that effect of, of, of meaning that people 
live ten, fifteen, twenty years, whereas previously they, they would 
only have lived a few weeks or months. They now live for many 
months or a few years, rather than several months or a year.
And do you think patients understand this?
I think patients’ expectations of … cancer treatments generally are 
… are over-optimistic.
These concerns are echoed across professional and social scientific 
literatures. Social scientists such as Davis (2015) have argued that 
patients’ overestimation of the benefits and underestimation of the 
toxicity of these treatments is a systemic problem rather than a 
feature of individual patient-clinician decisions. For Davis, permissive 
regulatory environments, government promotion of bioscience markets 
as a vehicle for economic growth and national competitiveness, and 
close ties and connections between industry, oncology, government 
and patient organisations have fuelled a culture of overtreatment, 
as have scientific and media reporting and medical practice intent 
on maintaining hope in the fight against cancer. As Davis notes, 
‘Publication bias, distorted scientific reporting, promotional material, 
and stories of “miracle” drugs percolate against a background 
discourse of “science at a crossroads” and “new eras”’ (2015: 213).
We must nevertheless recognise that patients are not simply dupes 
of this promissory bioeconomy. Instead they are active participants 
in its articulation and contestation. Patients in our study were by 
no means predominantly pessimistic nor wildly optimistic but, instead, 
were often strategic and nuanced in their engagement with these 
new therapies. Even patients funding treatments privately had a 
careful analysis of why they were taking this approach. Phil, a 
patient with advanced bowel cancer who was self-funding Avastin, 
explained:
look, you know, I’m in a situation where I’ve got advanced bowel 
cancer … I can afford to do it, fortunately, so I thought … although 
it’s expensive … I’m going to … give it a whirl. … I don’t want to 
… die wondering whether … it would’ve made a difference or not.
Others told us how they had accepted not being able to access 
targeted therapies. Alison, a patient advocate in her mid-sixties who 
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had previously worked in special education, who had experienced 
pancreatic and breast cancer, described her philosophy thus:
Now my brother works for [a pharmaceutical company], he used to 
work for them in America. He says ‘we’ve got a new drug’ but we 
spoke to the surgeons here, I couldn’t do it because … it hadn’t been 
passed [by the regulator] so nobody could administer this drug, they 
had great success. [My brother] got all my test results, he said ‘right, 
you have a very rare type of pancreatic cancer … and this drug seems 
to be working’. So he speaks to the oncologist [who says], ‘No you 
can’t do it because it’s not licenced.’
So I went ‘that’s fine’ … things happen in life for reasons, ok … 
it’s part of our journey … it wasn’t for me … It’s like … if you’re 
buying a house or something and you miss out on it, it wasn’t meant 
for you, don’t worry or stress about it … What’s meant for you, will 
happen and it might be even better.
Alison told us how her family rallied around her when she experienced 
her first cancer. Her daughter, a veterinary nurse specialising in 
cancer, made time to pick her up after her appointments, while her 
husband sought out second opinions and support networks. Drawing 
on their social and cultural capital, cancer patients and their families 
navigate the stage and subtype of their cancer and access to treatments 
that might extend their future. This not only involves building from 
and troubling cancer identities of survivorship and developing novel 
campaigning tactics and alliances, but it incorporates more ordinary 
ways of living with uncertainty and hope. Through these kinds of 
activities and other reflections, patients, relatives and practitioners 
come to terms with the opportunities and setbacks of personalised 
genomic medicine for cancer, even as they might also articulate 
other, much more overt promissory discourses elsewhere. These 
themes cut across the chapters to follow and are explored in particular 
depth in Chapter 6.
Personalising prognosis, prediction and diagnosis
Effectively targeting treatments relies on molecular markers; together 
they are reconfiguring how cancers are classified (Nair et al. 2018). 
New molecular markers, disease categories and targeted treatment 
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options are part of a nexus rather than a linear process of discovery 
and intervention. This means that prognostics, prediction and diag-
nosis, always rather dynamic in the context of cancer, are becoming 
even more so, as genomic tests and assays provide ever more data 
on a patient’s risks, mutating tumour and responses to treatment. 
Diagnosis and therapy ‘bleed into each other’ as Bourret et al. (2011) 
note, transforming clinical decision making as the results of genomic 
testing rework established understandings and practices.
In addition to molecular subtypes of blood and breast cancers, 
as discussed above, there are now a range of established molecular 
markers of other cancers such as colon, lung cancer, ovarian and 
melanoma. For example, colorectal cancers can be classified according 
to five biomarkers including KRAS. Particular mutations can also 
be found in different kinds of cancers; for example, the KRAS 
mutation has been identified in colon and lung cancers, and the 
BRAF mutation has been found in colon cancer and melanoma. As 
treatments are increasingly guided by molecular profiling, not just 
the location of cancer in particular areas of the body, professionals 
have begun to discuss a new paradigm of diagnosis and classification 
based on such molecular markers, as in the excerpt below:
It is the mutation-guided therapeutics, rather than the traditional 
cancer type-dependence classification, such as that based on classical 
anatomy and histology, that has etched a new context … This concept 
has compelled a paradigm shift. Now patients with BRAF V600E 
mutations would be prescribed the same drug regimen irrespective 
of their cancer type and location, for example, acute myeloid leukemia, 
breast cancer, or melanoma. (Nussinov et al. 2019)
Cancer has traditionally been diagnosed histologically, through the 
microscope. Serum markers such as the prostate antigen test (PSA) 
were subsequently developed for monitoring those with or at risk 
of cancer. This focus on biomarkers was also brought together 
with advances in the understanding of oncogenes and tumour-
suppressor genes and genomic technologies to develop a range of 
biomarker companion tests for proteins associated with specific 
subtypes of cancer, such as HER2. The successes of Gleevec and 
Herceptin were promising, but in fact the complexities of cancer 
are such that there is rarely only one gene of central importance in 
its development, and testing moved towards looking at groups or 
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clusters of molecular biomarkers that would assist with defining 
and, crucially, predicting the course of the disease or the usefulness 
of one particular drug, not least to avoid ineffective treatment. 
Gene-expression profiling has developed to identify patterns within 
cancer tumours and this has led to the identification of subtypes 
based on these patterns for cancers such as leukemia and breast 
cancer. This has developed into a range of tests to aid treatment 
decision making, particularly for breast cancer, many of which are 
commercially available and based on proprietary algorithms. Mam-
maPrint® (Agendia, Amsterdam) was one of the early multi-gene 
panel tests to be approved by the FDA in 2007 to predict breast 
cancer relapse. Oncotype DX® (Genomic Health, Redwood City, 
CA) is also used to predict the risk of recurrence of certain kinds 
of breast cancer in order to aid treatment decisions, as we go on 
to discuss in Chapter 2. Cambrosio et al. have written about how 
these tests were developed by scientific and commercial partners in 
concert with evolving regulatory arrangements, ‘forming heterogene-
ous assemblages that seek to singularize treatments’ (Cambrosio 
et al. 2019: 2).
Novel molecular tests are particularly interesting because they 
involve rearrangements of private–public relations, pathology and 
clinical decision making around prognosis and prediction (Kohli-Laven 
et al. 2011). For example, MammaPrint and Oncotype DX were 
developed in company laboratories to which clinicians must send 
samples for analysis. Results are returned in the form of reports of 
likelihood or risk of recurrence to form part of a broader set of 
results from other non-molecular tests and other information that 
clinicians use as part of clinical decision making. The roles of 
hospital-based and regional pathology services are also reconfigured 
through the development of oncogene sequencing, both in-house 
and externally, resulting in tensions and threats to professional 
autonomy that have to be managed. This includes pre-screening to 
identify low-risk cases where proprietary testing might not be cost-
effective (Dabbs et al. 2018; Beaudevin et al. 2019). As Nelson et 
al. have argued, these genomic tests, together with the therapeutic 
regimes they invoke, are part of a new paradigm of ‘actionability’ 
in cancer which is transforming alongside trial arrangements, regula-
tory processes and healthcare, where the ‘articulation of molecular 
hypotheses and experimental therapeutics become central to patient 
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care’ (Nelson et al. 2013: 413). They note, however, that this brings 
uncertainty about how to make meanings from molecular results: 
actionability is thus an ‘experimental space’ where different approaches 
and interpretations coexist and must be resolved in the ‘knowledge 
architecture of clinical oncology’ (Nelson et al. 2013: 413).
Within this space, clinicians and patients must also engage with 
molecular results about cancer as another layer of information that 
has to be analysed, interpreted and considered in relation to other 
aspects of the patient’s disease, including lifestyle, emotional state and 
social location, and their capacity and appetite for further treatment. 
Making a genomic test valuable as part of their decision making 
includes making sense of intermediate or ‘grey areas’ and crafting 
reassurance or managing the anxieties that ensue. Patient experiences 
of tests using biomarkers (not genomic technologies) highlight some 
of the intricacies of these processes. Bell and Kazanjian’s (2011) 
research on PSA, a molecular marker which is used to monitor 
the risk of prostate cancer developing, progressing or returning, 
shows how the responsibility to be well is managed by patients and 
practitioners through engagement with these results. Although its 
effectiveness as a screening or monitoring tool is highly contested 
because of questions about its predictive value (Bickers and Aukim-
Hastie 2009), its continued use in some contexts can be explained 
by neoliberal governance whereby individuals become responsible 
for identifying and minimising their risk of disease (Petersen and 
Lupton 1997). Bell and Kazanjian (2011) show how men experienc-
ing the test had to navigate considerable anxiety and uncertainty, 
together with expectations of action from family members and 
clinicians as part of the process of being responsible. They argue 
that molecular measures intensify a sense of living with cancer even 
when results suggest lower risks, echoing the findings of Hamilton’s 
(1999) study of women’s experiences of CA-125 biomarker monitor-
ing for recurrent ovarian cancer, another contested measure that 
lacks sensitivity and specificity. Quoting from Hamilton, Bell and 
Kazanjian note:
Many women begin to identify their CA125 levels of the evidence of 
disease status. If it is low, they feel relieved and in control … If the 
level is elevated from prior levels, they know the disease is back and 
must plan for more treatment. Unfortunately, even normal insignificant 
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fluctuations in CA125 levels take on enormous meaning. As a result, 
emotional well-being may come to depend on lower CA125 number, 
even if numbers remain in the normal range. Patients may find 
themselves on an ‘emotional roller coaster’ with ups and downs 
determined by the direction of serum blood levels. (Bell and Kazanjian 
2011: 193)
In later work, Bell goes on to note that this sense of what Gillespie 
(2012) has called ‘measured vulnerability’ can be intensified by 
molecular biomarkers, whereas for other patients these results do 
provide reassurance because of ‘the semiotic potency of biomarker 
numbers as transparent, material indices’ (Bell 2013: 230) in the 
context of ongoing uncertainty and fear around cancer.
Results such as these nevertheless create a space for patients to 
negotiate the meaning of their illness and treatment arrangements 
with their clinicians, ‘empowering patients to challenge physician 
decision making – especially in circumstances where physicians are 
seen to be overly passive or nihilistic’ (Bell 2013: 139). Genomic 
results add a further layer of complexity to these processes, promising 
more precise personalisation but also requiring work to make sense 
of results in a responsible manner. Our analysis of personal blogs 
and online forums discussing Prolaris (Yan 2017), a gene-expression 
profiling test to support therapeutic decision making for prostate 
cancer by predicting a tumour’s potential aggressiveness, suggests 
that the responsibility to be positive is powerful. Men crafted ‘peace 
of mind’ through their engagement with the test, even when the 
results were negative or unwelcome indicators of foreshortened 
futures. These positive registers of responsible patienthood were 
reinforced in company blogs and through virtual patient networks 
which together advocated for genomic testing as a means of patient 
support.
As molecular profiling to determine treatments matures and 
expands through the use of genomic technologies, many more patients 
with or at risk of cancer developing or returning will be drawn 
into this kind of work, managing uncertainty and the anxieties it 
can provoke, finding reassurance and making meaning out of test 
results with clinicians and/or other affected individuals they encounter 
in face-to-face and online support groups. Here they are crafting 
identities and futures together, seeking to realise value from tests 
in the process. Patients actively seeking access to tests might also 
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be drawn into regulatory decision making, just as with targeted 
treatments, perhaps working with industry, charities and/or clinicians 
and scientists as these experimental spaces become more mainstream. 
This involves crafting bigger futures and engaging in valuation work 
for industry and government, whereas for other patients who are 
less engaged, active or well, future-crafting takes place on a much 
more local scale. We go on to explore this further in Chapters 2 
and 3 where we focus on two very different tests and scales of 
future-crafting, work and value making for breast and gynaecological 
cancers.
Adaptive trials
Since the development of Herceptin and Gleevec a whole host of 
molecular markers and targeted therapies for cancers have emerged. 
Among these are therapies which target the BRAF mutation in 
metastatic malignant melanoma (Vemurafenib), the EGFR mutation 
in non-small-cell lung cancer (Erlotinib and Gefitinib) and the KRAS 
mutation in colorectal cancer (Cetuximab). Similar to the stories of 
Herceptin and Gleevec, these therapies emerged through complex 
trial and organisational arrangements, including the involvement 
of public–private partnerships, international collaboration and 
patient groups. Participation in trials for other targeted therapies, or 
combinations of therapies, has become a more common expectation 
for cancer patients, as has access to experimental drugs (although 
trials and drugs are not accessible for all patients, as this depends 
on their health, prior treatment, type or stage of cancer as well as 
genomic-based eligibility). This involves patients and their advocates 
in a range of activities to understand, source and secure particular 
treatments or combinations of treatments through being on trial, 
as access to personalised therapies becomes an expected part of the 
patient journey, reinforced by the promise of personalised cancer 
medicine.
Cambrosio et al. (2018) stress the importance of understanding 
this ‘reshuffling’ of the research/care distinction and new forms 
of ‘experimental care’ that have emerged in personalised cancer 
medicine. This draws our attention to the care enacted and received 
by patients while on clinical trials which are increasingly adaptive 
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or novel in other respects (for example, umbrella and basket trials 
which bring patients together based on their molecular profile, not 
their cancer types), as well as experiments in care that take place 
beyond involvement in trials through a culture of ‘trial and error’ 
approach to treatments. The world of targeted treatments is one of 
novel combinations, unknown side-effects, tumour heterogeneity, 
resistance, adaption and evolution. Patients, together with family 
members, clinicians and scientists, are researching together as they 
navigate the meanings and possibilities of molecular diagnostics and 
therapies. This is no longer simply testing and treating accordingly 
in a linear fashion, but treating and profiling in iteration, adapting 
treatments and, increasingly with the development of so-called liquid 
biopsies that test circulating tumour DNA (avoiding the need for 
invasive biopsies), retesting as a form of theranostics. Research is also 
becoming embedded in care through architectures such as the SHIVA6 
trial’s Molecular Tumour Boards and other larger-scale infrastructure 
such as cohort management systems that have remained in place 
after the trials have ended as a means of integrating research and 
care more routinely through directing patients to trials and/or novel 
experimental treatments as part of their care:
The body of the patient becomes simultaneously a locus of experimenta-
tion and the subject of hopefully more effective (because more precisely 
tailored) care. To put it in a slightly different way, experimentation 
on an individual patient also qualifies as a form of personalized care. 
(Cambrosio et al. 2018: 218)
Together, these new practices are reconfiguring patients’ and profes-
sional and institutional futures. Hopeful futures of remission and 
even cure are cultivated alongside visions of more efficient services 
and responsive professionals. These promissory big futures are enacted 
in trials and experimental treatments. But other kinds of more 
provisional and, at times, unwelcome futures remain in play, as the 
complex realities of vulnerable bodies and institutional processes 
emerge and impinge on these processes.
As well as being built around a multi-drug regimen, these new 
trial arrangements rework assessment criteria to demonstrate thera-
peutic benefit. As Keating and Cambrosio (2011: 365) note, this 
involves new ‘end-points’ such as ‘disease stabilization, time to 
progression and progression-free survival’ for phase 2 and 3 trials, 
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reworking goals for the future in the process. It is also worth noting 
here that although randomisation is common in other trials, this 
has always been controversial in cancer, and the genomic era has 
involved an acceleration of new trial designs which do not involve 
randomisation. Keating and Cambrosio (2011) note that a general 
feature of these kinds of trials is that they are not statistically robust, 
tending to involve small numbers of patients and a lack of ability 
to compare targeted therapies such as Herceptin with other combina-
tion therapies, thereby tending to bias findings in favour of Herceptin-
based combinations. Adaptive trials are part of the experimental 
process, rather than a fixed methodology to be applied routinely, 
and the nature of supporting evidence is co-produced in a clinical 
context where the promise of the drug holds great sway.
The changing nature of trials and issues over access and efficacy 
have not only drawn more patients into experimental practices as 
part of their treatment, they have also sparked international debates 
around measures of success and clinical trial design, as well as the 
processes for approval based on clinical effectiveness in which trials 
play a crucial role. Trial design, pricing structures and measures of 
efficacy of tailored, precision or stratified cancer medicines are all 
areas of flux at the present time, generating public doubt about the 
promise of personalisation and its role in cancer care now and in 
the future. This has taken the form of controversy around the extent 
to which precision or personalised medicine is worthy of the celebra-
tion and expectations in popular and professional discourses about 
its possibilities. Borad and LoRusso list some of the problems with 
establishing benefit in this area as follows:
selection bias present in single-cohort studies lacking a control arm, 
ascription of success to alterations being identified simply as actionable 
(instead of more rigorous criteria that would classify alterations as 
useful or not on the basis of strength as a predictive marker for 
therapeutic efficacy), or leading to change in therapy (irrespective of 
such a change producing a favorable outcome), heterogeneity of 
histologic tumor types, and inflation of value of broad-based NGS 
profiling in the setting of inclusion of patients with well characterized 
alterations (e.g., patients with BRAF V600E melanoma) in reported 
studies. (2017: 1583)
As the authors go on to discuss, the SHIVA trial mentioned above 
is an oft-cited example of the difficulties with researching precision 
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medicine. The first SHIVA trial did not find any benefit in therapies 
allocated on the basis of genomic profiling as compared to therapies 
allocated using conventional clinical decision-making tools. A second 
SHIVA trial is, however, ongoing and, despite the problems with 
the first trial, SHIVA has been hailed as a success in clinical trial 
design because it did suggest that targeted therapy based on profiling 
might be a valid approach in a subgroup of patients with a particular 
kind of molecular alteration.7 The lack of definitive proof of benefit 
from (randomised) trials has been taken by some critics as evidence 
that personalised or precision medicine is over-hyped. One haematolo-
gist, Vinay Prasad, who has a significant social media profile, has 
taken issue with precision medicine trial design in particular, especially 
relating to the lack of randomisation and replicability. This, in turn, 
has prompted criticism from advocates of personalised medicine, 
who suggest that flexibility is the new (and ethical) approach to 
meet patient needs, eschewing the rigid orthodoxies of the past.8 
Here we see some of the disputes about the promise of personalised 
cancer medicine laid bare as the valuation practices of trials are 
openly contested in professional and public forums.
We can situate the emergence of these trials and debates about 
their efficacy as part of the wider bioeconomy of promissory capital-
ism, where disease-free futures are continually re-envisaged (Cooper 
2008; Michael 2017b). Expectations about personal and collective 
futures feature prominently in these regimes (Good et al. 1990; 
Novas 2006; Haase et al. 2015) as ‘future-oriented discourses drive 
and shape innovation projects’ (Borup et al. 2006: 285). Yet as 
Brown and de Graaf (2013) demonstrate, both hope and despair 
are key to trial arrangements in practice (see also Cooper 2008; 
Will and Moreira 2010; Cooper and Waldby 2014). The cultivation 
of low expectations among patients has also been shown to be a 
way in which clinicians manage the hype of contemporary biomedicine 
(Gardner et al. 2015), something we return to in Chapter 4.
Brown and de Graaf (2015) analysed the lived experiences of 
advanced cancer patients involved in phase 2 and phase 3 randomised 
control trials. Their research found that hope can be a means of 
managing the uncertainties associated with prognosis and treatment 
success. However, when negative eventualities and limited time 
horizons are introduced, patients engaged in ‘bracketing off’ the 
future, to limit reflection on the difficult realities that might lie 
ahead. These descriptions challenge conceptions of time as ‘linear’, 
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with reflections on cancer necessarily encompassing an orientation 
towards the future in the present.
Montgomery’s study of adaptive trials suggests that moving away 
from standardised approaches to ‘predictable uncertainty’ is premised 
on ‘modes of knowledge production which claim to know the future’ 
(2017b: 232). As trials speed up to deliver treatments to patients 
sooner, Montgomery argues that probabilistic logics are replacing 
promissory logics on which standard randomised trial designs are 
based. Here, adaptive trials are oriented around negotiation of 
unknowns as part of ongoing experiments, creating moral value, 
not just commercial value, for a diversity of actors. Optimisation 
through adaptability and iteration becomes key here, maximising 
the best possible future for patients amid uncertainty. Montgom-
ery notes that such benefit tends to be framed as collective rather 
than as one for individual patients. There is a need to explore the 
implications of these processes for patients as they go through these 
trials.
We know from other studies that what Lamprell et al. (2018) 
aptly call ‘the road of trials and obstacles’ places numerous demands 
on patients. In their study of cancer patients’ experiences of BRAF 
mutation testing, targeted treatments and associated trials, they 
discuss how BRAF mutation testing might be offered as part of 
efforts to secure access to a trial, but this is not a straightforward 
process. As in the case of one patient in their study, delays can mean 
that the trial closes before the tissue samples are analysed, and 
patients can find themselves having to transfer to another hospital 
to participate in the trial. Patients also have to manage a host of 
side-effects from experimental treatments accessed via trials, some-
times becoming too ill to continue. For others, accessing the drug 
via a trial can prove to be a lifeline, although not without ongoing 
complications to be lived with while in remission, with other drugs 
prescribed to manage side-effects. This points to the importance of 
patients’ hope, trust and vulnerability in crafting futures in cutting-
edge cancer care, themes also in Brown et al.’s research on the 
imperative of hope and trust in clinical trials (Brown et al. 2015).
We find echoes of this across our research, captured in the extract 
below, taken from a joint interview with two breast cancer patients, 
Laura and Viv. Both had late-stage cancer diagnoses when they had 
young families and were now living with secondary breast cancers. 
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They got to know each other through their secondary cancers, which 
put them ‘in a completely different place [to primary cancer patients]’, 
as Laura explained. During the interview, they talked about the 
work they had done to find out about trials and their advocacy 
around access to drugs. Viv received a standard treatment drug to 
which she responded well, whereas Laura, after receiving various 
chemotherapies, got on to a trial of a targeted therapy which she 
takes in tablet form alongside Herceptin. Laura told us she had 
secured the ‘last place’ on the trial, at a point when she had ‘failed 
on quite a few lines of chemotherapy so … was running out of 
options and … probably only had less than six months to live’. She 
continues:
[Laura] I remember we went away to [city overseas] as a family 
because I kind of thought ‘this might be my last big holiday’. And 
my consultant … when I came back I thought I’d be going on possibly 
my last line of chemotherapy but when I got back he’d contacted his 
friend in [another city] and he said ‘there’s a slot on this trial’.
[…]
[Laura] … there’s an international trials database and I’d been sending 
… my consultant, links to … I remember trials in France and Belgium. 
And I think most of them were immunotherapy trials – I didn’t know 
that – but he said to me ‘oh, I’m not sure about these, it’s still pretty 
untested in breast cancer, the response rate is very low. I really don’t 
advise … you’d have to go and live in Belgium or France or wherever 
for a number of months, is that feasible?’ So he wasn’t keen. But to 
be fair to him, he obviously did contact the [cancer centre in another 
city] and there was one place left on this trial and I thought ‘I’ve got 
nothing, absolutely nothing to lose.’ But no, he knew nothing about 
my, you know, molecular profile at all. But within a fortnight my 
cough had gone, I felt I was, you know…
[Viv] It was quite miraculous, actually.
[Laura] It was, it was a really strong, very strong response. And after 
three cycles of the drug, I got scanned and the cancer in my lungs 
had been, you know, just obliterated and it stayed like that.
[Viv] The thing is, when you’re dealing with that sort of possibility 
of a trial with the drugs that are coming through, you just think, you 
know, it should be advertised.
[Laura] It should be.
50 Personalised cancer medicine
[Viv] It really should be.
[Laura] And it’s just been pure chance, luck.
[…]
[Viv] You can understand why we do what we do because you just 
think you’re given this second chance at life really, aren’t you, by a 
drug and you just think ‘OK, I might have two years or three years 
but I’m going to make that two years or three years matter within 
the whole scheme of breast cancer for women really.’
[…]
[Laura] What’s frustrating for me though is the drug has been really 
successful. So … I know there were 11 of us on the trial. There’s me 
and one other lady still on it after two years – I think sadly the other 
women have died. But I saw a poster presentation from the company 
and they said it’s had a 67% response rate in this very early phase 
one trial.
[Viv] Which is amazing.
[Laura] Which for women who’ve been heavily pre-treated, it’s a 
really good response rate.
[Laura] And they described it as being ‘unprecedented’ but for some 
reason they’ve not taken it forward to phase two. So when I tell my 
story at different places, I always have people coming up to me, saying 
‘what drug are you on, what trial is this?’ And I have to say ‘I’m 
really sorry but I’m kind of on it, I got the last place and they don’t 
seem to be … at some point they’ll take it forward but they don’t 
seem in any…’
[Viv] … rush, yes. Right, let’s just say ‘you’ve got to do it, you’ve 
just got to do it!’
As this exchange suggests, participation can extend from negotiating 
individual access, in concert with clinicians, to include more concerted 
collective efforts to open up more trials and more access to trials for 
other patients. It also includes managing hopes and expectations for 
oneself and others as the research progresses, and when personal 
benefits and findings do or do not materialise. Patients can take 
an active role in challenging clinicians, not just in relation to their 
own treatments but trial design too. This has included challenges 
to the exclusion criteria for clinical trials, as in the example of a US 
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physician, Dr Kelly Shannon, who has metastatic breast cancer and 
has campaigned with patient organisations METAvivor (established 
in 2009 to provide funds for research)9 and METUP (formed in 
2015 and drawing inspiration from the AIDS activists ACTUP)10 
to open up access to trials to patients who are not just what she 
describes as the ‘healthiest of the dying’.11 Patient representatives are 
also increasingly involved in trial-management processes via patient 
and public involvement advisory groups and panels. This is now a 
routinised feature of cancer research. But acting as a representative 
in complex adaptive trials and other kinds of studies such as whole 
genome sequencing initiatives, as discussed below, can involve detailed 
engagement with the complexities of genomic science as well as trial 
methodologies, project governance, engagement and ethics.
Yet as Llewellyn et al. argue, based on their research on patients 
with brain cancer, trials take place in the context of ‘the contingent 
and improvised nature of care’, where doubts and uncertainties can 
be overshadowed by ‘an unduly optimistic and “can-do” attitude 
to management based around a technological imperative and medi-
cine’s mandate to extend lives’ (Llewellyn et al. 2018: 413; see also 
Kaufman 2015). Focusing instead on the ‘unsettling and wavering 
terrains of disease and care’, they explore how patients navigate 
experimental treatments, necessitating detailed engagement with 
research, medical travel and NHS bureaucracy (Llewellyn et al. 
2018: 411). This includes managing being excluded from participation 
in trials to access new therapies such as Avastin, a targeted chemo-
therapy (not available to one patient in their study due to his prior 
involvement in an immunotherapy trial abroad), as well as crowdfund-
ing efforts to access drugs considered by the NHS to be of unproven 
benefit. These kinds of ‘unimaginable dilemmas and hard-to-swallow 
paradoxes’ are part of the terrain of targeted treatments for cancer 
(Llewellyn et al. 2018: 420).
It is also important to appreciate that patients who actively seek 
out trials do this from a range of backgrounds and perspectives, 
not always based on detailed engagement and knowledge. One 
oncologist gives an example of this:
I’ve had a GP … being treated in another institution … phone because 
they’ve read on the internet about a clinical trial that was taking 
place that they’ve seen the inclusion criteria for that they want to be 
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included in. [But this goes] all the way through to people having 
absolutely no idea, you know, really what a clinical trial is, a clinical 
trial is being a guinea pig … I’ve – somebody said it to me this week 
in fact … bizarrely this person said it to me … he said, ‘Oh, I just 
want you to know … that I’m quite happy to be a guinea pig.’
Adaptive trials of targeted treatments can make cancer patients 
partners in experimental healthcare, but the extent and type of their 
engagement in the processes of the trial, including its design, purpose 
and outcomes, varies considerably, as do their experiences of access 
and care. Trials might be based on optimising the future for patients 
as a whole, but individual patients are also heavily invested in 
extending their own future. Trials are complex, just like cancers 
and patients, which brings considerable negotiation and articulation 
work for patients and their practitioners, not just to enable access 
but to keep hope alive for patients in and around the trial, as we 
discuss further in Chapter 4.
Whole genome sequencing
Developments in large-scale genomic sequencing are another feature 
of clinical oncology and associated research. More genetic information 
is being collected about more kinds of cancers, often through research 
studies. Whole genome sequencing (WGS), in which the entire genome 
is sequenced rather than panels (or groups) of genes – an approach 
associated with molecular diagnostic tests (often proprietary) and 
targeted treatments – is an important aspect of these developments. 
As Nakagawa and Fujita comment,
Whole genome sequencing (WGS) approaches can be used to com-
prehensively explore all types of genomic alterations in cancer and 
help us to better understand the whole landscape of driver mutations 
and mutational signatures in cancer genomes and elucidate the 
functional or clinical implications of these unexplored genomic regions 
and mutational signatures. (2018: 513)
WGS has a profoundly exploratory logic, charting previously 
unknown territories of the genome to reveal its complexity (Martin 
2018). As Brown and Michael (2003) note, innovative technologies 
often build upon past ‘failures’ while ignoring the possibility of their 
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own failure. This pattern appears to be being replicated in the case 
of WGS: its role in transforming cancer care is being assured through 
major infrastructure developments in the NHS, and the lack of 
ensuing ‘actionable results’ is not being framed as problematic.
At this point, genomics meets biobanking, often incorporating 
other clinical datasets where patients have given consent for their 
data to be reused. Digital processes of analysis are crucial to handling 
these vast quantities of data, as are private–public partnerships to 
deliver the technology and interpretative power required. The creation 
of value from these datasets requires both the centralisation of data 
and its ultimate detachment from the state (Cool 2016), in a process 
through which populations become brands with bioeconomic potential 
(Tupasela 2017). The promise of a growing bioeconomy aligns with 
a vision of health services that deliver better care to more patients 
via ‘benefit sharing’ (Hayden 2007), for example, where companies 
offer medical innovations to the health service that provide the data 
at a preferential rate. Yet these benefits remain opaque and promissory, 
sometimes bewildering to patients and participants already caught 
up in ‘surveillance capitalism’ where rights to privacy are routinely 
signed away as part of ordinary consumption (Zuboff 2019), and 
where publicly funded health systems are struggling to pay for 
expensive medicines such as targeted cancer therapies. How the 
‘regularized, embodied work that members of the national population 
are expected to perform in their role as biobank participants’ (Mitchell 
and Waldby 2010: 334) is to be recognised or rewarded in such 
contexts is radically unclear. The ethical complexities of this are 
compounded in cancer, where benefits may not be felt, futures 
compromised and legacies uncertain.
Tarkkala et al. explore some of these dynamics in their research 
on personalised medicine in Finland – ‘an intensely state-driven and 
national endeavour’ (2019: 143) – analysing detailed policy plans 
and institutional strategies for embedding personalised medicine in 
Finnish healthcare. This work spans ‘business, from financing to 
marketing, resource and personnel management, scientific research, 
product development, consulting, and public governance and poli-
cymaking … experimenting with existing epistemic, professional, 
institutional, political, legal, administrative, and business orders’ 
(Tarkkala et al. 2019: 143–4). Wealth creation is a central theme 
of these efforts, realised via intensified innovation, commercialisation 
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and data-driven medicine, which they note builds on two decades 
of promise that can be traced to the development of deCode Genetics 
Ltd in Iceland (Fortun 2008; see also Rajan 2006).
The discourses that surround these ventures are highly promissory, 
focused on delivering benefits to the nation, as well as patients and 
individual participants, but often hedging the later possibilities against 
the complexities and risks of the processes and the need for new 
infrastructures to be developed. Institutions are constructed as slow 
or even resistant to change and the success of WGS is predicated 
on transforming laboratory services and professional cultures, echoing 
the democratising ethic of corporate actors such as 23andme 
(Prainsack 2017). As well as recruiting patients as active collaborators 
in its genesis and implementation, health systems too need to be 
made ready for personalised medicine as expressed in policy docu-
ments such as the following:
Predicting which patients will benefit ahead of time, using information 
from an individual’s cancer genome to improve overall outcomes and 
minimise toxicity and cost, is the clear path forward. To achieve these 
goals, health systems need to evolve from their current state, to a 
more personalised model of cancer care with targeted therapies, driven 
by more precise and genome-driven research and diagnostics. This is 
a central tenet of Precision Medicine. (Scottish Scientific Advisory 
Council 2019: 5)
Just as new institutional requirements to better manage interpretation 
and clinical decision making based on results emerge from these 
innovative, commercially oriented, data-intensive initiatives, so too 
do new arrangements for the professional training and ethics required 
to support data generation, curation and exploitation. Consent to 
participate in research and the management of so-called ‘incidental’ 
findings supplementary to a patient’s cancer (typically in relation 
to genetic risk for inherited disease) are a particular focus of attention 
here, given the importance of widespread participation to the success 
of these ventures (Dheensa et al. 2018). But these are complex 
endeavours, marked by numerous misalignments between policy, 
strategy and practice, given the complexities and pressures of 
healthcare systems. In the UK, and the NHS in England within it, 
the 100,000 Genomes Project is an exemplar of the kinds of large 
national initiatives that are delivering WGS, which we discuss further 
in Chapter 5.
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Conclusion
The promise of personalised or precision medicine for cancer is 
contested in medicine, science and beyond in the public sphere because 
of concerns about efficacy and cost in particular. As Interlandi (2016) 
argues, ‘early attempts to tailor disease treatment to individuals 
based on their DNA have met with equivocal success, raising con-
cerns about a push to scale up such efforts’. Tim Maughan, from 
the CRUK/MRC Oxford Institute for Radiation Oncology, notes 
that personalised medicine for cancer has thus far proven to be of 
limited clinical benefit, quoting a study which found that ‘overall 
survival from 71 targeted cancer therapies approved by the FDA 
between 2002 and 2014 was only 2.1 months’ (Fojo et al. 2014). He 
continues:
The consequences of heterogeneity, clonal evolution and the influence 
of the host response are that simple genetic tests are much less accurate 
in predicting prognosis and treatment response than was expected 
based on the CML imatinib paradigm. Similarly, targeted drug therapies 
may show an initial response, but this is rapidly overtaken by tumour 
regrowth due to emergence of tumour clones often demonstrating 
multiple different mechanisms of resistance. Despite this, personalised 
cancer medicine, now enhanced by immunotherapy, is still projected 
as the existing paradigm, and supported by major cancer centres 
across the world, by pharmaceutical and diagnostic companies alike. 
Researchers in the field and especially pharmaceutical companies are 
acutely aware of the challenges, but still clinicians, patients and their 
advocates pursue access to these targeted agents with enthusiasm. 
(Maughan 2017: 15) [our emphasis]
Maughan captures the key dynamic of anticipation and concern 
that we find across the various developments in genomic medicine 
for cancer reviewed in this chapter and explored further in the 
chapters that follow. Personalised cancer medicine is replete with 
promissory claims and instances of optimism and hope. Yet these 
tropes and possibilities are fragile and contested, when they emerge 
in everyday encounters, collective action and in the more stylised 
pronouncements in policy and the media.
What we stress here, however, is that these activities need to 
be understood as part of, rather than auxiliary to, the innovative 
and experimental processes in personalised medicine for cancer. 
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Innovation and experimentation extend outwards from the dataset 
or the laboratory, the scientist or the entrepreneur, to the clinic and 
beyond, to the regulatory and public sphere, and in networks and 
relations with fellow cancer patients, families and friends. Across 
these settings, practitioners, patients and their families are doing 
emotional and articulation work (Star 1985) as they co-produce the 
meanings of novel genomic treatments, tests, research and relations, 
crafting their and others’ futures as part of this process. Anticipation 
and moderation are part of navigating individual and collective 
futures and creating various kinds of value, from the big futures 
of bioeconomic growth for the nation to individual, more personal 
futures of feeling cared for and valued. Just as molecular diagnosis, 
targeted therapy and subtypes of cancer and cancer research and 
care are entwined, interactive and co-produced, so too are individual 
and collective futures. These experimental relations, processes and 
categories enrol increasing numbers of patients and practitioners not 
just in research or data collection but in new kinds of regulatory 
and funding arrangements, patient collectives and public engagement 
activities.
In what follows, we endeavour to explore these interactions and 
interweavings to give a detailed account of the kinds of value that 
various sorts of work create as genomics personalises cancer medicine. 
We explore the activities and narratives of patients, practitioners 
and family members that make genomic medicine valuable in policy 
and in practice but can be hidden or unacknowledged. Looking at 
the kinds of futures being crafted and how experimental and articula-
tion work in personalised medicine for cancer is distributed and 
enacted across these settings, we go on to consider what happens 
when we begin to value it as a contribution to innovation, and how 
this might change how we share the benefits and risks of personalised 
cancer medicine now and in the future.
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Genomic techniques in standard care: 
gene-expression profiling in early-stage 
breast cancer
Breast cancer has long been a focus of research and innovation in 
genomic medicine, from one of the first targeted therapies, Herceptin, 
as discussed in Chapter 1, to testing for mutations in breast cancer 
susceptibility genes such as BRCA1 and BRCA2, which developed 
through the course of the 2000s. Research into the molecular biology 
and gene expression of breast cancer tumours has spurred the 
identification of a range of variants or subtypes of breast cancer 
according to their molecular make-up. In addition to the development 
of Herceptin for HER2 breast cancers, estrogen receptors were also 
identified as targets for drugs in women with breast cancer before 
the menopause who had what is known as hormone-sensitive breast 
cancer. Cancers were classified into a range of subtypes according 
to genomic and other tests in the ensuing period. Olopade et al. 
reported that
individual cancers could be categorized, based on their gene signature, 
to at least five distinct subtypes: luminal A, luminal B, normal-like, 
HER2-like, and basal-like. Normal-like tumors resemble normal breast 
tissue, HER2-like are characterized by HER2 overexpression, luminal 
A and B are estrogen receptor positive, and basal-like are triple negative 
(estrogen receptor negative, progesterone receptor negative, and HER2 
negative). (2008: 7991)
These developments were the outcome of considerable research 
investment by public bodies, charities and commercial companies. 
Cancer research has been enabled, in part, by strong traditions of 
community and advocacy among breast cancer patients focused on 
prevention, research and survivorship in particular (Nahuis and 
Boon 2011; Gabe et al. 2012). Together, breast cancer research and 
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activism are considered to have made major inroads into tackling 
the disease. Many breast cancers are now highly treatable when 
detected early, and UK survival rates have doubled in the last four 
decades, bringing ten-year survival rates for women up to 78 per 
cent across England and Wales for those cancers diagnosed early 
(Cancer Research UK 2014).
Sequencing and microarray technologies arising from the human 
genome project have enabled gene-expression profiling within cancer 
medicine. This technique identifies which genes are being activated 
in a cell to give a global picture of cellular function.1 Oncotype DX 
is a gene-expression test developed by a US-based company, Genomic 
Health. It aims to provide a personalised prediction for a subset of 
breast cancer patients for whom the benefit of chemotherapy after 
surgery is less clear. The test estimates the likelihood of recurrence 
and can thus aid decisions about chemotherapy (Bourret et al. 2011). 
As Dowsett and Dunbier note, Oncotype DX was one of several 
‘multigene expression profiles that aim[ed] to outdo traditional 
predictive and prognostic factors’ in breast cancer diagnosis and 
treatment, developed to ‘quantify the residual risk of … recurrence 
in patients with lymph node negative, estrogen receptor-positive 
tumors receiving tamoxifen’ (2008: 8022).
Echoing ongoing discourses of optimistic and transformative 
futures associated with genomic medicine, Oncotype DX has been 
hailed by some commentators as a key tool to combat the over-
treatment of patients via chemotherapy (Joh et al. 2011; Ali-Khan 
et al. 2015). This has been welcomed because of its potential benefits 
for individual patients and practitioners in deciding on whether to 
recommend chemotherapy to prevent the recurrence of cancer, despite 
its sometimes serious side-effects and the disruption this causes (Bell 
2009). Reducing unnecessary chemotherapy could also save resources 
within the UK NHS (Loncaster et al. 2017), although use of this 
test is primarily to help define who, from a subset of patients, would 
benefit from chemotherapy.2
As we discussed in Chapter 1, gene-expression profiling tests such 
as Oncotype DX have also been part of a wider transformation in 
innovation and regulation. This has involved novel partnerships 
between commerce and healthcare, with tests utilising proprietary 
algorithms. It has also involved new regulatory arrangements and 
pressures, marked by complex negotiations in state-based health 
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systems such as the UK’s, involving multiple stakeholders from 
healthcare, industry and patient advocacy. As of 2018, the National 
Institute for Clinical Excellence recommends three such tests: 
Oncotype DX, EndoPredict and Prosigna, replacing its previous 
2013 guidance which included MammaPrint (see below). These tests 
have been introduced into an already busy diagnostic and treatment 
nexus in the NHS, which is not only non-linear, but is also already 
populated with a range of information and expectations, to which 
additional molecular information adds another layer. This means 
that, although molecular testing might promise certainty, it brings 
additional kinds of uncertainties too, all of which have to be navigated 
by researchers, patients and clinicians in the clinic and beyond.
In this chapter we look at these processes more closely, exploring 
the ways in which Oncotype DX, as one tumour-profiling test, has 
been made valuable to the health service, practitioners and patients, 
including via patients’ contributions to processes of regulatory and 
clinical decision making surrounding the test. We chose to focus on 
Oncotype DX after discussing our research with senior clinicians 
in our project advisory group, who pointed out that we ought to 
include an aspect of genomic medicine already embedded in the clinic 
alongside the other case studies we were developing on genomic 
medicine as part of a trial or research. As we discuss further in 
Chapter 7, we had been finding entry into the clinic to study ordinary 
care difficult because of the complexities of patient pathways, clini-
cal arrangements and ethical and governance approvals. However, 
clinicians were keen to understand patient experience of the test 
and of genomics more broadly, and helpfully assisted in recruit-
ment for this case study, as well as being willing to be interviewed 
themselves.
This chapter considers transformations in policies and practices 
surrounding Oncotype DX and what sort of work this involves for 
patients and practitioners. We draw on research from three settings: 
the (public) approval process for the 2018 reformulation of UK 
NICE guidance around tumour-profiling tests; online patient discus-
sions about Oncotype DX (between 2015 and 2017); and interviews 
with 18 patients who had had the test, interviews with nine healthcare 
professionals (between 2017 and 2019) and six observations of 
consultations (2017). To gather the online data, we searched for 
the term ‘Oncotype’ on publicly accessible online forums, hosted 
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by cancer charity websites, and analysed discussion about Oncotype 
DX among cancer patients therein (Ross et al. 2019).
As we shall see, bringing Oncotype DX into routine practice 
involved considerable ongoing negotiation around evidence of benefit 
to the NHS and to patients and practitioners, as its meanings and 
implications were negotiated across a range of policy, practice and 
personal contexts. We explore how patients and practitioners worked 
to give the test value in their practice and experiences across these 
contexts, and we consider ambivalence about, and at times rejection 
of, its value. This ambivalence was centred on how the test could 
amplify, not simply resolve, uncertainty in already unstable treatment 
pathways regarding the role of adjuvant chemotherapy in this group 
of patients. Investigating how policymakers and NHS providers 
framed the test, we also highlight its precarious innovation pathway, 
exploring how its value had to be renegotiated across policy, com-
munity and clinical contexts. Despite the common claim that per-
sonalised genomic medicine is mainstream for cancers such as breast 
cancer because of the long-standing use of targeted treatments 
facilitated by gene-expression tests, our case study of Oncotype DX 
suggests a more precarious and contingent story of genomic medicine 
in the mainstream.
Gene-expression profiling within the UK NHS: crafting 
genomic futures
Commercial molecular profiling tests for breast cancer have become 
established since the early 2000s (Bourret et al. 2011; Kohli-Laven 
et al. 2011). MammaPrint is a 70-gene cancer signature developed 
and commercialised by the Dutch company Agendia, and Oncotype 
DX, which analyses 21 genes, was developed by the US company 
Genomic Health. Oncotype DX remains one of the NICE-approved 
tests, as noted above.
Oncotype DX is available to early-stage breast cancer patients with 
estrogen receptor positive (ER+) and human epidermal growth factor 
receptor 2 negative (HER2–) breast cancer tumour tissue which has 
not spread to lymph nodes (LN–) where a clinician is unsure about 
whether they will benefit from chemotherapy to prevent recurrence. 
It is important to note that this patient group is quite specific – they 
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are already at low risk of recurrence and Oncotype DX may be 
used to help determine whether adjuvant chemotherapy might be 
beneficial. There is variation in the prognoses for these cancers 
(Nagaraj and Ma 2013), and for some of these patients the risks of 
chemotherapy, including long-term side-effects, can outweigh any 
potential utility in reducing the possibility of recurrence. Oncotype DX 
testing is typically performed when widely adopted risk-assessment 
calculators which look at markers such as ER and HER2 (e.g. NHS 
Predict)3 do not provide a sufficiently definitive recommendation 
with regard to treatment, placing these patients at what is described 
as an ‘intermediate’ or ‘moderate’ risk of cancer’s return in the 
context of an overall low risk of such recurrence. In these cases, 
according to NICE guidelines, clinicians can offer Oncotype DX 
testing (the list price is £2,580 and the discounted cost to the NHS 
is commercially confidential).4 This involves sending tumour tissue, 
taken at surgery, to a Genomic Health licensed laboratory in the 
United States for molecular profiling of the 21 genes it analyses. The 
Oncotype DX test generates a personalised prediction for cancer 
survival with endocrine treatment (such as tamoxifen) alone, and 
based on this, a quantitative assessment of chemotherapy benefit. 
This is represented as a numerical ‘recurrence score’ between 0 and 
100, categorised into risk bands. Initially this involved ‘low-risk’, 
‘intermediate’ and ‘high-risk’ groups, with those patients at higher 
and in some cases intermediate risk of recurrence recommended to 
undergo adjuvant chemotherapy, taking other factors such as age 
into account. These three categories were represented visually, with 
the patient’s place on the scale and corresponding ten-year survival 
prognosis, with or without chemotherapy, highlighted on a graph. 
Recently, following the outcome of the TAILORx trial, results have 
been presented in two bands – low and high risk.5
When NICE first recommended Oncotype DX for NHS use in 
2013 (NICE 2013), the announcement was widely welcomed in the 
UK media, prompting headlines such as ‘New Breast Cancer Test 
Could Spare Women Chemotherapy’ (Boseley 2013). Coverage 
positioned the test as an example of improvements to the health 
service which could arise from genomic techniques, with the chief 
executive of a national breast cancer charity declaring that its approval 
represented a ‘step along the road towards personalised treatment’ 
(Smyth 2013), echoing the big future promissory discourses that 
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commonly accompany developments in cancer science. However, 
five years later, during a 2018 reformulation of NICE guidance for 
tumour-profiling tests, initial recommendations suggested that the 
test ought to be withdrawn because there was a lack of evidence of 
its benefit. The value of the test for the NHS had to be re-established 
by the manufacturer, practitioners and patients, as we now go on 
to discuss.
In January 2018 NICE released a public consultation document 
following an expert advisory group (EAG) review of available 
tumour-profiling technologies. Following their diagnostics assessment, 
including a systematic review of clinical evidence and updated 
economic analyses (Harnan et al. 2017), NICE’s consultation docu-
ment asserted that:
There is not enough evidence to recommend the routine adoption of 
EndoPredict, MammaPrint, Oncotype DX Breast Recurrence Score, 
Prosigna and IHC4+C to guide adjuvant chemotherapy decisions … 
In particular, more evidence is needed to prove that these tests have 
a positive effect on patient outcomes. Their cost effectiveness compared 
with current practice is highly uncertain. (NICE 2018a)
NICE called for further research on the effect of these techniques 
on long-term patient outcomes and treatment decision making, when 
compared with established risk-calculation tools already used by 
clinicians to predict breast cancer recurrence, such as NHS Predict 
(NICE 2018a).
Though some stakeholders agreed with the EAG’s initial assessment 
in the consultation document, their recommendation to withdraw 
Oncotype DX from NHS care was met with considerable criticism. 
Following a call for stakeholder responses to the public consultation 
document, NICE received 255 comments from a range of actors 
including NHS professionals, charities representing patients and 
manufacturers (NICE 2018c). For these critics, the withdrawal of 
gene-expression profiling from NHS care was at odds with the 
transformation of the health service envisaged within wider UK 
discourses of the genomic revolution; around 170 comments were 
received from healthcare professionals, the majority of whom reported 
that the test had transformed their practice. Objecting to the recom-
mendation, they framed it as a retrograde step for the health service, 
with a minority citing concerns of a return to a one-size-fits-all 
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approach to breast cancer treatment. For example, one professional 
wrote:
Please do not reverse this recommendation which will have the knock 
on effect to reverse the progress made by NHS in breast cancer treat-
ment in the UK and have a huge negative impact on so many ladies 
who do not need or deserve the terrible impact they will endure in 
both short and long-term from having chemotherapy. (NICE 2018c: 
Comment 78)
Alongside these appeals to the responsibilities of practitioners and 
the NHS to prevent the harm of unnecessary chemotherapy, others 
pointed to the certainty and ‘relief’ offered by the test, as in the 
excerpt below:
Being able to request an Oncotype DX test for my breast patients 
where there is uncertain benefit has revolutionised my practice. It is 
difficult to put a price on the relief that a patient has when told that 
they do not need to have chemotherapy which is unlikely to help 
them. The more we can personalise treatment, the less wastage we 
shall have and be able to focus treatments on those who are likely 
to benefit. (NICE 2018c: Comment 1)
The responsibility of professionals and services to reduce waste and 
target resources at a time when services are already stretched was 
another common theme:
In 2018 we cannot ignore the advances technology has given us and 
go back to the dark ages of giving chemotherapy to everyone ‘just in 
case’. Our day units are too full, lets target our resources wisely and 
save patients from undergoing unnecessary treatments. (NICE 2018c: 
Comment 81)
These sentiments were also echoed by the charity Breast Cancer 
Now, which released a statement following the announcement of 
these draft recommendations:
[It is] very disappointing that NICE has been unable to recommend 
any of these prognostic tools to help guide chemotherapy use on the 
NHS. In particular, this appears to be a backwards step for some 
patients … for whom guidance published in 2013 previously recom-
mended the use of Oncotype DX. With studies to assess their long-term 
impacts ongoing, prognostic tests like these are showing real potential 
to personalise breast cancer treatment and ensure all patients are 
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given the best chance of survival, while reducing overtreatment. (Breast 
Cancer Now 2018)
Here we see the deployment of a familiar trope of personalisation 
as future-oriented transformation by both patient advocates and 
practitioners, who also referenced collective responsibilities to support 
the NHS and not fall behind the rest of the world. Reducing toxic 
chemotherapy generates cost savings for the NHS and offers patients 
better health and emotional relief.
However, very few individual patients submitted comments. Only 
two out of 255 comments were from patients, both of whom were 
supportive of approval because it reduced the burden of chemotherapy, 
including this one:
I was predicted a 70% survival rating by PREDICT (which you seem 
to think can take the place of genomic testing) as opposed to 98% 
by the Oncotype DX genomic test. I would have had to have chemo, 
the possible long-term drawbacks of which I do not think you have 
adequately taken into account in your documentation of the site. Not 
to mention the unquantifiable psychological effects of a relatively 
poor prognosis. (NICE 2018c: Comment 174)
This forms part of a broader pattern in NICE assessments of novel 
diagnostics and therapies, where evidence of benefit becomes a key 
terrain of dispute and epistemological activism (Keating and Cam-
brosio 2011) on the part of health economists and other policy 
experts, industry, practitioners and patients. A particular tension 
arises between the tendency of expert review groups to prioritise 
the evidence of overall benefit to the health service, while patient 
representatives and practitioners, sometimes in concert with industry, 
prioritise individual patient benefit, in this case the avoidance of 
the psychological and physical burden of unnecessary toxic therapies. 
Negotiations ‘spill over’ into the public sphere as part of the co-
production of these kinds of NICE decisions (Moreira 2011: 1334), 
with the entitlements and ‘moral worth’ of patients forming part 
of the evidence that stakeholders mobilise alongside practitioners’ 
and regulators’ responsibilities to deliver value for money for the 
health service as a whole (Moreira 2011: 1338).
As Abraham (1995) and Davies and Abraham (2013) have shown, 
pharmaceutical companies influence regulatory processes affecting 
their products, including via funding clinical trials and working 
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with regulators to speed up the approvals process. However, research 
has also shown that NICE committee members can be particularly 
sceptical about industry claims and those of patients who are seen 
as having conflicts of interest (Brown et al. 2016). The gene-profiling 
industry therefore adopted a muted tone in their submissions to the 
NICE committee, deploying a range of evidence of benefits and 
criticising the EAG for insufficient engagement with international 
study groups and trials.
However, it was the prospect of evidence from one trial that was 
particularly important in the advocacy work around Oncotype DX. 
Around thirty responses to the initial NICE report noted that the 
results of the Trial Assigning Individualised Options for Treatment 
(TAILORx) trial, a National Cancer Institute (US) sponsored large-
scale prospective trial assessing the benefit of chemotherapy for 
those receiving ‘intermediate’ Oncotype DX scores, were shortly to 
be released, stressing the importance of this evidence to the process. 
In response, the Diagnostics Advisory Committee paused the develop-
ment of their reformulated guidelines to conduct further analyses 
incorporating the trial results.
The TAILORx results were widely welcomed because they 
demonstrated that Oncotype DX offered more precise predictions, 
identifying the 70 per cent of women who would not benefit from 
chemotherapy (Sparano et al. 2018). The trial also found no need 
to use an intermediate score, as women in this category could be 
considered low risk and avoid chemotherapy. These results were 
reported with much fanfare in the UK media. When reporting 
on the technique and the TAILORx study, many news articles 
adopted terminology including ‘life changing’, ‘ground breaking’ 
(Matthews-King 2018) and a ‘breakthrough’ (Gallagher 2018). 
Headlines included ‘Most Women with Early Stage Breast Cancer 
Can Avoid Toxic Chemotherapy’ (The Independent) and ‘Breast 
Cancer Study Set to Free Women from Chemotherapy’ (Financial 
Times). Stories featuring personal testimonies included that of the 
Guardian journalist Joanna Moorhead, who recounted her own 
experience of Oncotype DX in the wake of the results of the TAILORx 
study, describing the technique as ‘revolutionising’ cancer treatment 
(Moorhead 2018).
These positive trial results, together with the arguments presented 
by contributors to the consultations, shaped NICE guidance, released 
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in December 2018. During its final meeting, the NICE Diagnostics 
Advisory Committee reported scepticism about the applicability of 
TAILORx results to the UK. Many of those who avoided chemo-
therapy in this study would not have been routinely offered it in a 
UK setting, demonstrating that even so called ‘gold standard’ evidence 
is not always translatable to other health systems, affording clinicians, 
patients and regulators flexibility in interpretation and practice (NICE 
2018b: section 5.6). Nonetheless, NICE retracted the earlier recom-
mendation to withdraw support for Oncotype DX. The committee 
also recommended the adoption of Endopredict and Prosigna for 
use with ER+, HER2– and LN– early breast cancer patients in NHS 
settings, where certain criteria are met, including whether other 
validated tools such as NHS Predict had already suggested an 
intermediate risk, and that information would help patients to choose 
whether or not to have chemotherapy (NICE 2018b). In Moreira’s 
study of dementia drug regulation, hybrid interactions between 
practitioners, patients and industry created the conditions for NICE 
to resolve disputes with pragmatic reasoning, balancing rules with 
individual cases, rendering the decision ‘socially robust’ rather than 
technocratic (Moreira 2011: 1340). We find similar processes in 
this case, as the regulator navigated a range of different types of 
evidence and advocacy around the value of the test for the NHS, 
practitioners and patients, recommending limited use of the test in 
conditions of uncertainty if the patient, together with their practitioner, 
would find this helpful.
In these processes of regulatory decision making we can see the 
articulation of value to patients and to the NHS being asserted and 
anticipated as an outcome of regulatory approval. The value to 
patients was articulated in evidence to the regulator, but this was 
largely second-hand rather than first-hand, via clinicians and patient 
advocates/representatives. The main form of value being asserted 
was the avoidance of unnecessary and expensive chemotherapy, 
something which was presented as mutually beneficial for patients 
and the NHS. Patients were also framed as deriving personal value 
from the test, which offered relief and prevented toxic side-effects 
when they could avoid chemotherapy with more certainty. The NHS 
was presented as deriving efficiency gains and financial benefits from 
these outcomes. The value of being ‘future-oriented’, not being 
backward or overtaken by other countries, was also asserted through 
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these processes. Oncotype DX became totemic of the future of 
personalised medicine, generating a sense of shared commitment to 
its realisation (Jerolmack and Tavory 2014). Reducing suffering, 
saving money for the NHS and paving the way for further advances 
combined national and personal goals and benefits. For patients 
and practitioners, gene-expression profiling offered certainty and 
reassurance that they could avoid chemotherapy, resolving lingering 
uncertainties produced by other algorithms such as NHS Predict. 
For the NHS, the technology offered greater certainty by reducing 
wastage, and for policymakers and industry it made the future of 
personalised medicine less uncertain as the test became an option 
within standard care pathways.
However, when we turn to practitioners’ and patients’ accounts 
of engagement with Oncotype DX, we find it is associated with 
more complex and contingent value than the three kinds of value 
(personal value, value to the NHS, totemic value) discussed above. 
As in Hedgecoe’s work on Herceptin (2005), the ‘messy realities’ 
of bringing Oncotype DX into treatment decision making meant 
that its value was contextually negotiated in practice. It was sometimes 
experienced as particularly valuable and unique, including because 
it is a novel commercial test, where tissue is processed in a US labora-
tory rather than an in-house hospital laboratory. On the other hand, 
it could also be experienced as unremarkable or lacking in special 
value, as just one of a raft of tests brought into decision making, 
and sometimes as lacking any additional value where its clinical 
utility was considered uncertain. All experiences involved patients 
and practitioners in particular kinds of emotional or articulation 
work (Star 1985), drawing on social and cultural capital to make 
meaning from the test in the here and now as well as for service 
and patient futures. This happened in the clinic and beyond in online 
breast cancer patient communities, as we now go on to examine.
Integrating genomic tumour profiling in practice
According to NICE guidelines, NHS clinicians are advised to 
administer gene-expression profiling in HER2+, ER– and LN– early-
stage breast cancer where there is uncertainty around whether to 
recommend adjuvant chemotherapy to prevent recurrence, and where 
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established tools such as NHS Predict are unable to offer a clear 
recommendation. This frames the test as a solution to such uncertainty. 
Yet as with many such tests, practitioners’ experiences suggest that 
Oncotype DX is a means of managing rather than simply resolving 
uncertainty.
We interviewed nine practitioners involved with Oncotype DX 
in their practice, including one clinical nurse specialist, seven oncolo-
gists and one pathologist. We also carried out six observations of 
consultations where discussion of the Oncotype DX score took 
place, and where decisions were made regarding the benefit of 
adjuvant chemotherapy.
As practitioners in our study frequently pointed out, opting into 
or out of chemotherapy involves careful consideration of a patient’s 
personal and social circumstances and clinical factors, where non-
genomic quantified risk prediction through NHS Predict remains 
paramount in determining whether to offer gene-expression profiling. 
As in other fields, clinicians exercised their professional autonomy, 
non-routine working and tacit knowledge to work flexibly within 
NICE guidelines (Timmermans 2005; McDonald et al. 2006) when 
it came to Oncotype DX. Practitioners told us that decisions about 
Oncotype DX testing were not just based on the patient’s cancer 
but included consideration of co-morbidities and individual patient 
characteristics, and in the words of one oncologist, their ‘scope to 
benefit’. This flexibility is anticipated in the guidelines which require 
that ‘information provided by the test would help them choose, 
with their clinician, whether or not to have adjuvant chemotherapy 
taking into account their preference’.6
We can illustrate how clinicians flexibly embed gene profiling in 
practice in collaboration with their patients through the account of 
one oncologist who reflected on their experience of treating a patient 
who had been resistant to undergoing chemotherapy because of the 
impact on their occupation. The oncologist had already determined 
that because the cancer was low grade, chemotherapy would not 
be a good option, and the Oncotype DX test simply confirmed this 
decision. As they stated, the test played a role in solidifying treatment 
recommendations that would already have been made: ‘we feel really 
reassured that we’re not doing the wrong thing. So that was really 
helpful for [the patient], but did it change our management? I don’t 
know that it did.’ As another oncologist attested, ‘Quite frequently, 
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it gives the result that you fully expected … It’s more often that it’s 
simply confirmed the view that we thought was more likely.’ Similarly, 
during an observation of a consultation where the patient was 
categorised as ‘high-risk’ following Oncotype DX testing, the clinician 
confirmed that the patient would benefit from chemotherapy, a 
decision that they imply they would have reached regardless of the 
test:
Speaking to the patient and her husband, the clinician explained that 
an additional test was required [didn’t say why this was the case], 
which is called Oncotype DX, that tests a number of genes, ‘21 genes 
to be precise and based on this score, patients are categorised into 3 
groups: “low risk”, which is “good cancer”, “intermediate’ group, 
and the group with high risk of recurrence in 10 years.’ The clinician 
confirmed that the patient is in the high risk group to which the 
patient’s husband replied, ‘yes, because it’s 44%.’ Based on this, the 
clinician went on to say ‘I would have recommended chemotherapy 
anyway even without gene testing results.’
According to these accounts the value of the test was as a confirmatory 
device, reassuring patients and according with decisions reached 
using other clinical tools and judgements. In other consultations, 
however, and particularly for patients ‘at the margins’ with this 
lower-risk cancer, the Oncotype DX result was a means of providing 
further, and more precise, information which aided the decision 
about chemotherapy, as the extract below highlights:
The consultant explained what the NHS Predict tool is and they went 
through each section together thoroughly. Because the patient is ‘so 
young’ [40 years old] the consultant predicted a good prognosis. They 
added that without the Oncotype test result [i.e. with just the NHS 
Predict result], it might have appeared that the patient doesn’t need 
chemotherapy but with this result it shows the benefit – explaining 
they are ‘trying to put different bits of information together’. The 
husband said ‘given the cost of chemo’, the benefit seems so small. 
The consultant said NHS Predict gives you ‘a rough average’ but 
because breast cancer is a big group of disease[s], this is ‘where 
Oncotype comes in’.
The test was also used as a means of reassuring the patient’s husband 
that chemotherapy would be beneficial given their concerns regarding 
efforts to balance the benefit and burden of chemotherapy. We see 
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consultant, patient and relatives acting together to reach decisions, 
taking responsibility for obtaining specific information as part of 
this process.
This is also captured in a further observation with the same 
consultant:
And then [consultant oncologist] gave an overview of the patient’s 
cancer that it’s common cancer and early grade (Grade 2 she said), 
21 mm with clear margin, and ER+ & HER2–. [Consultant oncolo-
gist] then explained that breast cancer is a very big family of cancer 
[exactly same wording she used in the previous consultation I observed]. 
[Consultant oncologist] explained, by drawing a diagram on a sheet of 
A4 paper (‘it’s easier with a picture, isn’t it?’ the consultant said) – while 
explaining two subtypes of breast cancer which are estrogen receptor 
positive and negative, she wrote down ER+ and ER– on the sheet and 
then each ER+ and ER– is branched out by lymph node status i.e. 
positive and negative – I couldn’t quite see from where I was sitting 
but I think they wrote down LN+ and LN– on the sheet. ‘This is when 
Oncotype test comes in’, [consultant oncologist] said – this looks at 
LN– within ER+ [categories] … ‘on surface this cancer might look 
good but Oncotype might tell us otherwise’ [this explanation is also 
very similar to what was said to another patient in consultation].
Here we see Oncotype DX being presented as providing certainty to 
resolve previous doubts around whether to proceed to chemotherapy, 
or even revealing more harmful cancers that might initially ‘look 
good’ on the surface, in the context of such a wide and varied 
‘family’ of diseases. The test was valued by some clinicians because 
they felt it assisted patients who were finding decision making dif-
ficult. This is visible in the following extracts, from a discussion 
with a consultant following a clinical consultation and a separate 
interview:
The consultation finished and the couple left the room to have a 
blood test done. Before I left, I asked the consultant if Oncotype DX 
is a useful tool and they said yes, as it helped the patient to change 
her mind or make up her mind.
Patients often find it quite useful because it’s difficult for them to 
make these decisions, so in a way having the test to tell you whether 
you should or shouldn’t have chemotherapy takes the difficulty away 
from you and you just do what the test says. I think that’s why a lot 
of patients quite like them.
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In other situations, and for some other clinicians, the test was 
less useful. A clinical nurse specialist working with the technique 
noted that the test could not always offer certainty or eliminate the 
‘grey areas’ experienced by patients and clinicians; nevertheless it 
was valuable because it was ‘making them smaller’. After ordering 
gene-expression profiling many times, one clinician had almost 
stopped using the tool, now largely reverting to their prior practices 
of clinical judgement to make personalised decisions about chemo-
therapy treatment:
The first year we did about eighty [patients] I think … I don’t know 
how many … so what that showed to me was that almost nobody 
should get chemo … they were all lower intermediate. So actually 
using it has been an education, because it reaffirms to me that I think 
almost nobody who has node negative breast cancer should get chemo. 
And now I think I’ve got enough data to feel confident about that, 
and that’s why I think we don’t need to get Oncotype to do that. So 
now I’ve kind of almost stopped using it … because it’s reaffirmed 
to me the UK backbone that was there all along, which was actually 
giving cytotoxic therapy to node negative hormone sensitive breast 
cancer, is almost always the wrong thing to do … now how do you 
pick out the three or four women out of a hundred? Well maybe you 
can’t, but how much benefit do those people get? In absolute terms 
not that much. And does Oncotype pick them out? We don’t know 
because in the high risk group it was never randomised. TAILOR X 
assumed that the low risk group didn’t need it, and assumed that the 
high risk did need it.
The oncologist above began using the test once it was recommended 
for funding, but found, over time, that their prior clinical experience 
and the decisions made were reinforced, not challenged, by Oncotype 
DX results, attenuating its value in practice. Nonetheless, the big 
future promises of personalised medicine remained, as they went 
on to say: ‘I’m sure one day the computer will beat the human at 
chess, but I don’t think Oncotype’s the thing that’s going to do it.’
We see, then, in common with other genetic tests as described 
by Latimer et al. (2006: 621), that Oncotype DX was just one of 
many resources involved in cancer diagnosis and prognosis, with 
the relationship between clinical judgement and laboratory testing 
complex, and by no means unilinear. This could include enacting 
professional responsibility to make judgements without tests that 
were perceived to be unnecessary, and questioning whether this test 
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is an efficient use of limited resources, as the following oncologist 
describes:
I suspect it’s fulfilling its promise but at the downside of maybe quite 
a lot of tests are being done, that may not be, you know, for example, 
in patients that maybe, like you wouldn’t really be giving chemotherapy 
to, but then you do it because they’re eligible and it’s low and you 
still don’t give them chemo … I just have slight concerns about how 
many, kind of, how accurately we’re using them, you know, by throwing 
it around a lot. Some of them were hitting the mark, some of them 
are, are not. And just based on, kind of, how expensive it is and how 
bankrupt the health service is…
These more equivocal accounts of gene profiling strike a different 
tone to the optimism and anticipation reported in the UK media 
about Oncotype DX transforming practice, after the TAILORx trial 
and NICE consultation of 2018. They form a kind of ‘backstage 
ambivalence’ that enabled clinicians to embed the technique in 
practice, using it as part of a package of support, confirmation of 
diagnosis and prognosis, and management of patients’ circumstances 
and expectations; yet a moderated frontstage commitment to such 
technologies can be maintained, as the oncologist quoted above 
went on to say:
These sort of technologies are the future, they’re not going to go 
away. Definitely they’re going to stay … but there may be a limit to 
how much predictive information you can get just from the cancer. 
Because the entirety of what’s going to happen in that patient’s next 
ten years is not just encoded in the cancer.
Being flexible also included situations where oncologists chose not 
to perform the test. For example, one oncologist described how 
they had chosen not to offer the test to one eligible patient because 
they did not consider it necessary:
I had someone recently who was quite a young patient … she had a 
grade three cancer and it was … only moderately ER positive and so 
technically we could have done Oncotype on her. But I prejudged it 
that there was really minimal likelihood that it would come back 
with a low score and therefore didn’t do it, just went ahead and gave 
chemo. I think doing the test almost certainly would have been a 
waste of the health service’s money, because there’s such a minuscule 
chance of it coming back low.
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The potential delay that Oncotype DX testing could introduce to 
treatment pathways, with results taking around two weeks following 
shipment of the sample to the US-based laboratory, was also a source 
of concern.
All of this meant that there was considerable variation in the 
extent to which the clinicians we interviewed used the test, with 
some having used it on fewer than ten occasions. As suggested 
above, cost and patient care may have played a role here, but clinicians 
were also sceptical about the commercial interests behind the test, 
and the involvement of the manufacturer in the evidence base that 
supported its adoption in standard practice, echoing Hedgecoe’s 
(2005) findings about Herceptin use being limited due to cost 
considerations.
The low usage among some clinicians interviewed was also associ-
ated with their high satisfaction with the standard tools and techniques 
used to estimate recurrence and chemotherapy benefit within the 
UK. UK pathology practice was framed as more comprehensive 
than in the US, where Oncotype DX was developed and trialled. 
Clinicians described feeling confident in the pathology reports used 
in the UK (these include markers not used in the US), and doubted 
the additional value provided by gene-expression profiling. One 
oncologist praised the pathologists they worked with in their practice, 
noting that they were very ‘accurate’ and provide a ‘good rock’ for 
clinical decisions. This was echoed by another, who contrasted 
pathology in the UK with the US:
[Oncotype DX] adds a lot less to UK practice than it might have been 
expected to add to US practice … and that’s important when, in trying 
to understand the implications and trials like TAILORx which … 
were predominantly run in the US … which in our opinion probably 
has been, overtreating people for quite a long time with chemotherapy 
in, in groups of patients that we would have used existing prognostic 
parameters to identify.
These accounts differ from the clinical practitioner contributions to 
the NICE consultation, which emphasised the value of Oncotype 
DX to the NHS as a means of reducing waste and making cost 
savings, and instead echo some of the scepticism about over-
interpretation of TAILORx trial results as expressed in the committee 
deliberations that followed. Here, Oncotype DX is framed as an 
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unnecessary cost in a system that is already able to deliver high 
levels of prognostic precision, and we see these clinicians rearticulating 
arguments about value to the NHS as a reason not to use the test.
Alongside these multiple rearticulations of value and responsibilities 
with respect to clinical decision making, guiding patients and being 
cost-conscious, elsewhere clinicians intimated that Oncotype DX 
and other gene-expression profiling technologies were part of the 
future of the NHS, as evidenced in our examples. The promise of 
genomic medicine reflected in the NICE consultation and responses 
to TAILORx results was recapitulated in even otherwise ambivalent 
accounts. This hopeful view for the longer-term future of genomic 
cancer medicine was also held by one oncologist who had been 
particularly sceptical about the added value provided by Oncotype 
DX testing. The fact that this was an ‘old’ technology impacted their 
view of genomic profiling in breast cancer; however, they maintained 
a view that in the future there is the possibility of ‘major impacts’:
You see Oncotype DX is old, whereas some of, some of the lung 
cancer mark[er], receptors are really quite, they are making a difference. 
So in a way Oncotype is old news, and I think there are other cancers, 
and it’s not my expertise, but there are other cancers where there are 
markers or things that can be, that do definitely define pathways and 
outcomes and information regards in prognosis. So I think it will 
impact actually. I think maybe breast cancer will impact less than 
some others. But other cancers, definitely there may be some major 
impacts.
These clinicians did not describe gene-expression profiling for breast 
cancer – presented in some accounts as a ‘poster child’ for the 
movement of genomic techniques from bench to bedside – as revo-
lutionary or transformative to their practice; in fact, many noted 
instead their satisfaction with long-established procedures. But in 
other respects, they mirrored public and policy contributions which 
positioned techniques such as gene-expression profiling as totemic 
of ‘the future’ of cancer care, maintaining anticipation while managing 
uncertainties in present practice.
This representation of the future of genomic medicine as on the 
cusp, but not quite attained, is a familiar trope that can be found 
in public discourse since the sequencing of the human genome almost 
twenty years ago. While this kind of ‘genohype’ has been a concern 
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for stakeholders, including policymakers as they attempt to reconcile 
it with the pressures of a constrained health service, such expectations 
for genomic medicine have also been recognised as a stimulus and 
as necessary to drive clinical change (Samuel and Farsides 2017). 
Ambivalence and flexibility in the use of gene profiling in practice 
functions alongside anticipation as part of these processes of change. 
For practitioners, flexibility and ambivalence about the value of the 
test was part of managing uncertainties in the clinic while maintaining 
optimism about improved services and prospects for patients in the 
future. Clinicians’ various renderings of the test as totemic of the 
future, confirmatory, provisional, incremental, and even at times 
obsolete, do not necessarily diminish but rather repurpose its value 
as an additional tool and another step along the way in improving 
cancer care. These accounts and activities are part of the articulation 
work through which they exercised professional responsibilities to 
their patients and the service as a whole.
Treatment decision making for early-stage breast cancer: 
patient accounts of Oncotype DX
In addition to the observations of consultations already discussed 
above, we also interviewed 19 breast cancer patients with experience 
of Oncotype DX (the majority of whom had the test as part of NHS 
care) and analysed 132 discussion threads on Oncotype DX from 
a total of seven online cancer patient forums. In this case study, 
patients’ narratives had a different form and emphasis than the 
clinicians’ interview accounts or their contributions to public consulta-
tions about the test. As with our other case studies, personalised 
medicine and genomic tests were but one part of patients’ stories 
of cancer diagnosis and treatment, which encompassed a range of 
experiences of tests, treatments, research and care. This was the 
case with Oncotype DX too. Patients, on the whole, did not make 
a detailed case for or against the technology, nor did they articulate 
an elaborate vision for personalised medicine and its place within 
the NHS. Instead they narrated intricate stories of managing uncer-
tainty, interpreting information, making choices, coping with feelings 
of hope and disappointment, pain and frailty and living through 
cancer with families and friends. Oncotype DX, like other tests, 
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featured in these accounts sometimes as a key actor (for example, 
in online forum discussions about what to do after surgery or when 
detailing its role in decision making), but it was more typically 
surrounded by a multiplicity of narratives about treatment, care 
and research.
Within this context, Oncotype DX was loosely framed as an 
advance by most patients who had experienced the test, for example 
when they compared their experiences with the care received by 
friends and relatives, particularly because the test was costly and 
sometimes because it was performed in the US. Patients faintly 
echoed some of the promissory discourses of personalisation that 
we have identified in media and policy accounts. One patient, Bethany, 
who described the technique as ‘state of the art’, told us she worked 
in an environment where any change to her appearance would be 
noticed and commented upon, so she desperately wanted to avoid 
chemotherapy, articulating her responsibility to remain active and 
competent in the workforce despite her cancer. However, because 
the test was seen by her as authoritative, due to its being more 
‘advanced’ than existing techniques, she conceded that should the 
result indicate she was at a high risk, the responsible thing to do 
would be to proceed to chemotherapy: ‘I thought if a sort of state-
of-the-art test is saying that’s what I need then of course, it might 
be unpleasant but of course I’ll go through that, you know, I’ll have 
chemotherapy.’ The scientific basis of the test was also a feature of 
its promise, as described by another patient, Julie: ‘I was very pleased 
when I heard how the test worked because I thought “right, that’s 
fine because that makes it much more specific and that will make 
me feel I’m not making a hunch decision, I’m making a decision 
based on actual science, actually related to me”’.
The advanced nature of the test was also referenced in online 
forums where some participants contrasted Oncotype DX with more 
widely used tools such as NHS Predict, positioning these as ‘low-tech’ 
when compared with gene-expression profiling. One user pointed 
to a dissatisfaction with established recurrence-risk estimation tools 
such as NHS Predict, which she noted ‘I can access myself’ (breast 
cancer charity forum). For these women Oncotype DX ‘is a lot more 
personal and specific than the original %s’ (cancer charity breast 
cancer forum), because ‘generalised tools could be very wrong’ (breast 
cancer charity forum).
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For patients such as this, Oncotype DX testing is a way to enact 
their responsibility to choose wisely, as it was considered to offer 
more certainty than established tools predicting risk. Patient accounts 
have much more congruence with the kinds of value articulated in 
the consultation responses discussed above, particularly in terms of 
aiding difficult decisions and offering personal relief and reassurance. 
This was the case for interviewees such as Alice. Like others we 
spoke to, she described a very ‘quick’ experience of her breast cancer 
diagnosis and treatment with a clear set of procedures to engage 
with, until the possibility of chemotherapy was raised by her clinician. 
Following Alice’s surgery, it was found that one of her lymph nodes 
was ‘slightly affected’ by the breast cancer, and the benefit/risk 
measure in her particular case for proceeding to chemotherapy was 
unclear. As Alice described, it was ‘touch and go’ from both her 
perspective and that of her oncologist, because the spread was ‘such 
a small amount’. Alice wanted to avoid chemotherapy due to her 
wish to return to ‘normal’, and an understanding of the treatment 
as potentially ‘worse than the cancer itself’. She described Oncotype 
DX as a ‘perfect fit for what I wanted to understand about … 
chemo’, and positioned the test as providing certainty in the context 
of complex treatment decisions:
I need certainty. I said, right, I’ll pay for this test if necessary, to make 
me make the right decision (laughing) … if I needed chemo, then I 
would just have to knuckle down and get it done … I just needed 
some certainty, as to whether I needed it or not.
Here Alice articulates her desire for certainty, and assumed responsibil-
ity for obtaining the test by paying for it herself if necessary. She 
was intending to act on the results, accepting chemotherapy if it 
was recommended, just to ‘get it done’. Alice’s feelings about 
Oncotype DX were echoed by Julie, who was very keen to avoid 
chemotherapy due to her concerns about her immunity being 
compromised during treatment; but she also felt that the treatment 
would be unavoidable if the test results predicted a high risk of 
recurrence. She described the information provided by the test as a 
‘crystal ball’.
These framings were also observed in online forum discussions. 
When users asked for information about the test, Oncotype DX 
was presented positively by some because, in the words of two 
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respondents, it ‘took the guesswork out of whether you should have 
chemo’ and meant the patient would ‘know whether you need chemo 
or not’, offering one kind of certainty in an uncertain future. Col-
lectively, patients on these forums encouraged and supported each 
other to take on the responsibility of accessing and acting upon 
Oncotype DX results. Oncotype DX was also praised by some as 
a means to aid chemotherapy decisions because of the way in which 
results are displayed as a single score representing recurrence risk 
and potential benefit from chemotherapy. Patients who had until 
that point experienced uncertain and shifting diagnostic pathways 
were particularly enthusiastic about this kind of scoring system. 
Oncotype DX testing was therefore valued by patients who told us 
they had found the uncertainties and ‘false horizons’ of diagnosis 
and treatment difficult. This was especially the case for those patients 
who had not initially anticipated having to consider chemotherapy, 
as it was not raised as a possibility until pathology results were 
obtained following surgery. For these patients, Oncotype DX results 
offered welcome guidance for an unexpected and unwelcome decision. 
Lillian, for example, told us of her experience of researching Oncotype 
DX online after her clinical nurse specialist (CNS) rang her to inform 
her about the test. Until this point, Lillian, an office worker in her 
early sixties, thought her cancer was a mucinous breast cancer, 
which is a rare cancer, but when she found out this wasn’t the case, 
for her, ‘it was kind of a sense of relief almost (laughs) … Because 
I thought, well, they’re more used to treating a more common cancer.’ 
Lillian found the CNS and online chatrooms were particularly useful 
in offering reassurance that the test was valuable for guiding treatment 
decisions. Of her Oncotype DX result, Lillian explained:
I think I could see things in black and white a bit more clearly. So 
you can be told your grade or your stage of your tumour, but to be 
able to know a bit more about likely recurrence and a bit more about 
prognosis and things like that, for me … it all came together and 
made it so much more understandable somehow.
For Lillian, being a ‘good patient’ involved taking on the mantle of 
responsibility to research and consider options, to understand and 
make sense of results and to choose wisely when it came to treatment 
possibilities. This also encouraged Lillian to take part in the 100,000 
Genomes Project (discussed in Chapter 5).
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In some cases, where participants were placed in the low recurrence 
risk category, the test also enabled them confidently to avoid 
chemotherapy. Susan, whose daughter also had breast cancer at a 
similar time, explained that the Oncotype DX result ‘reinforced’ 
her preference for rejecting chemotherapy. Seeing her daughter 
struggling with chemotherapy, ‘it was only because [of the] Oncotype 
result’ that she could avoid the temptation of ‘belt and braces sort 
of way of doing’. Bethany, meanwhile, described the test as allowing 
her to feel more ‘confident’ that it was not irresponsible to forego 
the treatment. The test results were also welcomed by some patients 
who were considered to be at a higher risk of recurrence and who 
might therefore benefit from chemotherapy to reduce that risk. Lois, 
who had her cancer detected at a three-yearly breast screening, 
described the meaning of the Oncotype test as ‘a second opinion’ 
which allowed her to avoid chemotherapy:
[They said] ‘we could just give you chemo or there is this test available, 
the Oncotype test’ so immediately we said ‘yes please, if we could 
get that’. And fortunately three weeks later it came back to say it 
was reading 6 so I was clear of needing any chemo so that was a 
great, a great day.
In other respects, however, certainty was not always provided by 
a straightforward reading of the test results, even when these were 
clearly at one or the other end of the spectrum, as the following 
example illustrates. Zoe, a medical professional, described her sense 
that there was a ‘right’ choice to be made about chemotherapy when 
she told us about her experience of the Oncotype DX. Using NHS 
Predict her cancer had been designated as at low risk of recurrence, 
but her oncologist voiced uncertainty about this designation because 
the cancer was high grade. Oncotype DX testing was recommended 
and Zoe started reading academic journal articles about the test, 
including the recent results of the TAILORx study. However, Zoe 
did not feel secure in rejecting chemotherapy when her Oncotype 
results came back with a low score of 7, and she deferred to her 
oncologist following the result, to further confirm that she was 
making the ‘right choice’. Without Oncotype DX testing, she 
explained, because her cancer was high grade it would have been 
a ‘constant worry’ whether not going for chemotherapy was the 
‘right thing to do’. But it took work on the part of Zoe and her 
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consultant to interpret the results of the test together in such a way 
as to achieve her sought-after certainty.
As clinicians emphasised, the interpretation of results was highly 
contextual. This is illustrated in the extract from fieldnotes below, 
in which an intermediate result is discussed:
And then [consultant oncologist] brought up Oncotype test results 
on the screen saying ‘Graph is very useful’. [Consultant oncologist] 
said ‘your score is 30 so it’s intermediate risk’. The consultant said, 
‘hormone therapy will be beneficial but the difficult decision is about 
chemo’. The consultant asked the patient to guess where they ‘belong’ 
– the patient answered ‘middle group’ with a burst of laughter. The 
consultant showed the graph on the screen again and compared the 
risk of recurrence when the patient has hormone therapy (14%) vs. 
when she has both chemo & hormone therapy (7%). In order to 
emphasise the difference, the consultant used her fingers to measure 
the gap. The patient replied by saying, ‘noticeable benefit’.
This is when the consultant brought up the patient’s heart failure and 
the patient asked how much chemo will affect her heart condition. 
[Consultant oncologist] explained that any chemo drugs that might 
affect the patient’s heart won’t be allowed to [be] prescribe[d] and 
also because of the patient’s history of pneumonia and kidney stone, 
alternative chemo drug called taxol will be recommended and the 
patient will be monitored very carefully. It’s ‘a diluted form’ and will 
be administrated weekly so it’s ‘not too bad’. [consultant oncologist] 
then went on to explain the side effects including hair loss (the patient 
laughed), infection, and weight gain – the patient laughed again at 
this and turned to her mother and joked ‘it will look really nice mom’. 
The consultant said they appreciated that the patient’s heart condition 
is ‘a significant setback’ given that she always has reservation for 
chemo under any circumstance. The patient said she is ‘between a 
rock and a hard place’ but she has always been ‘an unlucky person.’
Then the conversation shifted to talk about the patient’s care responsibil-
ity. The patient’s adult son is living with her and her husband and he 
has severe disability. The patient was concerned about her husband 
who is in his late 60s, which mean[t] he won’t be able to look after 
their son on his own so she was wondering whether she will be 
well enough to continue to help out while receiving chemotherapy.  
The patient said this is the reason why ‘this is difficult decision to 
make’. The consultant said ‘I am glad you said this’ and it’s important 
to know what kind of ‘limited reserve’ the patient has. The patient 
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said, ‘I am a mess’. The consultant said it’s possible to suspend chemo 
depending on the patient’s general health and the patient replied ‘it’s 
reassuring to know’ and suggested that she might ‘try and see’. The 
consultant explained again that they will recommend the chemo that is 
for frail patients or patients with existing health issues and suggested 
that the patient can read information leaflet that will be given to her 
and have a think about it. The patient said she is happy about this 
arrangement so she could have a discussion with her family. They 
went on to talk a bit more about other side effects. The patient’s 
mother asked if there is any alternative to chemo. The consultant 
reiterated the value of Oncotype test – there are some benefits of 
different treatment options but Oncotype test ‘teases out’ the benefits.
For this patient and her family, the intermediate test presented a 
‘difficult decision’ given her health and caring responsibilities, and 
required careful negotiation over the kind of chemotherapy that she 
could manage. Together with the consultant and her mother, she 
worked to articulate and balance her various responsibilities to be 
well and to care for herself and her family, making the Oncotype 
DX result, and more specifically the intermediate result, a valuable 
tool for navigating her particular circumstances. The uncertainty of 
the intermediate result was productive, creating a space for considera-
tion of this patient’s unique circumstances, and facilitating her and 
her family’s involvement in treatment decision making (see also 
Brown and de Graaf 2013; Swallow 2019).
As with the clinicians we interviewed, some patients also took 
other factors into account when making their decisions, rather than 
following the recommendations of their test result alone. Supported 
by her oncologist, one patient ‘in the grey area’ decided to go ahead 
with chemotherapy:
so, my understanding anyway was that it’s a low risk cancer but 
obviously the score on the Oncotype having been fed into that system 
… I was in the grey area as to, as to whether or not I would need 
[chemotherapy]. But in my head I’d already decided that it was 
inevitable.
Another woman with a low risk of recurrence score, writing on a 
breast cancer forum, noted that because of her young age and her 
experience of her father’s death from bone cancer she would proceed 
with chemotherapy, despite her Oncotype DX result suggesting a 
low risk of recurrence. Another patient described receiving a low 
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Oncotype DX score but proceeded to chemotherapy because of the 
size of her tumour. For other patients, results could be flexibly 
interpreted, particularly patients with scores in a ‘grey area’; for 
example, an intermediate result could justify stopping chemotherapy 
early due to unpleasant side-effects, as was the case with two forum 
users.
In these situations, the complexities of Oncotype DX did not 
always resolve uncertainty but raised questions and worries, sometimes 
making grey areas larger rather than smaller. These included situations 
where, long after the test had been conducted, patients continued 
to wonder about their prospects of recurrence. For example, in an 
interview with Wendy, conducted three years after her diagnosis, 
she told us she was not sure what the Oncotype DX test was, and 
‘never really asked’, although she described herself as ‘somebody 
who wanted to know as much as I possibly could’. Having gone 
through treatment and now being back at work full-time, Wendy 
explained why she never asked about the test:
I looked it up online later, I did find out quite a lot although it didn’t 
go into detail about exactly what the test was. And it’s quite interesting 
because I never really asked because I could never work out how to 
find the right words but I never asked whether, if it came back saying 
you won’t benefit from chemotherapy, is that because the tumour is 
unlikely to spread or is that because it won’t respond? Do you see 
the difference?
Wendy had received a low risk of recurrence score and had accepted 
the recommendation to forego chemotherapy, but she remained fearful 
of recurrence, a common feature of living with or beyond cancer, as 
poignantly discussed by Horlick-Jones (2011). She remained unsure 
about whether her low score was due to the fact that ‘the tumour 
is unlikely to spread’ or ‘because it won’t respond’ to treatment.
The introduction of the test to already complex diagnostic and 
treatment pathways created additional distress for some women. 
Several accounts attributed this to the fact that gene-expression 
profiling exacerbated the ‘rollercoaster’ experienced during initial 
diagnostic processes, with all this ‘thrown up in the air’ by the 
introduction of Oncotype DX (breast cancer charity forum), especially 
due to the time required to wait for the results from the US (up 
to two weeks). Echoing Gillespie’s (2012) findings of ‘measured 
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vulnerability’, a few participants told us that discussions about 
the test exacerbated their concerns about their cancer, including 
Bethany, discussed above, who was diagnosed with breast cancer 
at the same time as three of her friends. As the only one who 
was offered Oncotype DX testing, she questioned what this meant 
about the severity of her cancer as compared with others. Another 
patient, Chrissy, a woman in her sixties who detected a lump that 
led to diagnosis, also told us that gene-expression profiling raised a 
lot of questions for her about why she was being offered this test: 
‘Who debates whether it, it gets sent off or not? Who … makes that 
decision? The consultant or … I’ve got a friend that’s got tongue 
cancer … that’s not gone off for any testing. Why … me? (laughs) 
Why has mine gone off?’ When she was told to have chemotherapy, 
Chrissy said she was ‘shocked’ as she expected to go back to normal 
life after the surgery. Chrissy related her anxieties about the test 
to the fact that the test was ‘something new’, and processed in a 
laboratory in the United States:
So when they said they were sending samples to America, it was like, 
well, this is something new, something I don’t know anything about 
… you’d tend to think if it’s a well-known test they would be doing 
it in this country as well. So it was a bit of … an alarm bell ringing 
I suppose as to … what’s different that they need to send it away to 
do this?
Here the ‘newness’ of the test was a source of concern rather than 
a sign of its value. For some this was due to their unfamiliarity with 
the test and its mechanism. Participants were given a variety of 
levels of explanation about the technology by their clinician, and 
engaged with further information about the test in varying ways. 
The way the test might be used as a cost-cutting mechanism, denying 
patients treatments they might want, also occasionally came up, as 
in this quote from Ally, whose plans for an active retirement had 
been blighted by her cancer:
So then you start to think, knowing the NHS, knowing the state of 
budgets, whether that [drug] is not going to be [given], because you 
do hear in the news don’t you, that some people could benefit from 
having a certain type of drug for any particular condition, but because 
it’s expensive, ‘oh we can’t give that’; that isn’t rolled out to everybody 
just yet.
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Other interviewees did not engage with detailed information 
around the test, including patients who said they did not possess 
detailed knowledge of the different tests they had received or the 
implications of their results. Valerie, a young woman in her thirties, 
experienced her cancer diagnosis and treatment as ‘like a conveyor 
belt’. She had conducted her own research about breast cancer 
following her diagnosis, and involved her husband in the processes 
of treatment decision making following her Oncotype DX result. 
However, she remained unclear about how the result of the Oncotype 
DX test was achieved, and what this represented. She explained: 
‘I’ve found out various bits and pieces in the booklet that, that it 
goes to California … I think it’s difficult ’cause … everyone is clearly 
different with whether they want to read anything or not. I didn’t 
really want to read anything.’
Here Valerie draws attention to an experience related by many 
of the patients we interviewed across our wider research, for whom 
being a responsible patient meant avoiding ‘too much’ information, 
limiting their internet searching and the questions they asked, and 
taking their cancer management ‘one step at a time’. In the case of 
Oncotype DX, this resulted in some women and their loved ones 
engaging with minimum information about the test, because of the 
complexity and the amount of information they could take on board 
at this distressing time. Two patients signalled that they had only 
engaged with the test because they were required to make a choice, 
although it would have been, in the words of Alice, ‘easier’ if her 
clinician had initially given a clearer recommendation about chemo-
therapy, rather than offering her a treatment choice. For these patients, 
a strong sense of trust in their clinician’s assessment of the Oncotype 
DX result, in the context of other information, rather than the score 
alone was more significant than the intricacies of the test, highlighting 
the enduring importance of clinical judgement for patients (Latimer 
et al. 2006; Bourret et al. 2011).
Conclusion
Oncotype DX was totemic of advances and further personalisation 
of cancer care in the future across policy, practitioner and patient 
accounts. While there were a range of views about the clinical utility 
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of the test and its cost-effectiveness, there was nonetheless general 
support for the role of such technologies in an unspecified future. 
More pragmatically, the test was commonly associated with greater 
certainty, and relief for cancer patients from the burden of toxic 
chemotherapy, or else as providing compelling support for such 
therapy. Savings and efficiencies in the NHS were highlighted by 
some as key benefits of the technology being more widely adopted. 
Practitioners and patients told us the test was valuable as a means 
of confirming decisions and obtaining reassurance, providing more 
certainty that enabled them to act responsibly in making wise decisions 
about the need for treatment to decrease the likelihood of recurrence.
Nevertheless, its promise in practice was muted. There was scepti-
cism, uncertainty and resistance to its wider use, from practitioners 
choosing not to perform the test as they considered it costly and 
unnecessary, to patients finding that results did not deliver certainty 
and reassurance, raising further anxieties and questions (see Ross 
et al. 2019). At times, patients resisted the impetus to actively research 
and engage with test results as a means of navigating their illness, 
and instead sought to limit their engagement with this and other 
information as a means of maintaining their poise and managing 
anxiety. The value of the test was thus provisional and in-the-making, 
as practitioners and patients navigated its implications and experi-
mented with its uptake and interpretation. Being a responsible 
practitioner or patient could involve a range of orientations towards 
the test and its results, and choreographing these orientations involved 
articulation work in the clinic and beyond.
The approvals process was guided by a precautionary logic where 
uncertainties and scepticism about benefits were given weight, but 
we found that much of the flexibility and ambivalence we encountered 
in our study was absent from public discourses about the utility of 
the test. Although capturing patients’ investment in the test and the 
value it brought to their experiences of treatment, policy and media 
accounts did not often capture the uncertainties and grey areas that 
can abound for patients who have been tested, even when certainty 
is promised or anticipated. Patients’ and practitioners’ ambivalence 
was overlaid with more totemic, anticipatory regimes of personalised 
medical futures, even in processes which purported to question the 
value of the test and aimed to capture a broad range and variety 
of experiences to guide policy formulation. The arbitration of 
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contested and conflicting evidence from trials and patient and clinician 
testimony resulted in continued valuing of the test within the NHS, 
thus ensuring both that the commercial imperative and the promise 
of precision medicine continued apace.
Through these dynamics, our case study of Oncotype DX reveals 
that the promise of personalised medicine is highly contingent and 
flexible and enacted through articulation work backstage of policy 
and public discourses. This promise is nevertheless amplified in 
frontstage policy, advocacy and media framings which assert benefit 
at the same time as they tend to mask ambivalence. These processes 
also frame personalised medicine as mainstream, even as the technolo-
gies at its forefront may be rejected or become folded into the 
complexity of responsibilities and decision making involved in the 
navigation of cancer diagnostics and treatments by practitioners 
and patients.
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Molecular profiling for advanced 
gynaecological cancer: prolonging 
foreshortened futures
Commercially produced genomic tests for cancer diagnosis, prediction 
and treatment are being incorporated into NHS care, albeit unevenly 
and with much contingency in practice. A range of genomic tests 
are under research and development as part of the widening diag-
nostics market: a recent report estimated that the tumour-profiling 
market would be worth $12.4 billion by 2024, with genetic biomark-
ers accounting for the largest share.1 Companies are producing suites 
of tests for different cancers and/or tests which work on multiple 
cancers. For example, Oncotype DX, discussed in detail in the 
preceding chapter, is now part of a wider set of tests called Oncotype 
IQ manufactured by the parent company Genomic Health, including 
tests for other kinds of breast cancer, prostate and colon cancer.2
This chapter investigates the development of one such molecular 
profiling test that has the potential to guide future management of 
locally advanced or metastatic cancer, but is not yet fully embedded 
in standard NHS care. Exploring how smaller-scale clinical research 
creates and prepares the way for further public/private partnerships 
to deliver personalised medicine, we focus on a feasibility study in 
an NHS hospital for a commercial molecular profiling test developed 
by a US company that we are calling Virtue. The multi-platform 
profiling test can guide treatment decisions for locally advanced or 
metastatic, gynaecological cancers.3 First, we look at how the feasibil-
ity study was part of building an evidence base for molecular tumour 
profiling in gynaecological cancers and cancers more widely, and 
the kinds of value making this involved. This traversed efforts to 
attain precision and actionability and negotiate the place of commerce 
with a view to the health service of the future. Secondly, we explore 
the experiences of patients involved in the study and how they and 
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their family members navigated this experimental space, making 
sense of the benefits and limitations of the study and associated test 
as part of their wider cancer experience. We explore the promise 
of this study, routinely called a trial by the practitioners and patients 
involved, and the kinds of uncertainties and ambiguity this could 
bring for patients and their families even as they ‘add more evidence 
into clinical practice’ (Metzler 2010). Focusing on patients with 
advanced or metastatic gynaecological cancer also gives us insights 
into a different set of experiences from those of ER+/HER2–/LN– 
early-stage breast cancer patients discussed in the previous chapter. 
These patients are often older and have experienced cancer for 
longer, affording different kinds of investments in the future and 
engagements with new technologies and the certainties they promise. 
In short, they have a poor prognosis, have already experienced 
recurrence and are running out of treatment options.
We draw on multiple sources of data to build this case study, 
including news reports, commercial websites, online patient forum 
discussions, policy documents, interviews with 16 gynaecological 
cancer patients who participated in the study, and seven of their 
family members, conducted in 2017, and three practitioners who 
ran the feasibility study, interviewed in 2018 and in 2019, when 
we followed up with them about the results. Before we explore 
patient and family member accounts, we first look at the ways in 
which the test can be seen as part of ‘a new era for cancer survival’ 
for metastatic and advanced patients (Nawrocki 2018), focusing on 
the kinds of companies involved in this bioeconomy and the ways 
they work with clinicians. We go on to consider how Virtue’s test, 
currently only available privately outside of research studies, is being 
configured for entry into the NHS via this feasibility study (which 
we are calling VGT), setting out the negotiations around evidence 
performed in this experimental space.
Precision oncology for advanced gynaecological cancers
A swell of activism has recently grown around gynaecological 
cancers, historically regarded as a ‘Cinderella cancer’ (Jasen 2009). 
Gynaecological cancers, including womb (uterine and endometrial), 
ovarian, cervical, vulval and vaginal cancer, are more common in 
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post-menopausal women in the UK, with the exception of cervical 
cancer, which tends to affect younger women more. Although womb 
cancer is the most common of these cancers, it is ovarian cancer 
that is the most visible in gynaecological cancer activism, with an 
increasing number of ovarian cancer charities involved in ‘knowledge 
activism’ (Rabeharisoa et al. 2014)4 as public awareness of symptoms 
is still relatively poor globally and in the UK in particular. Survival 
rates have not improved greatly and diagnosis often comes late. We 
interviewed several ovarian cancer patient advocates during our 
research. These people were endeavouring to raise the profile of 
ovarian cancer, to ensure that ovarian cancer patients were not ‘left 
behind’ while resources went to more common or more high-profile 
cancers, such as breast cancer. They also saw themselves as playing 
a role in educating women about its symptoms and to make sure 
these were taken seriously.
The challenges faced by ovarian cancer patients were compared to 
those of other cancers, where improvements had already occurred. As 
a young patient advocate and statistician, Rebecca, who was diagnosed 
with a rare type of ovarian cancer in her thirties, commented:
it really annoys me, like, on Facebook … your ten friends, ‘I’m hosting 
this for breast cancer’ … I’m thinking ‘oh god, why don’t you just 
tell the woman the symptoms rather than, you know, have some of 
these chain emails that people just do?’ … there’s always something 
for breast, what about ovarian or … not all the cancers are in, are 
pink, there’s other colours …
These concerns about a lack of support for and awareness about 
ovarian cancer meant that Rebecca was particularly invested in 
social media campaigns such as Everything Teal. She was also 
optimistic about the prospects of a breakthrough in precision medicine 
research:
I reckon in about the next ten years … hopefully we’ll have a break-
through or … perhaps if we could just … get more funding and get 
more like what breast has done because breast has had such a significant 
increase in survival rate … I know no cancer’s nice, but that’s more 
like the gold standard of thing where I’ve got more the Cinderella 
type of cancer …
Many tests offering personalised genetic information are marketed 
directly to consumers – 23andMe being the best-known of these 
platforms. Direct-to-consumer genetic testing covers everything from 
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ancestry, traits and characteristics to polygenic risk screening for 
susceptibility to disease (Hogarth and Saukko 2017). This is part 
of a process of what Metzler has called ‘biomarketization’ where 
biomarkers take increasing salience in the prediction and diagnosis 
of disease (Metzler 2010; see also Hogarth and Saukko 2017; 
Prainsack 2017). Companies specialising in molecular tumour 
diagnostics are particularly focused on developing links with private 
and public healthcare providers to deliver their tests, given the need 
for expert analysis of results in a clinical context. This means they 
must find ways to work alongside or in line with clinical practice 
and in-house hospital pathology services which have a long history 
of testing genetic and other biomarkers as part of diagnosis and 
prognosis, and of meeting stringent research governance processes 
within public institutions.
There are a number of larger companies in this market, including 
Illumina (see Chapter 5), but many companies in this sector are 
smaller and relatively young. Ranging in size and configuration, the 
companies typically offer a range of services and/or tests framed in 
terms such as cancer diagnostics, personalised healthcare, functional 
precision medicine and/or precision oncology. Their websites feature 
a range of patient and practitioner testimonials in the form of case 
studies and short films, similar to direct-to-consumer genetic testing 
services (Arribas-Ayllon et al. 2011). An example of this is Guardant 
Health’s film about Guillermo, a man in his forties from Chicago 
with metastatic stomach cancer.5 The film tells us how Guillermo’s 
doctor ordered a range of molecular tests when he came to him for 
his (third) opinion, at a point where he was very unwell and only 
had a short time to live. The Guardant 360 proved to be crucial as 
the cancer showed the EGFR marker (EGFR amplification) and 
enabled the clinical team to target treatments which dramatically 
improved Guillermo’s health and well-being. Even though this is 
not a cure, the film offers hope that the team will be able to offer 
new therapies when his disease progresses and ‘get back on top of 
it’. Tests like these are part of controlling the disease by trying to 
anticipate drug responses in order to find further, more targeted 
options to stifle the disease’s progression, hopefully extending life 
and quality of life.
UK patients do not access molecular tests in the same way as US 
patients such as Guillermo, as most treatments are provided as part 
of NHS care. In England many of these tests are performed by a 
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network of regional laboratories as part of the Genomic Medicine 
Service, which specifies which genomic tests are commissioned by 
the NHS in England, the technology by which they are available, 
and the patients who will be eligible to access the tests in a National 
Genomics Test Directory.6 A national whole genome sequencing 
service has also been developed in partnership with Genomics England, 
following on from the 100,000 Genomes Project discussed later in 
Chapter 5. At the time of writing there are only two commercial 
tests listed in the directory – Oncotype DX (Chapter 2) and Prosigna, 
another test that detects the risk of certain types of breast cancer 
recurring.
UK patients paying for private healthcare can obtain tests not 
available as part of NHS care, or access them via private health 
insurance; others can only access tests via research studies (Moore 
et al. 2019). Diagnostic companies have therefore formed a range 
of partnership arrangements with private healthcare providers in 
the UK to facilitate uptake of the tests and to build the evidence of 
benefit required for licensed practice. For example, Cambridge-based 
Oncologica® UK Ltd (established in 2014) recently announced a 
partnership with ‘a leading UK private medical insurer’ that allows 
funding of the Oncofocus® cancer test. The company’s press release 
notes that customers who meet agreed clinical criteria will be able 
to access the test, which will inform the selection of targeted 
therapies.7 This includes patients with advanced common cancers 
not responding to standard treatment, cancers for which there is 
no standard therapy and carcinoma of unknown origin. Analys-
ing the DNA and RNA extracted from routine biopsy samples, 
Oncofocus® profiles 505 actionable mutations linked to 700 tar-
geted therapies and immunotherapies that are approved or under 
trial.8
Research partnerships with NHS clinicians are also crucial to 
this developing market, not just because there are many more patients 
being treated in these settings than in private healthcare in the UK, 
but because partnerships of this sort build connections with clinicians 
who can be important advocates for the test in evaluation and 
appraisal processes for its wider uptake in the NHS, based on their 
expertise and experience in using it in practice. This is especially 
important in the case of molecular diagnostics, as although improved 
overall survival with lower weekly healthcare costs resulting from 
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molecular profiling for advanced/metastatic cancer patients have 
been reported in the US (Haslem et al. 2018), the evidence base for 
benefit is limited in health systems such as that of the UK (Nawrocki 
2018). The longer-term benefits of targeted treatments are also difficult 
to establish in this group, as many patients relapse after a couple 
of years on the drugs (Marquart et al. 2018).
Virtue’s VGT: case study
Virtue is a US-based company with a European branch and inter-
national ‘partners’ in countries such as Australia. It provides multi-
platform molecular profiling for several cancer types. The test, which 
we are calling VGT, has been developed to identify molecular 
biomarkers that can help to target treatments for metastatic cancer, 
using a range of tumour-profiling techniques to analyse protein, 
RNA and DNA in a sample of the tumour tissue.
As the clinical oncologist who coordinated the VGT test told us 
in an interview, Virtue is ‘a company relatively small in the grand 
scheme of pharma but it’s one of many start-ups that have offered 
similar things’. Virtue’s online promotional materials include patient 
testimonials and links to films, information about the expertise and 
technologies involved in its platform, and the steps involved in 
developing personalised recommendations for each patient. Emphasis 
is placed on the breadth and power of molecular evidence and 
analysis to give precise results. Patient testimonials include a film 
featuring an older woman who has been living with cancer for over 
a decade, thanks in part to molecular profiling provided by Virtue 
which helped tailor her treatments. The patient praises the company 
for its support through the process and emphasises how thankful 
she is for the extra time that the tests have given her. She speaks of 
her sense of duty to advocate for other patients and how rewarding 
this has been. This film is part of a set of other patient films, all of 
which involve patients with metastatic or recurrent cancer who have 
benefited from this test after standard care options had been 
exhausted. The section with information for patients on the company 
website invites patients and family members to share their stories 
too, alongside details of physicians who have previously ordered 
the test and guidance on payment arrangements.
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VGT is currently only available privately in the UK and is not 
yet approved as part of standard care in the NHS, although it is 
accessible to some patients enrolled in research studies and trials 
taking place in NHS hospitals. Some private health insurance 
companies also cover VGT on a case-by-case basis. NICE has 
synthesised the limited evidence of benefit in a briefing document 
to support NHS commissioners and staff, including contributions 
from specialist clinical commentators with experience of using the 
test and of the study we researched. As is common with many such 
tests, some evidence suggests that the test does contribute towards 
improved outcomes for patients, but there are no randomised 
controlled trials or studies of particular cancers to confirm this and 
no evidence of cost-effectiveness. Most of the studies cited were 
prospective and non-randomised, comparing VGT-guided therapy 
with what clinicians said they would probably have done if it had 
not been available.
We first learned about the feasibility study of Virtue’s VGT test 
when we interviewed the principal investigator (PI) for the study, 
at the end of a wide-ranging interview in which he discussed his 
clinical experience with patients and his wider university and NHS 
roles. The study was part of a number of activities in which the PI 
was involved, focused on digital technologies in healthcare or what 
he called ‘next generation informatics’ in the NHS, evoking the 
power of ‘big’ data linkage across the region and institutions via 
the innovation of large, complex healthcare platforms incorporating 
a range of biological and social data.
The PI mentioned Virtue after we spoke about our plans for 
further interviews with patients and offered to help us organise 
access in the hope that we would be able to conduct ‘exit interviews’ 
with patients on the VGT study and feed our results into the overall 
evaluation of the test. Here we became recruited into the mission 
of improving personalised medicine for patients, albeit in a loose 
and unstructured way. We were also told that the VGT study came 
about through serendipity, when the PI met a Virtue representative 
at an international meeting and a discussion about how to generate 
evidence of the ‘cancer outcomes’ following the test ensued. The PI 
and Virtue subsequently went on to work together to design a 
single-centre study and source funding for the work. Initially, they 
planned to do a prospective study for cancers of unknown primary 
origin, but this presented logistical problems and would have required 
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them to work at scale, with a budget beyond the scope of funding 
available. The company was also unable to provide its test for free 
during the study, given that it was a small company without significant 
resources. As the PI explained: ‘that meant that we did the study 
as part of routine care and it was very much can the clinicians in 
the clinic just enter the data and do the testing and see how it 
influences the management decisions that were taken’; but it still 
‘felt like we were at the real cutting edge of molecular testing’. As 
a result, the study was designed to assess the feasibility of NHS 
adoption of VGT in the treatment of women with gynaecological 
cancers.9 Virtue’s solid tumour biomarker testing uses a range of 
tumour-profiling techniques to analyse protein, RNA and DNA in 
the tumour. A formalin-fixed paraffin-embedded biopsy was sent to 
Virtue’s laboratory in the USA for analysis. Virtue’s proprietary 
algorithm generates a patient report recommending a course of 
action, which is sent electronically to the clinician within 14 days 
to inform clinical decision making. NHS England funded this evalu-
ation through a Regional Innovation Fund, which aims to ‘support 
and promote the adoption of innovation and the spread of best 
practice across the NHS’.
According to the protocol, the study was categorised as a safety/
efficacy study with modest purpose, as the clinician who coordinated 
this study explained: ‘It was a pilot study to look at whether this 
is feasible within an NHS environment … whether it could theoreti-
cally lead to any benefits to the NHS in terms of costs and to see 
what the costs where of offering a commercial molecular profile.’ 
‘Ironing out’ adequate logistics included collaborating with the 
pathology department and handling specimens from packaging, 
labelling and sending off, to record keeping. Crucially,
a patient would firstly need to be relatively asymptomatic … we 
would have to send their tumour off to America … it would be 
profiled and we’d get the tumour sample back with a molecular 
profile. So, to do that, the patient needed to be able to wait twenty-eight 
days to get their next lot of chemotherapy.
The team were interested in what this would mean for patients, if 
it would be detrimental and if it was acceptable.
In trying to test and improve logistics the team were researching 
and innovating technical, bureaucratic and cultural as well as 
molecular processes of personalisation. Clinical participation also 
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had to be facilitated through the study design, as the coordinator 
explained:
one of the difficulties in, is that the … profile still requires a certain 
amount of interpretation because you, you get an answer in the sense 
that you get a green box that says ‘Recommend this drug’, or a red 
box that says ‘Don’t recommend this’, and a grey one that’s neutral. 
But actually, you have to be fairly confident … in trusting that profile 
and the evidence on which it’s based. And, of course, I guess one of 
the things that’s difficult is … empowering the clinicians to be confident 
about that.
So if you’ve got a consultant who knows the area well, as all of 
the consultants will, then they will know that they’re recommending 
three drugs based on trial A, B and C, and they’ll be able to tell you 
about A, B and C. They’ll be able to sit a patient down and tell them 
about A, B and C and how many patients responded and for how 
long, on average. With this profile, they get a green box, a, a grey 
box and a red box and a list of preferences, some of which apply to 
that cancer and some of which apply to other cancers. And so their 
ability to have an oversight of all of that, I think, is very low. And 
so that’s … a different way of working for the consultants and meant 
that there was a lot of discussion between them about what was the 
right thing to do.
Now, actually, we took a lot of the risk from that away in terms 
of they weren’t prescribing drugs that they wouldn’t be prescribing 
anyway … All of the drugs were already available to that patient. I’d 
imagine it’d be a lot more difficult if that wasn’t the case [pause], if 
that makes sense.
So it’s an entirely different level of evidence to a gold standard 
randomised controlled trial … which makes it very difficult. And so 
that’s where I talk about sort of there was lesser risk in ours because 
we’re only using things that have come out of a gold standard ran-
domised controlled trial.
Trusting the ‘black box’ of the algorithm for clinicians reliant on 
seeing and interpreting evidence from clinical trials was thought 
likely to be difficult, so the study team limited the treatments the 
profile recommended to drugs and associated trials that the clinicians 
were already familiar with in order to inculcate trust in the study 
and to derive value from it. Making evidence-based medicine more 
explicit, ensuring clinician buy-in and reducing risk by prescribing 
drugs that have already gone through an approvals process to establish 
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evidence of benefit allowed the study to focus on how to work in 
and with a limited range of grey areas.
The feasibility study generated uncertainty and interpretation 
work for clinicians. But coordination also involved negotiating 
uncertainties about the quality of evidence going into and being 
produced by the feasibility study itself. For the coordinator, who 
worked with the PI, this involved managing their own lack of 
understanding of the link between algorithm and evidence, as in 
the extract below:
Could you, could you explain the … nature of that literature being 
cross-checked?
I can and I can’t … So (laughs) … from my understanding of the 
algorithm, it would, if you like, just go through PubMed and say, 
well, let’s say someone’s got over-expression of HER2, which is a 
particular marker on the cells that’s commonly known from breast 
cancer … and it would then look through the literature and look for 
manuscripts that … abstracts … it would look at drugs that are most 
likely to cause a response or toxicity or any relevant outcome in cells 
with HER2 expression, or tumours with too much HER2. It would 
do that, from my understanding, in patient series trials but also in 
[laboratory studies] as well.
It also involved accepting limits in the quality of evidence being 
collected. As the coordinator also noted, the study team could not 
do a full study of cost-effectiveness, but could instead ‘provide a 
signal for benefit’ by collecting a range of data on health economics, 
outcomes (progression-free survival), quality of life, toxicity and 
technical data (time to send and retrieve sample), which has not 
been published at the time of writing. He continued: ‘it’s difficult to 
empower patients with this, I think, because we haven’t yet reached a 
level where we have the evidence base to empower the clinicans’. The 
study was nevertheless considered to be valuable because generating 
signals of benefit was a small contribution towards the development 
of a better evidence base, creating the conditions for better-powered 
research in the future.
As well as managing uncertainties among clinical colleagues about 
the value of the test and the study to generate incremental and modest 
value for the field of personalised medicine, the coordinator also 
had to manage patient expectations where the perceived value of the 
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study could be much higher. The coordinator told us they had to field 
requests to participate from patients being treated elsewhere. These 
patients had learned about the research from sites such as clinicaltrials.
gov or the CRUK website and included some patients who were 
planning to pay for the test privately and were willing to travel to 
be part of the study. The study only had ethical approval to include 
‘local patients’, so these requests were declined. The coordinator 
drew on these experiences to express concern that the proliferation 
of studies and trials which only some patients could access, either 
because they were fortunate to be treated in centres where more 
trials were running or because they were wealthy enough to be able 
to travel, would lead to inequities for patients. This was linked to a 
set of worries about the complexities of cancer and over-promises to 
patients, ‘matching’ the ‘promise and hope with this new approach 
to cancer … that patients hear a lot about in the media’ with ‘the 
reality of medicine’. In a similar vein to the oncologists interviewed 
for Chapter 2, the coordinator expressed scepticism about ‘hype’: 
‘part of me wonders … whether the proliferation in things like 
molecular profiles and so on [have] … moved so far ahead of where 
the evidence is to catch up that, that has its own risks’:
we don’t understand key bits of the study of biology to shape it yet 
… for [Virtue] we may, for instance, have sent off an ovarian tumour 
sample from straight after their chemotherapy … but that tumour 
sample may have different markers to one two months later. We don’t 
yet understand how that changes … there’s so much complexity now…
In these reflective excerpts the coordinator manages uncertainties 
to get buy-in for the study while at the same time dealing with 
excessive expectations and what they framed as patients’ need for 
certainty.
This gives us an insight into the ongoing work of negotiating 
expectations of personalised medicine for clinicians involved in these 
kinds of local small-scale studies or trials, including reflecting back 
on the worth of studies in which they have played a part. The nurse 
involved in recruitment to the study also looked back on how patients 
responded to requests for participation, emphasising their positivity 
and hope, and praising the staff involved:
I think we maybe had one patient who declined it. They were all 
quite excited by it. They all thought, you know, this is going to benefit 
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me. I need – I want to be involved with this. … so it was … usually 
a positive … discussion with the patient … and they were very 
interested. Some of the patients asked to take a copy of their report 
away … presumably they – they couldn’t understand it fully but – but 
they want – you know, they were very interested in it.
What made them … expect to … benefit … from [the profile]?
I think the gynae consultants are very good at … explaining … I’ve 
sat in with quite a lot of consultants over the years, and registrars as 
well. And some are better than others. But I think the gynae team 
are very good at explaining. And I think probably from – that they 
understood what … they were being told and what they were being 
asked to do. And that … potentially by identifying biomarkers … in 
their blood we could see which treatments would … help and which 
ones probably wouldn’t help … there’s a range of treatments you can 
have for ovarian cancer. And some of them, the … response to treatment 
rate is quite low; you know, less than 25%. … they felt that they’d 
have more control perhaps over their [pause] over their treatment 
and decision making, And their … clinician would have more informa-
tion how best to treat them, of course.
In this account the nurse underlined the value of participation in 
the study for patients as a key outcome, focusing on their willingness 
to participate and apparent sense of control as valuable in their 
own right and linking this to the skills of the clinicians involved in 
the study. The lack of opportunity to otherwise access more targeted 
treatments was also mobilised as a key reason why this test was 
experienced as valuable by patients.
In the next section, we focus more closely on how patients 
accounted for their participation and experiences of VGT and the 
benefits it brought. As we shall discuss, this included accounts of 
optimism, control and enthusiasm for the test offering more specific 
information and opportunities for tailored treatments. These positive 
accounts and expectations were, however, tempered by experiences 
of unmet expectations in some cases. For other patients, their accounts 
of expectations and/or experiences of the test and the study were 
much less positive. To make sense of these themes and this diversity, 
we explore how genomic approaches such as the VGT study were 
incorporated into patients’ different approaches to uncertainties 
provoked and at times resolved by the test as part of crafting 
foreshortened futures. We explore how these tests offered some 
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kinds of certainties but also generated uncertainty and ambivalence; 
we also consider when the test did not have resonance or meaning 
for patients, particularly patients who were not invested in future-
crafting beyond the day-to-day. However, we also show how engaging 
with the test enabled these advanced cancer patients to hope for 
‘other things’ even when their personalised results did not significantly 
impact on their treatment and prospects. This included being part 
of a bigger future via their research participation.
Patient accounts of participation in the VGT study
Practitioners in our study were keen to underline the benefits of the 
test and the study for patients facing foreshortened futures and 
limited treatment options. But in other respects, as in the discussions 
with the coordinator above, they were concerned about unrealistic 
expectations among patients because of a lack of evidence of benefit. 
Clinicians and patients were routinely operating in conditions of 
uncertainty in the clinic, and in this particular study, but the test 
offered hope of finding treatments to which the patient would respond 
well. It was, however, far from universally valued, and patients were 
elsewhere being cautioned by professionals and patient advocates 
about uptake of these tests because of a lack of evidence of benefit, 
albeit within an overarching regime of anticipation of benefit in the 
future. For example, in a cancer charity forum thread discussing 
two different commercial tumour-profiling tests, including Virtue’s, 
one of the moderators noted a lack of randomised control trial 
evidence of benefit, or evidence of benefit in particular cancers rather 
than cancer in general. Although welcoming the tests as a positive 
development, the moderator noted their cost and difficulties with 
interpreting the results to guide treatment decisions.
As we mentioned earlier in the chapter, we were enrolled into 
this accretion of evidence when we were invited to interview patients 
who participated in the VGT study by the PI. We were also steered 
away from observing consultations with patients where the results 
were discussed, given the potential sensitivities of these consultations 
and the logistics of being in the right place at the right time. The 
research nurse who was in charge of the VGT study informed us 
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of the dates of outpatient appointments for patients who were 
participating in the feasibility study (72 patients in total); we waited 
to be introduced to the patients by the oncologists, typically after 
the consultation. Oncologists only mentioned our study to their 
patients when they felt it was appropriate to do so. We approached 
21 patients and, as noted above, interviewed 16. Five patients either 
declined to participate or were unable to be interviewed due to ill 
health. Ten interviews were conducted on NHS premises, arranged 
to coincide with their hospital visit if possible, and six interviews 
were conducted in patients’ homes because it was more convenient 
for them. During these interviews we carried out an in-depth explora-
tion of participants’ experiences of cancer and care in general and 
the feasibility study in particular, including at which point in their 
treatment they were approached by research nurses, what they 
expected from the test and their actual experience of it, how the 
molecular results were discussed, and how treatment decisions were 
eventually made. We explored what participation in this study meant 
to interviewees, and how they managed and made sense of the 
research and clinical encounters in relation to their previous experi-
ences of care and participating in research, and their hopes for the 
future.
This particular cohort of late-stage cancer patients were ‘living 
in prognosis’ (Jain 2007) at the time of our study. Many of them 
had experienced difficult cancer journeys and were in the later stages 
of incurable cancer or faced a high risk of metastatic recurrence 
(Roberts and Clarke 2009; Brown and de Graaf 2013). This makes 
their experiences particularly valuable for investigating aspirations 
for personalised care and treatments, bringing fresh insights to a 
literature that is dominated by the experiences of younger, often 
more active patients or patients with well-researched cancers with 
a better prognosis, such as breast cancer (see Miller et al. 2014). 
For the VGT study participants, the priority was keeping cancer at 
bay with the hope that, in the future, their cancer might become a 
managed, chronic illness, rather than seeking a cure. Preparing 
themselves for future treatments was important for patients who 
had seen their cancer recur. Most of these patients had experienced 
long-term treatment or multiple cycles of chemotherapy alongside 
other treatments, so it was also important to secure decent intervals 
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between treatments to recover from treatment side-effects and more 
importantly to prepare for the next cycle of treatment.
Although a test such as VGT was, for us, an ideal example of 
implementing molecular personalisation in a research setting, it 
turned out that it was by no means central to patients’ long and 
complex cancer journeys. Some patients even struggled to recall the 
test as it faded into a blur of clinical/research encounters. Against 
this background, we were struck by how participants still managed 
to generate diverse accounts of the Virtue test. Our research par-
ticipants expressed different degrees of interest, understanding and 
knowledge about the science and technique behind molecular per-
sonalisation. But instead of focusing on ‘mis/understandings’ (Dixon-
Woods et al. 2007), we try to situate these accounts within their 
wider accounts of cancer and care.
As cancer becomes more treatable, if not curable, many people 
are living with advanced or metastatic cancer. In England it has 
been estimated that there are thousands of people who have survived 
for several years with the most advanced stage of cancer, according 
to recent research from Macmillan Cancer Support and Public Health 
England’s National Cancer Registration and Analysis Service (2017).10 
Patients with late-stage cancers have often experienced long and 
difficult cancer journeys, including delays in diagnosis and other 
complications such as multiple co-morbidities. Feeling like a ‘time-
bomb’ (Davies and Sque 2002), some of these patients are living 
with ‘contracted time’ (Lewis et al. 2016). For many, recurrence is 
a matter of ‘not if but when’, as one interviewee in our study put 
it. For some patients this awareness involves thinking ahead and 
preparing for the ‘multiple future-times’ (Brown and de Graaf 2013), 
trying to be ‘one step ahead’ of their cancer. But for others extended 
futures are set aside for living in the near future. For many of these 
patients, their priority was to make incurable cancer treatable and 
manageable for as long as possible, protecting and improving their 
quality of life. In so doing they are navigating a different kind of 
future than early-stage patients who might hope for cure or lengthy 
remission.
In what follows, we focus on three major themes that occur across 
our set of interviews: first, a wide range of promises and expectations 
as described by patients and family members; secondly, the multiple 
reasons for disappointment and frustration they had to deal with; 
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and finally, how for some patients, the VGT study was not as salient 
as it was for other more active, relatively younger patients.
Promises of Virtue
Virtue held considerable value for many of these patients and their 
family members with whom we spoke. Dennis described his under-
standing of the VGT offered to his wife Helen, both in their seventies, 
as a ‘magic formula they were using in America’. Together with his 
wife, he hoped that ‘re-testing the biopsy’ would suggest a ‘better 
treatment or more appropriate treatment’.
Such hopes were particularly marked among younger patients 
in our study, for whom Virtue was part of a more concerted effort 
to access tailored treatments and engage with the possibilities of 
personalised cancer medicine. These patients told us they were actively 
searching for trials of tailored treatments and seeking second opinions 
at teaching hospitals running trials. Researching alternatives to current 
or proposed treatment was an important strategy for maintaining 
a future, which included seeking private cancer care or overseas 
treatment. These patients were not, however, naïve about the promise 
of cutting-edge tests and treatments, carefully weighing benefits to 
quality of life against cost or side-effects (for themselves and for 
their family). This was a relatively solo set of pursuits for some of 
these patients. Although they supported their fellow patients by 
making the occasional donations to fundraising efforts, they did not 
all participate in collective action or support online. One patient, 
Donna, who was in her fifties, was an exception. A particularly 
proactive and well-informed patient, Donna was involved with a 
national ovarian cancer charity and other patient forums, where 
she told us the VGT study (which she called a trial) came up in 
discussion:
I’m also on … a Facebook site which is just for ovarian cancer … 
sufferers and we share information and links to different sites … it’s 
a comforting site; people really talk to each other … and they … 
might say, ‘Oh, … I’m going on the VGT trial. Has anybody heard 
of it?’ And then we’ll all add our comments and – if we’ve had it and 
that kind of thing, so that’s quite useful … So when I do the research 
or when I’m talking to people, people will talk about the VGT trial 
but they may have been on a different chemotherapy to me … So I 
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think there were one or two people but we tend to talk more about 
the side effects of the chemo rather than the trial itself. So there was 
something about some of your samples are sent away but then because 
of what that forum is about it was more about how you feel rather 
than the trial itself.
This excerpt gives us an insight into hopes about being on a trial, 
but focuses more on the comfort offered by comparing experiences 
even when these were different, with the emphasis on managing 
side-effects and emotions evoked by participation. Donna also told 
us that doing research, weighing information and archiving informa-
tion of clinical trials was a source of reassurance:
I do a lot of research and I save quite a lot of links to different trials 
and I just think well, okay, well, if I start to feel ill again and it 
comes back I’ll click on this one. So I’ve got a list of different things I  
can read.
For Donna, and others, participating in research like the VGT study 
was one small part of a menu of research opportunities for securing 
her own future, with the added benefit of helping future patients; 
as Donna said, ‘Hopefully it helps me and it should help others as 
well. So I will try anything really.’
VGT was also experienced by other patients and their relatives 
as valuable because it offered bespoke care as well as hope. June 
and her husband Bob told us about their particularly difficult experi-
ence with June’s previous care team who said there was no treatment 
they could offer her. For this couple, VGT study participation offered 
hope where it had previously been dashed. It also meant an extension 
of personalising care she had already been receiving from her current 
care team. Bob associated June’s participation in the VGT study 
with the insurance of personalised care:
I say, the only thing that I gleaned from that [meeting with clinician] 
was that they were going to take more interest in June’s case other 
than put her into the normal – what we used to call cattle market … 
where the whole process was like a cattle market.
For Bob, the VGT study was a gateway to more experimental and 
special options as opposed to standard ‘written in stone’ treatments, 
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and this was a risk they were prepared to take even though he was 
aware that this meant June would be a ‘guinea pig’.
just going for a regular treatment that they were offering … there 
were nothing outside that they could offer you. But my understanding 
with this is there’s a possibility that would be something that would 
benefit to treat June’s condition but it’s not necessarily what’s already 
available, it might be a, a trial that you would volunteer to do … I 
thought, well, if the outcome isn’t so rosy [on] the path we’re treading 
now, and there was any possibility that there was something that 
could improve the situation, either not guaranteed but possibly it’d 
be worth taking a chance, you know what I mean, for whatever 
reason. Whether or not it would be to prove a point that it wasn’t 
going to be successful if … they did that treatment, but June would 
[have] been like a guinea pig say, in order to trial this treatment.
This promise of molecular personalisation was also associated 
with being privileged to be part of a study where only a small 
number of people’s samples were ‘sent off to America’, in the words 
of Mary, a patient in her sixties. Mary’s cancer was picked up by 
a routine smear test when she was 57. When we asked her about 
motivation for taking part in this study, Mary explained:
They were doing this trial of sending off to America, the tumours 
that … I had and they were going to look at it in a molecular genetic 
level with a view to being able to personalise my treatment … Of 
course, if somebody says [that] to you, you’re not going to say no 
are you? And I was told that … there was only … about seventy 
or eighty people in the country that had been … allowed to have  
this done.
For other patients, VGT was an improvement on ‘standard’ forms 
of cancer care that they experienced. For instance, another associated 
Virtue with ‘individuality’ which is opposed to current ‘conveyor 
belt’-like care. Sally, who was diagnosed in her forties and had since 
experienced multiple recurrences, said,
treating everybody individual[ly] is a good idea … it’s difficult for 
doctors, nurses seeing so many people every day, and I suppose it 
can tend to be, like a conveyor belt, people coming in and you’re 
saying the same thing. Maybe a bit of individuality might be quite a 
good thing.
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Throughout these accounts of promise, the comfort and reassurance 
of what was perceived to be more personalised care emerge as 
important values of the test and the study, for patients and their 
relatives. Futures were being crafted through the experience of care 
being more advanced and tailored to the individual in the present. 
For other patients, and in other respects, the experiences of the 
study were less positive, and involved recognising and managing 
disappointment, as we now go on to discuss.
Managing disappointment
Across patients’ and family members’ accounts, it was common that 
the VGT study was described as not being particularly burdensome. 
Their participation was framed as requiring minimum effort, such as 
no extra visits to the hospital as might be the case with other clinical 
trials, and it was regarded as non-invasive. Participation did, however, 
bring additional emotional work in other respects, as participants 
and their families made sense of risks, disappointment with their 
results, and conflicting expectations and experiences of the study.
Before deciding to enrol on the study, patients had to weigh up 
the benefits and risks of participation; patients needed to decide, 
with consultants’ guidance, if they were okay about waiting for the 
results to come back (as it meant a delay in treatment for 4–6 
weeks), as the quote from Marjory below illustrates:
Because you have to delay your treatment so to go on the trial you 
have to accept that your treatment is going to be delayed by two 
months – six weeks [to] two months – something like that. So obviously 
there is a risk but I talked to Doctor [name of oncologist] about the 
risk and he didn’t think that it was a fast growing – so I decided that, 
and even if it was I still thought, I’ve got more scientific basis of it 
working out by going through the trial than I have if we just guess 
or take an educated guess.
Marjory told us about her scientific background as evidence of 
her competency in engaging with the scientific aspects of this and 
other research on ovarian cancer, as she described why she was 
prepared to wait for the VGT results. However, not all patients 
were happy about waiting. Another patient, Kate, told us quite a 
different story. For Kate, waiting for one month was ‘a bit tough 
because I wasn’t having any treatment at all and I was aware of 
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the fact that my tumour marker was going up and my cancer was 
getting worse’. Kate described her disappointment when the results 
came back,
I think that’s why I was disappointed that it was just the bog standard 
treatment [that was recommended]. I felt like saying, ‘I could’ve had 
this a month ago’, you know, cracked on and it would’ve, you know, 
perhaps caught it a bit earlier I know it’s only a month…
Here the value of the test declines when experiences do not match 
expectations of tailored treatments and the gamble of waiting does 
not pay off.
Participants also had to find ways of managing disappointments 
which arose when their sample was not of sufficient quality to 
generate meaningful results. As with other research we followed, 
there was a risk of sample failure with the VGT study. For instance, 
another patient, Sally was told that her sample ‘wasn’t brilliant’. 
When we asked how she felt about this she said,
Well I was a bit gutted really, ’cause I was expecting this miracle 
thing that was going to happen to me and, you know, but they did 
get quite a lot of information from it they said, so yeah.
Right, could you … elaborate, what do you mean by miracle? In 
what sense?
… because it’s a personal diagnostic test, I just thought, maybe they 
were going to find something that they’d not seen before, or something 
that maybe would work that I’ve not tried. Maybe I didn’t really 
understand it all properly, but, I don’t know, you just, it’s just hope 
I think, just hope, there’s always hope.
Sally described how she got some consolation from the fact that 
they did find ‘some good things’ which might help future patients.
Participants also told us of their disappointment at options for 
treatment being discounted by VGT because the patient did not 
have the ‘right mutations’. This could be experienced as part of a 
series of routes closing off. For instance, we spoke to Donna’s husband 
Ewan when he accompanied Donna for her last radiotherapy session. 
For Ewan, participating in research meant reversing Donna’s bleak 
prognosis,
I just know that trials give me a lot of hope because if we’re just 
going along the path of the chemo and the gap is getting less between 
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the chemo, then you’re on the downward slope really. By being on 
a trial, who’s to know that, you can make that shoot up, that slope.
Despite Ewan’s hope, Donna’s test results were disappointing, as 
Ewan explained:
[W]hen we sent the biopsy away it came back … they’re saying, ‘Well, 
that’s not a route that you can take because you don’t have the right 
mutation.’ So you just sort of ignore it then because you’re not going 
to pursue that route … Like I say … she didn’t have the BRCA; she 
didn’t have the mutation for [VGT] and … she can’t have immuno-
therapy so I don’t know whether that’s the stage of it or the … condition 
… that she’s got…
This extract captures another common strategy of patients and family 
members handling disappointment when the VGT results did not 
turn out to be a gateway to further treatments, focusing instead on 
the next steps and ‘moving on’ to source value from other research, 
tests and treatments. Ewan also talked about his efforts to support 
and maintain positivity for Donna as part of this process, although 
he acknowledged that it was challenging. Ewan said,
I think [pause] for her to deal with it positively, she has to in her 
mind I think, still think that it’s going to be cured. I don’t necessarily 
think that, which is difficult in a relationship. So obviously I don’t 
voice that … at all if I’m honest. I may discuss it with myself.
Ewan’s story captures the challenges for many carers as well as 
patients, navigating family members’ hopes alongside their own, 
calibrating how positive and sceptical they can be against each 
other’s feelings so as not to cause further upset and to maintain 
some equanimity.
The appeal of ‘precision’ promised by the Virtue test also sat at 
odds with patients’ desires to have a variety of options, as Jean, a 
teacher whose cancer had returned and spread to her lung, described:
So it [the test results] did say that paclitaxel was probably not a good 
one for me, and that was the chemotherapy that I’d absolutely hated. 
That was the one that made me feel really poorly, so … at that point 
I was really glad to see that it said paclitaxel wasn’t good, because 
I thought that meant I’d never have paclitaxel again, but actually 
I’ve realised that’s a silly thing to have been grateful for because it 
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might be one of my only options at some point, so … you want your 
options as wide as you can really, though I would prefer not to need  
it again.
Balancing expectations, individually and collectively, to craft value 
from participation in this or future research involved managing 
disappointment in the present and retrospectively, as emotions were 
reviewed and revised in the face of diminishing options.
Other patients described their disappointment about the lack of 
novelty from the VGT test result, that is, when the test just confirmed 
that the same treatment as before was the best option, as in the 
extract below from Tracy, a civil servant who had just turned fifty 
when we interviewed her:
I think when, when I first went onto the … trial and then waited for 
the results coming back, I imagined that’d be this whole big thing of 
information, that there’d be lots of information there and things that 
I could be given that I could look through and, and read up. I was 
a bit disappointed, to be honest with you (laughs), at the end of it 
when they just confirmed that they were going to give me … the same 
treatment, I think, that I’d had for the … cancer before. So it’s like, 
well ‘hello (laughs), where’s the rest of, where’s, where’s, where’s this, 
where’s this encyclopaedia that’s coming back then with all these 
results as to what works, what doesn’t work and everything?’
We see the clash of expectations around what was the reality of the 
study, echoing the promissory discourses around trials more generally, 
and the realities of a smaller-scale study which was already operating 
with limited treatment options as part of the incremental approach 
to ironing out logistics and gathering evidence to find a pathway 
for adoption into NHS care in the future. However, for Belinda, 
like others in our study, having ‘other options and things … when 
the disease progressing and gets any worse’ that ‘would help … 
further along the line’ was a way of keeping their futures open and 
remaining optimistic.
Participating in the VGT study was a means by which these 
patients preserved the possibility of future treatment even when it 
did not directly affect their current treatment. Regarding the test 
results as reserve for future treatment or a springboard for more 
cutting-edge treatment (for example off-label drugs or combinations 
of drugs) gave patients and their spouses hope and offset immediate 
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disappointment about not being given ‘more cutting-edge’ and novel 
treatments in the present.
The complexities of accessing drugs recommended by VGT on 
the NHS could nevertheless generate frustration and disappointment 
when promises of precision were unfulfilled. For instance, Tracy 
could not get a particular targeted drug, recommended by the test, 
until her cancer recurred. She compared her situation to gambling 
on ‘Bully’s Prize’, referencing a popular darts gameshow from the 
1980s, where competitors who gambled their winnings on a star 
prize and lost were invited by the host to ‘have a look at what you 
could have won’. Tracy elaborated her frustration as follows:
So it seems a bit ridiculous that I’d have to go through waiting for 
it to come back again and then go through all my treatment before 
I could be offered that drug. […] And from a cost point of view, it 
just doesn’t make any sense to me either.
I was told that you could pay for it privately … but you’d be 
looking at about £70,000 a year, and that once you start paying for 
it yourself, you’d have to continue because the NHS would never 
pick up the cost. Whereas if you go third line and they start you on 
it, after twelve months, drug companies give it for free.
So yeah, I did get the information about the additional drug, yeah. 
It’s a bit like Bully’s Prize, ‘come and have a look at what you could’ve 
won,’ isn’t it, really? (laughs)
Tracy criticised the organisation of care in the NHS and its rules 
of eligibility for treatments, which was not only frustrating for 
herself but she also felt was not cost-effective in the long term.
This echoes a more general sense expressed by some patients and 
captured in the excerpt from the ovarian cancer advocate quoted 
at the start of the chapter, about VGT being able to deliver tangible 
benefits given the limited options for gynaecological cancer treatments. 
One patient, Jean, told us she had learned from her own research 
that VGT was ‘related to breast cancer rather than ovarian cancer’, 
but expressed disappointment that there was much less of an evidence 
base in the case of ovarian cancer. She was told by her oncologist 
that ‘if you’d [got] breast cancer we would say straight away … a 
hormone blocker, but we don’t have that set in evidence’. This meant 
that the interpretation of the VGT results was not as ‘black and 
white’ as she expected. This made her realise that ‘I don’t think it’s 
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helped me quite as much as I hoped it would do.’ Like many other 
patients, Jean nevertheless expressed her gratitude and hope for 
future patients as follows: ‘I’m still grateful that somebody’s trying 
it. And presumably they’ll build up a bank of research from doing 
that that will help others as well, which has got to be a good thing.’ 
Jean’s framing of her participation being of value to future patients 
was linked to a strong sense of the value of the NHS and a concern 
that, left unchecked, pharma could be ‘bleeding the NHS to death’. 
Jean told us she had a solution to the problem of the high costs of 
genomic medicine for the NHS:
You cap what drug companies can charge. At the moment I do believe 
the drug companies are bleeding the NHS to death. That’s my belief 
… I understand they’re a business. I understand that and that their 
raison d’être is about making money for their shareholders, but I 
wish somewhere in their – in their ethics was something that was 
about helping people as well rather than their reason for existence 
to be to make profit. I believe that if there was a cap, if the government 
put a cap on what they were allowed to charge, the amount of profit 
they were allowed to make, that that would mean there’d be more 
money for this kind of thing.
When I was on the trial, one of the things that concerned me was 
I’m on a trial where they’re finding information that might be useful. 
Will they then charge so much for it that people – that it won’t 
actually be useful? … I think the pharmaceutical companies will bring 
the death of the NHS at some point, which is very sad … for people 
in the future and I think it’s really, really sad because I think the NHS 
is one of the most magnificent things that’s been set up.
Jean was unusual in the sense that she advanced an overtly political 
analysis of molecularisation and the need to limit profit and protect 
the NHS so that future patients could benefit. For other participants 
who had experienced or were contemplating the prospect of disap-
pointing results, the possibility of helping future patients was also 
important, although this was expressed in much more general terms, 
as a kind of consolation, for example: ‘if it doesn’t help me, it will 
help others but hopefully it will help me too’.
Through these various rhetorical strategies, personal ‘future diso-
rientation’ (Roberts and Clark 2009) was managed through appeals 
to ‘future patients’ by ‘hoping for other things’ (Ehlers and Krupar 
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2014) such as helping future generations, as in the quote from Tracy 
below:
But I do understand that it will help them in the future, you know, 
when they know that they’ve tried that and that hasn’t worked. Then 
they’ve got other options that are, that are there. I just thought it’d 
be a lot of information that they’d come back with. And I’m told 
that it is a lot of information but … they don’t obviously give me all 
that because that’s not going to help me.
Similarly, June and her husband Bob described their understanding 
of how research works by combining results and how they were 
part of it – many individual research projects will not work, but 
each ‘failure’ helps research as a whole, including themselves.
[Bob] Yeah, the only downside to that is that if it didn’t work they’d 
know that that’s a dead end but they’ve used you [June] to find that. 
But having said that, it’s worked for people coming behind that they 
know it’s – that route’s not going to be available
[June] … while you’re trying all these things, all that information is 
being pulled … So that it’s going to help other people … As well as 
you … Well, [if it doesn’t work] I would go onto the column where 
it didn’t work, into a percentage thing.
The value of participation for June became a matter of helping 
future patients.
Lack of salience
VGT results had to be processed by patients in relation to an array 
of treatment experiences and decisions, which sometimes resulted 
in this particular study blurring into other studies and trials they 
had previously experienced or anticipated as part of their future. 
We did, however, encounter a small group of patients for whom 
the VGT study held very little salience. These were among the oldest 
patients we spoke to and all faced a bleak prognosis: one patient 
told us she had reluctantly agreed to receive palliative care to address 
co-morbidities and other complications, another patient was on 
third-line chemotherapy, and two other patients were anticipating 
another recurrence of their cancer. While two of these patients told 
us that they had a lot of support from their husbands, the other 
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two patients had less support from family members. One of these 
patients had lost her husband to cancer while she was undergoing 
her own cancer treatment and the other patient’s husband had 
early-onset dementia.
For this group, putting trust in their care team was particularly 
important, much more so than embracing the idea that VGT would 
transform their prospects. Their participation in the VGT study was 
a matter of trust, and continuity of care was key, with the test 
slotting into rather than determining these arrangements. These 
patients were also not as well connected, digitally or otherwise, 
with other patients due to their limited mobility and/or their stoic 
inclination to ‘desire a private disease experience’ (Kaiser 2008: 79). 
This did not mean that these patients were completely disengaged 
from gleaning information and doing research. They spoke of the 
need to ‘keep fighting’ cancer, and they were doing what they could 
manage to support that effort, such as regularly collecting newspaper 
cuttings about new cancer treatments which they might be able to 
mention to their oncologist. However, the VGT test did not figure 
in accounts of their current and future care in any detail, and there 
was minimal engagement with what genomics involved or meant. 
Instead, a strong emphasis on stoicism or getting through each day 
was evoked in their accounts, rather than a strongly articulated 
sense of future, as the following encounter with one of our partici-
pants, Maureen, illustrates.
We interviewed Maureen in the chemotherapy unit while she 
was receiving her infusion. When we first met her at the clinic she 
was with her husband, but on this occasion she was alone. She 
apologetically explained that her husband would not have been a 
great interviewee for us as he has dementia. She added that both 
her and her husband found the waiting and boredom of a long 
chemotherapy session difficult, and she struggled to ‘entertain him 
for eight hours’ let alone encouraging him to engage in a research 
interview. In the interview, Maureen focused on her ongoing pain 
in her lower body and how hard it had been for her to address 
this, with the VGT test getting only a passing mention. Referenc-
ing reduced resources in the NHS, Maureen linked her depleting 
options with ageist media coverage, as she satirically commented: 
‘Oh, all these old people are taking up all the beds, they’re living 
too long and they’re costing us too much.’ Having had a discussion 
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about palliative chemotherapy, Maureen shared her worry about 
being regarded as an undeserving ‘bed-blocker’. For patients such 
as Maureen, VGT was a secondary part of their efforts to secure 
the kinds of personalised care they valued and hoped to maintain, 
a care she was concerned was under threat from rationing and 
discriminatory interpretations of deservingness.
These accounts sat within a wider narrative of cancer and care 
where the importance of stoicism was highlighted, which at times 
made these interviews particularly challenging when the perception 
was that there was no special story to tell. It was not surprising 
that two out of the four interviews in this group were the shortest 
among all sixteen interviews. Both patients’ dominant account was 
of getting on with things:
It happened. I’ve got to put up with it. it could’ve been somebody 
else. I didn’t say ‘why me?’… I’ve always been a very quiet type, a 
person that just takes it. It’s me, that’s the way it is.
[I] just take everything in my stride.
VGT in this context was not imbued with particular meanings or 
emotional work, as patients concentrated their efforts on managing 
day to day.
Conclusion
In this chapter we have considered how the feasibility of introducing 
a novel, commercial, molecular profiling test into the NHS was 
examined in a research study designed to develop an evidence base 
for wider implementation, as part of efforts to transform the way 
the NHS offers profiling and to understand how to make this valuable 
to patients and clinicians. A range of professionals (including social 
scientists) were being enrolled in these efforts, alongside patient 
participants. There were numerous uncertainties around the develop-
ment of the test and its future in the NHS, just as there were 
uncertainties for patients and practitioners making sense of test 
results from which evidence of benefit has to be drawn. The predictive 
potential of the tests was therefore highly contingent, as was the 
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extent to which the results being produced could prolong or maintain 
a future for patients with advanced cancers. The promise of precision 
was therefore vague and underspecified.
Chapter 2 explored the uptake of a genomic intervention in cancer 
care and its place in practice. This revealed that the technology was 
far from fully embedded and that its promise was much more 
contingent than some of the press coverage might have suggested. 
This chapter has presented further evidence of the conditionality 
and incrementalism in genomic medicine in the cancer clinic. Although 
there was a clear impetus to enhance precision and actionability in 
the case of VGT, its value could be fleeting or unrealised because 
of the complexities of cancer, health and family commitments. For 
some patients and their families engagement with the study offered 
a sense that options were being created or sought out by their care 
team and, even if no new options arose for them personally, they 
would arise for patients in the future, extending or transposing the 
promise of prediction and actionability into the future. For another 
group of patients, however, the test was not invested with particular 
promise and the personalised kinds of care they sought were more 
immediate as they focused on managing their cancer symptoms day 
to day.
This contingency and flexibility in the use of the test, its results 
and implications for patients was, of course, a product of professional 
efforts to find new pathways and protocols for embedding the test 
into practice, ‘smoothing out’ processes as well as delivering precision 
to individual patients. It also extended to the way the study was 
loosely framed as a trial by both practitioners and patients, and the 
various different ways the algorithm and the evidence base being 
developed were described to us as we proceeded with our research.
Through these processes we see the value of the test as something 
always in the making: value was dynamic in the sense that it was 
negotiated across place and time and interpreted differently by 
the actors involved. Practitioners, patients and family members 
appreciated the value of the test in various ways – ranging from 
its totemic value of precision and personalisation to its value as a 
source of reassurance or comfort in the face of uncertainty. But in 
other respects, the value of the test fell away, as its promise was not 
realised through the study design or processes (e.g. sample failure) 
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for professionals and for patients who had hoped for something 
more from their participation. Other kinds of value could sometimes 
be salvaged from these disappointments and setbacks, including 
the possibility of benefit for future patients, but value nevertheless 
retained a precarious and contingent quality and value making 
required considerable emotional and articulation work from patients, 
family and practitioners.
In the next chapter we turn to consider how these contingencies 
and complexities played out in another kind of personalised cancer 
medicine, focusing on a much larger-scale UK-wide trial with similar 
aims of developing infrastructure, tackling stubborn cancers, building 
evidence to make more treatments available for the future, and 
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Optimising personalisation: adaptive 
trials for intractable cancers
We have explored molecular profiling for some breast cancer patients 
for whom targeted treatments have a longer history than for most 
cancers, but where the introduction of commercial tests is relatively 
recent in UK contexts. We have also considered gynaecological cancer 
patients accessing another commercial test as part of a feasibility 
study. For other cancer patients, personalised medicine is experienced 
via a new generation of larger-scale, multi-sited adaptive clinical 
trials. It is to this platform that we now turn.
As we discussed in Chapter 1, randomised control trials (RCTs), 
the ‘gold standard’ of evidence-based medicine, have been superseded 
by what Keating and Cambrosio (2011) describe as a ‘new style of 
practice’ in medical oncology, based on large trials across multiple 
sites to develop targeted therapies for subtypes of cancers based on 
genomic profiling. Multi-arm trials test several different treatments 
at once. If a particular drug is not proving efficacious the trial arm 
can be closed and new treatment arms brought in (Medical Research 
Council 2014; West 2017), depending on response and recruitment 
rates. Trials adapt as results come in, a different methodological 
approach to traditional RCTs.
Such trials hold out particular promise for patients for whom 
prognosis is poor and treatment options are few. Lung cancer is an 
example of one such intractable cancer with very poor outcomes. 
Patients with lung cancers are typically diagnosed in the late stages 
of the disease, making it more difficult to treat. Later diagnosis is 
partly a feature of the difficulties with identifying cancer symptoms, 
but also a result of the stigma and shame associated with lung cancer 
in particular, as it is associated with smoking, which may further 
delay the seeking of help (Chapple et al. 2004). Lung cancer is also 
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associated with deprivation, where smoking rates are taking longer 
to decline, exacerbating inequalities (Powell 2019). Lung cancer is 
also difficult to treat due to the late stage of diagnosis, the challenges 
of surgery (and biopsy) and other difficulties with the health and 
social circumstances of patients. Genomic research has identified a 
range of molecular subtypes of lung cancer (EGFR, ALK) suitable 
for targeted treatments, and both mutations may be tested for during 
treatment pathways, but prognosis is still poor. The more successful 
developments of targeted treatments in breast and blood cancers 
have yet to be replicated in lung cancer, and current national efforts 
are underway to promote research and develop new targeted 
treatments.
Multi-site, multi-arm trials are important to building personalised 
medicine in health services such as the NHS, developing partnerships 
across centres, regions and with industry, embedding infrastructures 
of delivery, and investigating how to maximise participation and 
acceptability among clinicians and patients. Such trials are part of 
a programme of transformation of healthcare provision to embed 
personalisation, alongside other larger projects and initiatives such 
as the 100,000 Genomes Project, discussed in the next chapter.
In this chapter we investigate one such adaptive, multi-arm, 
multi-site trial for lung cancer, examining how the optimising logic 
of the trial was enacted and the kinds of value that emerged in the 
process (Montgomery 2017a; 2017b). We show the ways in which 
trial leaders, practitioners, patients and family members gave meaning 
to the promise of the trial and sought to realise value for patients 
now and in the future. This was clearly difficult to accomplish in 
practice, and we capture how patients’ and indeed clinicians’ disap-
pointments and anxieties manifested and were managed, in part, 
through efforts to calibrate expectations. This included lowering 
(personal) expectations (Gardner et al. 2015) and cultivating expecta-
tions that other patients would benefit in the future instead. In doing 
so, we draw on an analysis of professional literature, press and 
website coverage on the trial, as well as observations and interviews 
conducted between 2016 and 2018. We interviewed 14 practitioners 
(12 clinicians – including four nurses, three pathologists and two 
scientists), observed 21 encounters in clinics (two MDTs, two biopsy 
procedures for the trial, 17 consent meetings for participation in 
the pre-screening), interviewed five patients who participated in the 
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trial (and two of their family members) and five patients who 
participated in pre-screening for the trial. We also gathered data 
from two online forums and platforms where the trial was discussed 
by patients and their relatives between 2015 and 2017.
Stratified medicine and an adaptive trial
The National Lung Matrix Trial (Matrix) is a multi-site, multi-arm, 
adaptive trial of treatments for people with lung cancer, based on 
the molecular profile of their cancer, linked to a pre-screening Stratified 
Medicine Programme 2 (SMP2). It is funded by Cancer Research 
UK (CRUK) and run by the University of Birmingham CRUK Clinical 
Trials Unit in collaboration with the Experimental Care Research 
Network, NHS and industry partners (initially Illumina, Pfizer and 
Astra Zeneca). We became interested in researching this trial following 
discussions with one of the investigators, who was very engaged 
with precision oncology and saw the trial as a major exemplar of 
this new approach. With their assistance we were able to develop 
a case study of the pre-screening component and the trial at one 
site, which included interviews and observations with staff and 
patients. We subsequently expanded our case study to include another 
hospital, partly because it was difficult to recruit patients to our 
study (there were small numbers being recruited to the trial and 
patients were unwell, so approaching them to request interviews 
and observations was not always appropriate). As we will discuss, 
the trial turned out to be an exemplar of the difficulties with making 
personalised genomic medicine for cancer work for current patients 
in treatment.
SMP2 is an observational, pre-screening study, designed to screen 
up to 2,000 non-small-cell lung cancer (NSCLC) patients in order 
to identify genetic changes in their tumours. This determines their 
eligibility for entry into the Matrix trial, where they will be matched 
to treatments based on the genomic profile of their cancer, and the 
benefits of these treatments will then be assessed. SMP2 has an 
additional aim of ‘continu[ing] to pioneer the use of next-generation 
sequencing (NGS) technology in the NHS to prove large scale genetic 
testing works within the NHS’.1 The trial, while offering promise 
to patients, is also preparing the infrastructures and processes to 
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make personalised genomic medicine feasible. This includes the 
following developments, described on the CRUK website:
Our Technology Hubs are centralised, quality assured molecular 
diagnostic NHS laboratories in Birmingham (West Midlands Regional 
Genetics Service), Cardiff (All Wales Medical Genetics Service) and 
London (The Royal Marsden). They use innovative NGS technology 
to detect a variety of changes in a patient’s tumour DNA sequence. 
The NGS panel, consisting of 28 genes, was developed in close col-
laboration with Illumina, and can be updated regularly to reflect the 
needs of the programme.
The study design notes:
The management of patients with non-small-cell lung cancer (NSCLC) 
has been transformed in the past 10 years. The identification of 
EGFR-activating mutations as a predictive biomarker for the use of 
EGFR tyrosine kinase inhibitors ushered in the era of stratified medicine 
in NSCLC [1]. Only 4 years elapsed between the description of 
EML4-ALK fusions [2] and the registration of crizotinib for treatment 
of ALK fusion-positive disease. Alongside these therapeutic advances 
have been a change in the regulatory landscape; the provisional registra-
tion of crizotinib was based on high signals of activity in non-
randomized, single-arm studies [3]. A series of publications culminating 
in the data from The Cancer Genome Atlas (TCGA) for both adeno-
carcinoma and squamous cell lung cancer have considerably widened 
the number of potentially treatable targets, albeit in small molecularly 
defined patient cohorts [4, 5]. Efficient testing of drug–biomarker 
combinations is necessary in order to unlock the true potential for 
stratified medicine for NSCLC. The National Lung Matrix Trial 
(NLMT), funded by Cancer Research UK in partnership with 
AstraZeneca/MedImmune and Pfizer, includes many of the potentially 
actionable molecular aberrations identified in NSCLC. (Middleton et 
al. 2015: 2464)
SMP2 and Matrix followed on from SMP1, a ‘proof of concept’ 
study, which involved molecular pre-screening of cancer patients 
with melanoma, breast, ovarian, lung, colorectal and prostate cancer 
at eight hospitals to establish feasibility for the NHS and acceptability 
to patients. They are run via the Experimental Cancer Medicines 
Centres Network (ECMCN) formed in 2007, with funding from 
CRUK, NIHR and UK Departments of Health. The network involves 
18 adult and 17 paediatric cancer centres to ‘assist in the delivery 
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of early phase cancer studies between research partners to enable 
faster and more personalised patient benefit’.2
Presented by the trial website as ‘the largest precision medicine 
trial in non-small cell lung cancer globally’,3 Matrix involves a rolling 
programme of recruitment to treatment arms which can close and 
open as knowledge about the effectiveness of drugs develops through 
the research. In press releases about the trial, the principal investigator 
(PI), Dr Gary Middleton, based at the University of Birmingham 
CRUK Clinical Trials Unit, noted:
This is one of the largest ever personalised medicine trials in any 
cancer, one which attempts to match the right treatment to the right 
patient based on an in-depth understanding of what makes their own 
cancer cells grow and survive.
For our patients, it’s a tremendous opportunity to access a wide-
range of therapies tailored specifically to their particular type of lung 
cancer. For people caring for lung cancer patients in the UK, it’s 
exciting to be able to offer these treatments to patients when they’re 
still at a very early stage of clinical development.
With this Matrix trial, cancer medicine in the UK now becomes a 
key global player in the search for more effective targeted therapies 
for people suffering from this devastating disease.
As is common in narratives of this sort, the PI emphasises the 
excitement and promise of the trial and the opportunities it affords 
patients by giving them access to experimental treatments. The trial 
is also contributing to the scaling up of UK capacity in the promissory 
bioeconomy of genomic medicine.
By mid-2016, after it had been running for around a year, the 
ECMCN reported that the trial had recruited 50 patients, rising 
to 100 by November that year, with patients receiving one of ‘8 
Investigational Medicinal Products provided within this trial by either 
AstraZeneca or Pfizer, within 17 of the 21 distinct cohorts’.4 At this 
point the trial also received an extension and continues to recruit at 
the time of writing. Seven of the treatments being trialled during our 
research were targeted agents (provided by AstraZeneca or Pfizer) 
with the eighth arm for patients with non-actionable mutations. As 
the Birmingham University description of the trial notes:
A secondary objective of the trial is to provide the opportunity for 
industrial partners to test novel agents in the cohort of patients who 
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are not positive for any of the actionable targets in the trial, referred 
to as the no actionable genetic change arm. In particular, if interim 
analysis shows significant activity for one of the targeted drugs in a 
targeted group then it may be relevant to assess the putative biomarker 
specificity of this drug by including it as a treatment option for the 
no actionable genetic change arm. Such an assessment could be 
important to inform the design of future trials for that drug. During 
the course of the trial, any drugs that are selected for allocation to 
the no actionable genetic change arm will be included in a pipeline 
of options that become available sequentially. The first drug to be 
tested in this arm is durvalumab (Cohort NA1).5
This multiplied the experimental value of the trial, facilitating 
opportunities for drug companies and patients to experiment with 
novel drugs.
By December 2016, 87 out of 107 patients were receiving targeted 
treatments, and plans were underway to develop two new cohorts 
with treatments provided by another pharmaceutical partner for 
other patients. The trial was designed to expand in this way to 
increase the numbers of patients involved.6 The trial was also sup-
ported by expert review groups to improve the process of obtaining 
and analysing samples, including via training of appropriate staff: 
‘Through working collaboratively across disciplines we are committed 
to improving existing NHS clinical and laboratory pathways to 
increase the number of molecularly eligible patients identified and 
subsequently treated with novel targeted therapies.’ 7 The importance 
of developing better processes and technologies was a major theme 
in news about the trial featured in the ECMCN webpages that give 
an account of its progress. Although there was considerable optimism 
about recruitment continuing to improve, with new recruiting centres 
and treatment arms being opened up, more patients and more 
‘meaningful results’ were still needed for the trial to be a success. 
This all involves considerable work and engagement from healthcare 
staff, as well as patients, as the following extract shows:
SMP2 has recently completed the fifth comprehensive sample and 
data audit. The team will shortly be distributing audit reports to 
enable sites to identify areas for improvement. Performance across 
the network is steadily improving, and their focus now is to challenge 
sites to test as many patients as possible through SMP2 and carefully 
track eligible patients through to NLMT. We need commitment and 
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support from the entire ECMC network to increase recruitment and 
maximise translation between SMP2 and NLMT, to ensure that this 
study continues to deliver.
The SMP2 team has been working closely with Illumina, our genetic 
technology provider and the three Technology Hubs/genetic testing 
laboratories, to develop a new and improved version of the 28-gene 
NGS panel. The new version, launched on 20 March 2017, features 
increased probe coverage, particularly in poorly performing regions, 
to reduce the gene fail rate and the addition of gene regions to the 
panel to allow new drug treatments to be delivered via NLMT. These 
improvements should mean that a higher proportion of patients receive 
a more meaningful result from their first sample, increasing the number 
of patients molecularly eligible for NLMT without the need for a 
repeat biopsy or repeat sample being tested.8
Counting the numbers of patients screened in SMP2 (800 patients 
screened in 2017 ‘alone’) and recruited to Matrix (197 by the end 
of 2017) was an important means by which the trial leaders sought 
to establish markers of success in the earlier years of the project 
(an approach we will also find in the next chapter in relation to the 
development of WGS for cancer patients as part of the 100,000 
Genomes Project).9 However, after 2017 there is little information 
on recruitment in the public domain, with the main project website 
information for patients noting that the aim is to recruit upwards 
of 600 patients, around 30 per cohort,10 with the target ‘amended 
throughout the course of the trial with the addition of more treatment 
arms and cohorts and removal of arms and cohorts showing insuf-
ficient signal of activity’.11 CRUK reports that by November 2018 
the trial had recruited 250 patients. There is also a report of high 
attrition rates between screening and entry to the trial arm (circa 
90 per cent), including on social media where we found a slide from 
the trial entitled ‘The inevitability of attrition’. At the time of writing 
there are eight trial arms, and the non-actionable arm and two other 
arms have closed.12 It is also noted that recruitment is expected to 
end in 2021.
The trial is a prominent example of precision medicine, with the 
difficulties around recruitment and treatment benefit acting as a 
spur for further investment and organisational/professional change, 
rather than as a sign of failure (Hiley et al. 2016). The trial has 
been framed as a success for the state, cancer charities, professionals 
and the market. When the Secretary of State for Health, Matt 
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Hancock, visited a strategic University/NHS alliance in Birmingham 
in 2018 he learned about this ‘ground-breaking’ trial.13 When a deal 
was signed with the pharmaceutical company Mirati Therapeutics 
to include its experimental drug sitravatinib in another arm of the 
trial, its CEO noted that the programme presented an ‘exceptional 
opportunity for clinical research’.14 In a 2018 Telegraph article entitled 
‘Personalised Medicine “Transforms” Survival Chances in Incurable 
Cancer’ which focused on results from a US study presented at the 
American Society for Clinical Oncology (ASCO), a CRUK representa-
tive explicitly mentioned Matrix when interviewed about the topic:
Drugs that target changes in a patient’s cancer cells have transformed 
the way cancer is treated, as this study illustrates.
Cancer Research UK scientists are currently advancing this tailored 
approach via several studies aimed at personalising treatments, such 
as our National Lung Matrix Trial which is matching lung cancer 
patients to targeted drugs that will work for them with the ultimate 
goal of saving more lives by finding the right treatment for each 
person. (Bodkin 2018)
Through these processes it is not just the trial that is ‘rolling’ or 
evolving in terms of recruitment targets and arrangements, treatment 
arms and funding arrangements; its values also evolve as it is variously 
presented as, on the one hand, transformative, groundbreaking and 
part of a new era, and on the other, as part of a more modest process 
of incremental change and development of services, professional 
capability and infrastructures. Overcoming the difficulties and chal-
lenges of recruitment and attrition becomes part of the process of 
transformation as the value of the trial is reasserted rather than 
undermined. The development of new insights into knowledge, 
actionability, validation processes and valuation measures were also 
considered successes of the trial, rather than health gains for patients 
per se. The trial and the programme were, thus, optimised in practice, 
through efforts to improve treatments for patients, as we now go 
on to explore in more detail.
Making the trial work
The Matrix trial was often one of the last treatment options for 
patients following the completion of standard options (usually 
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chemotherapy and/or radiotherapy). Recruitment into and remaining 
on the trial was challenging, not just because the patient’s molecular 
profile had to match a trial arm that was open for recruitment, but 
because the sample also had to be of the right quality and the patient 
had to be well enough to participate and meet a range of other 
eligibility criteria. The SMP2 pre-screening study was the first step 
to being part of the trial. At this stage, patients gave their consent 
for surplus tissue from routine biopsies to be analysed using next-
generation sequencing technology. Entry into the trial also required 
patients to consent to a further separate biopsy procedure to collect 
tissue to be analysed using next-generation sequencing at a separate 
institution to direct entry into one of the trial arms. Ensuring that 
these samples were of sufficient quality and quantity involved 
considerable articulation work, or ‘artful integrations’ including 
configuration and customisation, ‘incorporating technologies into 
everyday working practices and keeping them working’ (Suchman 
1996: 407).
Enthusiasm and support for SMP2 and Matrix from one of the 
main investigators and one of the research nurses on the trial enabled 
us to develop our initial plans to follow patients and practitioners 
working on the trial at one site. For these actors, Matrix held 
considerable promise as a new paradigm of personalisation, but it 
brought with it the challenge of implementation, as one consultant 
oncologist noted:
It’s taken many years … to bring it into clinical focus … that genomic 
medicine is important. And I think the things that have really been 
the tipping points in doing that have always been … market authorisa-
tion of … a drug for an actionable mutation, and subsequent cancer 
drugs fund or NICE guidance supporting its use in, in practice … 
once they come into place … there’s been a headlong rush to try and 
institute it that wouldn’t have been possible if a lot of backroom 
work hadn’t been done for many months or even years …
… a lot of that work of building teams who are flexible and 
adaptive at the interface between clinical and laboratory medicine … is 
necessary to get a good … in-house solution to genomic testing. And 
that can’t be turned … on a sixpence when NICE give their guidance.
We also encountered considerable scepticism and concerns about 
the trial when we engaged with lung cancer practitioners involved 
in recruitment. This was linked to a general sense of the difficulties 
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of working with very unwell patients, difficulties with implementation 
and a vague sense of beleaguerment with the bioeconomy of which 
the NHS is a part. As another consultant noted:
I think the genomics has changed … threshold for some patients … 
by virtue of our own data on what the chance of these mutants is, 
it’s allowed us to have more … personalised discussion with the 
patient about whether or not they go for a biopsy, but … if they don’t 
want it, then they don’t get it.
[But] … our patient cohort … is quite deprived, low education 
achievement, low familiarity with medical advances … I’m sure in a 
breast cancer clinic that’s different, in the lung cancer clinic no one 
turns up with a Google search or anything like that, or hardly anyone 
… we have occasional middle-class patients, but they’re few and far 
between, so no … the population as a whole is very … has a very 
low level of understanding of [genomics]
My concern is the very cosy relationship between pharma and the 
other … groups, and the professional groups as well, and I think 
pharma will often be … behind the scenes cheering these people on 
… when they are in the newspaper … these are all tragic stories, of 
course they are, I mean I see these patients every week and it’s very 
sad that you have young … patients with young families and it’s 
devastating … but sometimes when you’re deciding how to invest 
limited funds there will always be losers and … there needs to be a 
degree of equity across the list in terms of … who loses out, because 
there are the people who lose out when expensive things get funded, 
you just never see them, they’re just never there in the papers.
Working in this context was challenging for clinicians trying to give 
patients the best possible care, and included managing some difficult 
dilemmas around supporting patients to pay for targeted treatments 
privately, despite the general view in the team that private medicine 
was problematic. As one consultant put it, ‘I don’t want to deal 
with money.’
Practitioners were engaged in an intricate balancing act to recruit 
patients on to the SMP2 pre-screening study and access targeted 
treatments on the Matrix trial, and ensure they were receiving the 
best possible care at the right time, protecting patients who were 
too unwell to participate (e.g. having another biopsy), or keeping 
the trial ‘in reserve’ for when the initial round of treatments was 
no longer working, and not raising hopes unnecessarily. Some were 
sceptical about the value of the study given its complexity and the 
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difficulties with getting a result which would direct entry into one 
of the treatment arms. Even those practitioners who were more 
positive, such as the nurses directly involved in recruiting patients 
to the pre-screening study and caring for patients on the trial, had 
to navigate numerous difficulties with recruitment, sampling and 
obtaining results from tumour tissue and managing patient expecta-
tions and disappointments. This involved working with a complex 
mix of organisational arrangements, materials and emotions, while 
trying to optimise the care of unwell patients with often rapidly 
deteriorating health.
Several described feeling ‘hopeless’ about the trial, with others 
describing it as a ‘soul-destroying’ process, because of the high 
attrition in recruitment from the pre-screening study to the trial. 
This included a series of ‘failed’ samples which either did not pass 
quality control to be suitable for analysis or did not produce evidence 
of genetic changes that would mean that the patient could be recruited 
to one of the treatment arms of the trial. This led some practitioners 
to change how they ‘sold’ the pre-study to eligible patients who 
could be well enough to participate in Matrix, including managing 
and, at times, lowering patients’ expectations of results being returned 
that would direct entry into the trial. Not explicitly mentioning 
Matrix or treatments available on the trial arms was one strategy 
that was sometimes adopted, illustrated in extracts from fieldnotes 
below, where two patients were separately being interviewed about 
consent for SMP2. The first extract follows on from a discussion 
about where the tissue will go for analysis and what form it will 
take (a section from a block, to another hospital) involving one of 
the clinical trials assistants (CTA) responsible for recruitment:
The CTA goes on to explain that by testing the tissue they’re looking 
for 28 genes, which might help ‘further down the line’ but also stresses 
that the patient ‘shouldn’t worry about this’. The patient nods and 
agrees, ‘yeah, alright, why not,’ and doesn’t ask any further questions. 
CTA: ‘you’re great’ (laughs). The patient thoroughly reads through 
the consent but doesn’t ask any further questions – seems more 
concerned about the CTA having to take blood ‘there won’t be any 
left’! Whilst the CTA labels the vial, she asks whether the patient has 
ever been a smoker, ‘yes (looks at me) but I’ve cut down now’. He 
describes how his daughter visits him and complains about him smoking 
– ‘we can smell it’! [Sense of shame here.] The CTA ended the 
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consultation by thanking the patient ‘for helping us’ and wished him 
luck with his treatment.
Here we see the CTA downplaying the possibility of SMP2 coming 
up with results quickly, lowering expectations (Gardner et al. 2015), 
taking on the burden of worrying about results on behalf of the 
patient and keeping the encounter focused around the patient’s 
positive outlook and willingness to help.
The process with the second patient is similar:
The CTA introduced herself and asked, ‘did the consultant give you 
a leaflet about stratified medicine?’ The patient explained that he 
hadn’t but she couldn’t be sure as her granddaughter deals with most 
of the information, ‘she takes everything in’. The CTA went on to 
explain what the study entails ‘it’s looking at the genetics to look at 
different types of cancer, we send a sample of your tissue to look at 
the DNA (little bits and pieces) and send to the Royal Marsden for 
analysis.’ The CTA explained that they’re looking for 28 genes, which 
may mean the patient’s eligible for research ‘further down the line’ 
(the patient nods and agrees). Again, the CTA stressed that the patient 
shouldn’t worry and that if they’re eligible the consultant will ‘talk 
this through with them’. The patient is given the opportunity to ask 
questions but doesn’t and just asks about whether they need to do 
anything ‘nasty’ to get the tissue sample. The CTA explained that 
they didn’t and that it would just involve sending old tissue along 
with a blood sample ‘one off sample’. At this the patient threw her 
hands in the air and said ‘get on with it, do what you’ve got to do’ 
and laughs. Throughout the appointment the patient seemed quite 
passive ‘yes, yeah, nodding’ and I was unsure exactly how much 
information they were retaining. The CTA took the patient’s blood 
and I waited by the ECG machine (no chairs). Ending the appointment, 
the CTA said that she hoped the patient would get some results back 
but that ‘I won’t bother you again’! She also thanked the patient who 
said again how much of an important role her granddaughter plays 
when accompanying her to appointments etc, ‘she’s fantastic, does 
everything’. The patient also told us … her granddaughter is expecting 
a baby and had just been to do some shopping. Once the patient had 
left the room and the CTA was finishing the paperwork she said ‘that 
lady’s got a great-grandchild on the way, it’s so depressing because 
she’ll probably die.’ ‘People just drop and die and there’s no way of 
knowing. I really think it’s all down to DNA; it’s a DNA lottery.’ 
‘Along with melanoma it’s my least favourite cancer.’
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This extract gives us an insight into some of the frontstage and 
backstage work (Lewin and Reeves 2011) involved in the pre-screening 
study and its potential as a gateway to recruitment to the trial. 
Frontstage the work could involve decentring some of the details 
and purpose of the trial and focusing on the pre-screening study in 
clinical appointments. This was a means of putting patients and 
family members at ease, being positive about their future, trying to 
reduce the burden of involvement (information to be processed, 
time spent in the appointment) and offering an opportunity for care 
and expressions of gratitude. Backstage, in team meetings and corridor 
talk, there were other kinds of emotions – frustration, sadness and 
disappointment to be managed, given the poor prospects of many 
of these patients. Staff also had to carefully negotiate approaching 
patients about the study, resolving conflicts among themselves in 
the process. For example, we were told patients with brain metastasis 
(mets) could be entered into SMP2 but they were not eligible for 
Matrix. This could result in tense conversations between the senior 
CTA and the consultants. Consultants were reluctant to approach 
patients with brain mets for recruitment into SMP2 because of how 
unwell they were and because they would not be eligible for Matrix. 
SMP2/Matrix were conflated as one study here (SMP2 leading to 
Matrix), but at times, when eligibility criteria conflicted, the senior 
CTA had to do a lot of work to convince consultants of the value 
of recruiting patients to SMP2 despite not being able to enter them 
in to Matrix, including the possibility of other treatments being 
recommended or contributing to future patient benefit.
Oncologists also sought to downplay the importance of the trial 
to treatment, as this clinician explained:
So one is when you see a patient initially … we don’t really go into 
much detail of what SMP involves ’cos when they come to see … the 
complexity of the treatment … is vast and we perhaps don’t have … 
all the results to make their initial treatment decision. So we’ll go 
through about four, five scenarios and by that stage, you know, they’re 
absolutely … saturated. So, you’ll mention the Matrix, saying, ‘Oh, 
and by the way, we’re doing this study which doesn’t involve anything 
else apart from blood tests. It’s looking for a potential treatment in 
the future … you may or may not be eligible for it.’ So, it’s a sort of 
loose conversation and then they obviously meet with [the research 
nurse] who has a more detailed conversation about it.
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But the way … at the initial diagnosis we mention it as … almost 
like an afterthought so it’s not … a focus ’cos it’s not a first line 
treatment so it’s not the focus of that. And then most patients actually 
don’t really remember it … it’s only when … they unfortunately 
relapse or … we then go back to them and … someone will say, ‘Oh, 
oh, did the results come back from SMP2?’ And then the major-
ity of time we say, ‘Actually, they have and you’re not eligible’ or 
they’ve failed, and then we have that dilemma about do you then  
re-biopsy them?
Making the pre-screen study and trial valuable to patients was 
therefore an ongoing process, a question of timing when to give 
information, as well as adjusting the amount and type of information 
being provided to the patient’s circumstances. By offering more 
established kinds of personalised care as part of the recruitment 
process, the personalising impetus of genomic medicine in the process 
is reworked within caring practices. This also involved having to 
manage disappointment and make further decisions about trying 
again to see if the patients could be recruited. We observed discussions 
and were given examples of patients whose samples had been 
reanalysed several times in a concerted effort to get them on to the 
trial at a point at which ‘time is running out’.
On other occasions where results from SMP2 were not expected 
to lead to involvement in the trial by clinicians but patients were 
nevertheless hopeful, practitioners sought to manage this, including 
via ‘avoidance tactics’ without ‘dampen[ing] hope’. For example, 
nurses spoke with us about avoiding walking through a waiting 
area so as not to encounter a patient who had been calling every 
day for results.
Cultivating a sense among patients that the benefits of participa-
tion were greater than their own individual benefit was another 
strategy for managing potential disappointment, in the words of the 
senior CTA:
Most of the patients will enter strat med [Stratified Medicine Programme 
2] with the understanding that it’s going to help somebody else … a 
lot of the patients don’t care if it helps them. They just care that it 
helps somebody else. I’ve had patients say, ‘As long as I don’t have 
to go through the same thing that I’m go – you know, somebody else 
doesn’t have to go through what I’m going through, then I’ll sign up 
to anything.’
132 Personalised cancer medicine
And why do you – why do you think that – that is?
I think they feel like they can give back, I think like they’re giving 
some value. Their life is like some kind of a value, their experiences 
have given value to … research and to patients in the future. I think 
they want to see … especially lung cancer cured, yeah.
Invoking benefits for future patients, rather than the patient in the 
pre-screening study who was not able to make it on to the trial, 
was a way of offering a sense of purpose and contribution for 
patients with few treatment options and foreshortened futures. 
Consultants also prioritised other opportunities such as immuno-
therapy (approved by NICE in 2017) where they viewed these options 
as more likely to prolong survival time. The trial therefore slotted 
into an ongoing process of managing patients’ hopes and optimising 
their chances by prioritising treatments and keeping other options 
in reserve according to the patients’ state of health and cancer type/
results – as well as their capacity to cope with this information and 
decisions.
‘Living in hope’ (CTA) about the potential of the pre-screening 
study and trial involved difficult and painstaking work to try to 
optimise the prospects of a successful result by caring for the tissue 
itself. This included the CTA stewarding and tracking tissue as it 
moved between local laboratories (for sample preparation and then 
DNA extraction) and onwards to the national laboratory, as well 
as chasing results. It was also evident during biopsy procedures 
and laboratory analysis as practitioners sought to extract value 
and optimise the patient’s chances of participation in a treatment 
arm of the trial. This was difficult and painstaking work given 
that the tissue sample being used for analysis was often very small, 
which meant that procuring and extracting DNA was a complex 
process resulting in a number of test failures. In order to offset the 
potential for failure, pathologists as well as geneticists and clinical 
trials staff described ‘maximising the tissue’ as well as thinking ahead 
to what might be needed from the tissue in the future (Swallow et al. 
2020).
Making the screening study and trial work as a package inevitably 
involved tensions between staff as they sought to balance the different 
priorities of treatment and research. This is further illustrated in 
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the extract from a fieldnote below, where the CTA is trying to find 
patients to consent to SMP2:
Each week the CTA double checks with each consultant whether she 
can recruit the patients she’s identified as being suitable for SMP2. 
She checks with the consultant who seems reluctant to discuss ‘I 
thought the Matrix had finished’ ‘it’s not you again’ … It transpired 
that three of this consultant’s patients wouldn’t be suitable – the 
consultant describes these patients as ‘knackered’ and the CTA explains 
that she’s not sure whether she believes him [this is the same consultant 
she feels doesn’t understand the meaning or utility of SMP2/Matrix 
for lung cancer patients]. One of the patients had dementia and so 
couldn’t be approached. The CTA checked with a different consultant 
whether she could consent the final 2 patients and following what 
was quite a lengthy discussion [I waited in the corridor] CTA explained 
to me that she would approach one of the patients …
As I was stood chatting with both the CTA and a research nurse, 
a patient and their family member/friend headed to the consultant’s 
room [consultant who is reluctant to allow CTA to recruit his patients] 
and the CTA smiles and whispers ‘[The consultant] smiled when he 
went past, did you see – he must have been the knackered patient, I 
didn’t believe him at first!’ Responding to this the research nurse asks 
‘is he … being obstructive?’ The CTA agrees and tells us how slow 
it’s been for recruitment lately although also she stresses her efficiency, 
‘I’ve consented everyone!’
In an earlier observation the issue of numbers and progress with 
the trial also came up:
I asked whether she could show me the report that she sends each 
month to CRUK. The CTA explained that at the moment her ‘numbers 
are really bad’ and stresses that this will look like she’s ‘not performing’ 
when actually ‘it’s not my fault’ – ‘I have my numbers of the year 
but it doesn’t look like that.’ I asked what happens if she doesn’t get 
her quota of patients consented each month ‘I don’t know, I probably 
get called in to an office somewhere’ – hesitant when I asked this 
question and kept reiterating that she’d consented enough patients 
for the year ‘just keep on going’ – showed January’s numbers – ‘look 
I consented 16 patients in this month’.
We got chatting about the observations we’re doing in the labs 
– ‘oh you can tell us why samples aren’t being processed then – why 
they’re just left … you can spy for us’ (laughs).
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Here we can draw further insights into the work that key personnel 
such as CTAs do to try to make the pre-screening study and the 
trial work, persistently cajoling consultants, chivvying laboratories, 
recruiting allies such as our researcher, in an effort to meet recruitment 
targets. These excerpts also illustrate the concerns of staff who 
acquired an unwelcome sense of responsibility for the trial’s slow 
progress, trying to recuperate its value by focusing on recruitment 
to the larger screening study instead – a study which also aims to 
transform the NHS’s capabilities in genomic sequencing.
In this section we have explored how practitioners sought to 
make the pre-screening study and trial work for patients, and for 
the network and trial coordinators, via an array of calibration, 
articulation and uncertainty work. Deriving value from the trial for 
individual patients, the research programme and future patients was 
difficult and could be secondary to efforts to care for patients in 
the here and now. Nevertheless, practitioners expended considerable 
energy on trying to get a result of value that would offer patients 
access to the trial and further targeted treatments, including retesting, 
tracking samples and encouraging other practitioners to join these 
efforts. Calibrating patients’ expectations was also an ongoing process 
of optimisation to offer sufficient but not excessive hope.
Patients accessing and being on trial
The complexities and attrition rate of the pre-screening study and 
trial, together with the poor health of patients and the pressures on 
the clinical team, also meant that we found it difficult to observe 
and interview patients through their journey from the pre-screening 
study to the trial. We only managed to interview a small number 
of patients on the trial, as well as another group of patients on the 
screening study who did not manage to get on to the trial. We 
approached recruitment with caution, aware of the precarious position 
of patients, the likelihood of deterioration, and difficulties with 
biopsy procedures and attrition. We were concerned not to add to 
the burden of work and engagement that the trial required from 
patients as well as healthcare staff.
As discussed above, part of the way in which practitioners 
sought to manage patients’ expectations of the pre-screening study 
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and trial was to provide specific details about their options at the 
optimum time so as not to ‘saturate’ patients with information 
or raise false hopes. They also sought to offer the opportunity of 
the trial at the right time when other options had been explored 
and exhausted. This meant that the patients we interviewed and 
observed when they were being recruited to SMP2 were often not 
told about Matrix explicitly. This was partly because of known 
problems with tissue analysis and the likelihood that no actionable 
mutations would be found, but it was also because some of these 
patients were very unwell and unlikely to survive to receive the 
results.
In observations and interviews with patients who consented to 
be part of SMP2, expectations of personalised treatments arising 
were nevertheless present, albeit in quite vague terms. An example 
was Richard, a man in his forties with advanced NSC lung cancer 
that was responsive to the ALK inhibitor, crizotinib. For Richard, 
surgery was not an option due to the spread of cancer to lymph 
areas and blood vessels. Personalised treatments were the very best 
the NHS had to offer and he wanted to play his part in their efforts 
to help him by being positive about his prospects:
But I believe that that’s an informed decision … other people have 
done that for me … we have this amazing system in this country … 
if they’ve gone away and done these tests then I believe them. People 
make mistakes in all walks of life, I would, I would understand that 
if, if something went wrong … at least you gave it a go and … we’re 
not … saying, well that’s the end of that then … I’m a fighter and 
I’d like to think everybody’s doing their very best … to help me …
… they’ve said, ‘right okay, this is targeted, this is what we think 
is the best plan of option for you, and if it doesn’t work, we gave it 
go and we’ll try something else. And if that doesn’t work, we’ll try 
something else.’ So … why would I close any of those doors?
I remember … [my oncologist] … telling me about these genetic 
mutations and that I was only a one in twenty case, and I actually 
had to say to him, ‘sorry, is this a good thing or is this a bad thing?’… 
I think I’ve been taking these tablets for about eleven weeks now … 
and they were talking about maybe a nine-month process … I have 
good days, some days I have bad days, some days … while I’ve got 
everyone, my family and professionals around me, while I’ve got 
everybody doing everything that they can, well, you stay positive 
don’t you? …
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As well as keeping his future open, Richard also framed being part 
of research and experimentation, and trusting in clinicians, as part 
of progress towards a cure for future patients:
people have said to me, ‘oh it’s a good job you didn’t have this twenty 
years ago’ … Well maybe in twenty years’ time, they’ll be saying to 
people, well thank god we’ve got a cure for cancer now, because if 
this had happened to you twenty years ago, you’d be in this, all this 
experimental stage where no one really was a hundred per cent sure.
For Richard, helping himself with more personalised treatments was 
also about helping other patients to access this kind of medicine in 
the future, as he explained earlier in the interview: ‘if I can be 
involved in that for my particular problems … not just for me … 
then why would I, why would I rebuff that opportunity … I think 
that would be silly’.
This balancing act between personal and collective futures was 
also evident in an interview with another patient, Michael, who 
told us that he stopped smoking instantly after his diagnosis because 
‘you [health service] help me and I’ll help myself’ is his ‘motto’, and 
how he tried to get his mother to stop too. He went on to reflect 
on how being on the trial was helpful:
It helps … the tablet, it helps your own mind. That’s it. But basically, 
you’re helping other people behind you. ’Cause then … my trial might 
say right, it works with their DNA. And then another part of it, that 
one, put the two of them together … Bang. We’ve cured him … I 
might go in … a fortnight and she’ll go, that tablet is working. It’s 
no[t] growing. And it’s no[t] breaking up. Take this other one. We’ve 
trialled it with other people … Put the two tablets together and it 
might shrink and disappear.
Through these kinds of accounts, patients established their sense of 
purpose and hope, bolstering their identity as a worthwhile, active 
and valuable person as a way of coping with what was often a 
shocking discovery of cancer which encroached on their future 
(Chattoo and Ahmad 2003; Hubbard et al. 2010; Brown and de 
Graaf 2013).
Although lung cancer patients are typically less active in self-
advocacy than other kinds of cancer patients, active engagement and 
self-advocacy was at times a strong feature of patients’ and family 
members’ accounts of Matrix in online lung cancer patient forums. 
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This included examples of patients encouraging each other to ask 
about Matrix, seek second opinions concerning eligibility and to 
chase results with the hospital. For example, in a discussion about 
the unpleasantness of the bronchoscopy to obtain a biopsy and the 
difficulties with waiting on results one patient commented:
we were told about a month ago that they were asking [the hospital] 
for my biopsy. only now told that they had mislaid it. we kept having 
to ring the [hospital] just to warn others that if they haven’t heard 
for a bit make sure that they haven’t lost you in the system.15
Patients and relatives supported and advised each other about how 
to get on to the trial too, for example:
First thing ask to take part in the National lung matrix, ours is in 
the [hospital] ask to be tested for EGFR its the cancer gene that 
determines whether they can use a non chemo drug such as immu-
notherapy. If your hospital doesn’t do trials like ours … get a consultant 
at one that does. It sounds like you can’t opt for radiotherapy if it 
has spread but everyone is different and how well you are.
Don’t take one person’s expert opinion do your own research and 
both decide. If we had my wife would have been in a hospice by now 
and I have no doubt about that, now she has been in the garden all 
day and gone out shopping amazing difference in hospitals, and this 
isn’t private our good old NHS.
You are at the worse stage as you don’t have enough info, like 
Brexit really, it gets better. The [hospital] is outstanding and I hear 
the [other hospital] is as good. Our Professor … is so passionate and 
yet the first thing the oncologist in [another hospital] said at diagnosis 
do you want some morphine to take home. Keep strong and keep 
positive
As this excerpt illustrates, patients expressed both gratitude and 
frustration with the NHS as part of these accounts, simultaneously 
evoking personal responsibility while also signalling commitment 
to a public spirit of care. Their accounts demonstrate the unevenness 
of information provision about the trial and about the capacity to 
access it. This mixing of emotions and values was a feature of what 
patients described as having ‘nothing to lose’ and a sense of taking 
control over advanced cancer through this kind of activity:
you can only but ask (OR SHOUT) if you think you might be right 
for this. If you don’t ask you don’t get.
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–
[name], just go for that link from [name] & see what happens.
COME ON SUNSHINE GO FOR IT !!!!!
Frustrations, typically focused on the NHS, ranged from difficulties 
with accessing the trial to waiting for results, as in the extracts 
below:
Had 10 week break should get results tomorrow of the matrix trial, 
hopefully I might get lucky and get on a trial this time
Having not qualified three times for new treatments so far. Don’t get 
me wrong I am very happy for those who have the protein to be 
accepted, but from what I can see that is only a minority, even though 
I am told that they work just as well for the people who haven’t got 
the protein but maybe not for so long, so to me in a word to me it 
is nothing short of rationing.
Through these kinds of exchanges forum contributors articulated 
their sense of individual and collective self-worth, resisting unwelcome 
kinds of stratification while advocating personalisation in other 
respects, framing the work of being a cancer patient or relative in 
this world of experimental medicine as one of persistence against 
the odds to try to get to the next level of access to treatment:
My brother was signed up for SMP2, leading on to the Lung Matrix 
Trial, but his original biopsy returned a technical failure on the gene 
testing. It was simply too poor quality. They can’t get another biopsy 
from his lung as his lung tumours are too small (the biggest is about 
1.3cm) and although he has extensive brain mets, including one at 
2.5cm, a biopsy of a brain met isn’t standard NHS practice. Anyway, 
the good news is he might be ALK+ too, as a review of his original 
ALK test (initiated by the request for his biopsy block for SMP2) has 
been interpreted as having granular positivity for ALK. They can’t 
confirm that without another biopsy, and they don’t consider this as 
definitely ALK positive, but it’s a ray of light. That review would 
never have come about if it wasn’t for SMP2/Matrix. So, go for it … 
like [another forum user] I would say you never know what might 
come out of it!
‘Rays of light’ provide a sliver of hope for the future for these 
more active patients pursuing treatments, even as scientists and 
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clinicians might have been much less optimistic. Although patients 
and relatives did engage with the molecular details of diagnosis as 
part of discussing their options, online exchanges were not places 
where lung cancer patients and relatives necessarily grouped around 
the details of specific subtypes. Instead they supported and encouraged 
each other, alongside family members, to move through the levels 
of access to acquire personalised information that might hold the 
promise of future therapies.
Other patients were less proactive in researching or engaging with 
detailed information, as was the case with the metastatic gynaecology 
patients encountering the VGT study as discussed in Chapter 3. 
Derek, a man in his sixties, had lung cancer which was diagnosed 
late and had spread to his spine. In an interview, he told us he too 
hoped for treatments from his participation in SMP2, something he 
described as ‘selfish’, but he also wanted to help future patients, such 
as his descendants. He was bewildered and shocked by his diagnosis 
and told us he coped with this by putting his trust in the clinicians, 
and not trying to find out too much about the details of his cancer. 
So his route into the study had been more passive than the kinds of 
approaches discussed above, as was the case with other patients we 
observed and interviewed. For these patients participation was part 
of their effort to ‘carry on living as I did before’, on the basis that 
something might come out of their participation, given that targeting 
treatments is better than a ‘blanket’ approach which ‘bombard[s] 
everybody exactly the same’. The SMP2 study, and the possibilities 
of targeted treatments, were but one part of a wider approach to 
living with cancer rather than a unique source of particular promise.
For patients who were successful in getting on to the trial the 
benefits could be self-evident, just as they were for patients such as 
Richard, already on targeted treatments and engaging with research 
in SMP2. When asked directly about her reason for participating 
in the trial, another patient, Marion, who had recently had brain 
surgery because her cancer had spread, and had recently joined the 
trial, explained:
Well I don’t see how it can hurt. Anything that’s going to … that 
might have any kind of positive result has got to be good. It’s better 
than doing nothing about it. And it might do something really positive. 
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And stop the cancer altogether. Because they can’t guarantee that the 
brain tumour won’t return again. Apparently, that’s a possibility.
The possibility of stopping the cancer growing, which her husband, 
Malcolm, later described as ‘arresting its development’, drove Marion’s 
involvement in the trial. As another patient in her forties, Victoria, 
noted, it ‘buys you a bit more time’. Victoria was just finishing 
treatment as we interviewed her. She had previously recovered from 
ovarian cancer but had gone on to develop lung cancer. She explained,
Because obviously my cancer’s not curable but it’s treatable, but every 
time something stops working, we have to think, well what’s the next 
thing, what is coming? I know there’s lots and lots of research that’s 
being done into lung cancer at the moment … how can you, how 
can you advance any sort of knowledge if you’re not involved in, in 
trials really? And also, it does give you a good understanding of what 
the treatment landscape looks like, or might look like, and to me … 
it’s helpful to know what things might be on horizon, or you know, 
what trials might be available …
Future-crafting of this sort involved the intensive and ongoing work 
of remaining hopeful. Janet recognised how treatments had improved 
since her sister had died from skin cancer several years previously. 
Janet was on the no-actionable genetic change (immunotherapy) 
arm of the trial (now in remission). She emphasised the importance 
of trust and fortitude:
You know, if it weren’t for them, there’d be a hell of a lot of us not 
around still … so what do you do? You turn round and say, ‘No I 
don’t think I’ll bother today,’ so I could wake up and think, ‘oh do 
you know what, I’ll have a bit of cancer today’. So it’s either put 
your trust in them and know that they can give you something what 
kills it or keeps it bay, or sit in a corner and slap your head against 
the wall. Fear worries me. Well sorry, I’m not that sort of person.
You know, just got to do what you’ve got to do, don’t you, at the 
end of the day and you don’t want to stop here, so you do it.
We interviewed Jenny, with her husband Paul, at a cancer centre. 
Both were in their seventies and Jenny had recently started a targeted 
treatment on one arm of the Matrix trial. They described how the 
Matrix trial (which Jenny transferred hospitals to join) had given 
them hope after Jenny had been told she was no longer responding 
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to treatment. For Jenny and Paul this involved resisting the idea 
that she had only five months to live:
[Paul] I’ve an issue with this because averages don’t work. Anyway, 
so … your response was, ‘Give me anything.’
[Jenny] Yeah, anything and everything (laughs) … I’m really pleased 
to be on the trial and I think I’m very lucky because of what the 
consultant said right at the beginning, because the first thing I did 
was count the five months … I think I really appreciate the trials 
because I think if it wasn’t for them, if I believed what that … consultant 
told me, I wouldn’t be here. So I really think it is the trials that have 
helped.
Being on trial was often a last hope for patients, but it also offered 
reassurance and care, in part because it signalled that consultants 
were working hard to keep up with her cancer:
[Jenny] Oh, they were absolutely fine. I mean they did say, they told 
me that it was affecting my liver … and that there would be alternative 
treatment.
[Paul] They were very positive about…
[Jenny] They were, yeah.
[Paul] … that there’s always something else. And they also … said, 
‘There is another trial.’ They’d already spoken (laughs softly) to [this 
hospital] and there’s a trial now called the, the Lung Matrix Trial, 
which tries to pinpoint people with similar DNA or whatever. And 
… she would go on that. So we were…
[Jenny] Really positive then.
[Paul] … told, given bad news and then good news. So that was … 
really good because it was ongoing. They also rang you later (laughs 
softly) didn’t they…
[Jenny] Yeah.
[Paul] And said, ‘If anything goes wrong, ring us. We may have 
another treatment for you here.’
Wow.
[Paul] Yeah. So I mean that side of it’s been fabulous.
[Jenny] Yeah, yeah.
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[Paul] The only issue is they don’t communicate very well (laughs 
softly) with each other, do they? Well this is it with hospitals. I don’t 
think they do, do they?
The work of the hospitals to keep options open was a source of 
reassurance and hope. Jenny and Paul continued,
[Paul] [They told us] ‘If that doesn’t work, we’ll … have something 
else here.’
[Jenny] ‘We’ll, we’ll always have something else for you.’
[…]
[Jenny] And that was a phone call to my house, you know, after I’d 
been, finished with [that hospital] … I thought that was amazing, 
you know. So I thought, well if this doesn’t work, maybe I can give 
them a ring…
Although these accounts contain familiar logics of promise and 
hope from trials which can also be found in patients’ accounts of 
other sorts of trials and treatment, they also reference the promise of 
adaptability and responsiveness to cancer according to personal and 
specific genomic changes – key distinguishing features of this new 
generation of trials and the personalisation of treatment on offer.
For Janet, Jenny and Paul, personalisation via the trial also offered 
a more precise hope. Janet, even though she was on the non-actionable 
arm of the trial (i.e. her treatment was not based on genetic changes), 
nevertheless experienced the treatment as personalised:
when they did the second [biopsy] and they said they’ve actually got 
whatever it was they were looking for, I thought ‘yes … they’ve found 
something, they have found it’ … I think what must have gone through 
my head at the time was, well if they find whatever they’re looking 
for in this DNA and they … made … some sort of drug or whatever 
the case may be … I’d expect them to sort of like say to me, ‘right 
we’ve done this, we’ve got this. This is what it is. It’s from your DNA, 
it’s from your body, so we know your body’s going to accept this 
drug and it’s going to help.’
I mean, it’ll never go, I don’t suppose. It’ll never ever go, but the 
one on my lung has shrunk because … I’ve had radiotherapy … These 
in my neck … I can’t even feel them now, but like I say, if it weren’t 
for … all these drugs and putting stuff together and seeing what 
makes this … do this, then I probably wouldn’t be here.
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For Jenny and Paul,
[Paul] … being on a trial, there’s always a risk of it not suiting you 
or it being cancelled because it suits you but it doesn’t suit a lot of 
other people.
[…]
[Paul] I think the Matrix way is better because it’s trying to aim at 
suiting you, or you and a small percentage of people, and say ‘for 
these people it’s great, so we’ll carry on; for these other people, it’s 
not so good, so we’ll do something else’. And I think that’s the whole, 
that’s –
[Jenny] It’s a lot more choice in treatments.
As Paul explained, this was more positive than his mother’s experi-
ences of undergoing chemotherapy:
[Paul] [going on the trial] that was a big relief to both of us, actually, 
because … although you said … you’d spend a fortune on wigs, you 
didn’t really want to, did you?
[Jenny] (laughs) And said, if I had to wear a wig, I would have a lot 
of them (laughs) and very expensive (laughs).
[…]
[Paul] Well, historically, I know … my mother died of cancer and 
had the most terrible chemotherapy, because it was just the same, 
they stuffed the same poisons into her as they did to everybody else 
… whichever cancer it was … And I think, nowadays, what they’re 
doing is it’s the same as going and getting a suit made to measure 
rather than buying one off the peg. It’s … better for you and it might 
only be a tiny tweak.
As Jenny noted elsewhere, the totemic value of the trial brought an 
enhanced sense of personalisation: ‘I got in my head that if they 
actually found some sort of treatment [that] shrunk mine … I should 
be offered it ’cause at the end of the day, it’s part of me. You know, 
it’s part of my body, it’s my DNA.’
Maintaining hope while on the trial was, however, a complex 
affair that involved numerous balancing acts. As Paul noted, more 
time had to mean quality time: ‘Well I think anything that holds 
out the possibility that she could have longer and better quality of 
life, I think these two things, longer, but we don’t want longer if 
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there’s not quality … So it’s longer and better quality.’ Patients on 
the trial also described hoping to keep the ‘cancer at bay’ in Janet’s 
words, while also keeping open the possibility of a longer-term and 
more remarkable result, as described by Michael:
’Cause that’s what the tablet’s to do. Just … it’s to stop it growing 
and stop it spreading, breaking up and spreading. And if that happens 
it just means then you get on with your life…
… it’s just something that’s there and it’s not going anywhere. 
That’s it. So then maybe such-and-such’ll get something that’ll make 
it disappear altogether. But at least it’s no[t] growing.
Other participants experimented with the hope that practitioners 
are going to produce a ‘magic cure’, as Marion’s husband Michael 
put it. For example, in Victoria’s interview she joked:
What I told my consultant when I started it, I said, I want nothing 
less than a headline out of this, and she said, ‘we’d go Daily Mail,’ 
so it was a new and unexpected life goal (laughs). So yeah, no … 
peer review journals for it, cause we were going straight, straight for 
the top (laughs).
Here Victoria reflects on building rapport with clinicians and leaving 
a legacy, thereby maintaining hope. As Michael explained this could 
also involve avoiding certain trains of thought: ‘I don’t ask them 
how long have I got … I’ll know myself. So … but I just hope the 
trial maybe worked for me and I get … I don’t know if I’ve got two 
weeks, two years or twenty years…’
However, in other respects, patients reflected on the need to lower 
expectations (Gardner et al. 2015), as Victoria explained:
I think also, as patients, there’s got to be some sort of acceptance, so 
I suppose of the limits of what medicine can do … of course you 
want research to always be, pushing the boundaries … but in reality 
how does that translate into what can it actually do for you and does 
that mean that, you know, just because we can do something, well 
does that mean we should be keeping people alive at all costs … if I 
was going into my consultant every few weeks and saying … ‘what 
are you doing to make sure that … you keep me alive, or you can 
cure my cancer?’ we wouldn’t be getting very far. We’re having to 
work together to understand that we can’t cure this, but we can … 
maintain my quality of life … and my health actually, you know, for 
as long as we possibly can.
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Victoria’s sense of partnership with the clinical team can, however, 
be contrasted with Janet’s doubts about her care. Janet received 
treatment on the trial that was not funded by the NHS and she 
described her anxieties that in a year’s time they might decide not 
to fund the treatment further. She raised these concerns with the 
consultant who said they would ‘cross that bridge when we come 
to it’, bracketing the future to protect patients from the possibility 
of failure and disappointment.
Being on the trial involved living with uncertain futures where 
much was at stake. It also involved managing side-effects and disap-
pointments with care, as the extract below from one of the Cancer 
Patient Discussion forums illustrates:
It’s been many months since I have posted an update for the simple 
reason is the phase 2 drug trial (matrix Arm C) has been doing what 
it says on the tin … keep the tumour growth at bay.
Side effects … feel very tired on the recovery week due to low red 
and white blood counts (3 weeks of drug and 1 week off for recovery) 
and cough gets worse near the end of each cycle however apart from 
that all has been all good.
Had 6 weekly CT scan just after xmas and they saw very slight 
growth of the tumour, plus a small secondary bone cancer (treated 
with radiotherapy) so ‘we’ started looking for a plan B which also 
included possibly moving my treatment [to another hospital].
The CT scan last week – the trial drugs have completely failed, or 
has the cancer mutated so the drugs are no longer effective? Noticeable 
tumour growth plus fluid on lung, second lymph node has growth 
to a possible infected size. Probable infection in liver.
All a bit of a shock as we had our rose-tinted glasses on and were 
hoping just small amount of small growth.
Well shit happens and we move on. We always knew that I would 
have to be off any treatment before moving onto another trial assuming 
something is available. We are just off the current trial a bit earlier 
than expected.
Bring on the next trial…16
Here we see the work of reinterpreting failure and orienting to the 
future, as well as some of the problems associated with too much 
hope being attached to these trials by patients and family members. 
Patients nevertheless welcomed the care they had received while on 
the trial, particularly the time spent with research nurses discussing 
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difficulties around treatment and uncertainties. For Marion and 
Michael the trial also provided them with the opportunity to feel 
more involved in their care, affording an extra level of care: ‘giving 
me an MOT’, in Michael’s words, and, for Marion, feeling ‘very 
closely monitored … that makes me feel good … it’s better than 
just leaving you not knowing what’s happening’. Victoria also 
welcomed this:
so I’d rather, in a way that they were taking a bit of care of me rather 
than sending me away, see you in six months and see if your arm’s 
dropped off or anything … I tell all of my friends it’s like going up 
another level in a computer game … Do not go to level one, go 
straight up the lift to level three, where five nurses are waiting for 
you. So yes, it’s lovely, I feel much more looked after.
The importance of developing relationships and spending time with 
healthcare staff was also important as Jenny and Paul described:
[Paul] And it is that sort of positive from some of the nurses. We had 
a lovely nurse, [name of nurse], in, in [hospital] who used to tell us 
all about what she was doing and where she’d been.
[Jenny] Yeah, everybody’s got…
[Paul] And the girls up here in the—
[Jenny] … time, time to talk to you.
[Paul] Yeah.
[Jenny] You know, it’s not as though you’re a – I don’t know. ‘Sit 
there and we haven’t time cos we’re busy.’
[Paul] Yeah.
[Jenny] You know, everybody has the time to sit down and have a 
chat with you.
[Paul] But … here … the nurses and the, the consultants always seem 
to have a decent time to spend with you.
[Jenny] Yeah, yeah, there’s no rush. There really isn’t.
[Paul] I’ve never felt rushed out of the consultancy…
[Jenny] No.
[Paul] … without being asked if there was anything else we wanted 
to talk about.
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[…]
I think that’s it really. We just feel that there’s caring people, with 
time.
As this exchange illustrates, being on the trial meant spending time 
and developing partnerships with clinicians which was experienced 
as comforting; an example of how trials create the space for addi-
tional carework from busy staff, which patients and relatives greatly 
value.
For patients facing an advanced lung cancer diagnosis, adaptive 
trials such as Matrix are an opportunity to extend severely diminished 
futures, keeping options open and being positive about living with 
cancer even though there is no cure. This was articulated in terms 
of being fortunate to be part of something advanced or cutting-edge 
in some cases, and via a detailed engagement with the particularities 
of research design or experimental treatments in other situations 
(particularly in the online forums), with the idea of tailored or 
targeted treatments resonating with commonsense understandings that 
precision is better than blanket or one-size-fits-all approaches. For 
some of these, often younger patients and their relatives, advocating 
for participation in trials and engaging in detail with the processes 
and its complexities as they tried to negotiate access to experimental 
treatments was a way of optimising their health despite the cancer 
diagnosis, somewhat mirroring the work of nurses chasing samples 
and results. For other patients their engagement with the trial and 
pre-screening study was more passive, a matter of trusting in the 
clinicians in an effort to gain more time, particularly for older 
patients, as was also the case among the gynaecological cancer 
patients discussed in the previous chapter. Persistence, fortitude and 
positivity were nevertheless key virtues for patients across these 
different groups.
Participation in the pre-screening study and trial was also, on 
occasion, an opportunity to demonstrate commitment to helping 
other patients in the future, although this was inevitably framed as 
a secondary benefit in favour of personal benefits. Accessing more 
personalised care was another valuable part of participation; spending 
time with nursing staff was particularly important for patients as 
they sought to carry on with their lives and maintain self-worth in 
the face of narrowing horizons. Participation could nevertheless 
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generate uncertainties and anxieties about waiting, about treatments 
after the trial or side-effects and lack of effectiveness of treatments. 
As with the breast and gynaecological cancer patients discussed in 
the previous chapters, adaptive trials generate promise and hope 
for the future among lung cancer patients, but this can be fleeting, 
contingent and overshadowed by ongoing and growing uncertainties 
and worsening health.
Conclusion
Adaptive trials are a key feature of the personalised cancer 
medicine landscape, offering patients experimental, targeted treat-
ments and reconfiguring institutional arrangements to mainstream 
next-generation sequencing as part of care. In the case of lung 
cancer patients, this offers a new set of options for patients with 
some of the worst outcomes, given that lung cancer tends to be 
diagnosed at an advanced stage. Patients affected with lung cancer 
also tend to have less financial and social capital with which to 
manage their condition, since it is associated with disadvantage. 
Practitioners are therefore keen to make these new opportunities 
work for these patients, but they are also operating in difficult 
circumstances, in services where resources are pressurised and 
outcomes are disappointing. The screening and trial arrangements 
of which they are a part are also complex and difficult to implement, 
not least because obtaining and analysing a sample of sufficient 
quality involves many intricate steps and numerous actors, taking 
time and asking patients to wait when their futures are already 
foreshortened and their health continues to deteriorate. Making 
this trial work – for institutions and for patients – therefore 
took considerable care, marked by calibration, articulation and 
navigation work for practitioners and, at times, patients and their 
relatives.
Such work always has to be weighed against the perceived needs 
of patients for whom care in the moment can trump the possibility 
of future treatments emerging from the trial. Practitioners and patients 
sought to maintain hope and salvage other kinds of value, such as 
care in the moment, when results were disappointing. Participation 
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or engagement with the trial and its possibilities could generate 
additional uncertainties, anxieties and disappointments that also 
had to be managed by staff, patients and families. Patients did this 
work alongside their relatives, sometimes in public forums where 
they engaged in detail with the trial arrangements and processes. 
But for other patients there was less engagement with the technicalities 
of the trial and more of a focus on relations of trust and care with 
clinicians – two different ways of enacting hope with persistence, 
fortitude and positivity. Together, these activities and expectations 
formed part of an ongoing process of optimising the possibility of 
the trial that worked alongside efforts to optimise treatments and 
sequencing infrastructures to deliver the new era of personalised 
cancer medicine.
In her study of adaptive trial methodologies, Montgomery notes 
that
the temporal politics of adaptive design straddle a … diffuse set of 
scientific institutions, from profit-seeking big Pharma to publicly- and 
philanthropically-funded academia. What is at stake is not so much 
the creation of commercial value through the promise of a given 
vision, but the creation of value – moral, epistemic and commercial 
– through the ability to know the unknowns and to fix the future as 
it unfolds. (2017a: 237)
We can see these forms of value emerge, diverge and fade across the 
different levels at which the trial and pre-screen study on which it 
depended were orchestrated and experienced by practitioners and 
patients. Making a success of the trial for practitioners and for 
patients could mean different things, but in each case it involved 
ongoing processes of careful tinkering in an effort to chase and 
realise value, even when this could be fleeting or minimal. This 
work kept the trial going, enabling the extraction of other kinds 
of commercial value in the future through drug development and 
improved trial processes. Big pharma was remote from the clinic, 
but the hopes inspired by the possibility of ‘drugs that work’ for 
current and future patients were ever present. Yet practitioners, 
relatives and patients trying to make the pre-screening study and 
the trial deliver personalised care to patients also generated value 
for the consortia, institutions, funders and investors in this new 
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form of personalised medicine. This spurred further faith and 
investment in the UK bioeconomy, enhancing scale, and innovat-
ing new kinds of pathways, research consortia, valuation practices, 
gene panels and, of course, the data required for the innovation of 
new drugs. As we go on to discuss in the next chapter on whole 
genome sequencing studies, these processes of generation and 
extraction of data are crucial to the promise of personalised cancer 
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Genomics at scale: participation to build 
the bioeconomy
Genomic research, with the aim of developing personalised cancer 
therapies, is not just being pursued through trials or smaller-scale 
studies in cancer clinics and laboratories. It is increasingly taking 
place on larger, national and industrial scales too, as data is gathered 
en masse from patients and publics (Hilgartner 2017). In this chapter 
we investigate one such flagship national genomic sequencing 
programme to explore how genomic data, alongside other health 
and social data, is being gathered via mainstream healthcare services 
and shared with companies so that its value can be rendered into 
new molecular profiling technologies and targeted drugs. Focusing 
on Genomics England’s 100,000 Genomes Project, we trace the 
ways in which data-rich healthcare futures are being crafted via 
cancer patients’ and professionals’ engagements with whole genome 
sequencing (WGS), exploring how participants’ everyday experiences 
sit within a wider nexus of complex relationships and rearrangements 
of the NHS. Throughout we trace the kinds of futures articulated 
and mobilised by ‘the genomics vanguard’ (Hilgartner 2017: 27) of 
politicians and policymakers, together with the experiences of 
practitioners and patients, contrasting bigger promissory futures 
with the range of contingent, sometimes doubtful, at other times 
quietly hopeful futures crafted by patients and practitioners involved 
in making this initiative happen on the ground.
We could tell the story of the development of these initiatives 
through familiar framings of innovation, focusing on the rapidly 
advancing capacity and reduced costs of DNA sequencing and 
information technology as the main driver of progress. But to do 
so would be to miss some of the crucial political, economic and 
organisational changes in how data, institutions and value are being 
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reconfigured to enable and extend these initiatives, changes which 
official discourses of success tend not to register. As Hilgartner has 
argued, to understand how technoscience such as genomic sequencing 
is a vehicle for the transformation of mainstream healthcare, we 
need to engage with the political and economic processes at stake, 
or in Hilgartner’s words, ‘how institutions, discourses, identities, 
constitutions, and imaginaries shape modes of decision making and 
guide public reason’ (2017: 6). This includes tracing the production 
and effects of promissory and official discourses that underpin these 
developments: the futures envisaged for patients, services and the 
nation, the measures and processes underpinning governance and 
successful implementation, and the personal stories and affective 
repertoires of practitioners, advocates and participants. Considering 
what kinds of value are created for whom through these processes, 
and the work this involves for particular actors, is also key to our 
analysis, including with respect to how it is revealed or obscured 
in practice, replicating or subverting the roles ascribed to key actors 
through official discourses.
We interviewed a range of practitioners involved with the project 
at one institution which was part of a regional consortium – four 
of the project leads, the three nurses involved, and clinicians and 
scientists involved in implementation (including nurse consultants, 
histopathologists, pathologists, geneticists, oncologists, clinical 
scientists and biomedical scientists). We also observed 16 consenting 
clinic sessions (sometimes with two or three patient appointments) 
and interviewed 17 patients and three family members about their 
experiences of taking part in the project after these consent meetings. 
Interviews and observations were carried out between 2016 and 
2018. We spoke to patients affected by breast, colorectal, gynaecologi-
cal, brain and blood cancers. Participants ranged in age from the 
forties to the eighties. Some of these patients were in the early stages 
of breast cancer, prior to treatment, others were in remission following 
surgery for colorectal cancer, and some had more advanced or 
recurrent breast, brain or gynaecological cancers or were on long-term 
maintenance treatments for blood cancer.
In the next section, we trace how the promise of national genomic 
data and its analysis are articulated and realised as a form of 
economic growth and marketising public services, focusing on the 
‘knowledge-control regimes’ (Hilgartner 2017: 13) of bioethics and 
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the ‘participatory turn’, arguing that both are crucial to the realisation 
of biovalue from these large-scale programmes. This includes two 
important ‘governing frames’ (Hilgartner 2017: 13) which elaborate 
previous forms of participation – extending informed consent and 
public engagement/participation, including via evolving ideas and 
practices of ‘genomic literacy’.
Genomics and the health of the nation
As Fortun wrote in his ethnography of the Icelandic genomics 
company deCODE’s sequencing of the genomic assets of the Icelandic 
nation:
Genomics is building new zones of intensities, places in and between 
the lab, the corporation, the experimental assemblage … the successful 
scientists and corporations will be those who can continually rearrange 
software, hardware, netware into hybrid combinations that create 
new intensities … Completion isn’t promised by genomics, future 
becomings are. (Fortun 2008: 47)
A decade after these insights, we see the further intensification of value 
in a complex global network of market-data assemblages offering 
the promise of further growth in the bioeconomy. Companies set 
up by nation-states, such as Genomics England, commercial actors 
and state-based assets such as the NHS all operate in these zones. A 
great deal of attention is focused on commercial direct-to-consumer 
genomic tests. But the marketisation of genomic data is taking place 
through the auspices of public health providers such as the NHS as 
well. This involves key partnerships with commercial organisations 
involved in sequencing and analysing genomic and other NHS data 
in order to build capacity in the UK bioeconomy.
Since its establishment, Genomics England has developed complex 
governance arrangements to ensure that companies working with 
patients’ genomic data are appropriately vetted, and that the data 
remains secure. Companies involved in this work become service 
providers, which might involve providing data and/or the interpreta-
tion of data or other technical services. These companies range in 
size and scale, but their international links to other national sequenc-
ing endeavours are clear. For example, Congenita, a spin-out company 
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from the UK’s Sanger Institute, funded by the Wellcome Trust, 
developed its clinical decision support software called Sapientia 
through involvement in Genomic England’s 100,000 Genomes Project. 
In 2018 Congenita signed Memorandums of Understanding with 
Chinese companies and health providers at a trade event in China, 
which took place alongside a state visit by the then prime minister, 
Theresa May. These meetings received considerable press coverage 
in the run-up to Brexit as they became, for some, emblematic of 
the UK’s capacity to develop global markets beyond the EU. The 
company’s press release noted:
Underlining Congenica’s expansion and potential in China, it was one 
of only 5 UK companies to attend the signing event held in Beijing. 
Hosted by UK Secretary of State for International Trade, Dr Liam 
Fox, and China’s ex-Vice Minister for NHFPC, Jin Xiaotao, each 
Government set out their vision for the future of digital health and 
confirmed the opportunities for international collaboration and trade.
The press release went on to give details of how the company had 
previously entered into an agreement to provide services for the 
Chinese ‘100K Wellness Pioneer Project’, hosted by the Beijing 4P 
Health Research Institute. Congenita also has a contract with BGI 
Genomics in China and Series B fundraising to build its business, 
including investment from BGI.
The 100,000 Genomes Project emerges as more than just a project 
to provide UK patients with genomic information and the possibility 
of targeted drugs sometime in the future. It is also more than a 
matter of delivering sequencing and laboratory services differently in 
English hospitals: it is part of the development of the UK’s commercial 
capacity, spun out by scientists who established their research with 
support from philanthropic and public funders committed to open 
genomic data, as UK businesses become embedded in a major new 
venture to transform the healthcare system through genomics.
The development of national genomic sequencing initiatives is 
not just driven by technological breakthroughs and reducing sequenc-
ing costs, as popular histories of genomics would have it. Instead 
this process was fundamentally enabled by a key set of political and 
institutional changes, led by state-actors and agencies and aimed at 
opening up population data and markets simultaneously. This is 
not so much a story of the ‘invisible hand of the market’ in Adam 
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Smith’s famous formulation, as it is a story of the ‘invisible hand 
of the state’ (Goven and Pavone 2015). Monetising the nation’s 
genomic assets is part of the marketisation of publicly funded health 
systems such as the NHS in post-austerity Britain (Hockings 2014).
This vision for genomic sequencing at scale, embedded across 
the health service, was largely ‘top down’ – what Hilgartner (2017: 
27) calls a ‘vanguard vision’. It was not broadly conceived within 
the scientific or medical community or the wider nation, but generated 
within elite scientific and government establishments. As Samuel 
and Farsides (2017) have written, the roots of what would become 
Genomics England can be traced to a House of Lords Science and 
Technology Committee report from 2009 (whose special advisor 
was Professor Tim Aitman, who would later become one of the 
leaders of the Scottish Genome Partnership), where the committee 
argued for ‘a strategic vision for genomics in the UK’. The government 
set up the Human Genomics Strategy Group in response, chaired 
by Professor Sir John Bell, who would go on to sit as a non-executive 
director on the board of Genomics England. Bell also holds this 
position on the board of Roche (a prominent pharmaceutical and 
genomics sequencing company) as well as a host of other public 
and corporate appointments, including a period as president of the 
Academy of Medical Sciences (2006–11). The group’s 2012 report, 
Building on our inheritance: Genomic technology in healthcare,1 
articulated the vision on which Genomics England would be based. 
Bell wrote in the Foreword:
At present, we are in a position of strength. As the recent life sciences 
strategy highlighted, the UK is a recognised world leader in biomedical 
sciences and is home to many of the leading academic and commercial 
research centres spearheading the global development of genomic 
medicine and furthering the use of Clinical Genetics. This gives the 
UK an outstanding opportunity to exploit its scientific lead, via the 
NHS – a unique service delivery environment in which clinically 
validated genomic medicine will be able to thrive. The challenge is 
to make our vision a reality for the benefit of the NHS, for the benefit 
of the UK biomedical industry and, above all, for the benefit of 
patients and their families.
It is also to move sufficiently rapidly that our leadership position 
is not undermined by other countries who have also recognised this 
opportunity and are now pursuing it. (Human Genomics Strategy 
Group 2012: 3–4)
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The emphasis on leadership, nationhood, economic growth and 
the NHS as a valued public asset to be put to work to preserve its 
benefits for patients now and in the future has come to dominate 
the promissory discourses of this emergent field (Tarkkala et al. 
2019). This gives a particularly British twist to the emphasis on 
genomics as a platform for global transformation, captured in a 
McKinsey Global Institute report of 2013 which called it one of 12 
disruptive technologies that will ‘transform life, business, and the 
global economy’.2
In the midst of a prolonged period of austerity in the UK, genomic 
research became a vehicle through which the British state, together 
with scientific and medical funding bodies and institutions, could 
transform the NHS to advance economic growth and social benefits 
in partnership with the private sector. Genomics England was set up 
as a state-owned company to coordinate and deliver these benefits, 
working in partnership with charitable funders and the private sector 
to sequence 100,000 genomes of cancer and rare disease patients by 
2017. At a time when state funding to healthcare services was being 
reduced,3 an initial £100 million of government funds was directed 
towards this flagship project aimed at transforming the NHS. This 
was part of a package of deals estimated to be worth £300 million, 
including a contract with the sequencing company Illumina (Sample 
2014). The launch of the 100,000 Genomes Project was timed to 
coincide with the 65th anniversary of the NHS, and was given the 
personal backing of the then prime minister, David Cameron. Cameron 
focused on the transformation of the diagnosis and treatment of 
‘devastating diseases’ in the NHS and beyond. Genomics England’s 
press release at the time described the project as ‘world leading 
research organisations join[ing] forces’.4 The deal with Illumina 
was reported as being worth around £78 million for the company 
to deliver WGS, but it was also noted that Illumina would invest 
more than double this amount in this work in England, ‘creating new 
knowledge and jobs in the field of genomic sequencing’. Alongside 
Illumina, the Wellcome Trust also invested a further £27 million 
in its Genome Campus in Cambridge where Genomics England’s 
operations would be based, together with the Sanger Institute, one 
of the leading institutions involved in the Human Genome Project. 
This clustering of investments and location was further enhanced 
by Medical Research Council funding of £24 million to develop 
computing capacity and an NHS contribution of £20 million.
158 Personalised cancer medicine
As well as building infrastructure, transforming healthcare and 
economic growth to position the UK at the forefront of the ‘global 
race to implement genomic technology’, it was noted that the 
expectation was that ‘around 40,000 NHS patients could benefit 
directly from the research’. A transformed NHS was positioned as 
leading the way in contemporary healthcare through this initiative. 
The press release on the launch of Genomics England quotes Simon 
Stevens, NHS England’s chief executive at the time:
The NHS is now set to become one of the world’s ‘go-to’ health 
services for the development of innovative genomic tests and patient 
treatments, building on our long track record as the nation that 
brought humanity antibiotics, vaccines, modern nursing, hip replace-
ments, IVF, CT scanners and breakthrough discoveries from the circula-
tion of blood to the existence of DNA.
The NHS’ comparative advantage in unlocking patient benefits 
from the new genomic revolution stems from our unique combination 
of a large and diverse population, with universal access to care, 
multi-year data that spans care settings, world-class medicine and 
science and an NHS funding system that enables upstream investment 
in prevention and new ways of working as demonstrated by this 
ground-breaking 100,000 Genomes Project.
In a session at the 2017 Bio International Convention, David 
Cameron, a prominent backer of the project, described his role in 
setting up the 100,000 Genomes Project as having been shaped by 
his experience of being a father to Ivan, his disabled son, who had 
a rare disease (and died at the age of 6 in 2009). He said that this 
had had a big influence on his thinking about science, discovery 
and life sciences, and was one of the reasons he commissioned 
the 100,000 Genomes Project and had the first sequenced genome 
delivered to his desk. Cameron said that he wanted to develop the 
life sciences and the wider economy through this project, reflecting 
that the NHS has the advantage of enormous amounts of usable 
data on which the project would draw.5 He also referred to another 
feature of the discussions and politics around the NHS during his 
government, which focused on failings and reforms. Cameron 
had written about this in the tabloid newspaper The Sun one 
year before the official launch of the 100,000 Genomes Project. 
Additionally, in a report in The Telegraph his criticism was set 
out in emotive language of ‘love’ for the ‘national treasure’ that is 
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the NHS, shaped by his experience of being a father to Ivan, yet 
contrasted with the need to deal with the problems of ‘cover ups’ 
and elderly care, and the need for medical advances in the NHS: 
‘We don’t demonstrate that love by covering up things that go 
wrong. Or by pretending the NHS can just ignore the big challenges 
it faces.’
As a King’s Fund report reviewing the NHS under the then coalition 
government (Ham et al. 2015) noted, Cameron and his government 
had a troubled relationship with this iconic British institution, 
spending much of their term of office developing, implementing and 
trying to repair the problems arising from the fraught Health and 
Social Care Act (2012) in the face of trenchant criticism from medical 
and patient communities. Cameron had to temper his focus on 
privatisation, service improvements and marketisation through this 
period, turning to focus on patient needs, for example through a 
commitment to keeping waiting times down.
The 100,000 Genomes Project was the ideal vehicle for transforma-
tion in this fraught context; a way of generating value by capitalising 
on the assets of the NHS, transforming the bioeconomy and healthcare 
for the twenty-first century. Its success hinged, above all, upon patients 
and their families participating in the venture, which, in turn, relied 
upon the trust and confidence of patients and the wider public. This 
would build on other large-scale projects, such as UK Biobank, and 
draw on the UK’s global reputation for robust oversight via bodies 
such as the Human Genetics Commission. The Commission had, 
in fact, been disbanded in 2012 as part of a process of removing 
Whitehall ‘quangos’, so a new committee and oversight process had 
to be established as part of Genomic England’s work. The close 
alignment of the project with NHS data and resources increased 
the perceived need for comprehensive and robust ethics, not least 
because of public controversy around the opt-out policies of the 
failed Care.Data initiative and deCODE Genomics Ltd. A series of 
public and professional consultation exercises underlined the impor-
tance of getting these processes right, given ongoing public concerns 
about insurance companies accessing data, the moratorium on this 
practice notwithstanding.
It was within this context that the then Chief Medical Officer 
(CMO) for England set up a group to provide advice on the ethical 
issues involved with the 100,000 Genomes Project, led by Professor 
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Mike Parker from Oxford University.6 Informed consent was especially 
salient here, given the difficulties with past national projects such 
as that of Iceland, and the technical and organisational arrange-
ments around this formed an important part of the group’s work. 
The advisory group outlined what they called an ‘appropriate and 
rational’ approach to the ethical issues in a letter to the CMO 
in 2013. Stressing the guiding principles of decision making and 
commitments to the public interest, patients and the NHS, they 
placed considerable emphasis on the processes of informed consent 
and patient and public involvement and engagement. The group 
noted that data could not be irreversibly de-identified, so there 
was a need for data-access agreements and accountable governance 
processes that would ‘provide participants, and the public, with the 
assurances they require and promote acceptability and involvement’, 
especially since private companies would be involved in testing and 
possibly also other services. Again, the group stressed the importance 
of policies and procedures to ensure that commercialisation was 
in the public interest and of benefit to the NHS to ensure public 
confidence and participation.
These considerations formed the basis of the group’s recommenda-
tions about informed consent processes, in which the importance 
of ‘broad consent’ that did not present too much of a burden to 
staff and patients was stressed. This involved considerable refinement 
and specification of what ‘informed’ should mean in this context. 
Although no doubt familiar with the extensive ethical and social 
scientific literature on how consent in many medical settings is not 
based on participants making dispassionate choices, but on a mixture 
of reasoning which depended on the context, including a sense of 
commitment to the health service and to the professionals involved 
in their direct care (Corrigan 2003; Dixon-Woods and Tarrant 2009), 
the committee had to use standard and established governance 
mechanisms to establish the credibility of the programme. This 
presented a number of challenges. A key issue was the difficulty of 
combining consent for data to be analysed as part of care and as 
part of research, both known and unknown. This blurred the line 
between care and research in a way that ethicists are often concerned 
to avoid because of the problem of ‘therapeutic misconception’, 
wherein patients consent because they are motivated by an expectation 
of improved care. This may leave them vulnerable to being misled 
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or disappointed, rather than enabling a form of ‘altruism’ which 
ideally should determine their involvement in the logic of contem-
porary research ethics (Dheensa et al. 2018).
The importance of securing consent to future use of the data, 
which would drive the service transformation and economic benefits 
sought from the programme, was such that patients’ opportunities 
to receive results became conditional on their consent for their data 
to be used in research. To avoid the need to go back to patients in 
the future about what precisely this research would involve, given 
that future uses cannot be known in advance, the group reasoned 
that a clear governance process for deciding on appropriate use and 
access would need to be put in place on participants’ behalf, and 
recommended that this should be discussed in the consent process 
to give participants confidence to proceed. Moreover, they noted, 
‘participants will also need to understand that consenting to research 
involves a waiver of any personal rights to benefit from commercial 
exploitation. Mechanisms will need to be introduced to ensure that 
the NHS benefits where data from this programme are put to com-
mercial use.’ These recommendations narrowed the burden but also 
the boundaries of choice considerably – participants were given 
choices about what kinds of additional information they might want 
to receive, but were not invited to decide what kinds of research 
their samples or data could be used for. Here the possibilities for 
future research using the data accrued were deemed more valuable 
than the opportunities for individual crafting of involvement, the 
latter of which was seen as more of a potential burden than an 
opportunity.
Processes for developing and enacting these complex arrangements 
for informed consent constitute important governing frames in projects 
of this scale and complexity – they are as key to their realisation 
as sequencing technologies and laboratory standards. Yet informed 
consent processes are known to be problematic in practice, given 
to ritualised and superficial performances, what Corrigan (2003) 
aptly called ‘empty ethics’. The committee therefore tried to make 
informed consent more meaningful by offering clarity and managing 
expectations. The group were particularly concerned with the question 
of how to report back information to patients in this emergent area 
of medical science, including how clinicians would be supported to 
make judgements and how families would be supported to manage 
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the implications of results. The need for participants to make choices 
about data relevant to other family members had to be managed, 
as was the need for ongoing professional development and resources 
for re-contacting patients over time. These considerations point to 
one of the key challenges in this area: how to make results meaningful 
in the absence of clear and established protocols for interpretation, 
given the experimental nature of the science and the complexity of 
the data involved.
This is part of a new style of scientific governance that Braun et 
al. (2010) call ‘reflexive governance’, encompassing participation 
and engagement with a range of experts, including critical social 
scientists. Another important aspect of these forms of governance 
is participation by patients and publics, with a great deal of emphasis 
placed on inclusion and engagement. Education, support and training 
for staff and patients was particularly important. This extended 
engagement and cultivation of ethical participation (Braun et al. 
2010) was seen as pivotal to the successful implementation of this 
part of the programme. A range of responsibilities for practitioners 
and patients to participate, learn and engage with new choices and 
forms of interpretation were therefore anticipated, in contrast to 
the circumscribed rights to choose how one’s data might be capitalised, 
as discussed above. This framed additional responsibilities for a 
wider pool of potential participants from the public more generally, 
anticipating an expansion of participation in genomic research in 
the future. At the same time, the committee also prescribed a range 
of responsibilities for project leads and other practitioners involved 
in its delivery to take a role in education and public communication 
about the project, including about the relationship between the state 
and the market that is at its heart.
Genomics England took up these recommendations as part of its 
efforts to ‘build a social contract’ for the initiative,7 and went on 
to establish a detailed informed consent and data governance process 
as well as a wide-ranging series of events, publications and a website 
with extensive resources for participants and links to training initia-
tives for staff. An ethics advisory group also became an established 
and important aspect of these governance arrangements. The consent 
form, initially lengthy and complex, went through a number of 
revisions and iterations as the project proceeded, partly in an effort 
to clarify and shorten sections to enable the process to be completed 
in less time. Genomics England has also sought to develop resources 
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aimed at educating publics, professionals and participants about 
genomics, after identifying a lack of awareness about this area of 
science as part of a programme of improving ‘genomic literacy’.8 
Here practitioners and publics acquire responsibilities for becoming 
more educated and educating others about genomics and its implica-
tions for health, in order that genomic medicine can be developed 
successfully. Notable among these initiatives is the ‘Socialising the 
Genome’ project, which includes a number of short YouTube videos 
utilising animation. One of these videos involves a play on the 
confusion between genomes and gnomes and features a cartoon 
gnome ‘fishing’ for pieces of DNA. This is prominently displayed 
on the Genomics England website and has been taken up in consent 
processes too.
The Genomics England website as a whole has more resources, 
case studies and patient testimonies concerning rare disease, as part 
of its efforts at engagement and education, reflecting the relative 
success of this part of the programme in terms of recruitment and 
delivery of results compared with those regarding cancer. For cancer 
patients there is, instead, a series of hedged statements about the 
ambition to deliver results in the future, and a lack of specificity 
about how and when this will happen, which contrasts with some 
of the earlier stated ambitions for the project. There is also a focus 
on explaining how the project has evolved and the technical difficulties 
that have been overcome in the process, for example the move from 
using formalin-fixed samples to fresh, frozen samples which are 
easier to analyse.
The website presents project news in relation to the numbers of 
genomes sequenced and features a counter to illustrate this. Numerical 
milestones are presented as important markers of success for the 
project. There is also considerable hype about the benefits of the 
programme, which sits at odds with the working groups’ recom-
mendations in this regard. For example, in a story about more than 
70,000 sequences being completed on the 70th anniversary of the 
NHS, it was reported that Health Minister Lord O’Shaughnessy said:
Genetic sequencing can revolutionise healthcare by offering truly 
personalised care to patients and their families. This project is a 
shining example of a partnership between the public sector, the life 
sciences industry and the research community – with NHS patients 
reaping the benefits. Genomic medicine is no longer a thing of the 
future, it’s here now and helping to save lives.9
164 Personalised cancer medicine
These kinds of promissory claims are more prominent than informa-
tion about the involvement of commercial companies in the project, 
which is scattered across the site and difficult to connect together 
to form a picture of what kinds of roles these companies are taking, 
and the financial arrangements involved.
Together, these recommendations and practices constitute the 
100,000 Genomes Project as a vehicle for the transformation of the 
national economy and health service, monetising the genomic data 
of the nation to change how medicine is delivered, and responsibilising 
practitioners, patients and publics to become genomically literate 
in order to deliver these benefits. To enable and enact this transforma-
tion, institutions, practitioners, publics and patients acquire new 
responsibilities for participation, engagement and deliberation, but 
these are carefully circumscribed within a web of governance and 
educational arrangements which limit participant choices and, for 
cancer patients in particular, have not delivered personalised informa-
tion on the scale envisaged by some of the more optimistic accounts 
of politicians and leading civil servants. The importance of not 
burdening patients with too much information and too many choices 
as part of the consent process can be contrasted with the emphasis 
elsewhere on educating and informing patients about the programme 
and the science involved as part of ‘socialising the genome’. Presented 
as short, fun encounters, these activities expose and seek to remedy 
the deficit in public understanding about genomics through a growing 
portfolio of educational tools and events, which produces an audience 
with responsibilities to engage in turn. At the same time, however, 
as we go on to consider later in this chapter, the details of the 
economic arrangements at the heart of the programme or the choices 
with regard to investment in personalised therapies versus other 
kinds of structural public health interventions targeting the causes 
of cancers are opaque and less easy to engage with and critique.
Transformations in cancer care: participation for practitioners
Transformative visions and the knowledge-control regimes that seek 
to implement them are, of course, key features of how genomics at 
scale took shape in the UK bioeconomy. But as Hilgartner (2017) 
amply demonstrates in the case of the Human Genome Project, 
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vanguard visions and governance frames are taken up but are also 
subject to resistance, struggles and challenges. Key actors can 
reconfigure processes, agendas and envisaged identities, reworking 
their responsibilities and asserting autonomy in the process.
Our first encounters with the 100,000 Genomes Project were at 
the early stages of our own project when we made contact with 
some of the project leaders in a nearby region. From the outset we 
were invited to be part of the development of a consortia bid for a 
regional genomics medicine centre (GMC), because the practitioners 
involved were keen to engage us in developing the participatory 
and evaluative agendas that they viewed as crucial to the success 
of their bid and the wider initiative. As part of this we attended a 
meeting with representatives from Genomics England and the NHS 
where the bid was assessed and discussed, alongside patient repre-
sentatives, laboratory and service leads and senior managers from 
relevant hospitals. This encounter, and discussions prior to and 
following it, were marked by a sense of the need for the practitioners 
and managers involved to present a suitably ambitious, coherent 
and compelling case for support, even as they also expressed doubts 
and concerns in more private settings about the difficulties that this 
would involve, given other service and resource pressures. In so 
doing our gatekeepers simultaneously performed the hopeful promis-
sory futures of genomic medicine and service transformation through 
recruiting practitioners and other allies to participate in the pro-
gramme delivery, and a more muted set of concerns and ambivalence 
about the prospects of success for the science and the services involved. 
The project leaders adopted a kind of strategic uncertainty as part 
of their negotiation of the demands for practitioner participation, 
empathising with the doubts and concerns that were also being 
expressed by colleagues expected to deliver on the initiative.
Our efforts to be part of the project, to follow how it was developed 
and enacted locally and to share results were, however, constrained 
by its complex architecture, changing personnel and difficulties of 
implementation across different cancer clinics, clinical leads and 
institutions. Jurisdictional disputes around the ownership and purpose 
of the project were ongoing, as was ambivalence among key actors 
about their role and its value. We encountered numerous uncertainties 
about how the project would be delivered. Consent processes were 
difficult to observe because of ongoing issues with staff training, 
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patients not attending, and clinicians not advising staff about suitable 
patients. The project was being introduced to a service under strain, 
where efforts to meet waiting time targets and manage staff absence 
and well-being came into tension with its delivery. Practitioner 
participation was patchy, uneven and markedly ambivalent.
The project lead, who was tasked with advocacy for the project, 
nevertheless framed it as the beginning of a new kind of healthcare 
based on ‘big data’ and Artificial Intelligence:
And the Genomics Project is part of the wider personalised medicine 
agenda of the NHS, which is a top level objective of the NHS. And 
very few people really quite get what that means. And in reality what 
it means is that – it’s really a big data project, so it looks like a lab 
based project but it’s actually – actually a project about the, the – about 
leverage of large datasets. And so the end point of the programme 
really is that genomics data, er, will be merged with all the other data 
that can be linked through someone’s NHS number into a central 
data repository.
And from that, tools will be developed that can then apply the, 
the power of that dataset to the care of individual patients. And that’s 
what really personalised medicine – the personalised medicine agenda 
is about. And that is an enormous transformation in medical care, 
um, absolutely huge.
But this was not a view that was widely shared among practitioners 
concerned about the practicalities of implementation. As another 
clinician involved in leadership of the project commented:
in order to know what’s relevant to that particular patient at that 
particular point of time of course you’ve got to know what their 
cancer is doing at that particular point in time. So it takes us from 
a situation where you’ve … almost got to have a real time readout 
at any point in time to know what are the particular drivers of … 
this particular patient’s cancer which brings us into personalised 
medicine … and as exciting as that is, the idea of personalised medicine, 
the practicalities of that are … really … challenging … financially, 
organisationally, um, um, diagnostically, therapeutically … in terms 
of comprehension and understanding (laughs), you know, of, of the 
clinicians and the population – all of those have … got challenges.
This meant that even as this grander vision of healthcare was being 
articulated at a range of meetings and events, it was hedged with 
caveats about the complexities of personalisation, not just in terms 
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of infrastructure, but in terms of the information it brought into 
clinical practice. As the project lead quoted above continued, the 
prospects of personalisation and precision were not necessarily 
straightforward, and could be difficult for practitioners and patients:
I mean, it’s easy if you’ve got a ninety-five per cent chance of being 
cured, but if you’re saying to somebody, ‘Actually, we know from all 
this data that this is just not going to work,’ then that’s … something 
that … people reject. Because if you open the box then you’ve got 
the information, if you don’t do it in the first place you can just 
carry on regardless. So that’s I think one of the big challenges of this, 
people see actually personalised medicine as something potentially 
very, very difficult.
The project leads also spoke of their sense that this project and 
personalised medicine more generally were ‘battling against the 
biology’, revealing much more uncertainty than the rhetoric of 
precision suggests and that patients might expect, and bringing chal-
lenges for practitioners in terms of implementation and interpretation 
(Metzler 2010).
Practitioners expected to implement the programme in their clinics 
by supporting patient recruitment also asserted their jurisdiction over 
healthcare, expressing wariness about top-down initiatives and in the 
words of one oncologist ‘politicians’ pet projects’, referencing David 
Cameron’s spearheading of the initiative. This oncologist commented: 
‘Happy to be proved wrong but … I am not a big fan of politicians 
interfering in healthcare … [with these kinds of initiatives] … we’re 
struggling to pay for other things and I’m not sure it’s good value 
for money.’ Others expressed concern about the project being less 
about evidence-based science than service transformation designed 
to introduce the automation and centralisation of laboratory services 
or limit the role of clinicians in interpreting data. This evoked a 
counter-narrative about the need for clinically embedded analytics, 
as in the excerpt from an interview with a pathologist below:
now we … feel strongly that that is in some situations dangerous 
because a lot of molecular testing is being undertaken by non-clinically 
… trained geneticists who don’t necessarily understand some of the 
complexities of the material coming in … some centres don’t even 
look at the material that goes through the sequencer so they will, will 
take sections of pathology material, put it through a box and come 
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out with an answer and unless you really understand the details of 
what’s gone in, you can’t understand the details of what comes out. 
So we strongly feel that there needs to be a lot more clinical input 
… we do have that balance to a degree … working alongside the 
genetic clinical scientists to deliver the service so we can provide some 
clinical oversight … But other centres will offer blanket clinical 
interpretations which may not necessarily be appropriate and the 
problem is oncologists act on those clinical interpretations, not neces-
sarily if they’re, if they’re up to speed and they’re academic and … 
they’ve been to the big meetings recently and they’re aware of the 
evidence and they understand how to interpret the result themselves, 
but if you’re … a busy general oncologist working in a smaller hospital 
you’re not necessarily up to speed with all the evidence for specific 
disease types then you make take at face value the clinical interpreta-
tions attached to these reports.
Here, concerns about service transformation were reframed not just 
as about being ‘put out of a job’, as one pathologist joked, but as 
a matter of ensuring that current patients benefited from participation. 
As another pathologist explained with respect to the need to collect 
fresh tissue for the 100,000 Genomes Project: ‘I would put a wager 
that [fresh tissue] is not that critical for patients in the majority of 
cases.’ Practitioners also expressed ambivalence about the cohort 
of patients being recruited, as illustrated in this quote from an 
interview with another pathologist:
not necessarily the right cohort of patients are actually being recruited 
… for example, we have recruited a large number of … GI tumours, 
but none of those patients will require any sort of treatment and the 
data that is going to come out from tumour profiling is not going to 
change how they are managed currently. Now whether it will be 
managed – whether it will change in the future, we do not know. So 
… I’ve got to be careful about this, so whether it would have been 
appropriate to actually gather the evidence first and then spend the 
money building the infrastructure …
In this excerpt the interviewee intimates that efforts are being made 
to improve recruitment and meet targets but this is not necessarily 
involving patients who will directly benefit from the project, as 
suggested in its design and promotion.
Nurses and one clinical trials assistant (CTA) involved in obtaining 
participants’ consent to the programme had less professional power 
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through which to resist or rework these new agendas. But they were 
also ambivalent about their role and the prospects of the project. 
Their ambivalence found particular expression in relation to their 
concerns about managing project information and encounters with 
patients, given the complexity of the project. These concerns often 
took the form of expressions of anxiety or jokes about our presence 
as observers in the consent meetings, where nurses sought to navigate 
their sense of being judged or evaluated against an established 
standard approach to consent where the virtues of the project were 
largely scripted in advance. Here the nurses framed our presence 
and that of the project around it as being a new ‘script’ to learn 
and implement, positioning themselves as in ongoing need of training 
and education around genomics to enable the programme to develop.
Nurses also expressed ambivalence about the project with respect 
to managing patients’ expectations around delivery of results. There 
were significant delays in getting results to patients, and nurses had 
to field additional phone calls from patients about this, but they 
had little sense of connection to the ‘background’ of results being 
analysed and delivered. At the same time, however, nurses were 
clearly developing new kinds of expertise and skills in tailoring and 
navigating the consent process to accommodate patients’ needs as 
part of their ethos of care. We can see some of this play out in an 
excerpt from an observation of and between consent meetings with 
patients where a specialist nurse and the GMC specialist nurse 
discussed their roles and how to support patients:
The nurses chatted about this patient. The specialist nurse said ‘she 
doesn’t sound clued up’ and it seemed like the patient was relying on 
her husband’s support [they could hear her husband helping the patient 
in the background]. Both said it must be particularly difficult for 
brain cancer patients. They said ‘the general gist is that getting sample, 
helping … and then a bit more of the nitty-gritty. And then ask if 
they understand.’ The specialist nurse said ‘you can pick that up’. 
The GMC specialist nurse said if you feel the patient doesn’t com-
prehend and you are not confident, suggest not to take consent and 
suggest face-to-face meeting, although they may not be well enough 
to come in for an extra visit as they will have to drive, park, and 
wait etc. They added that electronic consent was discussed as a pos-
sibility but there was debate around it – not implemented in the end 
although not clear why. The specialist nurse chipped in by saying 
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‘how do you know people understand?’ [when the consent has been 
done electronically] and went on to suggest that there seem to be 
‘hiccups’ in the project. The GMC specialist nurse said when the 
study was opened nothing was set up. The specialist nurse asked 
why? GMC specialist nurse: lots of high level activities went on to 
set up the Centre. Other Trusts used funding differently to engage 
nurses but for some there is no job security … Sounded like lots of 
people moved on to different work so constantly re-recruit the team 
and train. They ended up spending lots of her time in rare disease 
rather than cancer: resources could be better but exciting even though 
it wasn’t up and running when she joined … The specialist nurse 
commented: it’s like ‘giving you a car but not the key, situation’ … 
The GMC specialist nurse added that she doesn’t have a job to go 
back to [after the end of the 100K project], she is ‘not hopeful’.
A lot is going on in this excerpt: the nurses are engaged in training; 
they are trying to make a complex project work in the absence of 
guidance and resources, including lack of job security; and, at the 
same time tailor and make consent meaningful and participation 
valuable for patients without it becoming too burdensome. This 
results in a reframing of the project as problematic while maintaining 
and developing a professional commitment to try to make it work 
in the interests of patients.
Backstage, practitioners were cautious about the 100,000 Genomes 
Project, as well as being hopeful about its potential for patients. 
They wanted genomics to improve treatments for patients, but were 
sceptical of over-promising and concerned to maintain some of the 
boundaries between the state and the market that this project was 
designed to break down. Sometimes these concerns were shared 
with project leads and the visionary vanguard at events and other 
meetings. However, we observed that criticism was typically reworked 
by the project leads as a need for further training or buy-in from 
staff, or even as a form of professional inertia and protectionism. 
Difficulties with recruitment became institutional problems and the 
focus of the national initiative was on successes in terms of numbers 
of genomes sequenced as a key milestone of progress. In these ways, 
resistance was itself reworked to form part of the impetus for further 
transformation of services and institutions.
Practitioner resistance and concerns were also reworked frontstage 
where patient encounters were concerned, where the focus switched 
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to careful handling of patients’ expectations, balancing appeals to 
patients’ altruism and faith in research with management of their 
hopes and expectations. Practitioners also had to navigate some of 
the more complex issues around access to data and commercialisation 
with care, given their qualms about the intricacies and politics of 
these arrangements. Transformation, however fraught, relied upon 
practitioners recruiting patients to the project and good care relied 
upon spending time to reassure and support patients in these and 
other clinical and research encounters. As we shall now go on to 
discuss, patients and accompanying relatives were also active par-
ticipants in these processes, which involved their own resistance 
and reframing, particularly in relation to informed consent and 
genomic literacy.
Patient participation
Cancer patients were approached about their involvement in the 
100,000 Genomes Project at various points, including before initial 
surgery or after they had been living with cancer for a number of 
years (e.g. haematological cancers). They typically received a letter 
or a phone call inviting them to make an appointment to come 
along to hear more about the project and to consider participation. 
These initial encounters with the nurses or CTAs who were trained 
or in training to conduct the consent appointment lasted up to one 
hour and covered a range of complex information and deliberation. 
Patients were often, though not always, accompanied by a family 
member to these meetings.
A major concern of the project architects was to ensure that patients 
did not experience participation in this research as too much of a 
burden and that they understood that receiving potential results of 
interest to their care, or that of their family members in the future, 
was contingent on sharing their data and waiving rights to personal 
financial benefit. This resulted in a detailed consent process which 
caused concern for practitioners who felt it could be too difficult 
for patients to manage given their health and other pressures.
In our observations and interviews we found that patients, 
alongside practitioners, worked to reduce or resist this burden. One 
way in which this was achieved was by deriving care from the 
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consent meeting. This involved reframing participation from a research 
experience which might provide better care in the future into an 
occasion for care in the present. This meant discussions in the meetings 
could be wide ranging, as patients articulated their experiences and 
concerns about their cancer, the care they had received, and the 
prospects of further diagnostic information. The appointments with 
the consenting nurse or CTA were also a space where patients and 
family members could discuss immediate, ongoing concerns and 
worries for the future and to ask questions about their care. None 
of this was necessarily related to the 100,000 Genomes Project. This 
included questions about treatment and surgery, as in the following 
example:
[After agreeing to take part in the 100,000 Genomes Project] The 
patient then took out a couple of sheets of paper from her handbag 
and started to ask the research nurse a series of questions she had 
prepared. Her questions however were not relevant to the 100,000 
Genomes Project but were mostly about her surgery. The research 
nurse reminded the patient that she can get in touch with a nurse 
specialist who will be able to answer her questions. … The husband 
who had been silent then asked a question for the first time, but it 
was again about the logistics of the patient’s surgery: he wanted to 
know whether he needed to take time off from work. The patient 
jokingly said to her husband, ‘[the research nurse] is doing research, 
not work arrangement’ and laughed.
At other times patients sought more practical support, as well as 
reassurance and advice from the NHS and nurses in particular, as 
the following example from our observations illustrates:
The nurse went on to discuss data security and access and how there 
won’t be any financial benefits for patients although it will benefit 
the NHS. This is normally the point where patients quietly nod or 
smile/joke … but the patient says, ‘some financial help would have 
been nice; there’s no help at all’. And he goes on to talk about how 
he cannot work but hasn’t been offered additional help because his 
wife is working a few hours a week. The nurse signposted Macmillan 
nurses to discuss financial issues…
… The nurse then explained the main findings and extra findings e.g. 
about high cholesterol. The patient says he doesn’t worry really but 
his wife says ‘I’m the worrier.’ When the nurse explains the genetic 
carrier testing the patient’s wife talked about their decision not to 
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have children because they were ‘too selfish’ and wanted to keep 
enjoying motorbiking …
… the patient asks if people ever come into this meeting but don’t 
want to sign and the nurse says, ‘people want to contribute’. His wife 
agreed about the importance of ‘helping future generations’, continuing 
‘breakthroughs happen in science all of the time’. The nurse responded, 
‘science relies on people like you.’ The patient’s wife goes on to explain 
her husband’s history of blackouts and a pacemaker being fitted prior 
to his diagnosis with cancer and wonders if the blackouts were con-
nected to his cancer. The nurse says she cannot answer that question. 
The patient’s wife asks if the project might be able to find out more 
about this, but the nurse said she was not sure what kind of information 
was relevant to the project. She added that a copy of the form would 
be sent to their address and the patient said it will be ‘helpful to 
research but also helpful for my brain’ and the nurse added that the 
overall aim of the project is to ‘transform the health service’.
Although these exchanges might be framed as tangential to the core 
purpose of consent meetings, departing from the framing of the 
consent protocols and forms, they were key aspects of the meetings 
which enabled nurses to reciprocate care for patients’ involvement, 
and for patients and family members to generate tangible value 
from their involvement rather than the remote prospect of personalised 
results emerging in the future. Being able to articulate positivity and 
to express concerns, even though the nurses often responded by 
signposting other kinds of care, was also an opportunity for patients 
and relatives to perform good patienthood and care giving, bolstering 
their sense of self-worth in the process. Patients frequently sought 
the advice of the nurse, or used this unusually lengthy encounter 
with the nurse to explain their concerns or express gratitude for the 
care they had received from the NHS. Patients also frequently 
contextualised the possibility of receiving their results at some point 
in the future with accounts of their more immediate and pressing 
concerns about financial issues, pain management and disease progres-
sion, for example the question ‘Will I be alive by Christmas?’
In so doing, practitioners, patients and family members reconsti-
tuted the ‘consent to participate’ process as a moment of reciprocal 
care rather than an exercise in deliberation and choice, already 
generating experiences of care from the encounter rather than awaiting 
results and future care. As with other encounters with genomic 
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medicine discussed throughout this book, patients situated the 100,000 
Genomes Project as but one step on a lengthy and complicated 
personalised search for care, rather than as a matter of participating 
in a research project aimed at generating value from their data. This 
meant that each consent meeting was effectively tailored to different 
patient experiences, concerns and accounts, as the nurses sought to 
navigate the encounter as a way of delivering more personal kinds 
of care and consent. The consent process became an occasion of 
personalised medicine of a rather more immediate and mundane 
sort than the high-level, high-tech vision of the programme’s leading 
proponents.
The burden of consent and the specialness of the 100,000 Genomes 
Project was also resisted by normalising participation as part of 
‘routine’ involvement in other research studies or trials which were 
integral to being a cancer patient. As one breast cancer patient in 
the early stages of cancer commented, echoing comments from 
participants in SMP2 discussed in Chapter 4, ‘Why wouldn’t I 
participate? I have no good reason not to.’ Another patient, Joe, a 
former engineer in his sixties who had had surgery and chemotherapy 
for bowel cancer, commented about donating tissue being an obvious 
and easy way to help:
But like I said to (Research Nurse), as long as I don’t have to have 
my leg cut off, or I’m not going to be in pain for weeks and weeks, 
or I’m not going to be locked up in prison … I [am not] bothered.
Okay.
How else are you going to learn [and] advance cancer research …  
I mean you can’t go cutting people up who haven’t had cancer just 
to check, obviously, but … it’s the nearest thing you can do with … 
not live tissue, but with real tissue as opposed to doing it in the 
classroom.
Other patients, especially those who had recently had surgery or 
those who were about to have it, told us that getting rid of the 
tumour – ‘why would I want it?’ – by donating it to the project 
was an easy decision, perhaps as part of a wider effort to show 
their willingness to participate.
Reframing participation as obvious and routine, as opposed to 
special and burdensome, allowed patients and their relatives to 
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maintain self-worth in the face of cancer, asserting their agency and 
dignity as well as their care and concern for future patients. But in 
other respects we saw that participation was not routine – not only 
was the meeting quite time consuming, it also involved logistics 
such as transport and parking, enrolling relatives into the process. 
Patients and their relatives nevertheless made this workable by 
coordinating their involvement alongside other appointments at the 
hospital. This articulation work was key to the successful recruitment 
of patients to the project. For instance, one elderly patient, Brigit, 
who was frail and forgetful due to her recent major brain surgery, 
told us that if consenting to the 100,000 Genomes Project or speaking 
with us had required ‘special trips’ to the hospital, she would not 
have participated as she relied on her sons and a daughter-in-law 
to take turns to drive her to hospital. On the day of the consent 
meeting, her daughter-in-law accompanied Brigit, and when we 
interviewed her on a different day one of her sons had taken the 
day off to accompany her for a clinic appointment. In the interview 
they told us they were happy to help ‘as long as things like this 
interview could fit in with when we’re here’. Brigit also explained 
her desire to participate in the consent meeting to her son:
And I just said, ‘Well, I – as I told you, I was gonna do this,’ and I 
just says to him, ‘Don’t forget … it’s something that I want to do,’ I 
said, ‘But I’m not at a position where I can go like talking to anybody 
or go here or [there or] anything like that,’ I says, ‘But on paper I 
can do it.’ So that’s … was basically it, you know…
This reworking of participation as routine and unremarkable was 
also associated with ideas of their data already being available 
elsewhere and research of this sort as a social good which might 
also benefit the patient, and future patients, including family members.
Arranging an interview with one patient, Giles, was difficult 
because he was adapting to living with some complications after 
his surgery while undergoing a phased return to his work as a data 
scientist. However, Giles was particularly keen to participate, telling 
us he would have felt he was being ‘hypocritical’ if he refused. He 
told us that he already knew about the project and was confident 
it was beneficial:
I’d heard, I’d heard of it on a … level when I worked for the [name 
of company where the patient works], but I didn’t know any details 
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of it. So I knew, I knew such a thing existed and they were gathering 
genetics on people with cancer for future study.
So when [you were] formally approached by health professionals, did 
you, did you find more about the 100,000 Genomes Project then?
They gave me … plenty of information but I didn’t read a lot of it 
… I knew enough to know that it was a beneficial study based on 
genetics of cancer. And I didn’t see any reason not to take part in 
such a thing and I didn’t feel the need to learn more details about 
what I was helping with because I was happy to help.
He also saw data sharing as an unproblematic: ‘I don’t believe that 
storing data on people is going to cause me a disaster … I mean I 
didn’t pay that much attention to the opt-out process because I 
wasn’t particularly worried about it, or the data protection issues…’ 
Giles went on to ‘call out’ people who worry about this because of 
the acceptance of surveillance in everyday life, and even its inevitabil-
ity: ‘The ones selling [data] to people are not the NHS – it’s Facebook 
and Google … And if the government wants to spy on me they will 
regardless of whether or not I’ve signed a consent form!’ Another 
older breast cancer patient, Ally, introduced in Chapter 2, explained 
that she had chosen to participate in the hope that genomic informa-
tion that might help her extended family would be uncovered:
it outweighs the thought of, oh somebody’s got my details, for goodness 
sake, everybody has got people’s details nowadays … your mobile 
phone, if you’ve got your location on that, big brother is watching 
you! … at the end of the day, if you’ve done nothing wrong, what is 
there to worry about?
Patients were much more concerned with the practicalities of par-
ticipation such as whether it might involve more hospital visits, than 
about data security. Through these kinds of narratives participants 
were not necessarily expressing strong commitment to the project, 
including trust in its data security arrangements, but a sense that 
participation was not likely to be problematic, especially given that 
data is already being shared in ways we inevitably have little control 
over, by governments and corporations (Zuboff 2019). By actively 
not worrying about these kinds of things they once again asserted 
their self-worth as rational and sensible citizens willing to help others. 
The only exception to this concerned the possibility that insurance 
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companies might access data, which can be a source of concern for 
participants, as has been established through a range of survey and 
consultation exercises.10 The nurses therefore sought to incorporate 
information about this – for example, the moratorium in place – in 
the consent procedures. We noticed that as similar questions were 
asked at each meeting they presented this information upfront even 
before the related questions were raised by participants.
We also found that where concerns did arise, these were often 
softened afterwards. For example, Lillian, introduced in Chapter 2, 
explained how she and her husband were initially wary of private, 
for-profit companies accessing her genomic data when this came up 
in the consent meeting:
it was a bit of a knee jerk reaction … a lot of commercial organisations 
kind of jump on the bandwagon … to get your information … to 
prey on people … and once it’s gone outside this kind of ethical 
boundary … But then of course, I know that most medical research 
is done by this kind of company, when I thought about it, I thought, 
well how stupid. Private companies, they’re the ones that have got 
the finances … to put into medical research.
Here, being a good participant meant reflecting back on excess 
reactions and accepting the role of market forces and privatisation 
in genomic research.
Patients and relatives engaged with the information provided, 
including before and during the consent meeting, in a range of ways, 
sometimes asking a lot of questions or commenting on their own 
expertise in a related field to reinforce their understanding, and at 
other times disengaging or resisting a lot of information. For example: 
‘The patient says she does research in an allied health field so she 
understands ethics and consent. She added that personalised medicine 
has been practised in her field for a long time and for her “genomics” 
is too “medical” a term to describe this.’ Here, the patient establishes 
that she has sufficient expertise to make informed decisions.
Resisting information was another strategy we observed, when 
participants might wave away the consent form or interrupt the 
nurse to say they were happy to sign without her going through 
her scripted explanation. Participants also sometimes commented 
about there being too much information – ‘like an examination!’ 
– but laughed this off or didn’t read all the material because it would 
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‘take all day’, and went ahead and consented. When asked about 
the information previously provided, a colorectal patient in his late 
forties, Stevie, commented: ‘I read it. Don’t ask me about it ’cause 
I can’t remember.’ Nevertheless, Stevie expressed his excitement and 
interest in the 100,000 Genomes Project, telling us he was ‘fascinated’ 
and looking forward to seeing the results. This is also illustrated in 
the following extract from one of our observations of a consent 
meeting:
The nurse asks how they were informed about the project and they 
say it was a letter through the post. The patient’s wife then took the 
consent form out of the envelope. The patient says, ‘I haven’t read 
it’, with a big smile, and the nurse answers, ‘don’t worry, we’ll be 
talking it through’. The patient says he is not an expert and not a 
medic so ‘do whatever you want to do’. He says he knows how to 
mend bikes but not mend brains. When the nurse asks if his tumour 
has been removed they both say ‘biopsy’ and the patient went on to 
say ‘they wanted to drill but realised my brain wasn’t that big’ and 
we all laughed.
In these kinds of interactions humour was deployed as a mechanism 
through which participants could mediate their lack of knowledge 
and understanding while also building rapport with clinical profes-
sionals and bolstering their identity as a competent participant.
Participants also complied with, but subtly reworked, the edu-
cational aspect of the consent process by adopting the position of 
critical observer or media consumer when viewing the accompanying 
video used as part of the consent process, often nodding appreciatively 
or commenting on its quality, for example ‘very well put together’. 
In another consultation, we observed the following:
The 4-minute video clip played, and the couple watched it with 
concentration. Both smiled especially at the ‘Giant Super Secure 
Database’ section [explaining the security of the 100,000 Genomes 
database]. Once the clip ended both smiled and the patient’s husband 
said ‘Excellent! Sorry, that [video] answered my questions.’
Together these kinds of encounters and discourses reframed the 
consent process as an occasion for care and the performance of 
gratitude, competency and good patienthood.
Participation was also sometimes rationalised as a way of keeping 
practitioners on side to keep care foregrounded even when it was 
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lacking, something that takes more work than giving consent. For 
example, one breast cancer patient, Nicky, a healthcare practitioner 
and teacher who had lived with cancer for over a decade, told us 
how she was not concerned when her consent meeting was very 
short with little time for reflection or discussion (because the nurse 
was not experienced in the consent process for cancer patients):
to me it was just signing the forms, honestly … it’s funny, I think 
because I’ve had so many different experiences and positive and negative 
… you don’t get angry any more about if – if you’re not treated in 
the best way that you could do. You know, I used to get really angry 
at the start if I got bad care or someone wasn’t treating me, you 
know, right and, you know, and … to be honest, I just let it go now 
because, you know, people have bad days. People struggle, you know. 
There’s lots of stuff going off and really if I kicked up a fuss and got 
arsy, it makes … no joy for anybody, least of all me really … you’ve 
gotta work with these people and you might meet them again in the 
future, so that plays on your mind as well. Might it affect my future 
care, future, you know, how that person responds and is with me? 
Um, it shouldn’t do that, but … you do think about that.
This extract shows that patients situated their consent to this project 
in relation to a much lengthier ongoing experience with cancer 
and care. For some, participation in this project faded into the 
background of ongoing efforts to stay well, but in this case, it could 
also be a form of investment in future care and good relations with 
care staff.
These ways of reducing the burden of consenting to participate 
and deriving care in the present or future complement the efforts 
of those involved in the governance of the project to simplify and 
shorten the consent process as a way of ensuring higher levels of 
participation in the project. But they also trouble the model of 
consent in the project governance, where emphasis is placed upon 
patients engaging with the project on its own terms and being fully 
cognisant of the waiver of their rights to financial benefits, and the 
limited opportunities for results which will direct their care. Instead 
they involve patients by strategically ignoring or discounting the 
ways in which data and profit flow in the project, and importantly 
and empathetically searching for care within this encounter.
Through these practices, patients subtly reworked the governing 
frames of the 100,000 Genomes Project by turning the consent 
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meeting into an occasion to display a good enough level of expertise 
about genomics and cancer. This was an exercise in preserving dignity 
and competency as a person, not just a cancer patient. We see this 
kind of work as part of patients constituting themselves as worthy-
of-a-future, where care would continue to be offered and received 
on a reciprocal basis. Together these practices reclaimed dignity in 
a kind of ordinary personhood as distinct from a more educated 
patienthood which the 100,000 Genomes Project seeks to cultivate. 
At the same time, however, the overarching knowledge-control regime 
is enacted rather than undermined via these reworked forms of 
participation, as data is collected and participation is valued as a 
personal and social good.
Conclusion
The next stage in the mainstreaming of genomic medicine in the 
NHS, the development of the Genomics Medicine Service in England, 
aims to put the service in ‘pole position’ to make use of the technology, 
according to Dame Sue Hills, Chief Scientific Officer for England. 
Genomics once again became a key reference point in politicians’ 
vision for the service in 2018, as in this quote from Matt Hancock, 
the newly appointed Health and Social Care Minister: ‘The power 
of genomics plus AI to use the NHS’s data to save lives is literally 
greater than anywhere else on the planet.’ Initially, however, WGS 
will only be available for some rare diseases and ‘hard to treat 
cancers’, with an aspiration to sequence one million genomes by 
the NHS and UK Biobank within a year, and up to five million by 
the Genomics Medicine Service within five years. Illumina and other 
companies involved in organising and interpreting genomic data are 
key to turning what Hills described as the ‘cottage industry’ of 
genomic laboratories into ‘factories [with] higher quality, faster 
throughput and turn-round, and cheaper prices’, in her evidence to 
the House of Commons Science and Technology Committee inquiry 
into genomics in the NHS. But we remain unclear about how these 
‘factories’ will deliver the benefits of expensive targeted therapies 
to a cash-strapped NHS once it has delivered its genomic data to 
the commercial market.
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Genomic sequencing initiatives at a national scale are a major 
part of the bioeconomy and the personalisation of healthcare for 
common diseases such as cancer. For countries such as the UK, being 
a key part of these developments is crucial to economic growth 
and prosperity. To cultivate these values, a genomic vanguard has 
sought to leverage one of the UK’s true great assets, the NHS, 
transforming the service to embed genomic data collection and 
analysis across its cancer clinics and beyond. Patient participation 
on a large scale is vital to success, but the burdens and benefits of 
participation must be carefully circumscribed as part of the new era 
of reflexive governance, as patients’ data is being put to work in 
the national interest. Scientists, clinicians and social researchers are 
recruited into this task to develop appropriate methods of govern-
ance and understand how patients participate in order to improve 
levels of participation, including via enhanced levels of genomic 
literacy.
Patients and their families participate in these initiatives willingly, 
but the terms of their participation are reworked in the process as 
the value they realise consolidates around care in the moment and 
giving back to carers and future patients. Patients resist the burden of 
consent by asserting a good enough level of knowledge or normalising 
participation as a routine part of hospital visits and engagement with 
care givers. Their engagement with the economic value that their 
participation might generate is, however, curtailed, in a complex 
consent process which evokes trust in practitioners and providers to 
use their data for the common good. Facing a difficult diagnosis, or 
recovering from major surgery, patients are vulnerable, sometimes 
confused and emotional about their experiences and participation, 
and keen to make a good impression on the nurses who take them 
through the consent process. Staff also find ways of resisting and 
reworking the governing frames of the project, including consent 
and recruitment processes, prioritising care during consent meetings 
and querying efforts to improve recruitment and reorganise services 
backstage of clinical and policy encounters. Their resistance can, 
however, give further impetus to the genomic vanguard’s efforts 
to intensify transformation, locating responsibility for change with 
institutions already experiencing a range of financial and service 
pressures.
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1 https://assets.publishing.service.gov.UK/government/uploads/system/
uploads/attachment_data/file/213705/dh_132382.pdf (accessed 20 June 
2020).
2 www.mckinsey.com/business-functions/digital-mckinsey/our-insights/
disruptive-technologies (accessed 20 June 2020).
3 The Institute of Fiscal Studies reports that ‘The period between 2009–10 
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Going private: digital culture and 
personalised medicine
Tensions around the value generated by the complicated nexus of 
private, public and industry arrangements of large-scale genomic 
sequencing initiatives can also be found in the wider political economy 
of targeted therapies. Personalised cancer drugs promise cures and 
economic growth. But their expense presents a problem for healthcare 
providers and patients alike. Recent reports suggest that in one of 
the largest markets, the USA, spending on cancer drugs in the genomic 
era has increased dramatically – rising from $26 billion in 2012 to 
more than $45 billion in 2016, with targeted therapies accounting 
for 60 per cent of this increase (Bekelman and Joffe 2018). Others 
report that prices for targeted cancer therapies can be as much as 
$350,000 per patient per year (Tiriveedhi 2018: 36, quoting Gavan 
et al. 2018: 1). In insurance-based healthcare systems such as that 
in the USA, where not everyone is covered for these kinds of treat-
ments, this is plunging families into debt. Authors have written 
about the ‘financial toxicity’ that accompanies the chemical toxicity 
of cancer drugs, with the American Centers for Disease Control 
and Prevention reporting that one in three US citizens experience 
financial difficulties due to medical care, with the greatest burden 
falling on cancer patients who face a range of so-called ‘out of 
pocket expenses’ for cancer; for example, it has been reported that 
13 per cent of non-elderly patients spend over 20 per cent of their 
income on out-of-pocket expenses (Zafar 2015: 370).
For many cancer patients and their families, this is a price worth 
paying. Targeted drugs are also prized by the genomic vanguard 
(Hilgartner 2017) that we discussed in the previous chapter, who 
argue that personalisation will grow the economy and save the 
health service money as drugs are targeted more effectively. But 
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even in established and well-regarded public healthcare systems such 
as the NHS, it is difficult to meet these ballooning costs. ‘Buying 
in’ to this promissory future involves a costly ‘embrace’ of biomedi-
cine. As Good notes,
While the world’s dominant economies invest private and public monies 
in the production of biotechnology and aggressively seek to integrate 
these advances into clinical practice – thereby reaping financial as 
well as scientific returns on [often tax-funded] capital investments 
– all societies are confronted with difficult questions about rationing 
biomedical interventions assumed central to competent clinical medicine. 
(2001: 407)
In the UK this is made more complex by different decision-making 
arrangements across England, Wales and Scotland. NICE, the body 
responsible for deciding what treatments will be made available to 
patients in England, operates a Cancer Drugs Fund, a managed 
access scheme which tries to ensure that patients get early access to 
promising treatments and to encourage ‘responsible pricing’ by 
pharmaceutical companies to ensure value for money for the public 
purse.1 The Scottish Medicines Consortium advises NHS Scotland 
on the clinical merits and cost-effectiveness of new medicines. In 
many ways this arrangement reflects public opinion on the need to 
try to manage cancer drug costs in the same way as treatments for 
other conditions.2 However, bodies making funding decisions are 
also heavily criticised by cancer patients and their supporters when 
they are faced with a decision not to fund hoped-for treatments. 
There are numerous stories in the media of patients and families 
affected by these kinds of decisions criticising ‘NHS bureaucrats’ 
and the ‘postcode lottery’. As we write, one such story has hit the 
headlines. This is the case of an NHS worker with advanced cervical 
cancer who lives in Wales. She has been denied access to Avastin, 
a targeted therapy, by the All-Wales Medicines Strategy Group, but 
if she lived in England she would be able to access the drug via the 
Cancer Drugs Fund.3
Aside from these difficulties about the fairness and consistency 
of decision making across the UK, funding decisions are also beset 
by a range of problems regarding how to evaluate and establish 
what counts as an effective treatment. There is no shortage of 
economic formulae designed to work out what should be funded 
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based on cost and clinical effectiveness. But this is not an area where 
formulae are enough to satisfy the complex needs of patients, 
advocates and practitioners. So disputes abound about how to 
calculate benefit and what kinds of evidence count in this process. 
Of course, such disagreements are common across decision making 
around tests and treatments for an array of different diseases, not 
just cancer. There is also a long history of drugs being expensive 
and experimental in cancer care. But personalised cancer medicines 
make this situation even more complicated and difficult for three 
main reasons. First, the idea of personalisation brings with it a sense 
of individual patients’ entitlement to new and experimental treatments; 
not being treated as one of the ‘herd’ but as special and deserving 
of the opportunity to take the risk. This increases patient pressure 
on the decision-making body. Second, these therapies are, by their 
very nature, experimental, and as such there is limited evidence of 
effectiveness. The impetus to be permissive rather than restrictive 
is part of a wider experimental ethos perpetuated through major 
charitable institutions that fund cancer research – institutions that 
are embedded in the fabrics of our lives via a plethora of fundraising 
initiatives and charitable giving. This further increases pressure on 
decision makers. Third, and perhaps most importantly, personalised 
medicines are most effective for particular subgroups of patients, 
depending on their genomic profile, and yet evidence of this benefit 
can be difficult to generate. The way in which the effectiveness of 
cancer therapies is evaluated tends to rely on a lot of evidence of 
benefit across larger or mixed groups of patients. Gathering the 
right kind of evidence to satisfy the requirements of decision-making 
bodies is difficult because it means having to work out, in advance, 
what kinds of patients might benefit more than others and to put 
trials and studies into place to ensure that the drugs can be given 
consistently and safely, and monitored properly, to amass sufficient 
evidence. Patient pathways and trial arrangements are complex and 
cancers can progress quickly, making these kinds of studies difficult 
to conduct. Cancer is a complex and evolving disease, so the era of 
personalised medicine is not just about finding a one-off ‘wonder 
drug’ that makes all the difference. Instead, cancer therapies are 
offered in combination, and these combinations shift over time as 
the cancer evolves. This makes the benefits of one particular drug 
even more difficult to establish, putting researchers and funding 
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decision makers in a kind of Catch-22 situation: evidence of benefit 
is required but is difficult to establish because treatments are not 
yet permitted.
Behind the headlines about the revolutionary potential of per-
sonalised cancer medicines to cure cancer, there are complex and 
difficult stories of the benefits, and drawbacks, of targeted therapies. 
These therapies can give patients a few extra precious months or 
years of life, but is that enough to justify their high cost to the 
NHS? As Bekelman and Joffe recently discussed in the Journal of 
the American Medical Association, cancer drugs rarely show sub-
stantial improvements in life expectancy. They give the example of 
neratinib, a drug for patients with early-stage breast cancer, which 
has been shown to improve ‘invasive disease-free survival’ by 2 per 
cent. The monthly cost of this drug is $10,500 (Bekelman and Joffe 
2018: 2167). For experts and citizens this can be too high a price 
to pay for marginal gain, but other patients and relatives contest 
these kinds of calculations, pointing to other evidence they have 
gathered from their own experiences and those of fellow cancer 
patients, which shows that they are living longer and better lives 
because of these kinds of drugs. From the ‘exceptional responders’ 
we sometimes see in the media, to their own experiences and discus-
sions with patients and practitioners online and in person, cancer 
patients and their advocates can draw on this more diffuse, informal 
evidence to build a sense that the bureaucratic calculus of ‘benefit’ 
is unimaginative, perhaps even callous.
Another important feature of this prevailing sense of ambivalence, 
disappointment and frustration around the cost and availability of 
personalised cancer medicines is criticism of the predatory pricing 
and high profits of pharmaceutical companies. Concerns about the 
spiralling costs of precision medicine have been expressed in a range 
of quarters. In the journal Nature Biotechnology, Schellekens et al. 
criticise what they see as an ‘outmoded’ process of drug regulation, 
but they also state that ‘the main contributor to soaring costs is 
innovation in a market that is driven by what is offered, rather than 
by medical need’ (Schellekens et al. 2017: 507). Cancer charities 
also become involved in lobbying around pricing strategy. For 
example, the CRUK website ran a story about pricing, quoting 
Professor Richard Sullivan, director of the Institute of Cancer Policy 
at King’s College London: ‘Pricing is out of hand … The cost basis 
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of what’s happening to medicines is very elastic – the prices just 
keep going up. It’s not about value but what the market can bear.’ 4
Although it is widely acknowledged that the cost to companies 
of developing targeted therapies is high, concerns have been raised 
among US practitioners that big pharma is not actually spending 
as much of its profits on research and development as is sometimes 
claimed, for example by spending on marketing rather than research.5 
NICE and other government bodies, as well as economists and other 
academics involved in the review and evaluation of drug pricing, 
have had to be cautious about how they manage this disgruntlement, 
given how embedded these companies are in government plans for 
the life sciences economy as a means of boosting UK wealth. However, 
resistance to the high costs of precision medicine does emerge in 
negotiations around drug approvals, as part of a wider set of lobbying 
around access and pricing by patients and advocates. For example, 
in the face of considerable pressure from cancer charities and patient 
advocates, NICE negotiated over a number of years with Roche, 
the manufacturer of a cancer drug called Kadcyla for advanced 
breast cancer, before granting approval; this reportedly involved an 
undisclosed discount from the £90,000 ($115,000) per patient cost.6
In this chapter we explore what it means to be a cancer patient 
or advocate caught up in these systems of pricing, evaluation and 
access. How do patients and their supporters navigate access to 
targeted drugs that might be inaccessible via the NHS? What kinds 
of alliances and work does this involve? How does it feel to be told 
you can only access a treatment on which you have pinned your 
hopes by paying, or to find that you cannot benefit from this treatment 
despite having raised significant amounts of money from family and 
friends to do just that?
Cancer patients, many of whom are younger patients with a late 
diagnosis, together with their advocates, doctors and campaigners 
are increasingly seeking access to personalised cancer medicine via 
a range of routes. As we have already discussed, these include 
companies’ compassionate use schemes and research trials. But it 
can also involve self- and crowdfunding, alongside appeals against 
Clinical Commissioning Group decisions and more public challenges 
to company pricing structures. These activities have blossomed online 
in the genomic era, among new and established groups of cancer 
patients and supporters, some of whom have formed alliances around 
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types or stages of cancers, treatments and/or locale in their efforts 
to improve access to targeted chemotherapies.
Accessing and advocating for experimental therapies involves 
new biosocial arrangements. These bring patients and advocates 
together to campaign collectively and build a shared identity around 
cancer subtypes where experimental drugs offer hope but are not 
routinely available as part of NHS care. Survivorship as craft (Frank 
2003) involves telling one’s story and cultivating communities and 
responsibilities for fellow survivors. These activities also involve 
new kinds of expertise in advocacy and fundraising, extending 
entrepreneurial patienthood into the digital world of crowdfunding 
and profile raising. Digital media platforms are increasingly important 
means by which patients are active and engaged in these collective 
and individual battles (Lupton 2014; see also Vicari and Cappai 
2016). These form part of what Zuboff (2019) has called ‘surveillance 
capitalism’, where profit is derived from tracking, predicting and 
conditioning user behaviours, often without their knowledge. Cancer 
patients are actively involved in these platforms as they seek and 
offer support and advocacy around living with cancer, participating 
in research and accessing information, tests, treatments and care 
(Ziebland and Wyke 2012; Ross et al. 2019). Western-centric tropes 
of survivorship, prioritising enablement, self-responsibility and 
cheerfulness are common, notably in breast cancer forums (Orgad 
2005). As Petersen et al. (2019) argue, there is also growing emphasis 
in patient campaigning online, where patients work with science 
and business on profile raising and fundraising. These activities are 
amplified and monetised by traditional and digital media which 
‘align with a consumer-driven model of digital patient activism’ 
(Petersen et al. 2019: 489). Facebook and other social media platforms 
such as Instagram are where patients become involved in what 
Gerlitz and Helmond have called the ‘like economy’, where ‘like 
buttons enable multiple data flows between various actors, contribut-
ing to a simultaneous de- and re-centralisation of the web’ (Gerlitz 
and Helmond 2013: 1248).
We explore these activities by analysing 15 patients’ social media 
and press coverage and eight interviews with a range of mainly 
non-NHS patients and their advocates, including patients seeking 
or self-funding targeted cancer treatments that have been refused 
or not provided as part of standard NHS care. The interviews were 
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carried out between September 2018 and March 2019. They included 
patients and their supporters crowdfunding for these treatments 
using online platforms, campaigners advocating for access and a 
small number of patients who had gone public about their experiences 
of self-funding treatments. We also included patients who have 
accessed private medicine via their medical insurance schemes, 
typically provided as part of their employment benefits, some of 
whom avoid speaking about this in public.
These new arrangements transcend categories such as industry-
backed ‘patient groups’ and ‘adversarial consumerism’ (Williams et 
al. 2011) and rework theories of biosociality which foreground 
active partnerships between rare-disease communities and healthcare 
providers. Instead, following Frank (2003) we argue that these 
practices of private patienthood are creating and breaking down 
solidarities in novel and important ways. We highlight digital 
platforms as a key aspect of these processes, as the sites through 
which patients and their advocates join each other alongside charities, 
pharmaceutical companies, universities and healthcare institutions 
in constituting these new kinds of patienthood. But rather than 
being wholly benign, these platforms are part of the process of value 
creation, and are themselves extracting yet more value from patient 
behaviour now rendered digital. Crucially, we consider how these 
processes work via appeals to and accounts of the sorts of futures 
these patients and supporters craft for themselves and others as part 
of these new social and economic formations, as they try to live 
well in prognosis.
Private healthcare as right and wrong: personal futures and 
the future of the NHS
Private cancer medicine in the UK is a significant business. As pressure 
on NHS funding increases and the regulatory hurdles outlined above 
multiply, NHS cancer patients are increasingly faced with restrictions 
on the kinds of drugs they might seek as part of their care. For 
many NHS patients, this is not an issue – they accept the treatments 
on offer or join trials to access more experimental therapies. For a 
growing group of patients, however, private medicine is their main 
option.
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Going private is not necessarily to the exclusion of NHS care, 
but often patched together with NHS services, typically when patients 
are able to access private medicine through a workplace insurance 
scheme. As this patient advocate for ovarian cancer, Sara, explains, 
this does not necessarily involve speedier access to tests, results and 
treatment:
How did you go about getting a genetic test?
So I … think I raised it with my oncologist and … requested that I 
was referred for it. And he … was keen to make that referral. But I 
was seeing my oncologist privately … [I] think genetic testing, that 
was through the NHS … I think there was probably some delay 
because perhaps … I wasn’t having my treatment at the time on 
the NHS and then there were some complications with them having 
an old address on file … So it probably took about 12 months … 
from me initiating the conversation to actually having the test, which 
was a little bit frustrating. But … I got there in the end and I know 
there’s plenty of people who want genetic testing and struggle … to  
get it.
On the other hand, private medicine did bring Sara privileged access 
to certain therapies, such as Avastin, a biological therapy which has 
shown some success for particular groups of cancer patients such 
as those with a BRAF mutation:
because I was private, I was, I was having my surgery and my treatment 
privately, I was automatically eligible for Avastin.
Did you go private because it was covered by your work?
Yeah, it was … I initially went to an out of hours doctor based at a 
local NHS hospital and I was admitted there and had a lot of my 
initial tests and diagnosis there. And then my follow-up appointment 
was with the surgeon of that hospital, and when he said the next step 
is to have a hysterectomy, he said, ‘I can do it in three weeks on the 
NHS or I can do it in a week privately.’ And I had the benefit of 
private cover – so it’d be the same individual doing it, so it wasn’t 
as if I was getting any more – anybody any more skilled or less skilled, 
but at the time my reaction to it was I just want whatever is in there 
out of me as soon as, and it felt – because at the time one of the 
symptoms, I was quite bloated and it seemed to be getting – my 
stomach seemed to be getting bigger with like fluid, it was almost I 
just needed whatever it was out.
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… But one of the things – so whilst the follow-up treatment I’ve 
had privately, one thing that they haven’t got is the sort of support 
services that go around it, so I have been able to access the NHS for 
a psychologist. I went for reflexology whilst I was having treatment, 
somebody to talk about benefit, some – my Macmillan nurse was 
based at the hospital, so I have sort of taken bits from private and 
public sector, so I’ve been lucky to do that.
So going back to the question about Avastin, I think because I … 
had that cover, there wasn’t any question about it … I don’t know 
whether I would have been eligible had I been NHS … I don’t think 
it’s necessarily routinely available to everybody, there’s certain criteria, 
it might differ depending where geographically you live. So I do feel 
fortunate that I had the cover and was able to get that without 
question.
One particular group of patients who are seeking access to drugs 
not currently available on the NHS are advanced bowel cancer 
patients who are on their third or fourth line of treatment and 
would also like to access Avastin. This is not currently funded by 
the NHS because NICE has not approved access to the treatment 
due to what is considered insufficient evidence of benefit. But as 
with the case of the ovarian cancer patient above, some bowel cancer 
patients have been prescribed the drug privately, pointing to its 
availability in other countries and a small but growing evidence 
base that supports its use. These patients have the support of some 
of the larger charities for this cancer, although there is not a wide-
spread campaign as we saw with other high-profile challenges to 
NICE decisions about targeted treatments, such as from the breast 
cancer patient community.
Some patients, such as Lydia, access this drug through private 
medicine because they have insurance, often as part of their workplace 
benefits. Lydia, a young woman in her thirties diagnosed with 
advanced bowel cancer, did not experience many of the difficulties 
with getting a quick diagnosis and access to expensive treatments 
that she knows other people in her situation face, despite the relative 
rarity of her case. Lydia, like Sara, told us she was fortunate to have 
private healthcare insurance and has had access to the best surgeons, 
oncologists and treatments. She was able to choose to take Avastin 
alongside other chemotherapy drugs because the alternative treatment 
protocol might have harmed her ability to continue with her sporting 
192 Personalised cancer medicine
pursuits. This personalised care was more important to Lydia than 
the ‘numbers on the page’ about her particular cancer subtype. 
Lydia found the molecular information difficult to process and told 
us she avoided trying to find out too much about it as it was 
overwhelming. She felt very fortunate to be receiving private care, 
but it also brought a sense of guilt that she had to manage, partly 
by participating in other research and awareness-raising activities 
around prevention. Lydia felt that it was wrong that she should be 
able to benefit from excellent care whereas others could not because 
some unnamed persons were ‘acting like God’ to restrict treatments 
for some NHS patients. Her guilt also meant she kept what she felt 
was her privileged position as a private cancer patient secret and 
did not disclose this to other patients in her online community.
Other patients with private healthcare insurance switched to and 
from NHS and private medicine depending on their needs. This 
movement between public and private provision is a feature of the 
current system, as there is choice embedded in NHS service delivery 
alongside rationing. Alongside major private hospitals, some NHS 
hospitals might run private patient units (PPUs), including for cancer. 
These PPUs have an ambiguous position in the NHS, offering a 
quicker scan or a treatment not available on the NHS but also, as 
Guy has pointed out, sometimes being advertised as offering the 
opportunity to patients to help the NHS by reducing the strain on 
the service (Guy 2019). We interviewed another patient, Rachel, 
who, like Sara, had switched back and forth between NHS care 
and private care and was now receiving targeted therapies funded 
by her insurer which would not otherwise be available on the NHS. 
Rachel’s story illustrates the complexity of these transitions and the 
feelings these evoke, captured in this lengthy extract:
at the time it was … I was a bit like a deer in the headlights, as you 
can imagine … I didn’t know anything about cancer. I mean none of 
my family had had cancer … I was so completely inexperienced with 
any of it, but I was doing quite a lot of reading … on my condition 
and the different treatments available to me, and that’s when things 
started to, for me, become a little bit clear that actually … there might 
be something better for me out there. But actually, I’m not on it 
because I’m under the NHS.
… I did actually mention it to doctor but … to be honest with 
you … she’d pretty much written me off … that’s a common factor 
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for a lot of people that find themselves at stage four … with all the 
NHS pressures, that actually it’s ‘well you’re terminal anyway … 
we’re doing our best, it is what it is’ … that didn’t really sit that well 
with me, as you can imagine (laughs softly) so, I transferred my care 
[to another hospital].
But I, again I transferred as an NHS patient … and I sat down 
with my oncologist on the … first day and said to him, ‘Look, am I, 
am I actually on the best treatment here, or could I be on something 
better?’ And he said, ‘No, you’re on the best treatment.’ And I said, 
‘Well look, I’ve, I’ve read about this thing called Avastin, this drug 
called Avastin. Is it not worth [trying], because of my BRAF mutation?’ 
… and he said to me, ‘Well, it’s very expensive … so don’t worry 
about it too much … it’s not really that big a deal.’ And I said to 
him, ‘Well look, I’m … I’m potentially a private patient, I’ve just not 
really looked into that too much. I don’t really know much about 
the … private system, and I’ve got it through work.’ And he said, 
‘Well look, go and speak to – who are you with?’ and I said, [name 
of insurer] and he said, ‘Well look, speak to them and see, see if 
you’ve got, see if you’re covered, and if you are, let me know.’ And 
I did. And they said to me, ‘Yes, yeah, we would, we would absolutely 
fund Avastin,’ and I was like, ‘Okay, fine.’
Then, I emailed my oncologist to say, ‘They’ve said they will fund 
me. I’m fully covered,’ and he … phoned back within, between ten 
minutes and half an hour, and … the whole conversation completely 
changed. It was very much, ‘This is incredible. Absolutely, we need 
to get you on Avastin. Avastin really should be available on the NHS 
anyway, but it isn’t because, … NICE haven’t approved it. But it is 
a standard of care across major, other major countries in the world.’
And I think … that for me, I found quite shocking and … quite 
unfair really because it’s not like, I think it’s very separate to people 
being on clinical trials and new drugs coming along … But a drug 
that’s actually approved across all the other major countries, you know, 
with the, with the best performing healthcare systems in the world, 
you know, and it’s not approved here. And actually the, the criteria 
and the justification from NICE I don’t think particularly stacks up. 
Um, and that’s, again that’s something that, that my oncolog[ist] 
said to me, he said, you know, ‘The, the problem is that the overall 
data isn’t that great, but actually it’s good for specific types of colon 
cancer. And actually, yours is one of them, so we should put you on 
that,’ … which was, which was great. … I’ve been on that ever since.
But I’ve got lots and lots of friends now who are BRAF mutated 
and, actually quite scarily, what, what I’m tending to find is that the 
194 Personalised cancer medicine
majority of BRAF patients are, they, they tend to be a lot younger. 
They tend to be the younger lot and actually these are the ones that 
can withstand much greater, much stronger treatment and give 
themselves a much better opportunity and best chance in life to at 
least have, you know, I don’t know, three or four years rather than 
the one or two that they’re being handed.
Um, so the frustration for me is that the, the guideline … haven’t 
been approved in the correct way, I don’t think … the whole thing 
has been looked at in, in the most appropriate way … So I’m, I’m 
very fortunate, but I’ve got lots of friends now who are – I’ve got 
one chap in particular and he’s literally raising money for each session 
and it’s costing him about £1,800 every two weeks. So that’s quite 
frustrating.
Rachel found the guilt and anger at this injustice difficult to manage 
alone, and this spurred her to write a blog and set up a closed group 
on Facebook to share her experiences and support other patients 
to identify the best treatment options depending on their molecular 
subtype. She spoke about the need for patients to realise that their 
NHS doctors were operating with ‘one hand tied behind their backs!’ 
as part of her efforts to encourage patients to be more active and 
challenging so that they got the best care. This work sat outside of 
the more positive, moderated zones of the main charity in this area 
and included discussion about a range of alternative treatments 
alongside conventional medicine and targeted treatments. Rachel 
also spoke about her belief in the NHS and her distress that it was 
not being given sufficient funds to provide these more expensive 
treatments. Through these accounts Rachel balanced her identity 
as a private patient against her sense of biosociality with other 
similar patients as well as her citizenship and support for public 
services such as the NHS.
Other patients we interviewed were either already self-funding 
or planning to pay for treatments themselves. The scale of this 
market is difficult to quantify, but a recent report estimated that 
‘the market in self paying patients was heading for “double digit 
growth” over the next few years and that this was fuelled by longer 
NHS waiting lists, curbs on access to NHS treatments, and rising 
private medical insurance premiums’.7 Some of these patients were 
able to afford to self-fund without doing things such as remortgaging 
their homes. One such patient was Phil, another advanced bowel 
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cancer patient, who was self-funding Avastin. Phil was part of an 
online community of cancer patients and supported the work of 
one of the main charities for bowel cancer. Like Rachel, he had 
become something of a public patient through a blog and presence 
on social media, and his posts included discussion about self-funding 
the drug which referenced his sense of being fortunate that he was 
able to find this money. Phil also engaged with more political discus-
sions around NHS resources and funding, including retweeting posts 
by other advocates about the need to make his treatment more 
widely available on the NHS. But Phil’s decision to self-fund Avastin 
was careful and contingent, and he was aware of the uncertainties 
involved:
I suppose it’s a difficult one, isn’t it? I mean … it’s hard to … know. 
I suppose from my perspective, I kind of thought, look, you know, 
I’m in a situation where I’ve got advanced bowel cancer … I can 
afford to do it, fortunately, so I thought, well, you know, although 
it’s expensive, I’m gonna, you know, give it a whirl. You know, I 
don’t want to … die wondering whether … it would’ve made a dif-
ference or not. And I think one of the problems … with Avastin is 
it’s difficult to measure what the effectiveness of the drug is. … I’m 
taking it alongside chemotherapy and … if the overall treatment’s 
effective, it’s, it’s not really possible to … measure whether the 
effectiveness is through the chemo or through the Avastin … But, 
you know, I thought … I’m gonna give it a go for this cycle and see 
where it takes me, really.
This captures the ambivalence and contingency involved in self-
funding decisions, showing that this is not necessarily the activity 
of the overly optimistic or naïve.
Advocacy for access to personalised cancer medicines as part of 
NHS care takes on different forms and is not solely the preserve of 
patients. One advocate, Michelle, had a background in public relations 
and a high profile on social media and had been spurred into action 
by the death of a parent who had not been able to access targeted 
therapies as soon as she had hoped, as she explains in the quote 
below:
it’d taken me a year [to win the appeal], and it was literally a year 
before I, you know, that I’d found it and then it had taken a year to 
do it, so she was virtually in a hospice by the time we, we got this 
damn drug approved.
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… however, she took it, and … she lived, you know, and for her 
it was like, a victory anyway, it did extend her life, it did help her 
quality of life, but of course it was too late for her. So, it was important 
then to keep going. So I did about seventy Exceptional Case appeals; 
within the first six months after mum’s death, and overturned all of 
those, so there was a whole raft of cases, and that was all over the 
country, from Wales and England, and Scotland.
Michelle’s story is interesting because it speaks further to the crea-
tion of a new kind of expertise emerging in this area – expertise 
in challenging NHS funding decision making and advocating for 
targeted therapies for patients on a case-by-case basis. Michelle 
takes on cases and supports patients to challenge refusals of drugs 
by local Clinical Commissioning Groups within the NHS, operating 
in the absence of definitive approvals by NICE for a growing list of 
experimental treatments, as well as challenging the ‘postcode lottery’ 
between the different regions of the UK. She describes her work thus:
by the time they get to me, nobody’s listening to them … every 
avenue is shut to them. Nobody gives them an answer, and I think 
the most important thing that I do with patients, I’ve actually just 
got an email this morning about a patient saying, ‘if you hadn’t have 
empowered me, I’d have never have questioned’ … the first thing I 
do with a patient is, number one, I listen, I just let them tell their 
story without interrupting; and say everything that they feel they 
never get the chance to say.
And then, I say, ‘right let’s unpick it, and let’s take control of it 
and let’s see how we can help’, and I think, many, many of them, I 
would say are in crisis by the time they get to me … they’re exhausted, 
they’re devastated, they’re weak, they’re frightened, and [this] has 
brought about another part of what I want changing – advocacy 
within the NHS – as soon as they speak to me, I would say nearly 
a hundred per cent say, that’s the best time … I’ve felt in the whole 
journey because it’s for me, I focus on letting them feel a bit more 
in control and understanding the process, and understanding how it 
works; and the change that gives to a patient and their families is, is 
really quite miraculous. And to me, it is so easy, I can spend fifteen 
minutes with a patient and completely change their mind-set and their 
journey, and I’m appalled that that isn’t available to them in the NHS.
Michelle was a self-styled ‘warrior’ for her patients, who told us 
how she struck fear into NHS managers and bureaucrats as she 
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campaigned to get patients the treatments they needed. As part of 
this she sought to tell patients’ stories and to celebrate their achieve-
ments and characteristics, rendering them popular as a means of 
garnering support for her efforts to get them what they need. Michelle 
posted links to blogs, posts and crowdfunding appeals by ‘her patients’ 
online and sought gifts from donors to surprise them on special 
occasions, such as tickets to the theatre. She was funded by private 
donations and did not want to be too critical about the pharmaceutical 
companies or the NHS as a public institution. Michelle also expressed 
reservations about how quickly some patients sought crowdfunding, 
preferring to try to challenge the NHS first to secure treatment. In 
so doing she operated among the clash of evidence, expertise and 
values of public and private care, forging what she framed as a new 
expertise that was required to navigate their growing complexity 
in the genomic era.
The private patient and advocacy stories we have explored here 
are, of course, just a small fraction of the kinds of experiences 
patients faced with difficult decisions around targeted treatments 
they had to navigate in the course of their cancer. We have shown 
how being a private patient is not about being filled with hope or 
optimism, but is marked by ambivalence, including feelings of guilt 
and obligations to other patients that must be managed, sometimes 
in public and sometimes very much in private. We have also shown 
how these dynamics open up new kinds of biosocial collectives 
around subtypes and drugs sought, and roles for patients and their 
supporters as advocates and other kinds of experts in personalised 
cancer medicine. Yet we also have to appreciate that these kinds of 
activities are being enacted by, and reinforcing the cultural capital of, 
a relatively exclusive kind of patient and advocate – often younger 
professionals who are articulate and tech-savvy, able to use social 
media to good effect to explore their experiences and connect with 
others. These already privileged patients and advocates are operating 
at the intersections of private medicine and social media, which further 
‘buttresses their sense of personal action, freedom and responsibility’ 
(Van Dijck and Poell 2013: 10) as they access these treatments for 
themselves and others in an effort to extend their and others’ futures. 
At the same time, they enact critical interventions in public space, 
challenging what they frame as the failures and inequities of the 
NHS. But this is not presented as an attack on the foundations of 
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a public service. Instead, critique is offered in the spirit of improving 
the NHS, as private and public forms of medicine are inevitably 
entangled therein.
Crowdfunding: crafting futures in the digital economy
These entanglements of private and public care and privileged kinds 
of identities are particularly apparent in the arena of crowdfunding 
for cancer treatments. A British Medical Journal study reports that 
there has been a significant increase in online crowdfunding for 
alternative treatments on platforms such as GoFundMe and Just 
Giving, suggesting that, since 2012, £8 million has been raised, 
mostly for treatments in clinics abroad.8 Other patients are fundraising 
for experimental treatments not available on the NHS, including 
targeted therapies. A recent BBC report found that £20 million was 
raised on crowdfunding sites between February 2018 and 2019 for 
cancer treatments not available on the NHS.9 Clinics providing these 
treatments abroad also combine alternative and experimental treat-
ments, and there is confusion about what kinds of treatments are 
showing positive effects in media reporting on so-called ‘miracle 
cures’. For example, a recent Daily Mirror article10 on a ‘terminally 
ill mum’ who had received successful ‘alternative care’ at a clinic 
in Mexico was publicly criticised by an oncologist for not making 
it clear that Alectinib, a targeted treatment for a subtype of lung 
cancer (ALK positive), was probably responsible for this woman’s 
good outcome, rather than alternative therapies such as the coffee 
enemas featured in the article.11 The press has a central role in creating 
a profile for fundraisers as well as criticising the dangers of ‘quackery’ 
in this arena. As the BMJ notes, ‘Newspaper and TV reports on 
people with cancer drive donors to the crowdfunding sites, sometimes 
attracting the attention of celebrities, who boost funds. They also 
encourage others to seek the same treatment.’ 12
In this section, we will look more closely at the activities and 
experiences of cancer patients fundraising online for targeted therapies 
to explore what new kinds of cancer identities, work and public–
private arrangements are developing as these sites proliferate. To 
understand how financial and cultural value is created by these 
practices we will draw on scholarship about digital capitalism which 
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seeks to trace how value is accrued and by whom. This means we 
need to examine not just the efforts of fundraisers but of the platforms 
that host their activities, and the ways in which these are shared 
across other social media platforms and mainstream media through 
processes of cross-syndication which entwine social and mass media 
logics (Van Dijck and Poell 2013). We will also consider how fundrais-
ing becomes successful and what kinds of qualities and attributes 
fundraisers need to cultivate in order to be effectual. As Steinberg 
(2015) has argued, ‘survivorship’ has replaced ‘victimhood’ as a 
key subjectivity of ‘good’ cancer patienthood, and social media 
invites audiences to form judgements about the qualities and worth 
of the cancer patients seeking their help. Exploring how some 
fundraisers work to become popular to generate funds, we consider 
an array of other kinds of activities beyond raising money, such as 
being profiled in local media, blogging, undertaking charitable work 
and producing different cultural outputs such as books and art. We 
consider how fundraisers turn themselves into brands and establish 
popularity through the use of metrics that are key to the functioning 
of the social media platforms. Being a worthy investment is key to 
success with fundraising, but how does this happen, and how does 
it feel to those involved in doing this kind of work?
Crowdfunding sites are by now a familiar feature of life online. 
Many of us will have donated to fundraising efforts by family and 
friends, and perhaps we have also donated to strangers when their 
stories touch us. Seeking donations for cancer therapies online is 
typically driven by a sense of necessity as someone’s cancer progresses 
and options for treatment narrow. Fundraising sites are often run 
by family or friends rather than the patient directly, but patients 
nevertheless play an important role as the ‘face’ of the campaign, 
and this includes providing often quite intimate details about their 
hopes and aspirations, as well as their experiences of treatment, in 
a series of updates and links to blogs, Facebook pages and other 
social media posts. Analysing a set of 15 fundraising campaigns for 
personalised cancer medicine identified via online searches of the 
main crowdfunding platforms, we can identify a particular set of 
discourses or tropes about the worthiness of the cancer patient 
seeking treatment which point to their admirable qualities, caring 
responsibilities and track record/commitment to ‘giving back’ to the 
community through fundraising and campaigning for charities and 
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worthy causes. As Stage (2017) has shown, being positive, aspira-
tional, determined, grateful, funny, entertaining and caring are 
important in cancer blogging. Positivity is also important to successful 
fundraising, but so too is being a good parent or partner and a 
skilled worker or artisan. Gratitude to all of the donors, large and 
small, whether through direct donations or through organising discos, 
cake stalls or sponsored walks, is also vital.
One crowdfunder, Claire, whose posts we followed until her 
death from secondary breast cancer, skilfully combined these various 
discourses across her fundraising, blog and Facebook pages. Claire’s 
initial fundraising effort raised £15k over 17 months for targeted 
treatments not available on the NHS, and she moved to a different 
platform shortly before her death because the first platform had 
been taken over by another site and no longer supported PayPal 
payments for personal fundraising. Claire noted that at this point 
she had not had to use the money for the drugs, but that there was 
still a need to raise further money because treatments might be 
available soon and they are very expensive. Claire’s fundraising site 
was mainly shared through her Facebook page, various campaigns 
she supported, and press coverage that she attracted. The Facebook 
page includes posts that celebrated the numbers of likes and shares 
her page achieved and asked people to donate on key occasions 
such as ‘Giving Tuesday’. The page includes links to her blog, which 
tells Claire’s story of living with secondary breast cancer over a 
number of years, and is heavily focused on her desire to give her 
teenage child a normal life and her sense of guilt that this will not 
be possible. There are a lot of images on the blog of Claire and her 
child smiling together in their home, on holiday and at various 
events, which are reshared on the fundraising site and Facebook. 
Claire tells the story of having to give up a professional job to 
become a full-time cancer patient, recounting the ups and downs 
of treatments and results, describing her hopes and gratitude, disap-
pointments and frustrations. Her story includes details of her 
campaigning work with a breast cancer charity and campaign group 
for access to targeted treatments, with numerous links to press 
articles, profiles and TV news features. Although she provides some 
information about the specific molecular profile of her cancer and 
the kinds of drugs she needs, her profile pitches cancer as a disease 
that affects everyone. She shares humorous details of living with 
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cancer every day and stresses the importance of taking pleasure in 
the little things, like getting a new haircut. Combining these different 
registers and sharing content across these different digital platforms 
allowed Claire to build up a profile as a worthy investment herself, 
in part by creating a space where criticism of the need to do this 
work is articulated. Through these accounts Claire constructed her 
online identity as both ordinary and exceptional. She is at once 
thrust into the world of cancer care and politics, but she is also just 
like you and me, wanting to do the best for our families. The final 
post about Claire’s death, by her family, pays tribute to her campaign-
ing work.
For other crowdfunders, being an advanced cancer patient seeking 
targeted treatments not available on the NHS has opened up new 
vistas of cultural work as author, poet or artist. Tom was a successful 
artist prior to his diagnosis with advanced cancer, but his efforts 
to access targeted treatment on the NHS were unsuccessful, so his 
partner turned to crowdfunding. The fundraising campaign has been 
very successful, trending on the crowdfunding platform at one point, 
and raising over £200k in less than 30 months. The site and related 
posts and pages by Tom, as well as media coverage of his plight, 
are replete with emotions of gratitude, anger and hope. But they 
all start from the position that Tom is a loving husband and father 
and a successful and much-loved public figure with considerable 
cultural capital who has entered into an intense period of creativity 
as he faces up to his illness. In one broadsheet newspaper article 
about Tom, his story is recounted as one of success, followed by 
pain and despair and then a new life of art and privately funded 
treatments supported by online fundraising. Tom’s reluctance to 
seek funding this way, and his anger at underfunding of the NHS, 
pepper the accounts of his situation, as do his struggles to produce 
art, remain positive and inspire others. Art, politics and science 
feature in his personal story and engagement with public issues. The 
fundraising page is somewhat off-centre from these activities, not 
always mentioned or linked to, but nevertheless crucial to the way in 
which Tom is managing his condition. The site itself is managed by 
his partner, and this involves updates which include an emotionally 
charged video where his partner speaks about her family’s hope for 
the treatment, as well as her exhaustion and gratitude. It includes 
poignant stories about people who are themselves facing difficult 
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situations or do not have a great deal of money, such as a child who 
had lost a parent to cancer, who have donated to Tom’s treatment. 
In the midst of these emotive stories we find links to bank account 
information, but there are few details about what the money buys 
in the way of treatment; rather there is a sense that options are 
being held open should Tom choose to pursue alternative therapies 
or other treatments using the funds raised.
We also identified more overt appeals for funds by other public 
patients such as Gillian, who has advanced ovarian cancer. It is 
interesting to note, however, that this fundraising effort was not as 
successful as that of other crowdfunders in our study. Gillian raised 
just short of £25k in 14 months. Although this was not for a particular 
targeted treatment, it was organised around the prospect of needing 
such treatment in the future and, as with other fundraisers, it included 
the possibility of funds being used for alternative as well as targeted 
therapies. We were fortunate to be able to interview Gillian before 
her health deteriorated and as her fundraising initiative was launched. 
Many of the themes in her voluminous social media posts and media 
coverage are present in her interview. Like all of the crowdfunders 
we have followed, Gillian is a young woman who was diagnosed 
after a diagnostic odyssey of missed symptoms and near death, in 
her case with late-stage cancer of the ovaries. Gillian’s story is of a 
life that has fundamentally changed following her diagnosis, not 
just because of the extensive surgery and treatment regimes she has 
had to undertake, but because she has made being a cancer patient 
a full-time job. She has become an author and her books have 
achieved modest success in what is a busy market of cancer biog-
raphies and self-help books. Prior to setting up her crowdfunding 
page, Gillian was already deriving financial value from her cancer 
patienthood via her books and work as an alternative therapist and 
teacher.
Gillian has created a complex web of outputs and activities designed 
to inspire other patients, often based around memes or quotes that 
she thinks are particularly positive and upbeat. In her interview she 
told us about one of these:
I saw a quote the other day which I really liked and it was ‘did you 
have a bad day or a bad ten minutes you milked all day?’ and I think 
that’s so true, people focus on the negatives all of the time and people 
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are martyrs … a lot of people say to me ‘oh you must be so down 
all the time, you must cry a lot?’ and I’m like ‘why must I?’, it’s just 
about enjoying life.
This theme of resilience is further underscored by Gillian’s use of 
language from youth culture, when she refers to her supporters and 
followers as ‘bitches’ or ‘motherfucking warriors’ and tags her posts 
with hashtags such as ‘StillHereBitches’. At the same time, Gillian 
told us she ‘hates it’ when people say they have ‘lost the fight with 
cancer’: ‘I absolutely loathe any battle survivor victim fight terminol-
ogy’, because cancer is not the enemy but ‘part of me’. This captures 
the cacophony of competing emotions and aspirations that feature 
in this public version of cancer patienthood, reflecting the contradic-
tory position that patients find themselves in, where they aspire to 
high-quality targeted treatment personalised to them but fear that 
it will not work in the end. One way of managing this for Gillian 
is to appeal to the ubiquity of cancer: ‘we are all terminal; our life 
is precious’.
Gillian’s investment in complementary therapy, as a recipient and 
practitioner, is also mixed with her investment in high-tech therapies 
including targeted treatments. The personalisation she advocates 
and seeks is hybrid and fluid and her engagement with scientific 
expertise is as partial as it is complex. Gillian refers to targeted 
therapies as ‘Western medicine’ in her blog where she also writes 
about her experiences of being on drug trials alongside her alternative 
treatments and therapies such as crystal healing. Elsewhere the 
targeted therapy is positioned as a ‘maintenance drug’ which is a 
small part of her ‘holistic treatment regime’ or her ‘daily protocol 
for life’ (which she notes is detailed in her book).
Unlike some of the other crowdfunders we have followed, Gillian 
frequently refers to her fundraising, and her posts link to her fundrais-
ing page across her social media outputs. Her discussion of fundraising 
includes the typical mix of gratitude and reciprocity we have discussed 
above, but Gillian goes into more detail about how she has been 
spending the money raised as part of her efforts to provide fellow 
patients with a protocol for how to manage their cancer day by 
day. We learn from these posts that Gillian started off raising money 
for Avastin, but elsewhere she posts that she is not privately funding 
Avastin any longer, and has used money for, among other things, a 
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shaman. Her story has moved on to a focus on using complementary 
therapies to extend her life so that she is well enough to access an 
immunotherapy trial, the next hope for miracle treatments in the 
world of personalised medicine.
Throughout these various accounts we can see the importance 
of being a worthy investment to successful fundraising for targeted 
therapies not otherwise available on the NHS, including the dem-
onstration of expertise, being hardworking and aspirational, special, 
but ordinary, like you and me, and a good parent, partner and 
socially useful citizen. Being funny and likeable, interesting or 
provocative and thereby articulating the cancer patient’s personality 
as a strong ‘brand’ is also important to success. Accounts are 
inconsistent and at times contradictory, articulating a fluid and 
complex set of affective repertoires of gratitude, regret, anger and 
hope expressed through sometimes quite intimate and emotive stories 
and images. These accounts are part of the ‘like economy’ (Gerlitz 
and Helmond 2013) that extends Facebook’s network of counters, 
buttons and clicks across social media platforms which facilitate 
further donations and reach. Fundraisers use and build from their 
existing online and offline networks in cancer communities, alternative 
medicine, the arts and the media to further raise their profile and 
donations. Within this we see molecular profiles and therapies sit 
alongside alternative knowledge and therapies as people craft possible 
futures for themselves and their relatives.
When we turn to consider how this money is spent, we can see 
it supports private medicine providers and pharmaceutical companies 
who produce the targeted therapies, but it also supports alternative 
practitioners and therapies in some cases. What is less apparent is 
that these activities create profit for the social media platforms via 
fees, advertising and surplus value generated by the sale of user data 
(Zuboff 2019). But for fundraisers, producing these carefully curated 
stories of investable identities and managing how this value is derived 
and perceived by donors is not always easy or straightforward.
One of the crowdfunders we interviewed was particularly candid 
about her experiences and worries around these activities. Stacey 
discovered she had advanced breast cancer while she was pregnant, 
and, following the birth of her child, went on to receive surgery 
and chemotherapy. She was told at this point about drugs that might 
be good for targeting her kind of cancer in a further round of 
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treatment by her oncologist, but she was also warned that these 
drugs were not funded in her part of the country. The oncologist 
suggested that she might want to consider fundraising. Although 
grateful to the clinician for the early warning, this caused worry 
and upset for Stacey, who was initially ambivalent about fundraising. 
Her family decided to fundraise on her behalf despite her reservations. 
Stacey told us how her family was already fundraising to support 
her, so increasing the scale of fundraising to cover drugs was the 
next step. Over the course of 30 months nearly £200k was raised 
by her fundraising campaign.
Stacey spoke about her enormous gratitude and the sense of being 
loved and cared for that came with this experience. But she also 
expressed ambivalence about their activities, which centred around 
worries about the burden of being a good recipient of support. 
Stacey found that as a result of the decision to fundraise on this 
scale, she had to research different crowdfunding sites and how to 
open a bank account for these types of funds. Stacey also found the 
work of managing all of the donations quite intense:
It just went crazy and that is basically because, well, the fact my story 
was quite emotive and [where I live] there is still a very strong sense 
of community. Everybody knows everybody, and so immediately that 
I put it out there, it just … spread and everybody got involved … 
complete strangers were messaging me saying ‘I’m gonna do this for 
your fund’ … Snowdon, marathons … all sorts of crazy things.
The fundraising page and associated Facebook pages are filled with 
stories of the ups and downs of Stacey’s diagnosis and treatment 
and her family life, alongside pictures, posts and gratitude for these 
various fundraising events. But Stacey told us she also found this 
‘overwhelming, in a bad way’:
There were maybe like three or four different events happening every 
weekend … and lots of people understood that I couldn’t make it to 
all of them but some people felt I should be there. And it was really 
hard to say no to people who were raising money for me. It hit a 
point when I thought I cannot do this.
Stacey found the work of doing updates and thanking donors, as well 
as attending events and researching the best means of fundraising, 
exhausting alongside managing her illness and taking care of her 
young family. She also had to field inquiries from other cancer 
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patients about how to be successful at fundraising. She spoke about 
how, in the midst of this ‘fundraising whirlwind’, she began to feel 
guilty that the money had not yet been spent on the drugs she was 
fundraising for (one of the drugs had subsequently become avail-
able on the NHS and she was not yet in need of the other drug). 
Stacey began to ‘gently encourage people to donate elsewhere’. She 
also became concerned about what would happen to the money 
should she die – if it would result in tax on her estate. She spoke 
to the bank about whether or not it might be considered to be 
her savings and should be disclosed to the state, and renamed the 
account.
But the most striking part of Stacey’s story is her worry that she 
would be judged by her donors if they became suspicious that she 
was not using the money as intended. She told us about a controversy 
in her online community related to one relatively wealthy family 
who had crowdfunded for a cancer patient who had subsequently 
died, and there were concerns that the money had been spent on 
nice holidays and material possessions. This caused Stacey to worry 
about how she would be judged when her family bought a new car, 
and meant the family chose not to spend their other savings on a 
motor home in case it caused scandal. Stacey commented:
With these crowdfunding sites … it’s just a very grey area. I mean, 
is it your money? I’m not classing it as my money, but it is really … 
I could spend it on anything I want to. It wouldn’t be morally right, 
but I don’t think it would be illegal … but other people might not 
think like that … So, I do think that crowdfunding is … open … to 
abuse from people who might not have the same kind of … moral 
standard … say you’re raising it for treatment and you’re now dead. 
Can [the fundraising platform] say ‘Well, we’re not using it for that 
now, so you can’t use it for something else?’ It’s something that does 
definitely worry me because I don’t want to put my family in that 
position where they’re faced with any kind of criticism or open to 
any kind of questioning from anyone else.
This story reveals some of the hidden labour of crowdfunding 
for targeted treatments, including the emotional labour of managing 
obligations to friends, family and donors in what is a moral as well 
as a financial economy. Behind the carefully curated stories of positiv-
ity and hope as a solution to the despair and pain that comes as 
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cancer progresses, there is anxiety and concern that also has to be 
managed as part of being a cancer patient and making private troubles 
public in order to extend their future. Entering a ‘grey area’ between 
charity and the market, patients are raising money for future and 
current treatments (and sometimes other things) and contributing 
to the profits of digital platforms. There is ambiguity, too, around 
how funds are spent, including by relatives once the patient has 
died. Some sites remain open after death and donations can still be 
made in some cases. Sometimes the family does not inform donors 
how money raised for treatments that were not accessed was spent. 
As with private patients whose treatments are covered by insurance 
or who are in a position to self-fund using savings, crowdfunders 
such as Stacey can also feel guilty about patients with less support. 
As Stacey comments,
I’m fortunate enough to be in a position where I am able to write up 
my story in an articulate and … logical manner. I knew what I needed 
to say and how to say it … I don’t mean in a manipulative way, but 
I tried to be clear and open … so that people know what I’m fundraising 
for and why I’m doing it … not everyone is in a position to be able 
to do that … to express what they need and why … I think that’s 
really sad because again we’re discriminating against people who 
need the help as much as anyone else … So we are coming back to 
poor people being worse off which is depressing really because it’s 
all becoming like a two-tier system … it should be healthcare for all. 
That’s the premise of the NHS and it’s dividing people again.
We came across examples of these less successful fundraising cam-
paigns in our study, such as a page set up on behalf of a mother 
with brain cancer, seeking funds to cover four cycles of targeted 
therapy, which had raised £20 of a target of just under £7k. There 
are no updates on the site and we could not find any media coverage 
or Facebook sites about this patient.
Stacey, like other crowdfunders in our study such as Claire, 
managed this sense of frustration and guilt about relative privilege 
by supporting campaigns directed at increasing access to targeted 
drugs which are focused on challenging the pricing policies of 
pharmaceutical companies rather than the NHS: ‘It’s not the fault 
of the NHS that they can’t afford these drugs. They are being 
manipulated by drug companies.’
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Conclusion
Some patients faced with a cancer diagnosis are turning to private 
healthcare, advocacy and fundraising initiatives online in order to 
access targeted therapies. This creates new biosocialities in and 
through the digital economy. Younger patients with later stage 
diagnosis of particular cancers who might share a particular mutation 
come together to seek access to particular drugs to extend their 
futures by a matter of years, sharing experiences and advocating 
for improved care and access to therapies. As part of this, they share 
experiences of private and NHS care, sometimes revealing and at 
other times masking their status as a private patient, and in so doing 
manage a complex set of feelings of privilege and guilt. For some 
patients and their supporters (for example, relatives of deceased 
patients who might become advocates on their behalf) this involves 
the cultivation of new expertise, particularly in advocacy and 
negotiating NHS bureaucracy, and/or encouraging patients to be 
active as their own advocates and self-carers. Experimental treatments 
and molecular profiling in the UK are part of these stories, but so 
too are alternative therapies and clinics or trials abroad. The NHS 
is lauded and criticised (alongside pharmaceutical companies). These 
collectives and new kinds of experts are not ‘astroturfed’ patient-
groups (Largent et al. 2018), nor are they in the mould of traditional 
consumer-advocacy groups, but they operate at the intersections of 
public and private spheres and healthcare sectors.
Crowdfunding affords a particular kind of digital identity for 
cancer patients, marked by positivity, hope and intimacy around 
some of the details of their medical treatments and family lives. 
Successful fundraising involves cross-syndication, as fundraising 
efforts and stories need to be shared and liked on other platforms 
to intensify support. News media coverage in local papers and regional 
TV are also important in this kind of profile raising. Fundraising 
depends on capitalising on and extending patients’ existing cultural 
capital to project an investable identity in the so-called ‘like economy’ 
of digital media. The production of these identities, compulsory 
expressions of gratitude, and management of the funds raised 
nevertheless requires considerable hidden emotional and administrative 
labour that can add to the burden on patients managing treatments 
and family life. This work produces donations but it also produces 
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profit for the digital platforms that host these efforts, although this 
remains unacknowledged for the most part. Crowdfunding seems 
to be a popular option for patients who are already familiar with 
and engaged with cancer culture online, even before treatments are 
actually needed. Even after their death, crowdfunding patients remain 
as ‘data phantoms’ (Ebeling 2016) on some sites and pages, as 
exemplars for other patients who will inevitably follow in their 
footsteps. Through these practices we can see that cancer patients 
and their advocates are turning to the market for targeted therapies 
via the digital platforms of surveillance capitalism (Zuboff 2019) 
to craft a future for themselves in the face of a bleak prognosis and 
narrowing options on the NHS. An array of Facebook sites and 
groups, blogs, crowdfunding and other social media platforms support 
these future-crafting activities. An ‘elective affinity’ is thus forming 
between surveillance capitalism and expensive personalised cancer 
medicines in the molecular age.
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At the limits of participation
Throughout this book we have endeavoured to demonstrate the 
diversity, complexity and contingency of personalised cancer medicine 
in practice, focusing in particular on its meanings and implications 
for patients as they craft their individual and collective futures. We 
have encountered a range of ways in which personalised medicine 
does not meet the promise articulated in popular totemic versions 
of its transformative powers. We have also shown how its values 
and meanings multiply in practice, and the work that is involved 
in extracting or articulating this value by and for patients, even if 
it does not always result in effective treatments or cures. At the 
same time, we have explored how the value of personalised medicine 
endeavours, particularly larger-scale research initiatives, is linked 
to the future of the wider bioeconomy, focused on economic gain 
generated by providing better services for more patients. Across this 
landscape of value generation, patient participation is crucial – patients 
need to provide data, experiment with treatments and enact respon-
sibilities, to be engaged and remain active in maximising their own 
and others’ health. The development and mainstreaming of molecular 
diagnostics, monitoring and targeted treatments relies on patients 
to advocate, campaign, learn, test and tolerate tissue extraction and 
experimental approaches, for their own and others’ benefit.
Participation is, however, not guaranteed and cannot be taken 
for granted. Publics and patients do not always participate as the 
P4 agendas of predictive, personalised, preventative, participatory 
medicine envisage or promote. Sometimes tests or treatment options 
are not available despite patients’ or their relatives’ or clinicians’ 
efforts; at other times patients choose not to participate or are not 
invited to do so. Participation in research, tests or treatments can 
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also be irrelevant or experienced as unwelcome for some patients, 
particularly those who have fewer physical, economic and cultural 
resources or are otherwise alienated from medical and scientific 
institutions. Practitioners mediate participation too, sometimes 
being less likely to facilitate participation when they do not see 
advantages for patients or services more generally. In these contexts, 
participation can be framed or experienced as a burden rather than an 
opportunity.
As Michael (2012) discusses, ‘misbehaviours’ among representa-
tives, members of the public or research participants can encompass 
a range of ways of avoiding or declining participation, not all of 
which involve actively saying ‘no’. Ignoring, avoiding, prevaricating, 
querying, challenging, deflecting, reworking and subverting can also 
be part of avoiding or resisting participation, as can silent refusal. 
Non-participation can arise from a lack of opportunity, inclination 
or capacity, as much as an actual refusal. Participation can also be 
restricted or mediated in practice, purposely or sometimes without 
planning, for example when someone becomes upset or tired. In 
other situations, non-participation is more overt, shaped by a politics 
of what Benjamin calls ‘informed refusal’ by ‘those who attempt to 
resist technoscientific conscription’ (2016: 967). Developing Rapp’s 
work on ‘moral pioneers’ including ‘refusers and draft resisters’ 
who actively choose not to partake in tests in response to ‘a highly 
complex, highly structured social nexus within which they negotiate 
and exercise personal choice’ (Rapp 1998: 62), Benjamin asks us 
to consider how these acts of refusal offer a ‘necessary critique of 
the assumptions and excesses of forms of belonging that rest so 
heavily on biological claims’ (Benjamin 2016: 967).
This chimes with critical reflection in other STS and medical 
sociology research on public engagement with technoscience and 
biomedicine (see, for example, Horst and Irwin 2010; Degeling et 
al. 2015; Madden and Speed 2017). Michael’s (2012) work asks 
what we are ‘busy doing’ as social researchers in this field when the 
participants ‘misbehave’. Here, the parameters of engagement events 
are ‘over-spilled’ and in the process the constitution of identities, 
relevant agendas and technologies are troubled. Felt and Fochler 
(2010) have also argued that we need to attend to how participants 
‘resist’ the framing of participatory exercises, including how they 
reconstitute individual and collective identities and salient issues and 
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concerns. We take up these challenges to reflect on how participa-
tion was troubled through the process of our own research and 
engagement practices and in the genomic technologies and initiatives 
we studied. In this chapter we explore how non-participation and 
limited participation in interviews and observations unfolded over 
the course of our project as a means of critically interrogating the 
participatory impetus in personalised cancer medicine, offering this 
as a useful counterpoint to the stories of participation we have 
presented thus far, and extending our analysis of the threads of 
resistance we have identified.
We were inevitably limited in terms of the kinds of patients and 
other potential participants we were able to approach regarding 
our study because of research governance, including ethical approval 
to work in an NHS setting. There are well-known criticisms of the 
constraining effect of these arrangements on ethnographic research, 
but we will not rehearse these here (see Murphy and Dingwall 
2007). Instead we will reflect on the implications of the day-to-day 
and micro-instances of refusal, reworking and delimiting participation 
that we encountered over the course of the research, starting at the 
beginning of our work when we sought to ‘scope’ the field.
Scoping personalised cancer medicine
When we began our project and prior to obtaining NHS ethical 
approval to enter the clinic to talk to patients in real time, we 
conducted a series of ‘scoping’ interviews with former patients and 
their relatives, in an effort to understand their experiences of and 
perspectives on personalised cancer medicine. We also established 
two Public and Patient Involvement groups to guide our research 
design, recruitment, ethical practice and dissemination activities. 
These participants were not recruited through the NHS. Although 
we gained valuable insights into the different meanings and challenges 
of personalised cancer medicine for patients through these activities, 
which guided our analytical approach in the research that followed, 
the participants who were most easily involved were typically white, 
middle-class and female.
Using snowballing and other recruitment strategies that relied on 
professional gatekeepers, patient advocates, charities and social media 
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networks to recruit participants and representatives for our Public 
and Patient Involvement (PPI) panels captured a particular set of 
experiences and perspectives from patients, former patients and 
family members, who were often actively involved in efforts to 
control and manage their condition, be positive and contribute to 
research and treatment improvement – unlike other kinds of patients 
who were too unwell or alienated or otherwise disengaged from 
research and clinic care. Some of those who participated in our 
early scoping interviews or contributed to our PPI were nevertheless 
aware of their privilege, and made efforts to be reflective and to 
advocate for equality in the course of their encounters with our 
project. For example, some of the former patients we interviewed 
were involved in advocating for genomic medicine across various 
platforms, including in evidence groups in Europe, and as part of 
this they reflected on the (un)equal distribution of genomic medicine 
worldwide. One patient advocate, Toni, reflected on the extent to 
which this has the potential to exacerbate already existing health 
and social inequalities:
So we haven’t actually looked at personalised medicine, precision 
medicine, whichever you want to call it, nearly as much as what we’d 
like to. But, of course, it is going to be an issue. And part of the 
reason has also been that, in most countries with the highest level of 
deprivation, not only have they never heard of precision medicine or 
personalised medicine but they’ve absolutely no chance of having any 
access to it anyway … one of the problems of precision medicine is 
it’s got everything going for it in terms of making the gap even greater 
between the richer and the poorer countries because these drugs, by 
definition, are much more expensive but they have a huge difference 
in their, of their potential impact. I mean, the instances of melanomas, 
for instance, has completely changed because of precision medicines 
and so, and gene therapy and so on, and, and all of the areas where 
there’s absolutely no, no access to these things is the, in the low 
income countries.
So … we reckon that precision medicines will actually make things 
worse, not better, when it comes to access. And, of course, what will 
also happen is, is that it will, it will make it much more difficult for 
people to even get the, what we would consider the very simplistic 
treatments because the emphasis will have shifted over towards the 
much more effective treatments.
…
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They’re very uncomfortable when I speak because most of the time 
it’s all rampant, gung-ho, you know, isn’t it fantastic type of thing, 
how are we going to get everybody … onto these medicines and so 
on, and then along comes [someone] and messes the whole thing up 
in talking about the inequalities that are going to increase because 
of it.
In elaborating concerns about the (re)production and exacerbation 
of inequalities in access to healthcare worldwide and the implementa-
tion of genomic medicine, Toni challenged dominant tropes of promise 
and precision, drawing attention to what Hall et al. have argued is 
‘the transition from industrial to financial capitalism in Europe’ 
which has effected ‘deepening inequalities of income, health and 
life chances within and between countries’ (2014: 9).
Another patient advocate, Adele, who had survived melanoma 
and secondary lung cancer, noted that an important part of her role 
was to ensure that inequities were also attended to in terms of cancer 
types, with patients who suffered from rarer cancers often neglected 
by pharmaceutical companies and researchers:
There’s so many [cancer types] out there yeah, especially for example 
in ovarian cancer, high grade serous ovarian cancer is the most common, 
that’s about 70%, but you’ve got low grade serous, you’ve got 
endometrioid ovarian cancer, now you’ve only got a small number 
of people but those are the folks who suffer cause there maybe aren’t 
as many studies, because often clinicians will target the sub-types 
with the highest number. So part of my job as a patient is to say ‘no, 
no, no, no we’ve got to make sure everybody is included, and it might 
be a smaller number of patients therefore the pharma companies 
might not be as interested but you’ve got to include them’, so that 
was part of my battle the other day at a meeting saying ‘no you’ve 
got to include these people’ … Cause that was raised, ‘why don’t we 
just target the high grade?’ ‘No, what about those…?’ … they could 
overhear this conversation and think ‘we’re just being dismissed’.
However, the capacity to challenge and tackle inequality from a 
position of privilege risks further entrenching privileged voices, as 
with professionals advocating on behalf of patients (including social 
researchers). We can capture this by contrasting the account above 
with those of other participants in this early phase of our project, 
who told us how difficult it was to become involved in this kind of 
advocacy or support work. We met Karin through a local lung 
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cancer support group. After an unexpected cancer diagnosis, only 
months after she had quit smoking, Karin started to volunteer at a 
cancer charity and then developed her role as more of a campaigner 
on cancer awareness and prevention. However, she found it difficult 
to attend meetings as she had to rely on public transport. Karin 
shared her experience of attending a medical conference to which 
patient advocates and representatives were invited:
I’ve been to an odd one or two, [lung cancer patient meetings] and 
… to be quite honest, I don’t know what they called it now. It was 
a little bit too sort of medical-wise for us. And we went with the 
impression that, you know, we’ve had cancer, can we put our point 
forward, and it, we never got to that stage … I can’t really explain 
it. It was a little bit too technical, and all the groups that were there, 
they were groups, they weren’t odd individuals like [lung cancer patient] 
and myself. So we felt a little bit out of place on that.
… But the point is, the trouble is with that, doing these sort of 
meetings and conferences and what have you, it’s the travelling for 
me, getting to somewhere.
They’ll say, oh there’s a meeting at ten o’clock at [city in Yorkshire]. 
Now it’s virtually impossible for me to get there that early. I know 
it isn’t early in normal terms, but it is, to set off, I’m talking like 
seven o’clock in a morning to get a decent bus to get there, which 
you know, so it does put you off a little bit sometimes…
In addition to the structural barriers to participation and a feeling 
of being ‘out of place’ at meetings with professionals, participants 
also told us that online support groups were not always places 
where they felt and experienced support because the issues being 
discussed were not relevant to their day-to-day struggles. For example, 
John, who had experienced pancreatic cancer, told us that ‘dealing 
with money’ was much more difficult than the issues typically 
discussed in his support group, leading on to a long passage of 
reflection on these difficulties:
dealing with money, that’s one of the hardest things, benefits, 
nightmare.
… I stopped work … for the last three years I’ve done about four 
months work maybe. Yes, I got sick pay, but that runs out … after 
twenty-four weeks … or … twenty-eight weeks, something like that 
… The forms they send you are ridiculous … the employment support 
allowance, sixty pages. I’m not joking sixty pages, and they, and they 
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want you to go back further … than the tax people would go back. 
First mortgage and remortgage and all that. It’s ridiculous.
They turned me down, turned me down … because … I hadn’t 
earned enough national insurance in the last year. How could I if I 
wasn’t working? Absolutely, it’s like a kick in the teeth. It didn’t make 
sense. How can they turn you down for something you can’t – you’re 
not in control of? … I get PIP, so, so that’s separate from the accounts, 
for the moment they can’t do anything about that.
The day-to-day struggles of living with cancer, which included 
managing money and employment, and even the act of travelling 
to support groups, were readily discussed in interviews. Two pan-
creatic patients who were taking part in a world-leading trial involving 
genomic sequencing and novel combination therapies discussed the 
seemingly mundane issue of finding a parking space prior to their 
weekly clinic appointment in their interviews. One of these patients 
described the effort she made to arrive at the hospital early, to avoid 
the additional fees entailed in parking at a nearby hotel. This then 
impacted on research nurses’ work patterns, as they continuously 
adapted to accommodate those patients who were arriving earlier 
than their scheduled appointments. Through these kinds of accounts, 
we come to see that genomics and personalised medicine research 
depend upon patients devoting time as well as financial resources 
to their participation.
The structural and cultural limitations placed on participation in 
cancer support and patient engagement were further underscored 
by the difficulties of discussing genomics and personalised cancer 
medicine across these earlier interviews. Participants could have 
very little to say about this area of medicine, not just because they 
did not think they had experienced it directly, but also because it 
was difficult to make sense of. Many expressed concerns that they 
were not sufficiently knowledgeable to have a view worth recording, 
or that it was simply not part of their ‘zones of relevance’ (Parsons 
and Atkinson 1992). These interviews were typically detailed personal 
stories of cancer journeys and anticipated futures, and genomics 
did not tend to figure for many patients. Sometimes when it was 
raised by the interviewer we found interviewees reworking the 
question to deliver information and perspectives of more relevance 
to them. For example, in one interview with Jane, a former breast 
cancer patient introduced in Chapter 1, who spoke about all of the 
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research she had done as a patient, the following exchange took 
place:
in a brutal way that is what they do, they cut you, they burn you 
and they poison you, in that sense, but it’s got this nice friendly, you 
know, language around it.
This whole development in cancer research and treatment promised 
that we will do less of that by doing, by applying … genomic knowl-
edge. So, did you have chance to kind of read up that aspect of new 
developments in cancer treatment …
Well sort of, but the, I mean the genomic knowledge is, for example 
… I got eight out of eight for oestrogen and they tell you that, and 
then you go, ‘hurray, I’ve got full marks’, but you don’t know what 
you’ve got full marks for, and it’s, it reacts to oestrogen, and so 
therefore they can give you tamoxifen so it sounds like, you know, 
my personal cancer reacts to oestrogen and I, and I thought that’s 
interesting, but that, I mean that’s what tamoxifen’s for, is to, you 
know, replace, or to stop the oestrogen being, being taken up. They 
also told me that I got eight out of eight for, what the other one 
beginning with P, progesterone, and I did ask, because I’d read a book 
by an American … about … dealing with the progesterone sorry, and 
they, they weren’t interested in that at all. [But] when I said, so why 
do you test progesterone then, and they, they were sort of a bit [pause] 
they didn’t really, I don’t know, they didn’t really, they didn’t give 
me an answer … I was particularly interested because this guy was 
… tracing all sorts of things … because I’ve had a lot of miscarriages 
and … progesterone seemed to be, according to him, I mean he [was] 
quite a serious doctor, but he, he didn’t agree with the standard ways 
of treating cancer; and I thought, well that’s interesting, because I’ve 
had that … but they didn’t, they sort of didn’t want to know…
In this account Jane worked the question about genomics into an 
account of her cancer subtype to make salient the story of her own 
research, and her difficulties with getting the treating clinicians to 
engage with her personal story and concerns about why she had 
developed this kind of cancer, focusing on the journey travelled 
rather than the future we asked her to speculate about.
Former patients agreed to be interviewed for a range of reasons, 
but a common theme was their desire to ‘give something back’ to 
the health service or other patients by helping with our research – 
anticipating a beneficial future. This reciprocity is, of course, key 
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to participation in health and social research, and is actively encour-
aged in a lot of clinical research (although we were much more 
uncomfortable with being cast in this light, given that our research 
will not directly inform or improve clinical practice). In our study 
it also provided an occasion for participants to perform gratitude 
and responsible patienthood, crafting their own patient narrative 
as a process of recovery and reaffirmation after their cancer experi-
ences. Questions about genomics could therefore become a kind of 
prop for the articulation of their own subjectivities, desires and 
priorities, as in the following excerpt from an interview with Carol, 
who had gone through two different cancers, malignant melanoma 
and breast cancer, one after another:
Have you heard about the 100,000 Genomes Project? What do you 
think the benefits and/or challenges might be of being involved in 
these kinds of studies from your experience of having cancer?
Well I think benefits obviously if people can be better informed that’s 
great … the only problem with knowing is I think if you’re more 
susceptible to cancer is you’ve got to live with that you know and 
it’s how you cope with that really … day-to-day … some people are 
very frightened of cancer and … if they found out that they were 
more genetically susceptible then … it could rule their life. It’s all 
about mind-set for me cancer is all about mind-set.
Can you elaborate on that a bit more?
Yeah because … I’ve trained as a hypnotherapist as well … I understand 
the importance of the power of the mind and I do think that … if 
you’re terminally ill … you’re not gonna be able to change things 
around but I think the quality of life that you have is determined by 
your mind-set and trying to stay as positive as possible for as long 
as you can.
This illustrates how participation was an active process, where the 
meaning of participation was reworked, including via subtle forms of 
non-engagement with the details of particular questions. This could 
include occasions when invitations to speculate about the future were 
reframed, in some cases to articulate more familiar and productive 
narratives demonstrating responsible and active patienthood.
Former patients and their relatives could also critically reflect on 
care received and the limited place of genomics as part of the wider 
future of cancer research and care. As we have said, this included 
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situations where genomics was rarely touched upon. It also included 
participants ‘talking back to science’ by reflecting on particular 
barriers or challenges associated with accessing healthcare in the 
NHS that were marked by race, class and gender. One woman, 
Mina, who had lost her mother to cancer, told us about her uneven 
experience of care. Her mother, who she told us was a successful 
and independent woman and a manager in her workplace, spoke 
very little English, and so healthcare encounters did not always 
involve the kind of care the family expected:
They [Macmillan nurses] didn’t give any help because they couldn’t 
speak the language. So there were no Asian nurses. So I thought hang 
on, in a place like [this] … are you telling me that there’s no Asian 
nurse who can actually speak to my mum?
Although elsewhere this participant praised the NHS and the care 
her mother received, her experience of not being ‘fully part’ of the 
care infrastructures around cancer were reflected in her account of 
research participation as not being something she would herself 
consider:
I just hope they find a cure, full stop. Seriously I just hope they find 
a cure for it, sooner rather than later.
That’s it really … that’s the only thing I can say is just a cure isn’t 
it? … I think they did what they could have done … they did provide 
support. Yes, we didn’t take it … for our own personal reasons … 
let’s say, if someone like myself went through it, I’d probably deal 
with it differently … I’d probably take the support. I’d probably take 
the things … try things out because I would know what’s happening 
rather than not happening, and I would probably take an active 
interest in what’s happening. So I think, um, information is very 
important.
Do … you … try to take part in … any way possible?
No, no, actually no, no, I … donate a bit here and there … there’s 
studies that are going on, but they’ve not yet cracked it yet, so I 
would have said –
… so you – you want to wait for the right moment?
Yeah … I’m waiting for the right moment … Once they’ve cracked 
it, yes … I’ll be very interested then. At the moment, yes, ‘we’re 
researching on this’ … yeah, fine, alright, just get it. Just do it … 
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there’s nothing I can do. I’m not a scientist. I can’t help them with 
that. They need to … find a cure. They’ve been at it for ages … I 
don’t take any active interest in it…
This passage shows how the participant connected her experiences 
and capacity to take up care with active interest in information, in 
contrast to her mother, but did not go so far as to see this as invoking 
a reciprocal responsibility on her part to research, which was framed 
as something for scientists to ‘get on with’.
Another woman, Saira, also spoke about the burden of caring 
for her mother, including giving up full-time work to look after her 
and attend appointments. When asked to reflect on the inclusion 
of patients in healthcare initiatives and genomic medicine, her account 
captures the institutionalised disconnection between ‘science’ and 
older black and ethnic minority cancer patients through a focus on 
language barriers:
… nowadays more patients take part in not just trials as a trial 
participant but also take part in sort of designing research or how 
funding should be allocated and that sort of thing…
Very difficult for black and ethnic minorities because my mum was 
– her first language wasn’t English so she – she didn’t even like attending 
appointments … Sometimes they’re not in the right frame of mind 
to know what happened in – what sort of tests she had 5 years ago. 
I kept a track. In fact it was almost like a full-time job …That’s a 
very big barrier for somebody who, firstly for somebody whose first 
language isn’t English.
So I was acting as an interpreter for her at all times. So she refused 
to go to an appointment even with another family member because she 
felt they didn’t have all of the background information and she didn’t 
remember any of it, and – and again, English was a barrier for her.
So getting black and ethnic minorities on board is even harder 
because they don’t see how, if they don’t speak directly – and if you’re 
not a direct participant and you’re going through somebody else 
who’s interpreting, it’s not the same as having that direct contact 
sometimes. And I think it’s really hard getting them on board.
Later in the interview Saira stressed the importance of communicating 
directly with BAME communities via spaces such as mosques in 
order to build relationships as a step towards improving inclusion 
and engagement; a means of co-production.
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As Grace, a cancer charity representative, explained, building 
relationships was particularly important, given that interactions 
between the black community and health professionals were shaped 
by ‘historically grounded’ distrust over incidents such as the Tuskegee 
experiment.1 She reflected that this has contributed to an under-
representation of black and minority ethnic individuals in clinical 
trials, an issue which was also raised by Zoe, introduced in Chapter 
2. This brought other kinds of additional work to some patients 
from ethnic minorities in engaging with the science. For example, 
when researching the Oncotype DX test, Zoe, a health professional, 
questioned whether she could ‘rely’ on the US-based TAILORx trial 
because of its study population, and thus looked to research originat-
ing in other continents for additional insight:
There’s a Japanese paper I looked at, because, you know, genes can 
be different, because all the study has been done on the Western 
population. You know, the Sparano [TAILORx] study, the whole 
Oncotype DX. So what’s the relevance in a non-Western population? 
So a Japanese study has looked at it and … they’ve said there’s no 
difference. So I said, I’m not Japanese, I’m not Western, I’m like, 
somewhere in the middle, I suppose, and it doesn’t matter (laughs). 
Yeah, so it, it’s genes, it’s human genes, and, um, I suppose, ethnicity 
doesn’t come into that, is how I looked at it.
Zoe’s treatment decisions entailed an added layer of complexity as 
she reflected on the origin of study results and their applicability to 
her situation, issues not faced by the majority of our research 
participants.
Together, these examples of critical reflection about structural and 
cultural barriers to participation in cancer research and support, 
as well as instances where discussions were repurposed away from 
genomics to something more meaningful for participants, demonstrate 
the structural, ongoing ways in which certain voices and experiences 
are excluded from participation in social and genomic research. 
This highlights some of the reasons for the absence of less privi-
leged patients and advocates from our research and from precision 
medicine more generally, pressing us to think more critically about 
the limits on participation in our study, as we now go on to discuss 
further.
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Accessing personalised medicine participants
When we were negotiating access and recruitment of patients in 
the clinic, we encountered further complex dynamics of non- and 
reworked participation in our own research and the genomic tech-
nologies and research that we explored as potential or actual case 
studies. We were already constrained in the project design when 
we were only granted ethical approval to study specific genomic 
interventions in cancer clinics and to approach people who were 
interested in or had actually participated in genomic tests, treatments 
and research in order to prevent an undue burden being placed on 
those who had declined. This limited our capacity to understand 
why patients do not participate and further skewed our sample 
to patients with the resources to participate. This inevitably also 
resulted in our research only engaging with those patients in better 
health, as a common reason for non-participation, despite initial 
interest and even consent to contribute to genomic research, was 
that the patient was too ill to participate or passed away while we 
were recruiting for our research. Such constraints also led to a focus 
on particular kinds of cancers and not others. Although we tried to 
avoid concentrating on well-resourced and well-researched cancers 
such as breast cancer, this was the most appropriate area in which to 
study genomic profiling in mainstream practice, given its maturity in 
this patient population. We also focused on gynaecological cancers 
and lung cancers as less resourced and researched cancers, but this 
also skewed our sample towards a predominantly female population, 
given the focus on women’s cancers and the difficulties we faced 
in accessing lung cancer patients who were very sick. This limited 
our insights into how men manage cancer and incorporate their 
understandings of genomic medicine and research therein (Wenger 
and Oliffe 2014). Our study of the 100,000 Genomes Project allowed 
us to focus on a range of other cancers too, but the dynamics 
of research interest and investment across different cancer types 
meant we tended not to access many patients with rarer forms of 
cancer.
Participation was further restricted through the recruitment process, 
as we relied upon gatekeepers to facilitate the projects. Clinicians’ 
ambivalence about the meaning of genomics and personalised cancer 
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medicine was a striking and somewhat unexpected feature of these 
arrangements. After working with a group of supportive clinicians 
and scientists to obtain ethical approval for ethnographic research 
in hospitals, we focused on particular case studies of personalised 
cancer medicine involving genomics. We approached a range of 
oncologists and pathologists working across cancer clinics and 
laboratories to develop our cases, but quickly learned that the focus 
of our study had little resonance or meaning for some of those we 
spoke with, to the extent that it was often difficult or impossible 
to organise their participation in the research or a role as a gatekeeper 
to other participants. One particular breast cancer consultant who 
helped in the early stages of our project development expressed 
some of this in an interview, where he was notably sceptical about 
personalised cancer medicine with a focus on genomic tests, treatments 
and research:
I’ve been through … a number of different fashions … and also 
because in breast cancer we’ve had access to many of what I’ve seen 
as the potential roles of genomics in the future, we’ve actually been 
using this sort of information for many years. Now, the current 
obsession … around … the role of genetics and mutations changing 
life completely. As a breast cancer doctor … we are lucky in having 
the two most important targeted, groups of targeted therapies in 
cancer by a million miles, tamoxifen and Herceptin.
Tamoxifen, you do not test for genetic mutations; you check for 
expression. With Trastuzumab Herceptin, you do not test for mutations; 
you test for expression. So that puts me at the start … as being in a 
sceptical position about the role of genetic mutations because the two 
most effective genetically based treatments are actually based upon 
expression, not mutation.
Clinicians’ active non-participation in the promissory, transformative 
visions of genomics meant that accessing patients, tests and technolo-
gies to study could be difficult, as they were seen as insufficiently 
novel to be worthy of our (and clinicians’ attention). Beyond a fairly 
small group of pioneers and enthusiasts for genomic research medicine 
in cancer who were keen to support our work, there were other 
clinicians who were much more sceptical about the value of genomics 
and research into its implications.
Other clinicians were reticent or frustrated in their efforts to 
participate or facilitate patient participation in genomic medicine 
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and our study because of a range of factors. This could arise because 
the study or trial we wanted to follow was not yet recruiting or 
because there were concerns about the lack of progress in the initia-
tives we wanted to explore, for example when not many patients 
were being recruited and the trial or study was seen as precarious 
and in danger of failure (as discussed in Chapter 4). At other times, 
concerns about the burden of participation on patients or staff 
meant that we were not able to observe or approach patients for 
interviews – their situation was too difficult to warrant such an 
intrusion. These considerations were heavily shaped by the perspective 
of research nurses who acted as principal gatekeepers, but also our 
own sense of what would be intrusive, based on our research and 
personal experiences. As a team we constantly reviewed our ethical 
approaches, but also reflected on our ‘personal ethics’, which similarly 
regulated the participants we (re)approached. For example, in our 
work with pancreatic cancer, associated with poorer survival outcomes 
than many other cancers, of four patients being followed up in a 
particular study arm we were hoping to observe, two participated 
in our study. In one case, after the researcher approached the patient 
for interview in line with ethical approval, the research nurse disclosed 
that the patient had not received the scan results she had hoped for. 
At this stage, having gained the patient’s contact details, follow-up 
became solely at the discretion of the researcher. In this, as in other 
instances, researchers became their own ethical gatekeepers; reflecting 
on how many times to make contact, what this contact might be, 
and when to stop. In this case, due to the sensitivity of the patient’s 
situation, only one (unsuccessful) attempt at contact was made. This 
patient’s experiences of pancreatic cancer trial participation, which 
are seldom recorded in social research, were therefore not included 
in our study. Such decisions surrounding recruitment were personal 
and contextual due to the rapidly changing nature of individual 
patients’ health status and circumstances.
At other times participation was not possible because clinics were 
busy, appointments were missed or clinicians were too preoccupied 
with other, more urgent issues. We were advised to avoid relying 
on consultants as gatekeepers, limiting their participation and 
intensifying that of nurses, as in the fieldnote below: ‘The consultant 
explained that it may be best to approach patients at the point of 
consent and to leave consultants out of the situation, “take the 
226 Personalised cancer medicine
consultants out of the equation because we forget”.’ This capacity 
to forget also extended to recruitment for the studies we sought to 
follow, as captured in the fieldnote below:
Due to observe two patients – pre-assessment appointments at 11.20am 
and clinic at 2.30pm. On the morning of 05/06/17, I received an 
email from one of the research nurses to inform me that they would 
ring me once the patient had finished pre-assessment to let me know 
when to make my way to the clinic (the research nurses see the patient 
for 100,000 Genomes Project after the pre-assessment checks – up 
to 1.5 hours after their appointment time). Unfortunately, the research 
nurse phoned at 12.30pm to inform me that the clinician in pre-
assessment had failed to contact the research nurse and the patient 
had been sent home. The nurse was frustrated at the miscommunication 
as they’re unsure when they can next approach the patient – may 
have to be on the day of surgery. The nurse also informed me that I 
couldn’t observe the 2.30pm patient – disease has metastasised. The 
nurse was very apologetic and agreed to inform me of any other 
patients booked in that week.
Sometimes clinicians’ inattention or lack of facilitation was a more 
active refusal, albeit from a position of privilege, as in this excerpt:
As we were all standing around in the corridor the research nurse 
explained that they often ‘stand around on one leg’ between appoint-
ments in case they miss the patient. Each week [clinical trials assistant] 
double checks with each consultant whether she can recruit the patients 
she’s identified as being suitable for SMP2. She checks with [consultant 
oncologist 5] who seems reluctant to discuss ‘I thought the Matrix 
had finished’ ‘it’s not you again’.
These excerpts capture the emotional and articulation work of 
practitioners involved in recruiting participants to our study. It shows 
clinicians acting to protect patients and prioritise current care over 
research which might bring benefits in the future, the ‘waiting around’ 
involved, and the missed opportunities for recruitment, as well as 
the complexities of dealing with busy clinicians and very sick patients. 
Genomic research in this context was not standardised or routinised 
in the clinic, nor was it special enough to warrant practitioners’ 
strong investment in studies of its effects or potential, constituting 
another requirement in a long list of considerations for practitioners 
to negotiate backstage and at times frontstage with patients. We 
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experienced similar tensions around observations in some laboratories 
that were under pressure in terms of workload and resources, 
particularly histopathology, where there was a sense that genomic 
testing was adding additional work without additional support, that 
its promise was overblown and exaggerated, and that our presence 
would have taken up too much time.
The make-up of clinical teams we worked with reflected gendered 
hierarchies in medicine: the majority of consultants were men 
(although the breast cancer team had a high number of female 
consultants in comparison to lung cancer, which had only two female 
consultants in the team) and the majority of nurses and clinical 
trials assistants who were involved in recruiting patients and caring 
for patients on trial were women. This stratification of medical 
work by gender accords with a long history of social science literature 
which demonstrates the feminisation of care work (Tronto 1993; 
see also Allen 2014; Allen and Hughes 2017). This work was intensi-
fied as nurses were called upon to act as gatekeepers and to aid 
with the recruitment to our study, given that consultants were often 
too time-pressured and tended to ‘forget’.
Nurses took on much of the responsibility for the facilitation of 
our study in these challenging situations – crafting participation 
involved careful and intense articulation and emotional work across 
an ever-changing array of situations. This involved managing other 
clinicians’ refusals and deflections, juggling staff shortages, training 
and workloads, but it also involved managing discomfort and a 
sense of concern about participation exposing deficiencies in the 
nurses’ competencies or practice, as we noted in Chapter 5. Although 
we worked hard to avoid this and to limit the burdens created by 
our presence, we intensified and at times unsettled their work. This 
can be illustrated through our experiences of being told that nurses 
or clinical trials assistants were concerned about their level of 
knowledge about genomics and their capacity to participate in our 
research and enable the participation of patients in research more 
generally. For example, in one observation session, as we made our 
way to the clinic, the researcher asked the clinical trials assistant 
about observing other consent meetings for the 100,000 Genomes 
Project, and noted: ‘she seemed quite reluctant to discuss this despite 
agreeing – changed the subject and exclaimed “you can watch me 
make a mess of the consent process and judge how I do it, yes!”’ 
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Towards the end of the session the clinical trials assistant joked 
again about being observed:
Whilst waiting around in the corridor [clinical trials assistant] turned 
to me and said, ‘I bet I find out you’re secretly judging how I consent 
(writing things down in your little book) – that actually you’re a 
journalist (laughs)’ – I tried to reassure her this definitely wasn’t the 
case!
Here the clinical trials assistant expresses discomfort about the quality 
and implications of her participation and seeks reassurance from 
the researcher, further demonstrating a limit on participation we 
encountered across our research with practitioners and patients, but 
also troubling the identity of the researcher and challenging us to 
acknowledge the burdens we generate when we ask clinicians to 
facilitate our research.
As we have already noted, some cancers get more attention and 
resources than others, and some patients with particular kinds of 
cancers are more readily involved in genomic medicine than others 
as different kinds of privilege play out across research and clinical 
care. Patients, such as the advocate quoted at the beginning of the 
chapter, and clinicians can be acutely aware of these inequalities. 
A lack of privilege can be experienced as unwelcome forms of non-
participation or exclusion from the promise and investment of genomic 
medicine. We have already explored some of this in the accounts 
of clinicians concerning patients feeling left behind or excluded from 
the possible benefits of personalised cancer medicine. Patients also 
discussed this, as in the extract below from an interview with a lung 
cancer patient, Hilary, and her daughter, Rose:
[Rose] lung cancer’s not as publicised as breast or…
[Hilary] No, I don’t believe, no.
[Rose] …prostate…
[Hilary] Prostate.
[Rose] …even though it kills more people.
Yeah. What do you think about that? Why do you think that might 
be?
[Hilary] Because of…
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[Rose] Because of the stigma with smoking.
[Hilary] … the stigma of smoking. If I, if I got lung cancer, I’m letting 
everyone know that I’ve never been a smoker. If I got it, they’d be 
all sympathetic…
[Rose] Because she’s not a smoker … cos I’m not a smoker. So how’ve 
you got it? How’ve you got it?
[Hilary] It’s like … before I got cancer, if I heard somebody who had 
liver cancer…
[Rose] You’d think they were a drunk.
[Hilary] … you automatically think of alcohol. Because, because we’re 
not au fait yet on the environment, I don’t think we’re fully, fully 
aware of how the environment affects cancer, you know. Not just air 
pollution … Stress, your working conditions, your living conditions 
… they take that into account when it’s your heart disease but they 
don’t, I think, with cancers. There, there’s a lot of environmental 
factors, not just what you’ve done to your body, ’cos as I say, people 
die of lung cancer who’ve never been a smoker or had any family 
members smoke…
[Rose] I mean, I work in [town] and there were a young lass over 
there who’s actually taken a nurse to court because she was nineteen 
and she got diagnosed with lung cancer and the nurse turned round 
to her and said, ‘Well, how many do you smoke, then?’
Gosh.
[Rose] And she’d never –
[Hilary] It’s just an assumption.
[Rose] And it is just the stigma.
As well as discussing stigma and their sense of blame (see also 
Chapple et al. 2004), these interviewees implicitly criticised the 
focus on molecular rather than environmental factors in cancer, and 
highlighted the ways in which care providers as well as friends and 
family can make patients feel culpable and unworthy of support as 
they participate in care.
Accessing the experiences of working-class patients for whom 
cancers such as lung cancer were more prevalent was difficult given 
the extremely low survival rates of these patients. Although our sample 
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consists predominantly of middle-class voices, there were numerous 
instances during interviews where concerns around inequality were 
raised or discussed, particularly in relation to patients having to seek 
financial assistance (particularly those in precarious work), lone 
parents, or people who had not gone through higher education. In 
one interview with Janet, a patient involved in the SMP2/Matrix 
study we followed, who we introduced in Chapter 4, these barriers 
to participation in support, care and research were starkly illustrated:
you can go up to the [name of support centre] up the way, but they 
do it at silly times and ’cause I work, I … can’t get to one, even if I 
wanted to … it’s like me going to work and saying to my supervisor, 
‘Oh, I’m not coming in tomorrow ’cause I’m off blah, blah, blah.’ I 
mean, she’d [have] hissy fits! I’ve got to come for treatment and see 
doctors [and she asks] ‘Are you coming in?’ Well, no. I mean, at first, 
I went, ‘Oh yeah, no I’ll be in,’ and I thought why am I doing this 
to myself? You know, why am I sort of like getting down here, getting 
everything done and then running to get back to work? … I did work 
full days for a long time and then I can’t remember which one of the 
treatments it was [it] didn’t make me feel poorly but come the end 
of the week, I was just knackered; and I kept thinking, why am I 
doing this to myself. And I went in and I had three months off work 
’cause I went down to the doctors, ‘Can I have a sick note for a 
week?’ and he sort of looked at things and he went, ‘A week?’ and 
I went, ‘Yeah,’ and he went, ‘Why, what for?’ I said, ‘’cause I’m – I 
said I’m so tired, come Friday.’ I used to get home from work, have 
a coffee, maybe have something to eat and next thing I knew, it would 
be like Monday morning and I’d be thinking, where’s the weekend 
gone? … so I went down to the doctors and said, ‘Can I have a week 
off?’ and he gave me like a month, and he said, ‘Come back at the 
end of this.’ And I went back and he went, ‘Another one?’ I went … 
‘No I want to go back again.’ ‘Take another month.’ Then I took 
another month and when I went back then, I said, ‘I don’t want no 
more – don’t give me no more, no more,’ I said, ‘I need to go back 
to work.’ I was so bored at home … I think I actually needed that 
time off because when I went back, I thought I feel even better now.
Later, discussing her involvement in research, Janet expressed gratitude 
to medical science and willingness to ‘be a guinea pig’:
I do take my hat off to all these … when they get all these samples 
in and they sit there and … whatever you do … That is just amazing.
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I wouldn’t be able to stop with everything (both laugh). You know, 
we need a guinea pig, [name of participant] l’ll do it … I will try 
anything … they’d have to be … really honest with me … because 
the thought of them sort of thinking give her that, and then they’re 
knowing when they’re giving me it, then it’s not going to [help]. That’s 
the only bit what does scare me. Like if they said to me well we’ve 
got this, [name of participant] and we know for a fact it’s going to 
do something. We’re not 100 per cent sure what it’s going to [do] 
– but we know it’s not going to make it grow, and we know it’s not 
going to make it spread, I’d go, ‘Come on then, let’s do it. When are 
we starting it? Are we doing it today? Well go and do it now.’
Yeah, because I’ve got to put my trust in the people [who] make 
that drug and I’ve got to put my trust in this place, and that, to me, 
that’s a big thing … putting your trust in somebody.
These excerpts illustrate the tension in participation for patients 
from underprivileged backgrounds negotiating stigma and a lack of 
the time and resources required to receive care, let alone participate 
in research, including something as basic as getting sick leave. At 
the same time they signal an enduring commitment to support 
research, to trust in institutions and companies and a willingness 
to be experimental subjects as a gamble on becoming well again.
Our study design, like that of the genomic technologies, research 
and trials we sought to follow and understand, relied on patients 
participating. But as we have discussed, this was hampered and 
reconfigured by the contexts in which we approached patients and 
the ways in which those discussions were repurposed by interviewees, 
for example to perform particular versions of good patienthood or 
experience therapeutic benefit. We also encountered numerous situ-
ations where patients were not able or willing to participate in our 
research either in general or throughout the course of interviews/
observations, especially when we asked more specifically about 
genomics. Sometimes these forms of non- or reworked participation 
appeared planned or deliberate, but at other times they were more 
difficult or unexpected for patients, for example when they became 
very emotional or confused during an interview.
As we have already discussed, practitioners protected vulnerable 
patients from participation in our research and some of the research, 
trials, tests or treatments we were studying. This process of limiting 
participation was crucial to the ethical conduct of the research: the 
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emotional work of the nurses involved can be seen in the following 
excerpt:
I arrived at the nurses’ office … at approximately 2pm for the appoint-
ment at 2.20pm. We discussed the issue of consent and the nurse 
expressed her concern that the patient is very young and will be 
coming to the appointment concerned and anxious about diagnosis 
(too young to come through the bowel cancer screening programme). 
The nurse wasn’t sure whether it would be appropriate for me to 
observe and to approach patients about participating at this stage of 
the pathway – better to observe pre-assessment clinics or those patients 
who have come through the screening programme. We walked over 
to the out-patient clinic building … and made our way to the consult-
ant’s room. The nurse felt it was important that we checked with the 
consultant prior to the appointment about whether it would be 
appropriate for me to observe. I had spoken in the MDT meeting 
that morning and the consultant was in attendance – happy for me 
to observe.
Sat in a side room away from the consultation room with the nurse 
– trolley filled with patients’ notes – next to the waiting room. Clinics 
were running behind and the nurse kept having to check whether the 
patient had been called to the consultant’s room. The nurse said they 
often did a lot of waiting around…
The nurse is called into the consultant’s office and I wait for 
approximately 30 minutes. The nurse decided not to call me into the 
appointment to observe as the patient had been given a diagnosis and 
was very emotional.
I left the clinic at approximately 3.30pm and discussed with the 
nurse about our pathway for observation. She felt like she’d wasted 
my time but I stressed that it’s important for us to attend clinic where 
they might be consenting patients regardless of whether they decide 
that it’s not appropriate for us to observe.
Here the nurse facilitates non-participation in our research because 
of concerns about the health of the patient and the burden of being 
observed while being given a distressing diagnosis.
We can also see the complex work involved in the process of 
mediating participation in the following fieldnote:
I met with the research nurse in their office … at 1pm – discussed issue 
of consent and the pathway for the … trial. We discussed the hopes 
and expectations attached to the SMP2 ‘don’t even mention Matrix’ 
because of the high failure rate … [leads to] difficult conversations 
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with patients – feeling amongst patients that clinicians hold on to 
their results unnecessarily and question why it takes so long to see  
results…
First patient appointment at 1.20pm –
Sat and chatted with the two other research nurses about the possibility 
of observing patients through the SMP2 pathway – said this would 
be difficult as the percentage of people referred to Matrix is extremely 
low. She did however mention another biomarker test which might 
be of interest to us (is it a trial or standard care routine?) – need to 
follow this up with consultant. Unfortunately I didn’t get to observe 
as the patient was struggling with chemo and the consultant decided 
it wouldn’t be appropriate for the research nurse to approach the 
patient at this stage and seek consent to SMP2.
The next patient appointment wasn’t until 3.40pm so … typed up 
my notes … I was attending on an unusually disruptive day – the 
research nurse doesn’t usually go on the ward and the other clinic 
appointments were cancelled. The research nurse consented a patient 
to the 100k genome project (I asked if I could observe but she felt it 
wasn’t appropriate – first time she’d consented) for a gynaecological 
cancer patient. The patient had been particularly unwell but really 
felt like they wanted to participate for the sake of others in the future.
This excerpt further illustrates how recruitment and participation 
took considerable choreography in the context of busy, often 
understaffed clinics where clinical teams are formed on each occasion 
the clinic convenes. Participation in personalised medicine was acutely 
difficult to deliver for sick and vulnerable patients facing foreshortened 
futures in this complex, pressurised environment.
On other occasions patients or their relatives declined to participate 
because they were too unwell or overwhelmed by their experiences, 
as in the fieldnote excerpt below:
While waiting for the specialist nurse, the couple sitting in the waiting 
area carefully reading the information sheet. The wife was still reading 
the information sheet when her husband questioned her very quietly. 
I could see … that he was pointing out the end of the consent form. 
The wife carried on reading the information sheet carefully. After 
several minutes, the husband then come over and told me that they 
won’t consent for my observations. He said, ‘If it was ingrown toenail, 
she would do anything but it has been so traumatic’ and he awkwardly 
smiled. Then he said, they both have educational background and  
234 Personalised cancer medicine
appreciate the value of research. But he said participating in 100,000 
Genomes Project was enough and wanted her to focus on recovery.
This ‘informed refusal’ (Benjamin 2016) captures some of the burdens 
of participation in research, given that patients were often approached 
about research studies in the course of difficult and sometimes 
overwhelming treatment protocols. We can also identify some of 
this burden by reflecting on instances where patients initially agreed 
to participate but then did not respond to follow-up enquiries. At 
other times they did not attend appointments where their consent 
was being sought to participate in genomic research (and our 
research). This non-attendance was a common occurrence and can 
be explained in part by the complexities of the research recruitment 
arrangements and the requirement of patients to attend yet another 
appointment which could be quite lengthy. However, we might also 
think about non-attendance as a means of troubling or reworking 
the salience of our focus on genomics as special and of experiences 
of genomic studies as particularly worthy of social research – in 
this case the patient’s relative explained quite clearly it is simply 
not important enough to justify time and energy that is already in 
short supply.
Given how sick and how busy patients are, it is remarkable that 
they find the time to participate in research that does not benefit 
them directly, including our study. Their participation did gener-
ate opportunities to reflect on identities and to express concerns, 
and to tell their stories more generally, but it also formed part 
of their responsibilities to reciprocate care or help future patients, 
including perhaps their own families. This kind of participation 
was not, however, without its limits, some of which could be quite 
discomforting for all involved. Misunderstandings about the purpose 
of our research, the role of the interviewer and the potential to 
benefit were among the most difficult aspects of these limits on 
participation. This is not because participation was somehow not 
‘up to par’ as a result, but because it demonstrates some of the 
deep-rooted problems with the participatory logic of personalised 
medicine, which relies on a complex consent process to gather data 
but places considerable burdens on patients in terms of time and 
thinking through their participation, taking advantage of patients’ 
need to reciprocate care and glossing over the benefit they might 
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receive as a result. As we discussed in Chapter 5, patients can be 
inventive in obtaining value from participation despite these issues, 
eschewing the need to be genomically literate, for example. But this 
kind of revaluation also curtailed participation. We can illustrate 
this in the following excerpt from an interview with Terry, after her 
surgery for colorectal cancer, who was initially confused about the 
research she had participated in:
So I’m just going to ask you a little bit about the [research study].
Yes.
Yeah. Don’t worry, no technical questions (laughs).
Gosh, yeah. Keep reading that information leaflet you gave me then.
… so how were you approached about it? Was it [research nurse] 
who approached you …?
You know, no, things are very – getting very mixed up, cos I’ve seen 
so many people … I know [research nurse] approached me, yeah, no, 
I … so it wasn’t you then, was it, initially?
No.
Because I know you came in on –
I was there on the day that you had the surgery.
Yeah, the surgery, that’s it.
Yeah.
So obviously I’d been to – so it probably was [research nurse] then, 
I’m actually –
Don’t worry about it.
Yeah, yeah, I’m sure … because there was … your study, [research 
nurse] study and there was this other study that I did as well … and 
they were all – I think I must have been asked all on the same day, 
yeah, so it’s probably [research nurse] that said about the genomes 
as well then. Yeah.
And what kind of shaped your decision around it? Was it an easy 
decision to say yes…
Well, I’m not being funny, but I think anything, when it’s to do with 
research, if it’s not sort of – not [going to] take up a lot of time, but 
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it – you know, because obviously with everything else you’ve got 
going on, you know, with having what you’ve got, you’ve got cancer 
and that, you don’t want something that’s going to take [a long time] 
– cos … you’re, you’re focused on what’s wrong with you … So … 
if it was a study that was gonna, say I’ve got to do like sort of filling 
in of this and filling in of that or, just, I probably wouldn’t – might 
not have done it. But … when [research nurse] explained more or 
less that it wasn’t too … time consuming and I didn’t have to do 
loads of forms and that, yeah, I was quite willing to do it … I mean, 
this sort of thing could help somebody I know, my family, my grand-
children further down the line, you know, that’s how I look, look at 
things anyway …
Here Terry struggles to make sense of what she has agreed to be 
part of and our role therein, falling back on familiar logics of reciproc-
ity, future benefit and active patienthood to justify her involvement 
and collaborating with the researcher, while masking the lack of 
engagement in or salience of genomics.
Public engagement
Our study did not just take place in hospitals and clinics; we also 
endeavoured to study how cancer patients and relatives engaged 
with personalised medicine beyond these institutions, through 
advocacy, engagement exercises and involvement initiatives. As we 
have already discussed, these situations are not places where everyone 
feels that they can belong, nor are they always easy to attend given 
other commitments and barriers. Like our own Public and Patient 
Involvement panels, these forms of engagement are more often taken 
up by white, middle-class participants.
Lack of representation of ethnic and other minorities in genomic 
datasets and engagement exercises has, of course, been an ongoing 
source of concern for practitioners and policymakers. Much of this is 
framed in terms of a historic lack of trust on the part of marginalised 
communities, alienated by a series of scandals and exploitations 
including biopiracy, experimentation and commercial exploitation 
of tissue without any effort towards benefit sharing (Hamilton 2008; 
TallBear 2013; Skloot 2017). Together with contemporary experi-
ences of institutionalised racism, this means that Black, Asian, and 
minority ethnic (BAME) groups and other marginalised communities 
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also have a history of lower rates of participation in screening and 
research into cancer more generally. However, as Benjamin (2016) 
notes, there is a danger in framing these instances and patterns of 
non-participation as problems of trust, when the problem is perceived 
as being located with the community rather than the institutions 
and professionals who have behaved in systematically untrustworthy 
ways. And there is continued reason to be wary of a biomedical 
economy intent on data maximisation when BAME patients can be 
further disempowered by being framed as an untapped resource. 
This links to a wider set of challenges to the colonial and racialised 
practices of biomedicine, which have been dominated by white, male 
standpoints, framed as a ‘god’s eye’ view devoid of ‘bias’ (Haraway 
1988), but ultimately shaped by the interests of these dominant 
groups in maintaining power and privilege. It is reflected in Public 
and Patient Involvement practices focused on solutions and health 
improvements but reproducing health inequalities by amplifying a 
narrow range of perspectives, experiences and interests in the process 
(de Freitas and Martin 2015; Madden and Speed 2017).
Broadening and diversifying participation in engagement and in 
genomic research more generally becomes part of policy and insti-
tutional practices around these initiatives. The 100,000 Genomes 
Project involved a range of initiatives to access ‘harder to reach’ 
communities, particularly potential BAME participants. In 2019 the 
Yorkshire and Humber Regional Genomics Service that was part 
of Genomics England worked with playwrights and actors to produce 
a play in collaboration with ethnic minority community groups to 
promote inclusion in genomic medicine via ‘culturally sensitive’ 
education.2 The purpose of the play was also to address and ameliorate 
some of the concerns about biomedical innovation from within 
these communities. The play was described as follows on the Genomic 
Medicine Service website:
A play raising awareness of genomics and the impact of genetic disease 
that often runs unaware within families from Black and Minority 
Ethnic backgrounds…
Mixing humour, personal story and science, ‘Jeans, whose Genes?’ 
explores the specific concerns of harder to reach communities using 
the analogy of mobile telephone and internet technology to demonstrate 
life-changing or enhancing possibilities in scientific developments to 
improve healthcare.
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The play is focused around a conversation between two neighbours 
in which the black British Caribbean character expresses doubts 
and concerns about genomic research and the British Indian neighbour 
is more positive and hopeful about its potential to ‘ease suffering’. 
The issues raised, generated in discussion with people from these 
communities, include historic abuses and discrimination against black 
patients and research participants and ongoing scandals such as the 
Windrush affair, which involved people from the black community 
being deported despite having lived and worked in the UK for many 
years. The black character is, however, reassured by her neighbour 
that researchers, and science, are not racist and we ‘have to start 
trusting at some point’.
We also encountered similar concerns when we approached people 
from these communities about involvement in our work, including 
particular criticism of the use of informed consent forms as off-putting 
and needlessly bureaucratic. We offered reassurance about the ethical 
intent of this approach but this was not always convincing. Reflecting 
on this focus on resolving ‘distrust’ therefore requires further explora-
tion. As Benjamin notes,
by constructing trust as a cultural trait that some groups have more 
or less of than others, such discursive practices lead those engaged 
in trust talk to overlook differences within purported ethnoracial 
groups, disregard similarities across groups, and most importantly, 
ignore the larger institutionalised structures of inequality in biomedicine 
and beyond. (2014: x)
Accessing the experiences of subjugated populations is critical to 
driving inclusive genomic medicine and yet requires a systematic 
restructuring of systems of white privilege within biomedicine more 
generally, including in our case ethical protocols, informed consent 
processes and forms of engagement. It is also important to note 
that efforts to promote genomic medicine have the potential to both 
strip science of its cultural conditions of production – ‘science is 
not racist’ – and reify the problematic idea that race and categories 
of race are biologically defined; a notion which circulated in observa-
tions when patients were recruited to genomic medicine, as we see 
in the observation notes with a CTA below.
‘You know because we’re mixing more with different races it might 
tell us about different genetics; it’s going to be massive’ (family member) 
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[race circulating here which hasn’t been as explicit in other consulta-
tions]. ‘I hope so …’
Conclusion
Not participating at all, being unable, unwilling, uninvited or limited 
in capacity to engage are key features of patient and practitioner 
experiences of personalised medicine and the plethora of research 
on which it relies. This limits the kinds of data and value obtained 
from participation, as well as limiting the potential for harm to 
arise from too much or too intense participation. At the same time, 
it configures the futures crafted, voices and experiences of participation 
and associated care to those well enough or sufficiently motivated 
or enthusiastic to participate. Some of these dynamics intensify 
promissory and positive tropes and underplay negative experiences 
in the process. They privilege enthusiastic voices and framings which 
emphasise the novelty or neutrality of science and technology. But 
attending to non-participation allows us to reflect on how practitioners 
and patients can refuse, resist and subvert these kinds of anticipatory 
logics through silence, or by turning away from the future to ground 
reflection in the mundane realities of managing day-to-day, or in 
stories rooted in the past, and privileging other kinds of care as a 
way of reconstituting identity in cancer’s wake.
Reflecting on these processes of non-participation or limited 
participation also highlights how some cancers and patients are 
better resourced in terms of treatment and support infrastructures 
as well as research opportunities. Capturing the experiences of other 
more marginalised cancers with lower survival rates and less research 
investment (see All Party Parliamentary Group on Cancer 2009) 
was difficult in our study, because genomic medicine is being 
implemented with most success in cancers with a track record of 
research and improved treatment and via well-established organi-
sational infrastructures. This can map on to some kinds of privilege 
for patients; for example, breast cancer is an area with considerable 
research investment and improved prospects, and is also associated 
with visible activism and is more common among those living in 
advantaged circumstances. These confluences can mean that patients 
with these kinds of cancers, outcomes and backgrounds are more 
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likely to participate in research and its associated care, including 
social research like our study, as part of their active patienthood, 
and to have more hopeful visions of the future. This further constrains 
the kinds of experiential accounts on which we can draw to under-
stand the impact of personalised medicine, rendering less visible 
experiences of the dark side of care, including failure, ambivalence, 
despair, disengagement and rejection. Exploring the margins or limits 
of participation, whether deliberately imposed or arising from 
organisational complexities, invites us to think more carefully about 
the kinds of practitioners and patients who are not able to (fully) 
participate in the promise of personalised medicine, and the need 
to attenuate and challenge overly optimistic promissory visions to 
attend to these limits. It also challenges us to think critically about 
the responsibilities and expectations of participation in the P4 era, 
particularly the intensification of work for key practitioners such 
as nurses and for patients as well.
Notes
1 See www.cdc.gov/tuskegee/timeline.htm (accessed 20 June 2020).
2 www.genomicsengland.co.UK/understanding-genomics/jeans-whose-genes/ 
(accessed 15 October 2019).
Conclusion
Future-crafting
Personalised cancer medicine is developing unevenly across a range 
of tests, treatments and research initiatives. Traversing local and 
personal quests for care, together with global networks of services, 
research and innovation, molecular information and tailored treat-
ments involve a complex array of opportunities and expectations, 
where access and success are stratified along multiple lines. Patient-
hood, value, big and little futures all multiply through these arrange-
ments, but coalesce into specific, more common or acceptable 
repertoires of empowered, hopeful patients, prospective economic 
growth and valued national assets. The future of informed, optimistic, 
reassured patients, living longer with or beyond cancer by virtue of 
molecular monitoring and tailored treatments, is aligned with a 
vision for UK wealth and prosperity, and a health service leveraging 
assets to work for the benefit of all of its citizenry.
But alongside these optimistic, promissory scenarios, there are 
numerous stories of disappointment, disengagement and deflection 
where patients and their relatives do not experience molecular 
information as empowerment, or cannot access molecular monitoring, 
tailored treatments or trials offering experimental therapies. Practition-
ers, too, are engaged in a series of compromises and a complex 
choreography of care to tailor treatments and tests as best they can, 
while supporting research efforts now and for the future, in conditions 
of limited time and resources. Ambiguity surrounds the blurred 
boundaries between research and care, with each transition between 
caring for a patient in the present and thinking about patients in 
the future requiring moral reflection as well as organisation and 
logistics.
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Through these activities, the future comes into the present, as 
Adam and Groves comment: ‘the future is not simply beyond the 
present but is a latent and “living future” within it’ (2011: 17). This 
makes the work of crafting futures a matter of living and working 
well, or as well as possible, in the here and now, while also thinking 
beyond this immediate horizon to future selves or others. The extent 
to which care for oneself and/or others in the present or future can 
be tolerated varies across time and across different kinds of settings 
and patients, with those with the lowest reserves of cultural and 
economic capital having much less time or capacity to care with or 
about genomics, given how little they themselves are cared for by 
society at large.
Our study of personalised cancer medicine exploring these different 
dimensions of genomic-driven research and care was designed to 
inquire about the work and value of these activities – who does 
what, who benefits, why? Within this we have sought to pay particular 
attention to how care and futurity operate, as forms of work and 
anticipation merge to produce cancer patienthood anew in the genomic 
era. We have documented an array of activities, discourses and 
expectations across our case studies, the sheer variety and complexity 
of which are difficult to summarise. Our impetus for summary is 
further blunted by our sense of discomfort about mining our data 
for academic capital in the form of new theories or concepts, given 
our questioning of these activities when it comes to molecular as 
opposed to social data. At the same time we owe it to our readership 
to return to our initial questions and reflect on how future-crafting 
operates, the kinds of work and value involved, and how we might 
rethink and revalue care and other work, value and futures, given 
what we have discovered. We organise these reflections into three 
main sections in this final chapter, exploring the work of future-
crafting, its collective impetus and implications for identity and 
solidarities, and how value is produced and reconfigured in the 
process, before moving on to our final thoughts on revaluing research 
and care in personalised cancer medicine.
Crafting futures as care work in personalised cancer medicine
To care is to anticipate and tend to an uncertain future, to enable 
and enliven an ongoing identity and maintain a place in the world. 
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Care features prominently in feminist analyses of technoscience and 
biomedicine, drawing our conceptual and empirical attention to its 
constitutive and political dimensions (Puig de la Bellacasa 2012). 
As Adam and Groves have written:
in caring for another, we attempt to judge what futures they project 
for themselves – what they want and need – and what they are 
becoming, both because of what they want and need and in spite of 
it. What we attend to is the unfolding potential of an individual and 
to what events will mean in the context of the fate we share with 
those we care about. (2011: 22–3)
Caring, like crafting, involves working with numerous materials, 
patterns, technologies, colleagues, friends, family. It can be relentless, 
at times rewarding, and at other times difficult and unpleasant; it 
can cause tensions and build rapport, involve misunderstandings, 
fractures and disputes, as well as new alliances, a sense of purpose 
and solidarity. Sometimes caring comes with a script, an acceptable 
way of operating; at other times it is a process of trial and error, 
working out, salvaging, seeking help and being open to doing things 
differently. Our work finds both well-established practices of care, 
of making do, alongside new forms, for example through social 
media and through the research/care interface. But care is often 
under-recognised and undervalued as work, left to undervalued actors 
or in between other activities, privatised and typically the preserve 
of women and lower-status workers or carers.
Our studies of personalised cancer medicine have encountered 
institutions and organisations at various levels of operation – from 
the ‘high-level’ government or scientific elite pronouncements of the 
genomics vanguard (Hilgartner 2017), policymakers such as NICE 
or Genomics England Ethics Advisory Group, to project leaders, 
principal investigators, patient advocates, through to practitioners 
operating in laboratories and clinics to deliver genomic medicine, 
and, of course, to patients themselves and their families. Across 
these dimensions we have seen a plethora of activities designed to 
institutionalise or embed genomic medicine in practice, through 
protocols, research initiatives, training and education. Each, in their 
own way, are forms of articulation work that invoke or deliver 
versions of care for particular kinds of institutions, individuals and 
materials. At one end of the spectrum, considerable emphasis has 
been placed on standardising and optimising partnerships across 
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nations, institutions and public/private sectors, because of the 
prospects this offers for delivering better, more precise kinds of 
healthcare and economic prosperity, enacting care on a macro scale. 
This is complex and sometimes fraught work. But at a more local 
scale, caring is especially messy, involving everything from taking 
care in encounters with patients and colleagues to tending to the 
logistics of sample preparation, delivery and analysis, consent 
mechanisms, clinician behaviours, patient pathways and results 
interpretation.
Organisations and their actors are expected to innovate and be 
open to innovation through these various activities, which inculcate 
a ‘can do’ attitude premised on caring enough to be open to learning 
and change, crafting a more certain future, as well as inviting a 
range of articulation work to make processes flow and put patients 
at ease. Yet much of this work remains hidden and unrecognised, 
despite its vital contribution to the institutional transformations 
required to make genomic medicine work in practice. It takes place 
in the margins, between quantifiable activities such as numbers of 
patients diagnosed, recruited, surviving, and is often delivered by 
staff working in conditions of precarity – on short-term contracts 
or projects, in laboratories and clinics that are being reorganised, 
and in services facing staffing shortages. It happens in corridor 
conversations, phone calls out of hours, hastily arranged meetings 
and cobbled together solutions to problems as they arise. These 
neglected forms of care work for tissue, colleagues, institutions and, 
of course, patients are an enduring feature of the work of personalising 
cancer medicine, yet they remain largely hidden from view in official 
accounts of precision healthcare and research agendas.
Strongly aligned with these activities are the intricate practices 
of managing the emotions provoked and sustained by personalised 
cancer medicine, an activity in which patients and carers, together 
with practitioners, are deeply engaged. Cancer diagnosis, prognosis 
and treatment invokes a cacophony of emotions of fear, grief, loss, 
hope, stubbornness and stoicism, and personalised cancer medicine 
intensifies this rollercoaster ride across the rise and fall of emotions 
at key points of transition and opportunity. Caring for patients 
along this journey is difficult and ongoing work for carers and 
practitioners; it also involves work for patients who need to be seen 
to care enough about themselves and to continue to care for others 
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around them, including imagined future patients, by not being too 
negative, ungrateful or demanding. Being careful about hoping too 
much also requires work from all of these parties, and this can be 
a source of tension about the benefits of personalised care, not just 
in the sense that hopes can be dashed, but when disappointments 
are avoided or discounted and care is experienced as absence or 
neglect. Working in these ways does not always deliver the kinds 
of outcomes or experiences patients or practitioners value or expect.
Experimentation is another key feature of the work of personalising 
cancer medicine. This, too, involves considerable care work for 
multiple actors. Even when tests or treatments are relatively well 
established, their uptake in practice is highly contingent on personal 
circumstances and expectations; their very novelty can be a source 
of reassurance and comfort for some, but, at other times, a generator 
of further doubts and anxiety. When tests and treatments are 
experienced as part of research, or sourced through private means 
or charitable giving, the idea of being on trial or on the cutting edge 
can give a sense of being cared for enough that one’s future is worth 
investment, offering hope that is sustaining. But experimenting, by 
its very nature, is marked by frustrations, tinkering and uncertainties, 
and this demands particular kinds of care work to manage side-effects, 
maintain eligibility, source alternatives and cultivate a sense of control 
of uncertain futures. Here the work of being on experimental therapies 
involves care as a kind of risk taking, which inevitably means creating 
burdens for others who must bear witness or manage risks as a 
result of their obligations to patients or kin. Personalised cancer 
medicine intensifies this work by embedding research as part of care 
via the kinds of studies we have followed – adaptive trials, WGS 
and even smaller feasibility studies taking place locally. Tailoring 
that care to the particularities of individuals’ DNA and that of their 
tumours demands work on the part of those individuals to maintain 
their sense of uniqueness and potentiality to remain on treatments 
and stay alive, and to support those who are ineligible for genomic 
and for other reasons.
This uncovers a particular kind of trouble with personalised cancer 
medicine that is inscribed into the heart of the endeavour. Knowing 
about cancer and its, and thereby your own, future in ever greater 
detail intensifies the care work of practitioners and patients, as well 
as their families. But knowing is not always welcome or reassuring; 
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it is seldom certain knowledge, it can make patients, practitioners 
and relatives feel hopeless and despairing, and it can undercut the 
moral and cultural obligation to be empowered through knowledge. 
Not being able to access a hoped-for treatment, or being told that 
one’s risk is actually rather higher than had previously been thought, 
being too ill or otherwise ineligible to join a trial, waiting a long 
time for results or treatments that turn out to be unremarkable, or 
not ever finding out about that personalised genomic profile because 
results or samples ‘failed’ is not empowering, and requires an 
additional layer of repair work to keep going in the face of disap-
pointments and setbacks. Improving genomic literacy is unlikely to 
be the empowering solution to these experiences, given their depth 
and complexity.
Attention and resistance to these intense logics of empowerment, 
progress and the promise of precision are, however, difficult to 
sustain. For the genomic vanguard, when practitioners adapt, query, 
ignore or forget as a means of mediating or moderating the drive 
for molecular personalisation in favour of more holistic notions of 
personalised care, such resistance can be a reason to accelerate 
transformation, education or reorganisation of their services. When 
patients are uncompliant or disengaged, their resistance can be 
dismissed, managed or explained away by relatives and care givers 
seeking more optimistic territory. Other patients sublimate their 
concerns and critiques to keep care givers onside, given that they 
do not want to alienate and risk restrictions on future care. Relatives, 
too, can end up silencing their disappointments and fears in favour 
of being supportive, optimistic, caring. Non-participation can be 
difficult to achieve or sustain in these circumstances.
This proliferation of care work underpins the design and delivery 
of personalised cancer medicine and its repercussions for patients, 
carers and practitioners beyond individual encounters with molecular 
information or tailored treatments. Care work is oriented around 
crafting and balancing liveable presents and possible futures, even 
when options are narrowing or eclipsed as results and treatments 
do not always bring relief or hope. Care work is also profoundly 
relational – a collective activity. As personalised cancer medicine 
develops, these collectives and identities are rearranging, as we now 
go on to discuss in more detail.
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Crafting futures together
Our initial approach to answering the question of how personalised 
medicine for cancer is transforming what it means to be a patient 
was to foreground the experiences and accounts of patients, focusing 
on their identity stories, alliances, commitments, engagements and 
expectations. This was driven by a sense that much of the STS work 
in this area is focused on professional practice and activities. But 
as we interviewed and observed patient experiences, the role of 
practitioners and relatives in shaping and enacting these practices 
and accounts came to the fore too, and our focus necessarily shifted 
beyond patients to this wider nexus of care. This was not just 
because interviewing patients and speaking about genomics with 
them was difficult due to their vulnerabilities and other more pressing 
priorities (although this was often the case), nor was it a matter of 
prioritising more expert or authoritative voices in the face of confusion 
or resistance from patients. Instead, our more expansive focus came 
about because of the repeated experience of patients, relatives and 
practitioners crafting futures together, as a loosely collective and 
relational, rather than an individual, enterprise. We observed this 
across our research: in interviews where relatives attended and 
contributed alongside the patients who were participating, configuring 
the interview as a source of reassurance and an opportunity to 
reflect together on how things were going; in observations in clinics 
where practitioners, patients and relatives mulled over results, their 
implications or expectations and settled on a course of action together; 
in corridor conversations and other backstage arenas such as labo-
ratories or team meetings where, although patients were not physically 
present, practitioners were actively keeping them in mind when 
deciding what to do next; on fundraising and other websites where 
patients’ stories were narrated by and in relation to family, friends 
and wider publics. So we expanded our approach, focused on profes-
sionals as well as patients, and included the activities and accounts 
of relatives in our study, to better capture these dynamics of collective 
future-making.
Genomic medicine is complex, and practitioners often worried 
about patients’, and sometimes their own, ability to grasp its meanings 
and implications for patients now and in the future. This did not, 
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however, result in a ‘top-down’ paternalistic approach where consult-
ants managed results and decided on treatment, but typically involved 
dialogue and sense making between a range of practitioners, patients 
and relatives as they tried to develop a shared understanding of 
priorities, expectations and opportunities. Even when patients were 
less engaged, more stoic and trusting, less interested in ‘the numbers’ 
or their subtype, personalising cancer medicine demanded that 
patients, relatives and practitioners collectively enacted therapeutic 
and diagnostic approaches tailored to patients’ needs. For more 
active, involved, information-seeking patients, who are often younger, 
more educated and affluent, these collective activities might be more 
frequent and intense. Yet even for the most entrepreneurial patient, 
their experience of genomic medicine was always mediated by 
engagements with and between practitioners with whom they 
developed shared understandings and agendas as a means of navigat-
ing genomic complexities and opportunities. Of course, these relation-
ships and shared understandings could break down, or involve tension 
and distrust which varies across time and place, but even when 
under strain the collective process of sense making remains. We 
emphasise this point to counter one of the most dominant registers 
of personalised cancer medicine: that of the empowered, individualised 
patient, making choices, sourcing opportunities, tailoring treatments, 
and of the power of genomic information in those processes. The 
patients we found in our research were doing all of these things, 
but never alone, always in collaboration, and in a way that was 
intimately shaped by their networks, relationships and encounters 
with professionals, family and friends all acting as care givers. 
Genomics was just one part of this wider story.
Reciprocity was a key dimension of these relationships: it occurred 
when patients and relatives obtained personalised care in real time 
or for the future; when they enacted gratitude for that care by 
participating in other kinds of research, charitable giving or campaign-
ing on behalf of other patients; and when they sought to be likeable 
and accommodating in everyday encounters in clinics and beyond. 
Patients and relatives used interviews, clinic appointments, consent 
meetings and a range of participatory and representational activities 
as occasions to enact reciprocity, to tell their stories of more or less 
personalised care and its deficiencies within an overall narrative of 
deep gratitude and commitment to the NHS and its staff, and a 
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desire to help future patients. Even private patients accessing per-
sonalised care that is not available on the NHS expressed their sense 
of gratitude towards it and their discomfort with not accessing care 
on the NHS; they worked to offset this through other kinds of 
campaigning activities. Alongside efforts to achieve or demonstrate 
reciprocity we also identified multiple instances of its absence, as 
patients, practitioners and relatives experienced ruptures or discomfort 
in relationships and shared understandings and agendas. Personalised 
cancer medicine, like other kinds of care, is not always attuned to 
people’s feelings and needs, it is not always available as it should 
be, and it can be an additional burden or interruption to care which 
stretched reciprocity to breaking point, generating silence, disap-
pointment and distress.
The collective experience and delivery of personalised cancer 
medicine has also seen the intensification of particular kinds of 
biosocial solidarities associated with entrepreneurship and novel 
kinds of expertise among patients and their supporters. Biosociality 
is typically associated with rare disease patient groups, working in 
close alliance with researchers, and, in the case of cancer in the 
genomic era, we might expect patients and their supporters to be 
formed into groupings around particular subtypes of cancer, perhaps 
even across cancers, where a shared mutation traverses these. Yet 
our research does not suggest that these arrangements are developing 
at pace; instead, we have identified numerous examples of patients 
forming tentative alliances around particular efforts to access tailored 
drugs, trials or tests, often based around the type and stage of their 
cancer, including its molecular profile. Lung cancer patients seeking 
access to trials of stratified medicine, late-stage breast cancer patients, 
ovarian cancer patients, and bowel cancer patients seeking drugs 
such as Avastin – all of these groups were engaging with molecular 
subtypes and targeted therapies, but not to the exclusion of others 
with different molecular subtypes. Instead, their alliances were 
premised on the struggle for more tailored information and options, 
and involved the navigation of the landscape of trials and approvals, 
charitable campaigns and NHS/private provision. They were often 
online, and therefore engagements could be episodic and fleeting, 
as well as more committed in the longer term, particularly for those 
supporting such activities, including families and those living ‘beyond 
cancer’.
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Entwined with these biosocial collectives we can also identify 
new kinds of expertise being developed by particularly entrepreneurial 
actors, combining public relations, counselling and support, politics, 
alliance formation and challenges to advocacy, charitable, professional, 
political, philanthropic, public sector and corporate actors. We are 
thinking here of the successful artists, authors, campaigners, advocates, 
fundraisers and spokespersons for personalised cancer medicine 
seeking better access to molecular tests and targeted treatments, 
often outside the NHS. These entrepreneurial experts are key actors 
in the personalised cancer medicine landscape – facilitating networks, 
multiplying patienthood and crafting new roles for their relatives 
which hybridise traditional ‘advocacy’ or ‘consumer critic’ roles, 
working across public and private sector agendas actively to craft 
futures for individual patients and their collectives.
Recrafting value
As we have endeavoured to show throughout this book, the promise 
of personalised cancer medicine is an enduring big future vision 
which can be found across policy and vanguard accounts of genomic 
medicine. It also finds its way into ordinary discourses in the clinic 
and elsewhere, holding a kind of totemic power that enables personal 
and collective futures to overcome cancer. Patients, relatives and 
professionals were far less interested in personalised medicine as a 
source of economic gain either for pharmaceutical companies or 
the life science economies of the nation. Apart from critical interven-
tions around access to treatment (which, in any case, often focus 
on the failings of the state, not the profiteering of corporations), 
the economic value generated by personalised medicine tended to 
be opaque and disconnected from people’s vision of its promise and 
their futures.
As authors such as Jain (2007) and Steinberg (2015) have empha-
sised, this economic value is inexorably dependent on cancer patients’ 
capacity to experiment and take risks with their care in the hope 
of extending their life. In so doing it relies upon a broader moral 
economy where being a good patient means embracing suffering 
for the ephemeral goal of cure, as Steinberg notes: ‘The willingness 
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to undergo treatment’s “cutting edge” takes on a talismanic power. 
What it promises to confer is not so much “freedom from cancer”, 
as it does moral standing, a certain brand of cultural entitlement 
and recognition as an edifying subject’ (Steinberg 2015: 130). Our 
case studies are replete with this kind of opaque exchange, as ‘high-
level’ promissory discourses of economic benefit to the nation dissolve 
into affective repertoires and encounters of care loaded with pain, 
suffering and optimism, as together patients and their carers tried 
to craft worthy futures. For all their complexity and variety, these 
stories share a common pattern of emphasis on investable identities, 
working hard to be well, to be positive, grateful and determined.
Yet patterns – like recipes and other instruction manuals – can 
be hacked: repurposed, reworked, adapted and refined. This happens 
in patient encounters with personalised cancer medicine too: scripts 
could be resisted, other kinds of patienthood enacted and valorised, 
difficult questions and awkwardness laid bare, and opaque relations 
partially revealed. Through these practices new kinds of value 
emerged, among which care in the present took on a special value 
of its own.
We have discussed some of these reworkings across our case 
studies and in relation to our interview practices, where we encoun-
tered patients and participants refocusing attention on other aspects 
of their care beyond or instead of genomics, or resisting the burden 
of genomic literacy. Through these activities, patients and participants 
realised other kinds of value from their encounters with personalised 
medicine, gaining comfort and reassurance and bolstering their sense 
of self-worth in the process. One way in which this happened was 
by turning away from the future to the past, to tell their stories and 
reflect on their meanings and implications. This is, of course, common 
in cancer cultures, as Jain captures below:
Trying ‘to know what the past holds,’ what alternatives and what 
necessities it contained, can become a near obsession for a person 
with advanced cancer faced with the slender pages of a medical report. 
Learning, for example, that cancer was there and went undetected in 
earlier tests, unannounced in earlier reports, turns the faulty reports 
into the material remnants of lost opportunities – of times when 
treatments may have been less invasive, more efficacious. Because 
cancer is always about time. (Jain 2007: 83)
252 Personalised cancer medicine
Genomics adds an extra dimension to these ways of ‘living in 
prognosis’, prompting reflection on molecular subtypes, dormancy 
and mutation for some. But for others, the salience of genomics 
was overwhelmed by the process of reflection and remembering, 
where it faded into the background of complex narratives of lifestyle, 
heredity and environment. By resisting the urge to focus on molecular 
futures in favour of phenotypic pasts, participants decentred genomics 
and reworked the emphasis on ever more complexity and detailed 
information as a source of progress and cure. Personalised medicine 
reasserted itself as the holistic assessment of need and shared decision 
making: genomics was evanescent in that context, while nonetheless 
becoming embedded in our health services.
This disappearing of genomics also happened in other ways across 
our studies. We found it difficult to identify, follow and appreciate. 
Studies were sometimes delayed or faced difficulties recruiting; tests 
or treatments were not widely adopted or available; and it was not 
always clear that we were looking at genomics when we explored 
encounters with personalised cancer medicine involving molecular 
monitoring or associated targeted therapies. Practitioners as well as 
patients were unclear about this with us. Genomic results also had 
less purchase and salience than we might have expected, from patients 
ignoring the numbers, to practitioners nuancing interpretation, to 
missing or absent results. But genomics also disappeared into the 
background of professional activities and patient experiences more 
generally: it was not a core part of many of their jobs or concerns, 
it could be just another bit of information or test or treatment or 
research study for some patients, a vanity project, a doomed venture 
or a niche activity – for someone else, not for me, more hype than 
reality. Each act of ignoring, criticising or reframing recrafted the value 
of genomics, decentring it for patients and practitioners, refocusing 
attention on the meanings and benefits of care more generally.
At the same time, inequities, deficiencies and problems in delivering 
care were ever-present concerns for practitioners, relatives and 
patients. Caring requires time and resources and these were sometimes 
in short supply. So, in practices like reworking and reclaiming care 
in the consent meeting for research, patients and practitioners were 
inadvertently highlighting care’s absence elsewhere. In squeezing in 
meetings, telephone discussions, consenting and training, in recrafting, 
and often minimising, expectations, practitioners and patients were 
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highlighting the limited opportunities to care for the staff and patients 
on whose participation value-generation for the companies and 
institutions leading the genomic revolution depends. Patients’, carers’ 
and colleagues’ expressions of gratitude and respect for each other 
for going beyond their contractual duties and obligations also highlight 
the absence of sustained institutional support in the form of time 
and resources for people at the genomic coalface.
Exaggerated promises of the value of personalised medicine to 
patients also came under strain in stories of delays, disappointment, 
ambivalence, irrelevance or failures of results or access across our 
case studies. This was most acute when it came to crowdfunders and 
other kinds of private patients seeking treatments beyond the NHS. 
Here a tension in the promise of genomic medicine was partially 
revealed – what good are all of these investments that patients and 
practitioners make in research studies, trials, experimentation with 
novel tests and personalisation of care if the tailored treatments that 
are subsequently developed are too expensive for health services 
and, therefore, for many patients to access them? Alongside formal 
evaluations of the clinical and economic value of these drugs, we 
can find a process of recrafting value among patients and some 
practitioners where the question of the worth of a life is uncomfortably 
apparent, and the immediate personal value of accessing the drug 
is such that patients and their supporters will go to considerable 
lengths to generate the funds required. These patients and their 
supporters take on emotional and digital work in the process, and 
experiment with treatments to generate personal value as well as 
further value for other patients who might access these drugs in the 
future by turning their experiences into a source of evidence and 
exemplar. In so doing, they also highlight, in passing, the inequities 
and exclusions of care and the absence of value for some patients. 
A notable absence from many of their reflections, however, was 
critical engagement with the political and economic arrangements 
through which drugs are developed and funded by and through 
the state working with the private sector. There was a tendency to 
blame the state, not the market, a lack of appetite for thinking about 
how profits are derived from patients and from public institutions 
funding research. Although a few patients raised this with us, it 
was notable how little scope there was to explore and question 
these arrangements.
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Conclusion: revaluing research and care
We can draw inspiration from these and other stories of engagement, 
accommodation, resistance and tension across our research to try 
to ‘imagine different ways of acting responsibly in creating futures’ 
(Adam and Groves 2011: 17). In so doing we must resist the allure 
of standardising what Puig de la Bellacasa aptly calls ‘the messiness 
of the present’ and try not to dismiss things that do not fit with 
neat analyses and recommendations (Puig de la Bellacasa 2012: 
203). At the same time, it is important to take care not to represent 
or speak for patients as a whole, and in so doing silence their dif-
ferences and divisions, and to recognise that we must ‘work for 
change from where we are’ alongside our participants (Puig de la 
Bellacasa 2012: 210). In this concluding section we reflect on three 
opportunities for revaluing research and care in personalised cancer 
medicine.
At one level, our case studies of personalised cancer medicine are 
versions of the same story, which is that research can no longer be 
considered separate from cancer care; instead, it is intrinsic to the 
delivery and expectations of (health) care now and in the future. 
Cancer patients are experimental patients in the genomic era by 
default: even those outside of mainstream NHS services are experi-
menting with new treatments whether they are on trials or not. If 
we think of all genomic research in cancer as a form of care, and 
vice versa, then we need to reimagine what we are doing when we 
invite participation or consent or education and training for some 
patients but not others. We need to rethink the burden of consent 
and genomic literacy and the opportunities for care that follow from 
these encounters, following patients’ lead, allowing our ideas about 
‘what care is’ to be challenged and reworked in the process. Most 
importantly, this labour needs to be accounted for in how the benefits 
and challenges of genomic medicine are portrayed and audited.
Thinking of personalising cancer care as work is a political act; 
it draws attention to value creation, monetisation and extraction 
of molecular and clinical data, and invites us to ask what happened 
to those results and tests and drugs that were developed because of 
all that research – how are patients benefiting? It also invites us to 
think about the other workers, the nurses, scientists, doctors, counsel-
lors, advocates, fundraisers and informal carers. How can they be 
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supported to deliver personalised cancer medicine through care as 
well as research? Revealing the lengths that patients and family 
members go to to attend clinics, source opportunities, facilitate 
research, stay well enough to get and stay on a trial, be suitably 
educated and competent to participate, underlines questions about 
who benefits and who decides who benefits from personalised cancer 
medicine. Running counter to the individualising logic of personalisa-
tion, this asks us to think about solidarities between and among 
these different kinds of genomic workers, and how best to realise 
and share the fruits of their labour.
We can also draw on these stories of the messiness of people’s 
experiences and differences of perspectives as a means to resist the 
allure of speculative mono-futures of entrepreneurial active patients, 
alongside many feminists and others within cancer advocacy move-
ments. As Jain has written,
Instead of focusing on hope, cure, and the survivor figure, elegiac 
politics yearns to account for loss, grief, betrayal, and the connections 
between economic profits, disease, and death in a culture that is 
affronted by mortality. If the term ‘survivor’ offers a politics steeped 
in an identity formation around cancer, ‘living in prognosis’ offers 
an uneasy alternative, one that inhabits contradiction, confusion, and 
betrayal. (2007: 90)
Our exploration of practices of molecular prognosis sharpens our 
elegiac politics and presses upon us the need to continue to account 
for and think about all the other kinds of experiences and subjectivities 
caught up in the politics and economics of personalised cancer 
medicine, including patients and communities who are silenced, or 
who actively refute or reject its possibilities and benefits. Being 
uneasy with this, bearing witness to contradiction, is a necessary 
condition of collective and individual future-crafting.
Bibliography
Abelson, J., and Collins, P. A. (2009). Media hyping and the ‘Herceptin 
access story’: an analysis of Canadian and UK newspaper coverage. 
Healthcare Policy, 4(3): e113.
Abraham, J. (1995). Science, politics and the pharmaceutical industry: 
controversy and bias in drug regulation. London: UCL Press.
Abraham, J. (2009). Partial progress: governing the pharmaceutical industry 
and the NHS, 1948–2008. Journal of Health Politics, Policy and Law, 
34(6): 931–77.
Adam, B., and Groves, C. (2007). Future matters: action, knowledge, ethics. 
Leiden: Brill.
Adam, B., and Groves, C. (2011). Futures tended: care and future-oriented 
responsibility. Bulletin of Science, Technology & Society, 31(1): 17–27.
Adams, V., Murphy, M., and Clarke, A. (2009). Anticipation: technoscience, 
life, affect, temporality. Subjectivity, 28: 246–65.
Ali-Khan, S. E., Black, L., Palmour, N., Hallett, M. T., and Avard, D. (2015). 
Socio-ethical issues in personalized medicine: a systematic review of 
English language health technology assessments of gene expression profiling 
tests for breast cancer prognosis. International Journal of Technology 
Assessment in Health Care, 31(1–2): 36–50.
Allen, D. (2014). The invisible work of nurses: hospitals, organisation and 
healthcare. Abingdon: Routledge.
Allen, D., and Hughes, D. (2017). Nursing and the division of labour 
in healthcare. Basingstoke: Macmillan International Higher Education.
All Party Parliamentary Group on Cancer (2009). Report of the All Party 
Parliamentary Group on Cancer’s Inquiry into Inequalities in Cancer 
(MacMillan Cancer Support). London: All Party Parliamentary Group 
on Cancer.
Arnold, M., Rutherford, M. J., Bardot, A., Ferlay, J., Andersson, T. M. L., 
Myklebust, T. A., Tervonen, H., et al. (2019). Progress in cancer survival, 
mortality, and incidence in seven high-income countries 1995–2014 (ICBP 
SURVMARK-2): a population-based study. The Lancet Oncology, 20(11): 
1493–505.
 Bibliography 257
Arribas-Ayllon, M., Sarangi, S., and Clarke, A. (2011). Promissory accounts 
of personalisation in the commercialisation of genomic knowledge. Com-
munication & Medicine, 8(1): 53–66.
Beaudevin, C., Peerbaye, A., and Bourgain, C. (2019). ‘It has to become 
true genetics’: tumour genetics and the division of diagnostic labour in 
the clinic. Sociology of Health & Illness, 41(4): 643–57.
Bekelman, J. E., and Joffe, S. (2018). Three steps toward a more sustainable 
path for targeted cancer drugs. JAMA, 319(21): 2167–8. doi:10.1001/
jama.2018.3414.
Bell, K. (2009). ‘If it almost kills you that means it’s working!’ Cultural 
models of chemotherapy expressed in a cancer support group. Social 
Science & Medicine, 68(1): 169–76.
Bell, K. (2013). Biomarkers, the molecular gaze and the transformation of 
cancer survivorship. BioSocieties, 8(2): 124–43.
Bell, K., and Kazanjian, A. (2011). PSA testing: molecular technologies 
and men’s experience of prostate cancer survivorship. Health, Risk & 
Society, 13(2): 183–98.
Benjamin, R. (2014). Race for cures: rethinking the racial logics of ‘trust’ 
in biomedicine. Sociology Compass, 8(6): 755–69.
Benjamin, R. (2016). Informed refusal: toward a justice-based bioethics. 
Science, Technology, & Human Values, 41(6): 967–90.
Bickers, B., and Aukim-Hastie, C. (2009). New molecular biomarkers for 
the prognosis and management of prostate cancer – the post PSA era. 
Anticancer Research, 29(8): 3289–98.
Birch, K. (2017). Rethinking value in the bioeconomy: finance, assetization, 
and the management of value. Science, Technology, & Human Values, 
42(3): 460–90.
Bodkin, H. (2018). Personalised medicine ‘transforms’ survival chances 
in incurable cancer. The Telegraph, 6 June, www.telegraph.co.uk/
science/2018/06/05/personalised-medicine-transforms-survival-chances-
incurable/ (accessed 8 July 2019).
Borad, M. J., and LoRusso, P. M. (2017). Twenty-first century precision 
medicine in oncology: genomic profiling in patients with cancer. Mayo 
Clinic Proceedings, 92(10): 1583–91.
Borup, M., Brown, N., Konrad, K., and Van Lente, H. (2006). The sociology 
of expectations in science and technology. Technology Analysis & Strategic 
Management, 18(3–4): 285–98.
Boseley, S. (2013). New breast cancer test could spare women chemotherapy. 
The Guardian, 26 September, https://www.theguardian.com/society/2013/
sep/25/women-breast-cancer-test-spares-chemotherapy (accessed 20 June 
2020).
Bourret, P., Keating, P., and Cambrosio, A. (2011). Regulating diagnosis 
in post-genomic medicine: re-aligning clinical judgement? Social Science 
& Medicine, 73(6): 816–24.
Braun, K., Moore, A., Herrmann, S. L., and Könninger, S. (2010). Science 
governance and the politics of proper talk: governmental bioethics as a 
258 Personalised cancer medicine
new technology of reflexive government. Economy and Society, 39(4): 
510–33.
Breast Cancer Now (2018). Breast Cancer Now responds to NICE 
decision to not to recommend use of tumour profiling tests. https://
breastcancernow.org/news-and-blogs/news/nice-decide-not-to-recommend-
use-of-tumour-profiling-tests (accessed 5 March 2018).
Brown, N., and Michael, M. (2003). A sociology of expectations: retrospecting 
prospects and prospecting retrospects. Technology Analysis & Strategic 
Management, 15(1): 3–18.
Brown, N., and Rappert, B. (2017). Contested futures: a sociology of 
prospective techno-science. Abingdon: Routledge.
Brown, P., and de Graaf, S. (2013). Considering a future which may not 
exist: the construction of time and expectations amidst advanced-stage 
cancer. Health, Risk & Society, 15(6–7): 543–60.
Brown, P., de Graaf, S., Hillen, M., Smets, E., and van Laarhoven, H. 
(2015). The interweaving of pharmaceutical and medical expectations as 
dynamics of micro-pharmaceuticalisation: advanced-stage cancer patients’ 
hope in medicines alongside trust in professionals. Social Science & 
Medicine, 131: 313–21.
Brown, P., Hashem, F., and Calnan, M. (2016). Trust, regulatory pro-
cesses and NICE decision-making: appraising cost-effectiveness models 
through appraising people and systems. Social Studies of Science, 46(1): 
87–111.
Busfield, J. (2006). Pills, power, people: sociological understandings of the 
pharmaceutical industry. Sociology, 40(2): 297–314.
Callon, M., and Rabeharisoa, V. (2008). The growing engagement of emergent 
concerned groups in political and economic life: lessons from the French 
Association of Neuromuscular Disease Patients. Science, Technology and 
Human Values, 33: 230–61.
Cambrosio, A., Campbell, J., Keating, P., and Bourret, P. (2019). Multi-polar 
scripts: techno-regulatory environments and the rise of precision oncology 
diagnostic tests. Social Science & Medicine [online only/early view], 21 
May 2019, 112317. https://doi.org/10.1016/j.socscimed.2019.05.022.
Cambrosio, A., Keating, P., Vignola-Gagné, E., Besle, S., and Bourret, P. 
(2018). Extending experimentation: oncology’s fading boundary between 
research and care. New Genetics and Society, 37(3): 207–26.
Cancer Research UK (2014). Breast cancer survival statistics [online]. 
www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-
by-cancer-type/breast-cancer/survival (accessed 31 May 2019).
Chapple, A., Ziebland, S., and McPherson, A. (2004). Stigma, shame, and 
blame experienced by patients with lung cancer: qualitative study. British 
Medical Journal, 328(7454): 1470.
Chattoo, S., and Ahmad, W. I. U. (2003). The meaning of cancer: illness, 
biography and identity. In D. Kelleher and G. Leavey (eds), Identity and 
Health, 19–36. Abingdon: Routledge.
 Bibliography 259
Clark, A. E., et al. (2003). Biomedicalization: technoscientific transformations 
of health, illness, and US biomedicine. American Sociological Review, 
68(2): 161–94.
Cool, A. (2016). Detaching data from the state: biobanking and building 
big data in Sweden. BioSocieties, 11(3): 277–95.
Cooper, M. (2008). Life as surplus: biotechnics and the transformations of 
capital. Seattle, WA: Washington University Press.
Cooper, M., and Waldby, C. (2014). Clinical labor: tissue donors and research 
subjects in the global bioeconomy. Durham, NC: Duke University Press.
Corrigan, O. (2003). Empty ethics: the problem with informed consent. 
Sociology of Health & Illness, 25(7): 768–92.
Dabbs, D. J., Clark, B. Z., Serdy, K., Onisko, A., Brufsky, A. M., Smalley, 
S., Perkins, S. and Bhargava, R. (2018). Pathologist’s health-care value 
in the triage of Oncotype DX® testing: a value-based pathology study 
of tumour biology with outcomes. Histopathology, 73(4): 692–700.
Davis, C. (2015). Drugs, cancer and end-of-life care: a case study of phar-
maceuticalization? Social Science & Medicine, 131: 207–14.
Davis, C., and Abraham, J. (2013). Unhealthy pharmaceutical regulation: 
innovation, politics and promissory science. Basingstoke: Palgrave 
Macmillan.
Davies, S. C. (2017). Annual Report of the Chief Medical Officer 2016, 
Generation Genome. London: Department of Health.
Davies, M., and Sque, M. (2002). Living on the outside looking in: a theory 
of living with advanced breast cancer. International Journal of Palliative 
Nursing, 8(12): 583–90.
de Freitas, C., and Martin, G. (2015). Inclusive public participation in 
health: policy, practice and theoretical contributions to promote the 
involvement of marginalised groups in healthcare. Social Science and 
Medicine, 135: 31–9.
Degeling, C., Carter, S. M., and Rychetnik, L. (2015). Which public and 
why deliberate? A scoping review of public deliberation in public health 
and health policy research. Social Science & Medicine, 131: 114–21.
Derks, M. G., and van de Velde, C. J. (2018). Neoadjuvant chemotherapy 
in breast cancer: more than just downsizing. The Lancet Oncology, 
19(1): 2–3.
DeVita, V. T., and Chu, E. (2008). A history of cancer chemotherapy. Cancer 
Research, 68(21): 8643–53.
Dheensa, S., Samuel, G., Lucassen, A. M., and Farsides, B. (2018). Towards a 
national genomics medicine service: the challenges facing clinical-research 
hybrid practices and the case of the 100,000 genomes project. Journal 
of Medical Ethics, 44(6): 397–403.
Dixon-Woods, M., Ashcroft, R. E., Jackson, C. J., Tobin, M. D., Kivits, 
J., Burton, P. R., and Samani, N. J. (2007). Beyond ‘misunderstand-
ing’: written information and decisions about taking part in a genetic 
epidemiology study. Social Science & Medicine, 65(11): 2212–22.
260 Personalised cancer medicine
Dixon-Woods, M., and Tarrant, C. (2009). Why do people cooperate with 
medical research? Findings from three studies. Social Science & Medicine, 
68(12): 2215–22.
Dowsett, M., and Dunbier, A. K. (2008). Emerging biomarkers and new 
understanding of traditional markers in personalized therapy for breast 
cancer. Clinical Cancer Research, 14(24): 8019–26.
Dussauge, I., Claes-Fredrik, H., and Francis, L. (eds) (2015). Value practices 
in the life sciences and medicine. Oxford: Oxford University Press.
Ebeling, M. F. E. (2016). Healthcare and big data: digital spectres and 
phantom objects. Basingstoke: Palgrave.
Ehlers, N., and Krupar, S. (2014). Hope logics: biomedicine, affective 
conventions of cancer, and the governing of biocitizenry. Configurations, 
22(3): 385–413.
Ehrenreich, B. (2001). Welcome to Cancerland: a mammogram leads to a 
cult of pink kitsch. Harper’s Magazine, November, 43–53.
Felt, U., and Fochler, M. (2010). Machineries for making publics: inscrib-
ing and de-scribing publics in public engagement. Minerva, 48(3): 
219–38.
Fojo, T., Mailankody, S., and Lo, A. (2014). Unintended consequences 
of expensive cancer therapeutics – the pursuit of marginal indications 
and a me-too mentality that stifles innovation and creativity. JAMA 
Otolaryngology: Head & Neck Surgery, 140(12): 1225–36. doi:10.1001/
jamaoto.1570.
Fortun, M. (2008). Promising genomics: Iceland and deCODE genetics 
in a world of speculation. Berkeley, CA: University of California Press.
Frank, A. (2003). Survivorship as craft and conviction: reflections on research 
in progress. Qualitative Health Research, 13(2): 247–55.
Fujimura, J. H. (1996). Crafting science: a sociohistory of the quest for the 
genetics of cancer. Cambridge, MA: Harvard University Press.
Gabe, J., Chamberlain, K., Norris, P., Dew, K., Madden, H., and Hodgetts, 
D. (2012). The debate about the funding of Herceptin: a case study of 
‘countervailing powers’. Social Science & Medicine, 75(12): 2353–61.
Gallagher, J. (2018). Breast cancer: test means fewer women will need 
chemotherapy [online]. www.bbc.co.uk/news/health-44347381 (accessed 
5 March 2019).
Gardner, J., Samuel, G., and Williams, C. (2015). Sociology of low 
expectations: recalibration as innovation work in biomedicine. Science, 
Technology, & Human Values, 40(6): 998–1021.
Gavan, S. P., Thompson, A. J., and Payne, K. (2018). The economic case 
for precision medicine. Expert Review of Precision Medicine and Drug 
Development, 3(1): 1–9.
Gerlitz, C., and Helmond, A. (2013). The like economy: social buttons and 
the data-intensive web. New Media & Society, 15(8): 1348–65.
Gillespie., C. (2012). The experience of risk as ‘measured vulnerability’: 
health screening and lay uses of numerical risk. Sociology of Health & 
Illness, 34(2): 194–207.
 Bibliography 261
Good, M. J. D. (2001). The biotechnical embrace. Culture, Medicine and 
Psychiatry, 25(4): 395–410.
Good, M. J. D., Good, B. J., Schaffer, C., and Lind, S. E. (1990). American 
oncology and the discourse on hope. Culture, Medicine and Psychiatry, 
14(1): 59–79.
Goven, J., and Pavone, V. (2015). The bioeconomy as political project: a 
Polanyian analysis. Science, Technology, & Human Values, 40(3): 302–37.
Greenhalgh, T. (2009). Patient and public involvement in chronic illness: 
beyond the expert patient. British Medical Journal, 338: b49.
Guy, M. (2019). Between ‘going private’ and ‘NHS privatisation’: patient 
choice, competition reforms and the relationship between the NHS and 
private healthcare in England. Legal Studies, 39(3): 479–98.
Haase, R., Michie, M., and Skinner, D. (2015). Flexible positions, managed 
hopes: the promissory bioeconomy of a whole genome sequencing cancer 
study. Social Science & Medicine, 130: 146–53.
Hall, S., Massey, D., and Rustin, M. (2014). After neoliberalism: analysing the 
present. In S. Hall, D. Massey and M. Rustin (eds), After neoliberalism? 
The Kilburn manifesto, 8–22. London: Lawrence & Wishart.
Ham, C., Baird, B., Gregory, S., Jabbal, J., and Alderwick, H. (2015). The 
NHS under the coalition government. Part one: NHS reform. London: 
The King’s Fund. https://www.kingsfund.org.uk/sites/default/files/field/
field_publication_file/the-nhs-under-the-coalition-government-part-one-
nhs-reform.pdf (accessed 20 June 2020).
Hamilton, A. B. (1999). Psychological aspects of ovarian cancer. Cancer 
Investigation, 17(5): 335–41.
Hamilton, C. (2008). Intellectual property rights, the bioeconomy and the 
challenge of biopiracy. Genomics, Society and Policy, 4(3): 26.
Haraway, D. (1988). Situated knowledges: the science question in femi-
nism and the privilege of partial perspective. Feminist Studies, 14(3): 
575–99.
Harnan, S., Tappenden, P., Cooper, K., Stevens, J., Bessey, A., Rafia, R., 
Ward, S., Wong, R., Stein, R., and Brown, J. (2017). Tumour profiling 
tests to guide adjuvant chemotherapy decisions in people with breast 
cancer (update of DG10). Technology Assessment Report: Final report 
to the National Institute for Health and Care Excellence. Manchester: 
National Institute for Health and Care Excellence.
Harrison, C. J., Spencer, R. G., and Shackley, D. C. (2019). Transforming 
cancer outcomes in England: earlier and faster diagnoses, pathways to 
success, and empowering alliances. Journal of Healthcare Leadership, 
11: 1–11.
Haslem, D. S., Chakravarty, I., Fulde, G., Gilbert, H., Tudor, B. P., Lin, K., 
Ford, J. M., and Nadauld, L. D. (2018). Precision oncology in advanced 
cancer patients improves overall survival with lower weekly healthcare 
costs. Oncotarget, 9(15): 12316–22.
Hayden, C. (2007). Taking as giving: bioscience, exchange, and the politics 
of benefit-sharing. Social Studies of Science, 37(5): 729–58.
262 Personalised cancer medicine
Hedgecoe, A. (2004). The politics of personalised medicine: pharmacogenetics 
in the clinic. Cambridge: Cambridge University Press.
Hedgecoe, A. (2005). ‘At the point at which you can do something about it, 
then it becomes more relevant’: informed consent in the pharmacogenetic 
clinic. Social Science & Medicine, 61(6): 1201–10.
Hedgecoe, A., and Martin, P. (2003). The drugs don’t work: expectations 
and the shaping of pharmacogenetics. Social Studies of Science, 33(3): 
327–64.
Hiley, C. T., Le Quesne, J., Santis, G., Sharpe, R., De Castro, D. G., Mid-
dleton, G., and Swanton, C. (2016). Challenges in molecular testing in 
non-small-cell lung cancer patients with advanced disease. The Lancet, 
388: 1002–11.
Hilgartner, S. (2017). Reordering life: knowledge and control in the genomics 
revolution. Cambridge, MA: MIT Press.
Hockings, E. (2014). Why we should opt out of the government’s new patient 
database. The Guardian, 31 January, https://www.theguardian.com/science/
political-science/2014/jan/31/why-we-should-opt-out-of-the-governments-
new-patient-database (accessed 20 June 2020).
Hogarth, S., and Saukko, P. (2017). A market in the making: the past, 
present and future of direct-to-consumer genomics. New Genetics and 
Society, 36(3): 197–208.
Hood, L., and Auffray, C. (2013). Participatory medicine: a driving 
force for revolutionizing healthcare. Genome Medicine, 5: article no. 
110.
Hood, L., and Friend, S. H. (2011). Predictive, personalized, preventive, 
participatory (P4) cancer medicine. Nature Reviews Clinical Oncology, 
8(3): 184–7.
Horlick-Jones, T. (2011). Understanding fear of cancer recurrence in terms 
of damage to ‘everyday health competence’. Sociology of Health & 
Illness, 33(6): 884–98.
Horst, M., and Irwin, A. (2010). Nations at ease with radical knowledge: 
on consensus, consensusing and false consensusness. Social Studies of 
Science, 40(1): 105–26.
Hubbard, G., Kidd, L., and Kearney, N. (2010). Disrupted lives and threats 
to identity: the experiences of people with colorectal cancer within the 
first year following diagnosis. Health, 14(2): 131–46.
Human Genomics Strategy Group (2012). Building on our inheritance: 
genomic technology in healthcare. London: Department of Health.
Interlandi, J. (2016). The paradox of precision medicine. Scientific American, 
314(4): 24–5.
Jain, L. S. (2007). Living in prognosis: toward an elegiac politics. Representa-
tions, 98(1): 77–92.
Jain, L. S. (2013). Malignant: how cancer becomes us. Berkeley, CA: University 
of California Press.
James, N. (1992). Care = organisation + physical labour + emotional labour. 
Sociology of Health & Illness, 14(4): 488–509.
 Bibliography 263
Jasanoff, S. (2015). Future imperfect: science, technology, and the imagina-
tions of modernity. In S. Jasanoff and S-H. Kim (eds), Dreamscapes 
of modernity: sociotechnical imaginaries and the fabrication of power, 
1–33. Chicago: University of Chicago Press.
Jasen, P. (2009). From the ‘silent killer’ to the ‘whispering disease’: ovarian 
cancer and the uses of metaphor. Medical History, 53(4): 489–512.
Jerolmack, C., and Tavory, I. (2014). Molds and totems: nonhumans and 
the constitution of the social self. Sociological Theory, 32(1): 64–77.
Joh, J. E., Esposito, N. N., Kiluk, J. V., Laronga, C., Lee, M. C., Loftus, L., 
Soliman, H., Boughey, J. C., Reynolds, C., Lawton, T. J., Acs, P. I., Gordan, 
L., and Acs, G. (2011). The effect of Oncotype DX recurrence score on 
treatment recommendations for patients with estrogen receptor-positive 
early stage breast cancer and correlation with estimation of recurrence 
risk by breast cancer specialists. The Oncologist, 16(11): 1520–6.
Kaiser, K. (2008). The meaning of the survivor identity for women with 
breast cancer. Social Science & Medicine, 67: 79–87.
Kaufman, S. R. (2015). Ordinary medicine: extraordinary treatments, longer 
lives, and where to draw the line. Durham, NC: Duke University Press.
Keating, P., and Cambrosio, A. (2011). Cancer on trial: oncology as a new 
style of practice. Chicago: University of Chicago Press.
Kerr, A., Swallow, J., Chekar, C. K., and Cunningham-Burley, S. (2019). 
Genomic research and the cancer clinic: uncertainty and expectations 
in professional accounts. New Genetics and Society, 38(2): 222–39.
Klawiter, M. (2004). Breast cancer in two regimes: the impact of social 
movements on illness experience. Sociology of Health & Illness, 26(6): 
845–74.
Kohli-Laven, N., Bourret, P., Keating, P., and Cambrosio, A. (2011). Cancer 
clinical trials in the era of genomic signatures: biomedical innovation, 
clinical utility, and regulatory-scientific hybrids. Social Studies of Science, 
41(4): 487–513.
Lamprell, K., Chin, M., and Braithwaite, J. (2018). The plot thickens: arche-
typal narrative structure in the melanoma patient journey. Cogent Medicine, 
5(1): 1484053. https://doi.org/10.1080/2331205X.2018.1484053.
Landzelius, K. (2006). Introduction: patient organization movements and 
new metamorphoses in patienthood. Social Science & Medicine, 62(3): 
529–37.
Largent, E. A., Fernandez Lynch, H., and McCoy, M. S. (2018). Patient-
engaged research: choosing the ‘right’ patients to avoid pitfalls. Hastings 
Center Report, 48(5): 26–34.
Latimer, J., Featherstone, K., Atkinson, P., Clarke, A., Pilz, D. T., and Shaw, 
A. (2006). Rebirthing the clinic: the interaction of clinical judgment 
and genetic technology in the production of medical science. Science, 
Technology, & Human Values, 31(5): 599–630.
Lewin, S., and Reeves, S. (2011). Enacting ‘team’ and ‘teamwork’: using 
Goffman’s theory of impression management to illuminate interprofessional 
practice on hospital wards. Social Science & Medicine, 72(10): 1595–602.
264 Personalised cancer medicine
Lewis, S., Willis, K., Yee, J., and Kilbreath, S. (2016). Living well? Strategies 
used by women living with metastatic breast cancer. Qualitative Health 
Research, 26(9): 1167–79.
Light, D. W. (2010). Bearing the risks of prescription drugs. In D. W. 
Light (ed.), The risks of prescription drugs, 1–39. New York: Columbia 
University Press.
Llewellyn, H., Higgs, P., Sampson, E. L., Jones, L., and Thorne, L. (2018). 
Topographies of ‘care pathways’ and ‘healthscapes’: reconsidering the 
multiple journeys of people with a brain tumour. Sociology of Health 
& Illness, 40(3): 410–25.
Loncaster, J., Armstrong, A., Howell, S., Wilson, G., Welch, R., Chittalia, 
A., Valentine, W. J., and Bundred, N. J. (2017). Impact of Oncotype 
DX breast recurrence score testing on adjuvant chemotherapy use in 
early breast cancer: real world experience in Greater Manchester, UK. 
European Journal of Surgical Oncology, 43(5): 931–7.
Longo, D. L. (2013). Personalized cancer care is not new. The Oncologist, 
18(6): 644–5.
Lupton, D. (2014). Digital sociology. Abingdon: Routledge.
MacKenzie, R., Chapman, S., Salkeld, G., and Holding, S. (2008). Media 
influence on Herceptin subsidization in Australia: application of the rule 
of rescue? Journal of the Royal Society of Medicine, 101(6): 305–12.
Madden, M., and Speed, E. (2017). Beware zombies and unicorns: toward 
critical patient and public involvement in health research in a neoliberal 
context. Frontiers in Sociology, 2: 7.
Madhu, N. (2017). Book review: Kaushik Sunder Rajan, Pharmocracy: 
Value, Politics, and Knowledge in Global Medicine. Sociological Bulletin, 
66(3): 370–3.
Marcon, A. R., Bieber, M., and Caulfield, T. (2018). Representing a ‘revolu-
tion’: how the popular press has portrayed personalized medicine. Genetics 
in Medicine, 20(9): 950.
Marquart, J., Chen, E. Y., and Prasad, V. (2018). Estimation of the percentage 
of US patients with cancer who benefit from genome-driven oncology. 
JAMA Oncology, 4(8): 1093–8.
Martin, P. (2018). Genomic hope: promise in the bioeconomy. In S. Gibbon, 
B. Prainsack, S. Hilgartner and J. Lamoreaux (eds), Routledge Handbook 
of Genomics, Health and Society, 79–89. Abingdon: Routledge.
Matthews-King, A. (2018). Most women with early stage breast cancer can 
avoid toxic chemotherapy, major trial finds. The Independent, 3 June, 
https://www.independent.co.uk/news/health/breast-cancer-chemotherapy-
genetic-test-hormone-therapy-survival-a8380906.html (accessed 20 June 
2020).
Maughan, T. (2017). The promise and the hype of ‘personalised medicine’. 
The New Bioethics, 23(1): 13–20.
McDonald, R., Waring, J., and Harrison, S. (2006). Rules, safety and the 
narrativisation of identity: a hospital operating theatre case study. Sociology 
of Health & Illness, 28(2): 178–202.
 Bibliography 265
Mead, N., and Bower, P. (2000). Patient-centredness: a conceptual framework 
and review of the empirical literature. Social Science & Medicine, 51(7): 
1087–110.
Medical Research Council (2014). Clinical trials: why multi-arms are better 
than two. [online]. www.insight.mrc.ac.uk/2014/07/25/clinical-trials-why-
multi-arms-are-better-than-two/ (accessed 30 August 2018).
Merletti, F., Galassi, C., and Spadea, T. (2011). The socioeconomic deter-
minants of cancer. Environmental Health, 10(1): S7.
Metzler, I. (2010). Biomarkers and their consequences for the biomedical 
profession: a social science perspective. Personalized Medicine, 7(4): 
407–20.
Michael, M. (2012). ‘What are we busy doing?’ Engaging the idiot. Science, 
Technology & Human Values, 37(5): 528–54.
Michael, M. (2017a). Enacting Big Futures, Little Futures: toward an ecology 
of futures. The Sociological Review, 65(3): 509–24.
Michael, M. (2017b). Futures of the present: from performativity to prehen-
sion. In N. Brown and B. Rappert (eds), Contested futures: a sociology 
of prospective techno-science, 21–39. Abingdon: Routledge.
Middleton, G., Crack, L. R., Popat, S., Swanton, C., Hollingsworth, S. 
J., Buller, R., Walker, I., Carr, T. H., Wherton, D., and Billingham, L. 
J. (2015). The National Lung Matrix Trial: translating the biology of 
stratification in advanced non-small-cell lung cancer. Annals of Oncology, 
26(12): 2464–9. https://doi.org/10.1093/annonc/mdv394.
Miles, D. W. (2001). Update on HER-2 as a target for cancer therapy 
Herceptin in the clinical setting. Breast Cancer Research, 3: 380–4.
Miller, F. A., Hayeems, R. Z., Bytautas, J. P., Bedard, P. L., Ernst, S., Hirte, 
H., Hotte, S., Oza, A., Razak, A., Welch, S., and Winquist, E. (2014). 
Testing personalized medicine: patient and physician expectations of 
next-generation genomic sequencing in late-stage cancer care. European 
Journal of Human Genetics, 22(3): 391.
Mitchell, R., and Waldby, C. (2010). National biobanks: clinical labor, 
risk production, and the creation of biovalue. Science, Technology & 
Human Values, 35(3): 330–55.
Montgomery, C. M. (2017a). Clinical trials and the drive to material 
standardisation: ‘extending the rails’ or reinventing the wheel? Science 
and Technology Studies, 30(4): 30–44.
Montgomery, C. M. (2017b). From standardization to adaptation: clinical 
trials and the moral economy of anticipation. Science as Culture, 26(2): 
232–54.
Moore, D. A., Kushnir, M., Mak, G., Winter, H., Curiel, T., Voskoboynik, 
M., and Forster, M. (2019). Prospective analysis of 895 patients on a 
UK genomics review board. ESMO Open, 4(2): e000469.
Moorhead, J. (2018). No chemo: the test that made me a lucky breast 
cancer patient. The Guardian, 4 June, https://www.theguardian.com/
commentisfree/2018/jun/04/chemo-breast-cancer-oncotype-dx-test (accessed 
20 June 2020).
266 Personalised cancer medicine
Morange, M. (1997). From the regulatory vision of cancer to the oncogene 
paradigm, 1975–1985. Journal of the History of Biology, 30(1): 1–29.
Moreira, T. (2011). Health care rationing in an age of uncertainty: a 
conceptual model. Social Science & Medicine, 72(8): 1333–41.
Murphy, M. (2012). Seizing the means of reproduction: entanglements of 
feminism, health, and technoscience. Durham, NC: Duke University Press.
Murphy, M. (2015). Unsettling care: troubling transnational itineraries of 
care in feminist health practices. Social Studies of Science, 45(5): 717–37.
Murphy, E., and Dingwall, R. (2007). Informed consent, anticipatory 
regulation and ethnographic practice. Social Science & Medicine, 65(11): 
2223–34.
Nagaraj, G., and Ma, C. X. (2013). Adjuvant chemotherapy decisions in 
clinical practice for early-stage node-negative, estrogen receptor-positive, 
HER2-negative breast cancer: challenges and considerations, Journal of 
the National Comprehensive Cancer Network, 11(3): 246–51.
Nahuis, R., and Boon, W. P. C. (2011). The impact of patient advocacy: 
the case of innovative breast cancer drug reimbursement. Sociology of 
Health & Illness, 33(1): 1–15.
Nair, M., Sandhu, S. S., and Sharma, A. K. (2018). Cancer molecular 
markers: a guide to cancer detection and management. Seminars in Cancer 
Biology, 52: 39–55.
Nakagawa, H., and Fujita, M. (2018). Whole genome sequencing analysis for 
cancer genomics and precision medicine. Cancer Science, 109(3): 513–22.
Nawrocki, S. (2018). Molecular profiling of tumours for precision oncol-
ogy – high hopes versus reality. Contemporary Oncology, 22(1A): 3.
Nelson, N. C., Keating, P., and Cambrosio, A. (2013). On being ‘actionable’: 
clinical sequencing and the emerging contours of a regime of genomic 
medicine in oncology. New Genetics and Society, 32(4): 405–28.
NICE (National Institute for Health and Care Excellence) (2013). Gene 
expression profiling and expanded immunohistochemistry tests for guiding 
adjuvant chemotherapy decisions in early breast cancer management: 
MammaPrint, Oncotype DX, IHC4 and Mammostrat. Manchester: 
National Institute for Health and Care Excellence.
NICE (National Institute for Health and Care Excellence) (2017). Tumour 
profiling tests to guide adjuvant chemotherapy decisions in people with 
breast cancer (update of DG10): Final Scope. Manchester: National 
Institute for Health and Care Excellence.
NICE (National Institute for Health and Care Excellence) (2018a). Diag-
nostics consultation document: tumour profiling tests to guide adjuvant 
chemotherapy decisions in early breast cancer. Manchester: National 
Institute for Health and Care Excellence.
NICE (National Institute for Health and Care Excellence) (2018b). Tumour 
profiling tests to guide adjuvant chemotherapy decisions in early breast 
cancer. Manchester: National Institute for Health and Care Excellence.
NICE (National Institute for Health and Care Excellence) (2018c). Tumour 
profiling tests to guide adjuvant chemotherapy decisions in early breast 
 Bibliography 267
cancer: Diagnostics Consultation Document – Comments. Manchester: 
National Institute for Health and Care Excellence.
Novas, C. (2006). The political economy of hope: patients’ organizations, 
science and biovalue. BioSocieties, 1(3): 289–305.
Nussinov, R., Hyunbum, J., Tsai, C.-J. and Cheng, F. (2019). Precision 
medicine and driver mutations: computational methods, functional 
assays and conformational principles for interpreting cancer drivers. 
PLoS Computational Biology, 15(3): e1006658.
Olopade, O. I., Grushko, T. A., Nanda, R. and Huo, D. (2008). Advances 
in breast cancer: pathways to personalized medicine. Clinical Cancer 
Research, 14(24): 7988–99.
Orgad, S. (2005). The transformative potential of online communication: the 
case of breast cancer patients’ Internet spaces. Feminist Media Studies, 
5(2): 141–61.
Parsons, E., and Atkinson, P. (1992). Lay constructions of genetic risk. 
Sociology of Health & Illness, 14(4): 437–55.
Petersen, A., and Lupton, D. (1997). The new public health: health and 
self in the age of risk. London: Sage.
Petersen, A., Schermuly, A. C., and Anderson, A. (2019). The shifting 
politics of patient activism: from bio-sociality to bio-digital citizenship. 
Health, 23(4): 478–94.
Powell, H. A. (2019). Socioeconomic deprivation and inequalities in lung 
cancer: time to delve deeper? Thorax, 74(1): 11–12.
Prainsack, B. (2017). Personalized medicine: empowered patients in the 
21st century? New York: NYU Press.
Puig de La Bellacasa, M. P. (2011). Matters of care in technoscience: 
assembling neglected things. Social Studies of Science, 41(1): 85–106.
Puig de la Bellacasa, M. P. (2012). ‘Nothing comes without its world’: 
thinking with care. The Sociological Review, 60(2): 197–216.
Rabeharisoa, V., Moreira, T., and Akrich, M. (2014). Evidence-based 
activism: patients’, users’ and activists’ groups in Knowledge Society. 
Biosocieties, 9(2): 111–28.
Rajan, K. S. (2006). Biocapital: the constitution of postgenomic life. Durham, 
NC: Duke University Press.
Rapp, R. (1998). Refusing prenatal diagnosis: the meanings of bioscience 
in a multicultural world. Science, Technology, & Human Values, 23(1): 
45–70.
Roberts, K., and Clarke, C. (2009). Future disorientation following gynaeco-
logical cancer: women’s conceptualisation of risk after a life-threatening 
illness. Health, Risk & Society, 11(4): 353–66.
Rose, N. (2001). The politics of life itself. Theory, Culture & Society, 
18(6): 1–30.
Ross, E., Swallow, J., Kerr, A., and Cunningham-Burley, S. (2019). Online 
accounts of gene expression profiling in early-stage breast cancer: 
interpreting genomic testing for chemotherapy decision making. Health 
Expectations, 22(1): 74–82.
268 Personalised cancer medicine
Sample, I. (2014). PM: Genome project will transform cancer care. The 
Guardian, 1 August, www.theguardian.com/society/2014/aug/01/nhs-
genetic-analysis-serious-diseases-diagnosed-treated (accessed 20 June 
2020).
Samuel, G. N., and Farsides, B. (2017). The UK’s 100,000 Genomes Project: 
manifesting policymakers’ expectations. New Genetics and Society, 36(4): 
336–53.
Schellekens, H., Aldosari, M., Talsma, H., and Mastrobattista, E. (2017). 
Making individualized drugs a reality. Nature Biotechnology, 35(6): 
507–13.
Scottish Scientific Advisory Council (2019). Informing the future of genomic 
medicine in Scotland. Edinburgh: Scottish Science Advisory Council.
Selin, C. (2008). The sociology of the future: tracing stories of technology 
and time. Sociology Compass, 2(6): 1878–95.
Shack, L., Jordan, C., Thomson, C. S., Mak, V., and Møller, H. (2008). 
Variation in incidence of breast, lung and cervical cancer and malignant 
melanoma of skin by socioeconomic group in England. BMC Cancer, 
8(1): 271.
Skloot, R. (2017). The immortal life of Henrietta Lacks. Portland, OR: 
Broadway Books.
Smyth, C. (2013). Test could spare women the ordeal of chemotherapy. 
The Times, 26 September, https://www.thetimes.co.uk/article/test-could-
spare-women-the-ordeal-of-chemotherapy-b50tbbmmwf0 (accessed 20 
June 2020).
Sparano, J. A., Gray, R. J., Makower, D. F., et al. (2018). Adjuvant chemo-
therapy guided by a 21-gene expression assay in breast cancer. New 
England Journal of Medicine, 379: 111–21.
Stage, C. (2017). Networked cancer: affect, narrative and measurement. 
Basingstoke: Palgrave Macmillan.
Star, S. L. (1985). Scientific work and uncertainty. Social Studies of Science, 
15(3): 391–427.
Steinberg, D. L. (2015). The bad patient: estranged subjects of the cancer 
culture. Body & Society, 21(3): 115–43.
Suchman, L. (1996). Supporting articulation work. In R. Kling (ed.), 
Computerization and controversy: value conflicts and social choices, 
407–23. London: Academic Press.
Sulik, G. (2009). Managing biomedical uncertainty: the technoscientific 
illness identity. Sociology of Health & Illness, 30(7): 1059–76.
Sulik, G. (2014). #Rethinkpink: moving beyond Breast Cancer Awareness 
SWS Distinguished Feminist Lecture. Gender & Society, 28(5): 655–78.
Swallow, J. (2019). Constructing classification boundaries in the memory 
clinic: negotiating risk and uncertainty in constituting mild cognitive 
impairment. Sociology of Health & Illness [online only/early view], 14 
November 2019. https://doi.org/10.1111/1467-9566.1301.
Swallow, J., Kerr, A., Chekar, C. K., and Cunningham-Burley, S. (2020). 
Accomplishing an adaptive clinical trial for cancer: valuation practices 
 Bibliography 269
and care work across the laboratory and the clinic. Social Science & 
Medicine, 252: 112949. https://doi.org/10.1016/j.socscimed.2020.112949
TallBear, K. (2013). Native American DNA: tribal belonging and the false 
promise of genetic science. Minneapolis, MN: University of Minnesota 
Press.
Tarkkala, H., Helén, I., and Snell, K. (2019). From health to wealth: the 
future of personalized medicine in the making. Futures, 109: 142–52.
Timmermans, S. (2005). From autonomy to accountability: the role of 
clinical practice guidelines in professional power. Perspectives in Biology 
and Medicine, 48(4): 490–501.
Tiriveedhi, V. (2018). Impact of precision medicine on drug repositioning 
and pricing: a too small to thrive crisis. Journal of Personalized Medicine, 
8(4): 36. doi:10.3390/jpm8040036.
Tronto, J. C. (1993). Moral boundaries: a political argument for an ethic 
of care. London: Routledge.
Tupasela, A. (2017). Populations as brands in medical research: placing 
genes on the global genetic atlas. BioSocieties, 12(1): 47–65.
Tutton, R. (2012). Personalizing medicine: futures present and past. Social 
Science & Medicine, 75(10): 1721–8.
Tutton, R., and Jamie, K. (2013). Personalized medicine in context: social 
science perspectives. Drug Discovery Today: Therapeutic Strategies, 
10(4): e183–e187.
Twigg, J., Wolkowitz, C., Cohen, R. L., and Nettleton, S. (2011). Concep-
tualising body work in health and social care. Sociology of Health & 
Illness, 33(2): 171–88.
Van Dijck, J., and Poell, T. (2013). Understanding social media logic. Media 
and Communication, 1(1): 2–14.
van Helvoort, T. (1999). A century of research into the cause of cancer: is 
the new oncogene paradigm revolutionary? History and Philosophy of 
the Life Sciences, 21(3): 293–330.
Van Lente, H., and Rip, A. (1998). The rise of membrane technology: 
from rhetorics to social reality. Social Studies of Science, 28(2): 
221–54.
Vasella, D., and Slater, R. (2003). Magic cancer bullet: how a tiny orange 
pill is rewriting medical history. New York: Harper Business.
Vicari, S., and Cappai, F. (2016). Health activism and the logic of connective 
action: a case study of rare disease patient organisations. Information, 
Communication & Society, 19(11): 1653–71.
Ward, E., Jemal, A., Cokkinides, V., Singh, G. K., Cardinez, C., Ghafoor, 
A., and Thun, M. (2004). Cancer disparities by race/ethnicity and 
socioeconomic status. CA: A Cancer Journal for Clinicians, 54(2): 78–93.
Wenger, M. L., and Oliffe, L. J. (2014). Men managing cancer: a gender 
analysis. Sociology of Health & Illness, 36(1): 108–22.
West, H. J. (2017). Novel precision medicine trial designs umbrel-
las and baskets. JAMA Oncology Patient, 3(3): 423. doi:10.1001/
jamaoncol.2016.5299.
270 Personalised cancer medicine
Will, C., and Moreira, T. (2010). Medical proofs, social experiments. In C. 
Will and T. Moreira (eds), Clinical trials in shifting contexts. Aldershot: 
Ashgate.
Williams, S. J., Martin, P., and Gabe, J. (2011). The pharmaceuticalisation 
of society? A framework for analysis. Sociology of Health & Illness, 
33(5): 710–25.
Yan, S. (2017). Prostate cancer patienthood in the genomic era: a study of 
patients’ online accounts. Master of Public Health dissertation, University 
of Edinburgh.
Yeo, S. K., and Guan J.-L. (2017). Breast cancer: multiple subtypes within 
a tumor? Trends in Cancer, 3(1): 753–60.
Zafar, S. Y. (2015). Financial toxicity of cancer care: it’s time to intervene. 
Journal of the National Cancer Institute, 108(5): djv370. doi:10.1093/
jnci/djv370.
Ziebland, S., and Wyke, S. (2012). Health and illness in a connected world: 
how might sharing experiences on the internet affect people’s health? 
The Milbank Quarterly, 90(2): 219–49.
Zuboff, S. (2019). The age of surveillance capitalism: the fight for a human 
future at the new frontier of power. London: Profile Books.
Index
100,000 Genomes Project 54, 119, 
124, 152, 155–9, 164–5, 
168–80, 223, 227, 237
23andMe 90
Abelson, J. 32
Abraham, J. 31, 65
access
to participants for research 
223–36




adaptive trials 44–52, 118–25, 
148, 245







austerity measures 5, 157
Avastin 36–7, 51, 184, 190–1, 
203, 249
Bekelman, J. E. 186
Bell, Sir John 156
Bell, K. 42
benefit obtained from research 
254–5
Benjamin, R. 212, 234, 237–8
Berg, Sancha 31





Borad, M. J. 46
Bourret, P. 40
bowel cancer 191, 195
Braun, K. 162
breast cancer 29–35, 41, 58–64, 
67, 119, 148, 188, 191, 223, 
227, 239
early-stage 76–85
Breast Cancer Now (charity)  
64–5
Brexit 11, 155
British Medical Journal 198
Brown, N. 52–3
Brown, P. 47
Bully’s Prize (game show) 110
‘bureaucatic calculus’ 186
Callon, M. 26–7
Cambrosio, A. 25–8, 32–3, 44–6, 
118
Cameron, David 157–9, 167
Cameron, Ivan 158–9
campaigns for access to drugs 
36–7
see also media coverage and 
campaigns
‘can do’ attitude 244
272 Index
Cancer Research UK (CRUK) 
120–1, 124–5, 133, 186
cancer types 223
caring 241–55
blurred boundary with research 
241, 254
forms of 244
at local level 244
on a macro scale 244
proliferation of 246
valuation of 243, 252
as work 245–6
central data repository 166
cervical cancer 36–7
charities and charitable donations 
5–6, 185–6




clinical trials 23–5, 118
clinical trials assistants (CTAs) 
128–34, 227–8
clinicians
failure to participate in research 
225–6




Collins, P. A. 32
compassionate use of drugs 36, 
187
complementary therapies 203–4




consent process and consent forms 
160–6, 169–81, 234, 238, 
254
Corrigan, O. 161
cost considerations 23, 28, 74, 86
cost-effectiveness 23
crowdfunding 37, 51, 187–9, 
197–209, 253
cultural capital 208
‘cutting edge’ treatments 251
Daily Mirror 198
data protection 176
Davies, Dame Sally 65
Davis, C. 38
day-to-day management of cancer 
symptoms 115
deCODE (company) 154
de Graaf, S. 47
deprived groups and areas 5, 
118–19
digital platforms 90, 189, 208–9
disappointment, management of 
106–12
dosages 24, 27
economic benefits from new 
treatments 250–1
embedding of new processes 119, 
243
emotional labour 28, 106, 116, 
206, 208, 226–7, 231–2, 253
empowerment 246
enthusiastic voices, privileging of 
239
entrepreneurial approaches 250
‘epistemological activism’ 26, 30, 
65
ethical approach to research 225, 
238
ethical approval for research 
223–5
ethnic minorities 221, 236–8
ethnographic research 14, 224
evidence-based practice 9, 24, 96
expectations, lowering of 119, 144
experimental value of trials 123
experimentation 185, 188, 198, 
208, 241, 245, 250, 254
expert review groups 65
expertise
in challenging funding decisions 
196–8, 208
new kinds of 250
 Index 273







Food and Drug Administration 
(FDA) 27, 30, 41
foreshortened futures faced by 
some patients 99–100, 132, 
148, 233
former patients’ motivation for 




Frank, A. 9, 189
Fujita, M. 52
funding of treatment 183–7
fundraising 188, 199, 203–8, 253
hidden labour of 206
success in 204–8
future patients, benefiting of 112, 
131–2, 136, 147, 175, 
248–9
future-crafting 7–9, 241–7, 251–2, 
255
Gabe, J. 32–3
gastrointestinal tumours (GIST) 
26–7
gatekeepers 223–7
gendered hierarchies in medicine 
227
gene-expression profiling 41, 
59–63, 66, 68, 73–5, 83
Genetech (company) 30–1
genomes 1–3, 14
Genomic Health (company) 59, 
61, 88
Genomic Medicine Service 92, 180
genomic workers, solidarities 
between 255
Genomics England 154–7, 162–5, 
237, 243
genomics (and genomic medicine) 
22–3, 52–6, 75–6, 88, 115, 
118–19, 126–7, 142, 152–8, 
162–4, 170, 181, 214–15, 
224–8, 234–9, 242–3, 247, 
252–4
clinicians’ views on 224–5
decentring of 252




level of patients’ understanding 
of 127, 235
portrayal and auditing of 254
Gerlitz, C. 188
Gillespie, C. 43, 83–4
Gleevec 25–32, 35–7, 40
Good, M. J. D. 184
Google 176
gratitude, expressions of 253
Groves, C. 242–3
Guardiant Health (company) 91
gynaecological cancers 88–116, 
118, 148, 223
haematological cancers 171
Hamilton, A. B. 42
Hancock, Matt 124–5, 180
Haraway, D. 237
health inequalities 5, 214–15, 228, 
237
Health and Social Care Act (2012) 
159
Hedgecoe, A. 33–4, 68, 74
Helmond, A. 188
HER2 30–5
Herceptin 25, 30–7, 40, 46, 58, 
68, 74
Hilgartner, S. 153–6, 164–5, 243
Hills, Dame Sue 180
hollowing-out of public services 5
hope, culture of 4
Horlick-Jones, T. 83
Horton, Richard 31
Human Genetics Commission 159
274 Index
Human Genome Project 59, 157, 
164–5
Human Genomics Strategy Group 
156
humour, deployment of 178
Iceland 154, 160
Illumina (company) 91, 157, 180
imagined communities 10
imatinib see Gleevec
incidence of cancer 5
incrementalism and incremental 
change 115, 125




Institute of Cancer Research 35
institutional structures 13
insurance schemes 189–90, 192
Interlandi, J. 55
involvement, extent of 23, 25, 51
Jain, L. S. 250–1, 255
Jardine, Lisa 31





Keating, P. 25–8, 32–3, 45–6, 118
King’s Fund 159






LoRusso, P. M. 46
lung cancer 36, 118–22, 148, 223, 
227, 249
McKinsey Global Institute 157
Macmillan nurses 220
MammaPrint 41, 61, 63
marginalised communities 236–7
marginalised patients 12–14
marketisation of genomic data 154
Matrix Trial 120–49
totemic value of 143
Maughan, Tim 55
May, Theresa 155
media coverage and campaigns 
31–3, 184, 208
metastatic cancer 102
Metzler, I. 89, 91
Michael, M. 9, 52–3, 212
middle-class bias 229–30, 236
Middleton, Gary 122
Mirati Therapeutics (company) 
125
Mitchell, R. 53
molecular profiling 2,22, 26, 
39–44, 118, 241, 252, 255
for advanced gynaecological 
cancer 88–116
‘molecular turn’ in cancer 
treatment 25, 33
monoclonal antibodies 25






National Cancer Institute, US 30
National Health Service (NHS), 
UK 5–6, 31, 36, 53–4, 
156–9, 181, 197–8, 207–8
NHS Predict tool 69–70, 77,  
80
National Institute for Health and 
Care Excellence (NICE), UK 
31, 36, 60–8, 86, 94, 187, 
191, 243
Cancer Drugs Fund 184




non-attendance at appointments 
234
Novartis (company) 26




Oncotype DX 41, 60–3, 66–88,  
92
optimisation of treatment 29, 52, 
118, 149
optimism about prospects 241, 
246
O’Shaughnessy, Lord 163




participation in research 26, 
212–13, 219–40
accessing candidates for 223–36
limitations of 212, 223, 231–4, 
239
misbehaviour in the course of 
212–13
obtaining value from 235, 251
practicalities of 176
reframed as obvious and 
routine 174–5
see also patient participation; 
public engagement
partnerships between private 




see also Public and Patient 
Involvement groups
patient pathways 185
personalisation of prognosis, 
prediction and diagnosis 
39–44
personalised cancer medicine 1–7, 
12–15, 22–4, 47, 54–6, 62, 
68, 76, 87, 94, 97–8, 106, 
118–21, 126, 147–50, 
166–7, 174, 181, 183–7, 




and holistic assessment of need 
252
linked with the wider 
bioeconomy 211–12
origins of 23–4
patients’ responses to 28–9
politics and economics of 255
promise of 250, 253
personhood, ordinary and 
educated 180
Petersen, A. 188
petitioning by patients 26
P4 medicine 2, 211, 240
Pfizer (company) 122
pharmaceutical companies 29, 




precision medicine 7, 120, 124, 
186–7
Precision Medicine initiative (in 
the US) 22
pre-screening study (SMP2) for 
Matrix Trial 120–35, 139, 
147
prevention of disease 5–6
pricing of drugs 27, 183, 187,  
207
private healthcare 36, 38, 78, 92, 
94, 98, 127, 187, 189–98, 
249, 253
private patient units (PPUs) at 
NHS hospitals 192
professional status of clinicians  
30
Prolaris 43
promissory scenarios 122, 240–1
promotional films 93
276 Index
Prosigna (company) 60, 63, 67,  
92
public engagement with research 
236–9
Public and Patient Involvement 
groups for present study 2, 
213–14, 236–7
Puig de la Bellacasa, M. P. 254
Rabeharisoa, V. 26–7
racism and racialisation 236–8
randomisation in trials 46
randomised controlled trials 
(RCTs) 94, 96, 100, 118
Rapp, R. 212
rare cancers 215, 223
reciprocity 248–9
recurrence risk 59, 62, 79–83, 
101–2
‘reflexive governance’ (Braun et 
al.) 162
regional innovation funds 95
regulatory decision-making 67
relationship-building 222
remission 26, 28, 45
research governance 213
resilience 203
resistance to treatment 27, 246
resources, concern for see cost 
considerations
Rip, A. 24
Roche (company) 3–30, 156,  
187
salience, lack of 112–14
Samuel, G. N. 156
Sapientia software 155
Schellekens, H. 186
science and technology studies 
(STS) 7, 12, 212, 247
scoping of personalised cancer 
medicine 213–22
Scottish Medicines Consortium 
184
Scottish Scientific Advisory 
Council 43








social contract theory 6, 162
social media 90, 188, 197, 199, 
204, 243
socio-economic circumstances 5
sociology of health and illness 9
speculative mono-futures, allure of 
255
spending on cancer drugs 183
Stage, C. 200








survival rates 5, 59
‘tailored’ treatments 241
tamoxifen 218
targeted therapies 24–7, 44–5, 52, 
92–3, 118–19, 122, 127, 






‘therapeutic misconception’  
160
transformative change 125, 
164–71
Trial Assigning Individualised 








Centers for Disease Control and 
Prevention 183




van Lente, H. 24
Vasella, Dan 26
VGT study 100
Virtue (company pseudonym), 
promises of 103–6
Waldby, C. 53
Wellcome Trust 2, 157
whole-genome sequencing (WGS) 





worth of a life 253
Yorkshire and Humber Regional 
Genomics Service 237
Zuboff, S. 188
